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Abstract 
Over the past ten years huge advances have been made in the field of genetics and 
genomics. Genetic mapping has evolved from laborious linkage and homozygosity based 
approaches to high-throughput genome-wide association studies using whole genome 
SNP array technology. Through massively parallel sequencing technology, gigabases of 
sequencing data can now be produced in a single experiment. The domestic dog has 
been increasingly recognised as a model for human disease and mapping of inherited 
disease in the domestic dog is facilitated by fixed and genetically isolated populations. 
The aims of this thesis were to demonstrate advances in mapping and sequencing 
techniques by investigating the genetics of five inherited disorders, representing 
significant welfare issues in the purebred dog. An additional aim was to develop 
diagnostic DNA tests to identify affected individuals and asymptomatic carriers. 
A parallel mapping approach was used to map two autosomal recessive conditions in the 
Cavalier King Charles Spaniel. The use of a single common set of controls for two 
independent genome-wide association studies was demonstrated as an efficient mapping 
strategy when studying two conditions affecting a single breed. Newly available target 
enrichment and massively parallel sequencing methodology was used to simultaneously 
sequence both disease-associated loci, with one condition acting as a control for the 
other. 
A genome-wide homozygosity mapping approach using microsatellite markers was used 
to investigate spinocerebellar ataxia in the Italian Spinone. The disorder was successfully 
mapped to a single chromosome using six cases and six controls, and fine mapped with 
additional microsatellite markers. Subsequently, a progression of sequencing techniques 
were used to identify the disease-associated mutation, with the study highlighting the 
potential difficulties of using massively parallel sequencing technologies.  
Spinocerebellar ataxia (or late onset ataxia) in the Parson Russell Terrier was investigated 
using a genome-wide association study followed by a target enriched massively parallel 
sequencing approach. Further sequencing was performed to reduce the large number of 
potential causal variants, with the entire workflow achieved in-house.  
The final experimental chapter describes the use of a genome-wide mRNA sequencing 
(mRNA-seq) approach as a method of candidate gene sequencing of a single case of 
neonatal cerebellar cortical degeneration in a Beagle dog. The mRNA-seq approach 
demonstrates a simple, fast and cost effective method of targeted resequencing of 
expressed genes when a suitable tissue resource is available. 
For all five disorders under investigation, disease-associated mutations were identified 
leading to the development of diagnostic tests. Three of the mutations were in genes not 
previously associated with similar conditions in humans or other model organisms. 
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1.1. The domestic dog 
The domestic dog, Canis lupus familiaris, has ancient origins and descended from the 
grey wolf around 33 thousand years ago based on the most recent archaeological 
evidence (Ovodov et al., 2011). The location of domestication is highly debated. 
Mitochondrial and Y chromosome evidence suggests an East Asian origin (Ding et al., 
2011, Pang et al., 2009), whereas genome-wide single nucleotide polymorphism (SNP) 
analysis and archaeological findings imply a European and Middle Eastern origin 
(Vonholdt et al., 2010), although it is agreed that multiple origins are likely, with 
interbreeding between early domestic dog and wolf populations occurring through a period 
of domestication.  
 
Humans share a unique relationship with the domestic dog. From the point of 
domestication, the dog has been bred by humans for companionship, novelty and 
numerous working attributes such as herding, hunting and retrieving. Dog breeding as a 
hobby first became fashionable in the middle of the 19th Century. The rapid rise in the 
popularity of breeding and showing dogs led to the formation of the Kennel Club on the 4th 
April 1873 as a regulatory governing body. Today hundreds of dog breeds have been 
established worldwide, with the British Kennel Club alone recognising 210 breeds and 
registering over 200,000 purebred dogs each year (The Kennel Club 2012).   
1.2. Disease in the purebred dog 
Collectively, purebred dogs suffer from a wide range of diseases.  The development of 
pure breeds produces closed populations with fixed and limited gene pools. Individual 
breeds have closed stud books and dogs can only be registered as a particular breed if 
both its parents were also registered as the same breed.  This means that each breed is 
genetically isolated. The problem is amplified by the existence of breed standards, 
detailing a “perfect” example of a breed. Breed standards provide a strong artificial 
selection pressure, resulting in only a small subset of dogs being used as breeding stock, 
which causes a further reduction in genetic diversity. Within the reduced breeding stock 
there are often dogs that are particularly fashionable because of their close resemblance 
to the breed standard. These dogs are often extensively used for breeding purposes 
which leads to an overrepresentation of particular gene variants within a breed. This is 
commonly known as the popular sire effect. Closed populations and limited breeding 
stocks, often containing popular sires, can lead to random deleterious mutations reaching 
very high levels. For example, if a popular sire is a carrier of an autosomal recessive 
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disease, on average the causal mutation will be passed on to 50% of the offspring, rapidly 
increasing the frequency of the mutant allele within the breed population.  
1.3. The dog as a model organism 
Dogs suffer from a range of disorders that have comparable human conditions, and 
therefore provide naturally occurring models for human disease. The total number of 
canine genetic diseases was estimated at 479 in 2004 (Sargan, 2004), and the Online 
Mendelian Inheritance in Animals (OMIA) database suggests at least 286 disease 
phenotypes are potential models for human disease (OMIA 2012). In addition to showing 
disease phenotypes comparable with human disorders, the dog is considered to be 
physiologically similar to humans and physically more similar in size than traditional model 
organisms such as the mouse, making them more appropriate as a comparative tool and 
for trialling therapies. Dogs are relatively long lived and disease treatments for both canine 
and human conditions are often very similar. Even the domestic dog’s living environment 
and lifestyle often mirrors that of humans.   
 
One example of the suitability of the dog as a comparative model is its current use in the 
field of gene therapy, with the reversal of blindness in dogs with a homozygous mutation 
in the RPE65 (retinal pigment epithelium-specific 65 kDa protein) gene (Acland et al., 
2001, Le Meur et al., 2007). RPE65 mutations cause a form of Leber congenital 
amaurosis in humans, a severe retinal dystrophy which progresses before the age of one 
(Cremers et al., 2002). It was recently reported that three human Leber congenital 
amaurosis patients showed significant improvements in vision after being subjected to two 
rounds of gene therapy with an adeno-associated virus vector, illustrating successful 
transition from the dog model through to use in human medicine (Bennett et al., 2012).    
 
The discovery of the genetic cause of canine narcolepsy is an example of how a 
breakthrough in the dog has made a major contribution to human studies. Two 
independent mutations identified in the hypocretin-2-receptor gene (HCRTR2) were 
shown to cause aberrant splicing patterns, resulting in the skipping of exon 4 in the 
narcoleptic Dobermann Pinscher and of exon 6 in the narcoleptic Labrador Retriever (Lin 
et al., 1999). Following the discovery of the gene causing narcolepsy in the dog, 
hypocretin deficiencies and a reduction in the number of hypocretin neurons were 
subsequently described in association with human narcolepsy, showing how the study in 
the dog had helped accelerate the understanding of human disease (Nishino et al., 2000, 
Peyron et al., 2000, Thannickal et al., 2000).  
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The research into canine narcolepsy was a long term study. The investigation started with 
a linkage-based genome scan using a genome-wide set of microsatellite markers, 
identifying one marker on chromosome 12 in complete linkage with the disorder for both 
the Dobermann Pinscher and Labrador Retriever. A canine BAC (bacterial artificial 
chromosome) library was then constructed and probed for the initially linked marker. 
Chromosome walking by BAC end sequencing was used to build a 1.8 Mb region around 
the linked marker consisting of 77 contiguous BACs. Eleven polymorphic microsatellite 
markers identified by probing the BACs were all concordant with Labrador and 
Dobermann Pinscher cases, and the mutation containing region could not be narrowed at 
this stage. Basic Local Alignment Search Tool (BLAST) searches of BAC end sequences 
against human databases revealed close sequence similarity with MYO6, helping to 
identify the syntenic human chromosome. Human expressed sequence tags (ESTs) in the 
MYO6 region were then used to probe for further BACs, which could be used in 
fluorescent in situ hybridisation (FISH) against metaphase spreads of canine 
chromosomes to confirm their existence on canine chromosome 12. Backcross breeding 
was undertaken in parallel with positional cloning experiments in the hope of producing 
affected animals with recombinations between the initially linked marker and the 
narcolepsy locus to narrow down the associated region. Over 100 backcross animals 
were used in conjunction with a litter of narcoleptic Dachshunds to narrow the critical 
region to approximately 800 kb, which contained just one previously identified gene, 
HCRTR2. Degenerate primers for cDNA sequencing were designed using published 
human and rat HCRTR2 cDNA sequences, which were successfully used to sequence 
canine HRCTR2 mRNA and identify the causal exon skipping events. Although the study 
into canine narcolepsy was one of the first examples showing the potential of the dog 
model for identifying novel disease-associated genes, the complexity of the investigation 
clearly showed that the canine genome would need to be sequenced in order to make the 
dog a more realistic model that could be used routinely.  
1.4. Canine genomics 
1.4.1. The canine karyotype 
The canine karyotype was first characterised in 1928 as 2n = 78 when a study of meiotic 
cells revealed 38 pairs of acrocentric autosomes and one pair of metacentric sex 
chromosomes (Minouchi, 1928). Although the number of chromosomes in the canine 
genome was discovered at an early date, allocating numbers to chromosomes using 
standard banding techniques alone proved difficult, despite the efforts of several 
investigators. The Committee for the Standardisation of the Karyotype in the Domestic 
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Dog (CSKDD) was set up to find a definitive answer, and in 1996 an agreement was 
reached for allocating numbers 1-21 to canine chromosomes using standard cytogenetic 
techniques (Switonski et al., 1996). The use of FISH, with whole-chromosome paint 
probes, helped define the entire canine karyotype, and resulted in a consensus being 
reached over chromosome nomenclature in 1998 (Breen et al., 1998).      
1.4.2. The development of genetic maps 
To allow canine geneticists to utilise genetic markers in mapping studies, an initial linkage 
map of the canine genome was constructed in 1997, by genotyping 150 microsatellite 
markers across 17 three-generation pedigrees to define 30 linkage groups (Mellersh et al., 
1997). As genetically close loci are inherited together, linkage mapping works by 
analysing the inheritance of marker alleles through generations of a pedigree to assess 
whether they are in close proximity to one another by generating a statistical score known 
as a logarithm of odds (LOD). Scores of greater than three indicate significant linkage 
implying that two markers are close together on a chromosome. Scores of between two 
and three are defined as being suggestive of linkage. This may mean that markers are on 
the same chromosome, but linked inheritance is often disrupted by recombination events 
between the two loci. Scores less than two exclude linkage, indicating that markers are on 
separate chromosomes or are sufficiently distant to effectively be inherited independently 
(Lander and Kruglyak, 1995). Just prior to publication of the initial linkage map, copper 
toxicosis in the Bedlington Terrier became the first canine disease loci to be mapped 
using the linkage approach (Yuzbasiyan-Gurkan et al., 1997). Radiation hybrid mapping 
(RH-mapping) approaches were used to further build on previous linkage mapping efforts 
to produce integrated genome maps (Priat et al., 1998, Vignaux et al., 1999). In the RH-
mapping approach a culture of canine fibroblast cells is gamma irradiated to fragment the 
genetic material. Irradiated canine donor cells are then fused with thymidine kinase-
deficient hamster cells. During the fusion process donor chromosome fragments are 
incorporated into recipient chromosomes by insertion or translocation. Fused cells are 
then grown in selective media, so only cell lines that have acquired the thymidine kinase 
gene survive, indicating successful fusion and incorporation of donor genetic material. 
Colonies are tested by polymerase chain reaction (PCR) to determine which genetic 
markers are present, with closely linked markers more likely to be contained in the same 
cell lines. By using microsatellite markers from previous linkage mapping studies in RH-
mapping experiments, unlinked regions were joined to form larger regions. Known canine 
genes and human ESTs were also used in early RH-mapping experiments, allowing 
regions of synteny between the canine and human genomes to be considered for the first 
time. These initial linkage and RH maps provided the foundations for a second generation 
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of linkage maps (Neff et al., 1999) and combined RH-linkage maps (Mellersh et al., 2000). 
With the completion of the human and mouse genomes, further resources became 
available for building subsequent canine genome maps, culminating in a map consisting 
of 1,800 markers, covering all canine chromosomes (Breen et al., 2001). 
1.4.3. The canine genome project 
The first attempt to sequence the canine genome was undertaken by Celera Genomics. 
Genomic DNA from a Standard Poodle was used to produce a total of 6.22 million 
sequence reads, equivalent to 1.5x coverage of the dog genome and sufficient to give 
77% base coverage of the genome (Kirkness et al., 2003). Over 25% of the sequence 
data generated aligned uniquely to the human genome, allowing a full map of synteny 
between canine, human and murine chromosomes to be produced. Over 18 thousand 
sequences aligned to annotated genes in the human genome. Building on this information 
a high resolution RH map was created using 10,348 markers, of which 9,850 were canine 
orthologue sequences of human genes (Hitte et al., 2004).  
 
The National Human Genome Research Institute (NHGRI) also saw the potential of the 
dog as a model of genetic disease and invested $30 million towards sequencing the 
canine genome, which was previously only commercially available. The first open-access 
assembly of the canine genome was completed and became available in 2004 (Lindblad-
Toh et al., 2005). A female Boxer, named Tasha, was chosen for the project as 
preliminary analysis indicated the sequence of this particular dog to be highly 
homozygous. The project produced 7.8x coverage of the canine genome from 35 million 
sequence reads, and the assembly is freely available online via the Ensembl and UCSC 
genome browsers (Hubbard et al., 2002, Kent et al., 2002). The sequence is annotated to 
show predicted genes, gene alignments and syntenic regions between species. This 
annotation was an essential prerequisite for the development of gene arrays for the 
analysis of genome-wide gene expression, such as the Affymetrix Canine GeneChip, 
which has probes to monitor over 18,000 canine mRNA/EST-based transcripts and over 
20,000 non-redundant predicted genes. By comparing the genome sequence against the 
1.5x partial poodle genome sequence and 100,000 sequence reads generated from nine 
other breeds of dog, a dense SNP map consisting of 2.5 million SNPs was formed. This 
SNP resource was the key requirement for the development of early high throughput SNP 
genotyping arrays such as the Affymetrix Canine Platinum sets v1 and v2, the Illumina 
CanineSNP20 beadchip, and most recently the Illumina CanineHD beadchip, which 
assays for over 170,000 genome wide SNPs and is most commonly used in today’s 
genome-wide association studies (GWAS).  
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1.4.4. Genome-wide association studies 
In the GWAS approach, case-control sample cohorts are collected and genotyped on high 
throughput genotyping arrays such as the Illumina CanineHD beadchip. Illumina 
beadchips consist of microscope slides that are covered in thousands of tiny wells, which 
are designed to hold 3 µm wide silicon beads. Each bead is covered in a clonal population 
of oligonucleotides, which act as specific capture probes for the SNP genotyping assays 
(Figure 1.1).  
 
 
Figure 1.1 The Illumina Infinium assay 
In the Infinium assay, genomic DNA is fragmented, annealed to bead bound probes and allele determined by 
detection of the dye-terminator nucleotide incorporated. 
 
The genomic DNA under investigation is whole genome amplified, fragmented and 
specifically hybridised to the bead bound oligonucleotide sequences. Annealed fragments 
then undergo a single base extension at the polymorphism loci, using a DNA polymerase 
and fluorescent dye terminator nucleotides. The identity of the incorporated base, which is 
dependent on the SNP allele, is identified by fluorescence.  
 
The genotyping data generated from SNP arrays is subjected to statistical testing known 
as allelic association analysis, with the null hypothesis that there is no significant 
difference in allele frequency between cases and controls for a particular SNP marker. 
Because of the huge number of SNP markers that are under investigation in GWAS 
approaches, there is a high probability that significant association signals are produced by 
chance. Permutation analysis is therefore often performed to adjust the results for multiple 
testing. Results that are significant at the 5% level after permutation testing are often 
referred to as being genome-wide significant.   
 
Careful selection of controls for GWAS is critically important to avoid the potential effects 
of population stratification. Population stratification refers to the variable level of 
relatedness of individuals within a cohort. Population stratification may have a negative 
impact on association studies when the individuals in the control group are from a different 
sub-population to those in the case group. Controls from a different population subset may 
be genetically different because of artificial selection or genetic drift, and will result in false 
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positive statistical signals being produced. The potential effects of population stratification 
can be avoided by using controls that are closely related to cases, but in situations where 
this is not possible computational methods exist to adjust for population stratification in 
datasets.   
1.4.5. Candidate gene studies 
Candidate gene studies can be performed when similar diseases occur in humans and 
dogs. In silico literature searches can be used to identify genes that are associated with 
disease in humans, and using the available online genome browsing facilities, canine 
orthologues of these genes can be found. Candidate genes can be investigated for their 
role in canine disease, typically by testing for association between closely linked markers 
and the disease under investigation. Microsatellite markers flanking candidate genes can 
be located directly from the genome sequence, and genotyped using PCR followed by 
capillary electrophoresis, to look for a pattern of linkage disequilibrium (LD) (Mellersh, 
2008, Mellersh et al., 2006). 
1.4.6. Linkage disequilibrium in the dog 
Linkage disequilibrium is defined as the non-random association of alleles at two or more 
loci, ie the region of shared haplotype around a particular genotype or a disease mutation. 
Dogs of the same breed show a high level of LD across the genome, which in some 
breeds is up to 100 times more extensive than in humans (Sutter et al., 2004). The 
extensive LD is the result of most breed populations being formed within the last 200 
years from small numbers of founding individuals. Gene mapping studies can be aided by 
extensive LD as broad shared haplotypes around the disease-associated mutation are 
often seen, making it easier to identify disease-associated critical regions in GWAS, as 
fewer markers need to be analysed. In some instances it is possible to find a disease-
associated region from very small numbers of starting cases and controls (Hillbertz and 
Andersson, 2006). The extent of LD in the dog does however present a more challenging 
task once the critical region for a disease has been isolated. Disease-associated regions 
are typically long, as a result of the extensive LD, and if the mapped critical region 
happens to be gene dense, prioritising candidate genes can be difficult. The challenging 
task of pinpointing precise causal mutations can be alleviated in some cases by utilising 
the close relationships which are present between many breeds. If related breeds suffer 
from clinically similar diseases, there is a high probability that the diseases have an 
identical genetic cause. Since the similar breeds diverged, independent recombination 
events will have occurred around the causal mutation, resulting in each breed having 
slightly different disease-associated haplotypes. The overlapping critical regions of the 
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different breeds can be combined to identify a single shared critical haplotype, helping to 
home in on the faulty gene. Examples of using breed relationships and overlapping 
regions of homozygosity to aid disease mapping include the studies of progressive rod-
cone degeneration (PRCD), a late-onset autosomal recessive photoreceptor disorder, and 
Collie eye anomaly, a complex ocular development disorder (Parker et al., 2007, Zangerl 
et al., 2006). Interestingly, Collie eye anomaly was initially mapped in 2003, but the causal 
mutation was not identified until 2007. Fine mapping the disease haplotype using the 
multi-breed approach, helped to reduce the critical region from an initial 3.9 Mb region to a 
691 kb region on chromosome 37. Even after fine mapping the disorder, no exonic 
mutations were found in the four known genes in the region. The causal mutation was 
eventually found to be a 7.8 kb deletion in a partially conserved intronic region.  
1.4.7. Complex disease mapping in the dog 
With the dog proving to be a useful model organism, the Lupa project was set up in 
January 2008 funded by the European Commission (Copeland et al., 2008). The aim of 
the Lupa project was to use canine genetics to unravel common human diseases such as 
cancer, cardiovascular disease, inflammatory disorders and neurological diseases. These 
diseases have traditionally been difficult to study in humans due to their genetic 
complexity and phenotypic heterogeneity. In the dog, cases are collected from genetically 
isolated breed populations and subjected to GWAS using SNP array technologies. The 
high frequency of particular disorders within certain breed populations allows for quick 
collection of case samples, and the reduced phenotypic and genetic heterogeneity 
between cases means that significant results can often be obtained with far fewer 
samples than in human studies. For example, there is a high incidence of histiocytic 
cancers in the Flat Coated Retriever and the Bernese Mountain Dog, allowing large 
sample cohorts to be collected in a reasonable timeframe. Dual investigation of the 
genetics of histiocytic cancers in these two breeds may help to unravel genes associated 
with cancer formation and also the effects of genetic background on tumour development 
(Hedan et al., 2011).   
 
The dog model could help in the study of epilepsy; a term which is used to cover a broad 
spectrum of complex neurological conditions. This heterogeneity makes it a particularly 
difficult disease to study in the human population, as each individual idiopathic epilepsy 
case may be caused by a number of mutations in several genes, all which have a small 
contribution towards the disease phenotype. This means that within a case-control cohort 
there could be many epilepsy genes represented, and as a result a huge number of 
samples would be required to give the study sufficient power. Because of the complexity 
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of human epilepsy, finding the underlying genetic causes is not possible on a case by 
case basis and the inroads that have been made to date have largely been made through 
the study of rare autosomal recessive epilepsy syndromes (Sanchez-Carpintero Abad et 
al., 2007, Steinlein, 2008). The genes identified as causal in these syndromes help to 
improve the understanding of the molecular pathways involved and can be screened for 
mutations in idiopathic epilepsy cases. Because dog breeds exist as genetically isolated 
populations, epilepsy in a single dog breed is likely to be less genetically complex with far 
fewer genes involved, meaning a much smaller number of samples would be required to 
map the associated genes. A recent success story is the identification of a novel epilepsy 
locus in the Belgian Shepherd, which is currently being sequenced with the hope of 
identifying a novel genetic risk factor (Seppala et al., 2012). Identification of an associated 
gene will provide a new candidate for human idiopathic epilepsy cases.   
1.5. The development of massively parallel sequencing techniques 
The development of new massively parallel sequencing techniques, nicknamed “next 
generation sequencing” (NGS), has revolutionised the speed at which large disease-
associated regions of the genome can be investigated. With NGS, genomic libraries are 
created consisting of millions of short strands of DNA, which are sequenced in parallel to 
produce enormous datasets. Sequencing of megabases of DNA from a single experiment 
is easily achievable, and is a huge advance on Sanger sequencing reactions which 
generate a maximum of around one kilobase of sequence data. The four main next 
generation sequencing platforms currently available are Illumina (Solexa), ABI SOLiD, 
Roche 454 and most recently Ion Torrent.  
1.5.1. Illumina sequencing 
Illumina sequencing is probably the most established next generation sequencing 
technology currently available. The technology has the greatest availability for outsourcing 
and is the machine that the Wellcome Trust Sanger Institute has most heavily invested in 
at their genome campus. 
 
Illumina sequencing technology originally stemmed from two companies; Lynx 
therapeutics, which developed a technique known as Massively Parallel Signature 
Sequencing (MPSS) (Brenner et al., 2000) and Solexa who developed solid phase 
sequencing using fluorescent reversible bases, now commonly known as sequencing by 
synthesis (SBS). In 2005 Solexa merged with Lynx therapeutic to form an international 
company, whose combined expertise culminated in the development of Solexa’s first SBS 
machine, the Genome Analyser.  
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This SBS machine was capable of generating 1 Gb of sequencing data in a single run, 
and subsequently Illumina have gone on to increase capacity through the development of 
the Genome Analyser IIx and the HiSeq 2000, which has the capacity to generate over 
600 Gb of sequencing data per run. In the fourth quarter of 2011 Illumina launched a 
benchtop machine, the MiSeq, marketed as a user friendly personal genome machine for 
use in smaller laboratories and for point of care work.  
 
Illumina sequencing is widely regarded as the most accurate massively parallel 
sequencing technology, although has not been able to produce the long reads obtainable 
through some other next generation platforms. Maximum read lengths for Illumina 
machines currently stand at 250 bp, however, chemistry to support 350 bp reads on the 
MiSeq platform is currently being developed, which is projected to become commercially 
available in the fourth quarter of 2013. 
 
Illumina sequencing experiments start with the preparation of a DNA sequencing library 
(Figure 1.2). The starting DNA, which may be genomic, plasmid, PCR amplicon or 
otherwise, is fragmented either enzymatically or mechanically before end repair and dA 
tailing reactions are carried out. A DNA adapter is then ligated to the ends of fragments 
allowing the fragments to be amplified and an index sequence incorporated if libraries are 
to be combined for multiplexed sequencing protocols.  
 
 
Figure 1.2 Stages of the Illumina DNA library preparation 
In the Illumina library preparation DNA is fragmented, end repaired and dA tailed. Adapters are ligated onto 
fragment ends, before amplification by PCR if required.  
 
The next stage of Illumina sequencing is to bind library fragments to the surface of a 
flowcell, for the generation of clonal clusters in a process known as bridge amplification. 
Flowcells have a lawn of oligonucleotides bound to their surface which are complementary 
to adapter sequences. As the sequencing library is passed across the surface, fragments 
randomly anneal to the bound oligonucleotides, before a process of bridge amplification 
occurs (Figure 1.3). Resulting clusters contain approximately 1,000 clonal sequences. 
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Cluster density is dependant on library concentration. If the concentration is too high 
clusters will be too close together resulting in mixed signals and sequencing inaccuracies. 
If the concentration is low data output will be low as a consequence. 
 
Figure 1.3 Cluster generation by bridge amplification. 
The generation of clonal clusters on flow cell surfaces by bridge amplification PCR (Shendure and Ji, 2008). 
 
On the completion of cluster formation the process of sequencing by synthesis can begin. 
Firstly reverse strands are cleaved to ensure that all sequenced strands are in the same 
orientation. A sequencing oligo is then bound to fragments and the SBS process is started 
by the addition of reversible dye terminator nucleotide bases (Figure 1.4). After a 
nucleotide is incorporated, clusters are excited by laser and photographed. The colour of 
the photographed cluster is dependant on the nucleotide base that is incorporated. The 
dye terminator groups are removed from the bases allowing the next dye terminator 
nucleotide to be incorporated and the process repeated up to 250 times to build the 
sequence of each cluster. 
 
 
Figure 1.4 Sequencing by synthesis 
On the surface of the flowcell a sequencing primer is annealed to bound fragments. Dye-terminator 
nucleotides are then incorporated and detected by fluorescence. Removal of the “block” between cycles 
allows the next dye-terminator nucleotide to be incorporated and identified. Several cycles are completed to 
enable the sequence of the fragments in the clusters to be determined.  
1.Introduction 
 
 
 
 
 
 
31 
Other applications of Illumina sequencing include RNA sequencing (RNA-seq) and 
chromatin immunoprecipitation sequencing (ChIP-seq). RNA sequencing can be used as 
a method of transcriptome sequencing, which may be total or just coding if messenger 
RNA is isolated before the library preparation. Library preparation is essentially similar in 
theory to the DNA library preparation, but includes a reverse transcription stage. RNA-seq 
can be used as an alternative method of expression analysis, and can also be used to 
help enhance genome annotation by filling in missing genes and improving accuracy of 
gene predictions, and has recently been suggested for the canine genome (Derrien et al., 
2012). Protocols are also available for the isolation of microRNAs and other small non-
coding RNAs. 
 
With ChIP-seq, protein-DNA interactions can be investigated, such as those seen 
between transcription factors and promoter DNA sequences. ChIP-seq works by binding 
and cross linking proteins to DNA sequences. Proteins are then captured by magnetic 
particle bound antibodies. The DNA strands bound to the capture protein are then 
unlinked, releasing them for sequencing. ChIP-seq may be a potential method of 
investigating the cause of gene down-regulation in complex disease studies. 
1.5.2. 454 sequencing 
The 454 sequencing technology is based on a technique known as pyrosequencing 
developed by Pål Nyrén in the 1990s (Ronaghi et al., 1996), and was introduced 
commercially in 2005 (Margulies et al., 2005). The pyrosequencing process relies on a 
three enzyme system consisting of DNA polymerase, sulfurylase and luciferase (Figure 
1.5). As the DNA polymerase incorporates a nucleotide, a phosphate group is released 
which is converted to ATP by the sulfurylase. The luciferase then catalyses the conversion 
of luciferin to oxyluciferin using the ATP generated, a reaction which releases a burst of 
light which can be measured.   
 
Figure 1.5 The pyrosequencing process 
As a nucleotide is incorporated by DNA polymerase a pyrophosphate group (PPi) is released, which is 
converted to ATP by sulfurylase. In the presence of ATP, luciferin is converted to oxyluciferin by luciferase, 
producing a burst of light.  
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Adenine, cytosine, thymine and guanine are added sequentially and cyclically to the 
reaction, with the intensity of the burst of light produced being proportional to the number 
of bases incorporated and can be used to calculate the sequence. 
 
The library preparation for 454 sequencing is essentially similar to the method used for 
Illumina sequencing. DNA is first fragmented and then short adapter sequences are 
added. Adapter linked fragments then undergo a process of emulsion PCR to produce 
clonal populations on bead surfaces in a process similar to bridge amplification, with 
individual fragments isolated in a bead containing droplet rather than on the surface of a 
flowcell (Figure 1.6). 
 
 
Figure 1.6 Emulsion PCR 
Emulsion PCR to produce a clonal population of a library fragment on the surface of a bead for 454 
sequencing (Shendure and Ji, 2008). 
 
Beads from the emulsion PCR process are pre-incubated with DNA polymerase and 
flooded onto a picotitre plate (PTP), with each well having a single bead capacity (Figure 
1.7). Bead immobilised sulfurylase and luciferase are also added to the wells. As reagents 
are flowed onto the PTP, the pyrosequencing reaction begins, with bursts of light being 
produced in wells where nucleotide bases have been incorporated.  
 
 
Figure 1.7 454 sequencing in picotitre plates (PTPs) 
Each well of the PTP is filled with a single clonally populated bead. As nucleotides are sequentially introduced, 
wells of the PTP light up if a base is incorporated, enabling the sequence to be determined.  
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The main advantage of 454 sequencing is the length of read that can be produced by the 
technique. Reads of 1,000 bp can be produced using the latest chemistry, although 454 
sequencers have difficulty accurately determining the length of homopolymer repeat 
sequences. There are currently two 454 systems on the market; these are the GS FLX+ 
which can generate 700 Mb of data in a single run, taking approximately a day, and the 
GS Junior, which can generate around 30 Mb of data in 10 hours.  
1.5.3. ABI SOLiD sequencing  
The Sequencing by Oligonucleotide Ligation and Detection (SOLiD) platform, uses a 
sequencing method first described by Shendue and colleagues in 1995 and developed by 
Agencourt Personal Genomics before they were acquired by Applied Biosystems in 1996 
(Shendure et al., 2005). The SOLiD system is unusual in the fact that nucleotide 
sequences are not identified consecutively and several rounds of sequencing using 
synthesis by ligation are required to build the consensus sequence of a particular strand. 
 
Library preparation for SOLiD sequencing requires DNA fragmentation and adapter 
linking, followed by a bead-based emulsion PCR approach. At the end of the emulsion 
PCR, bead attached amplicons are 3’ modified, allowing covalent bonding to the surface 
of a slide. Sequencing begins by annealing the first of five sequencing primers to the bead 
attached strands.  Eight nucleotide probes, consisting of two identifier bases, three 
degenerate bases and three universal bases linked to one of four different fluorescent 
tags, are then specifically ligated to the sequencing primer, depending on the template 
sequence. In total there are 16 identifier combinations and a total of 1,012 possible probes 
(two identifier bases + three degenerate bases = 45).  After the first probe has been 
incorporated and identified by laser, cleavage occurs between bases five and six to 
remove the universal bases and fluorescent tag, allowing the second probe to be 
incorporated. This sequencing by ligation process is repeated for several cycles. Base 
positions 1 and 2, 6 and 7, 11 and 12, etc, are identified in this round of sequencing, 
before the synthesised strand is removed and a second sequence primer is annealed at 
position (n-1). In the second round bases 0 and 1, 5 and 6, 10 and 11, etc, are read. A 
total of five rounds of sequencing by ligation are completed, with each nucleotide base 
being read twice to enable the sequence of the DNA strand to be determined (Figure 1.8). 
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Figure 1.8 SOLiD sequencing 
Probes consisting of two identifier bases (red), three degenerate bases (XXX) and three universal bases (ZZZ) 
are specifically incorporated at the priming site by ligation and detected by fluorescence. The universal bases 
are cleaved ready for the second cycle of ligation and detection. Several cycles are completed before removal 
of the synthesised strand and repetition of the process with four other sequencing primers at alternative start 
positions (green).  
 
The current SOLiD system is the 5500xl, which has maximum reads lengths of 75 bp and 
can generate up to 20 Gb of data per day.  
1.5.4. Ion Torrent sequencing 
The Ion Torrent platform is a non optical method of sequencing, which utilises semi-
conductor technology. Ion Torrent was launched in 2011, with a paper describing the 
methodology published by J. Rothberg and colleagues (Rothberg et al., 2011). Rather 
than relying on chemistry that requires the use of lasers to detect incorporated nucleotides 
such as the Illumina and SOLiD technologies, or the need for additional enzymatics in the 
case of 454 pyrosequencing, the Ion Torrent system works by detecting the shift in pH 
that naturally accompanies the incorporation of a nucleotide into a DNA sequence via the 
release of a hydrogen ion. 
 
Similar to other sequencing technologies, library preparation consists of DNA 
fragmentation followed by the addition of adapters to the fragment ends, which are then 
amplified onto beads in an emulsion PCR process. Beads containing clonally amplified 
products are then placed into the wells of a chip. Perfectly aligned underneath each well is 
an ion-sensitive field-effect transistor-based sensor (Figure 1.9) (Rothberg et al., 2011).  
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Figure 1.9 Ion Torrent sequencing 
Nucleotides are sequentially flooded across the sequencing chip. If the bases are incorporated hydrogen ions 
are released causing a shift in pH which is detected by the sensor. 
 
The simple chemistry of the Ion Torrent system allows for fast sequencing times and 
because the sequencing reactions and detection are done on the chip, different options on 
well capacity are available making sequencing reactions easily scalable to match 
requirements. Ion Torrent sequencing is also capable of producing long reads, but (like 
454 sequencing) is inaccurate over homopolymer tracts. 
 
Two machines are available for the Ion Torrent platform; the Personal Genome Machine 
(PGM) and the Ion Proton. The Ion Proton was launched in the first quarter of 2012, with 
the manufacturers aiming to launch a second version of the Proton sequencing chip 
(Proton II) capable of sequencing the human genome in one day. 
1.6. Target enrichment 
The amount of data produced by next generation sequencing is so vast that large 
genomic regions spanning several megabases can be sequenced in a single experiment. 
Generating a template of this size using standard PCR techniques is possible, but can be 
time consuming, expensive and technically difficult. With a need for fast and large-scale 
template generation in next generation sequencing, several array based and in-solution 
target enrichment techniques have been developed to allow specific capture of genomic 
regions (Mamanova et al., 2010). These include Roche Nimblegen SeqCap, Illumina 
TruSeq Enrichment Kits and Agilent SureSelect. Agilent, with their SureSelect system, 
were the first company to offer a custom in-solution kit, allowing capture designs to be 
tailored to the dog genome (Figure 1.10).  
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Figure 1.10 SureSelect target enrichment 
Library fragments hybridise with biotinylated RNA baits, which are captured by streptavidin coated magnetic 
bead. 
 
The great advantage of an in-solution kit is that capture experiments can be performed in 
the standard laboratory environment, without the need for specialist equipment. In-house 
sequencing library preparation is desirable as it is far more cost effective than 
outsourcing. Capture in the SureSelect system is achieved using a system of RNA based 
probes, also known as baits (Gnirke et al., 2009). Using the online tool, e-array, baits can 
be designed for specified regions of a genome, totalling up to 6.6 Mb (55,000 RNA baits of 
120 bp in length). The DNA library is prepared in a similar way to a standard method using 
fragmentation and the addition of adapter sequences to the ends. RNA baits, which are 
also biotinylated, are then hybridised to the library fragments to capture the sequences of 
interest. Biotinylated RNA baits which are hybridised to target DNA fragments are then 
selected for using streptavidin coated magnetic beads, which strongly bind to the biotin 
molecules, allowing unbound non-target fragments of the library preparation to be 
removed. RNA baits can then be digested to leave target fragments of DNA that can be 
amplified and used as a template for sequencing.  
 
Pre-designed capture enrichment products are also available including exome enrichment 
kits and cancer panel enrichment kits. Agilent technologies launched a canine exome 
capture kit in the fourth quarter of 2012 and although not commercially advertised is 
available on request. An alternative method to probe-based target enrichment is ultra-high 
multiplex PCR (Porreca et al., 2007). Custom kits for this method include the Illumina 
TruSeq Custom Amplicon kit and the Ion Ampli-seq kit.  
1.7. Summary 
It is an exciting time to be a molecular geneticist as the toolset of technologies available is 
rapidly expanding for both broad spectrum and canine specific applications. With these 
technological advances there is an inevitable increase in the complexity of techniques and 
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a considerable challenge is to select the most appropriate research methodology relevant 
to a particular disorder. In particular, smaller laboratories need to find ways to explore 
these techniques and optimise the procedures where possible to make them more 
financially and technically accessible. Use of the most up to date techniques is absolutely 
critical to ensure that any laboratory remains competitive with other groups within the 
same field and stays an attractive proposition in terms of collaborative work. Staying in 
touch with available technologies also helps to reduce the timescale of proposed work, 
increasing the chance of goals being reached on time. This may convince funding bodies 
that the group is at the forefront of research in the field and will give confidence that 
project aims are achievable, maximising the chance that a grant proposal will be 
accepted. 
 
Historically technological restrictions have meant that knowledge would flow in a single 
direction from the human to dog field, with the dog being a rather theoretical model. With 
the recent availability of new technologies, and the ability to adapt these technologies for 
use in canine genetics, the dog model is likely to become a more applied model for 
identifying novel genes that could shed light on human disease.   
1.8. Aims 
In this study molecular techniques have been used to investigate five inherited conditions 
afflicting four canine breeds. The study demonstrates how current research 
methodologies can be optimised to best suit the particular characteristics of each disease. 
The disorders investigated in this study included episodic falling (EF) and congenital 
keratoconjunctivitis sicca and ichthyosiform dermatosis (CKCSID), both in the Cavalier 
King Charles Spaniel (CKCS), spinocerebellar ataxia in the Italian Spinone (IS), cerebellar 
ataxia in the Parson Russell Terrier (PRT) and neonatal cerebellar cortical degeneration in 
the Beagle. The phenotypes under investigation demonstrated a wide variety of clinical 
signs, and had different ages of onset, progressions and prognoses. These factors meant 
that each disease had to be treated very much on an individual basis when investigating 
the molecular biology. The type of investigation performed also depended on the 
availability of samples and strength of diagnosis. For instance, when clinical signs were 
non-uniform between cases and diagnosis of disease was difficult because a spectrum of 
disease from a mild to more severe phenotype was displayed, then a greater case-control 
cohort was needed to gain significant results. 
 
Outsourcing of some work was unavoidable, where facilities were neither available at the 
University of Glasgow or the Animal Health Trust (AHT). However, wherever possible, the 
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aim was to perform the bench work and analysis in-house. This had the advantage of 
saving considerable amounts of money and also helped to improve understanding of the 
techniques being utilised and the results being obtained. Some techniques needed to be 
customised for in-house use. 
 
The conditions investigated are highly debilitating so any advances in the molecular 
genetics made as part of this study also helped the understanding of both canine and 
human forms of the diseases. Neurological diseases make up four of the five disorders 
under investigation. The nervous system is relatively inaccessible for investigative work 
and for treatment, so building an understanding of the molecular pathways involved in 
nervous system disease is vital and may aid the development of novel therapeutic 
approaches for treatment.  
 
The primary experimental aims of this study were to A) demonstrate the research 
methodologies available and to show how these could be best optimised to investigate the 
molecular biology of five different disorders in the dog, B) to attempt to identify the disease 
causing mutations in these disorders, and C) where the disease causing mutations were 
identified, to develop diagnostic tests for these disorders. 
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2.1. Definition of cases and controls 
2.1.1. Definition of EF cases 
Episodic falling cases were defined as dogs that were reported by their owner or 
veterinarian to have a clinical phenotype consistent with EF as described in the veterinary 
and scientific literature. Cases were confirmed in consultation with a veterinary 
neurologist, using video evidence where possible. Full neurological work-ups were also 
performed in some cases to rule out other possible causes of the clinical signs. There is 
no definitive way of diagnosing EF, and diagnosis is therefore made on presentation of a 
consistent clinical phenotype with exclusion of all other possible underlying causes. Age of 
onset was confirmed for all cases on DNA sample submission. 
2.1.2. Definition of CKCSID cases 
All cases of CKCSID were clinically assessed by a single veterinary ophthalmologist 
(Claudia Hartley). Diagnosis was based on the presentation of clinical signs consistent 
with previously seen cases and reports in the veterinary literature. Age of onset was 
recorded by Claudia Hartley for all confirmed cases. 
2.1.3. Definition of Italian Spinone spinocerebellar ataxia cases 
Cases of spinocerebellar ataxia in the Italian Spinone were diagnosed by a veterinary 
neurologist, based on clinical signs of ataxia presenting at 4 months of age and exclusion 
of all other possible causes by means of a neurological work-up. Age of onset was 
determined and recorded after consultation with dog owners once the clinical status had 
been determined by means of a neurological examination. 
2.1.4. Definition of Parson Russell Terrier spinocerebellar ataxia cases 
Cases of spinocerebellar ataxia in the Parson Russell Terrier were reported by owners, 
veterinarians or veterinary neurologists, and diagnosis made using the available 
veterinary notes and video footage, in consultation with a veterinary neurologist. Age of 
onset was determined by analysis of veterinary notes and by liasing with individual dog 
owners.  
2.1.5. Definition of Beagle neonatal cerebellar cortical degeneration cases 
A single case of Beagle neonatal cerebellar cortical degeneration was seen at the AHT 
which was diagnosed by Elsa Beltran and Dr Luisa De Risio when the dog was four 
weeks of age. Clinical signs of ataxia were consistent with previous reports in the 
veterinary literature. A full neurological work-up and histopathology ruled out other 
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possible causes and confirmed the diagnosis. A second case was diagnosed 
retrospectively after re-assessment of the reported clinical signs and cerebellum tissue 
histopathology.  
2.1.6. Definition of controls  
Controls were defined as individuals reported by owners as clinically normal. Individuals 
selected as controls for the episodic falling and Parson Russell Terrier ataxia studies were 
free from clinical signs and at least four years of age, with no history of suspected 
inherited disease. All controls were selected from the same breed group as the case 
individuals. Age of individual dogs on sample submission was recorded for all controls. 
Owners were contacted for a health update if DNA from their dog was to be used in an 
investigation, but the dog was less than four years of age on sample submission.  
2.2. Sample collection 
Genomic DNA samples were collected from the general pet dog population, either in the 
form of residual ethylenediaminetetraacetic acid (EDTA) blood, collected as part of a 
veterinary procedure, or by collection of buccal cells on cytology brushes. Genomic DNA 
was also extracted from formalin fixed paraffin embedded (FFPE) tissue for two IS ataxia 
cases and one neonatal cerebellar cortical degeneration case and from formalin fixed 
spleen for an additional IS cerebellar ataxia case.  
2.3. DNA extraction 
2.3.1. Extraction of DNA from whole blood 
Genomic DNA was extracted from whole blood using an adaption of the Nucleon BACC2 
genomic DNA extraction kit (Tepnal Life Science). In 50 ml tubes whole blood (<10 ml) 
and Reagent A (Appendix 1) were combined to a total volume of 50 ml. Tubes were mixed 
by inversion 20 times and centrifuged at 4,500 x g. Supernatants were removed and 
discarded, and an additional 25 ml Reagent A added to tubes, which were mixed by 
vigorous shaking for 20 seconds. White blood cells were pelleted by centrifugation at 
4,500 x g for 5 minutes. After removal of the supernatant, 2 ml of Reagent B (Appendix 1) 
were added to pellets, and incubated at 37°C for 16 hours to lyse cells. The lysis mixtures 
were transferred to 15 ml polypropylene tubes containing 800 µl 5 M sodium perchlorate 
solution and mixed by inversion 10 times. To the mix 2 ml of ice cold chloroform were then 
added, mixing by inversion 20 times. Phases were separated by centrifugation at 
4,500 x g for 5 minutes, before the upper aqueous phases were transferred to new 15 ml 
tubes. DNA was precipitated by addition of 5 ml of ice cold 100% ethanol. If a visible 
precipitate could be seen, the DNA was then spooled onto glass hooks, which were dried 
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for 5 minutes, before dissolving DNA into 300 µl tris-EDTA (TE) solution (Appendix 1). If 
no visible DNA precipitate could be seen tubes were centrifuged at 4,500 x g for 30 
minutes, supernatant removed, pellets washed in 70% ethanol and tubes re-centrifuged 
for 10 minutes at the same speed. The 70% ethanol was then removed, DNA dried at 
37°C for 1 hour, before rehydrating in 100 µl TE. DNA samples were stored at -20°C. 
2.3.2. Extraction of DNA from freshly frozen tissue samples 
Small sections of tissue (<100 mg) were dounce homogenised before addition of 2 ml of 
Nucleon Reagent B and 50 µl proteinase K (600 mAU/ml, solution) (Qiagen). Samples 
were incubated at 37°C for 16 hours to allow full digestion of the tissue. Proteins in the 
lysis mix were precipitated by addition of 800 µl sodium perchlorate and DNA purified 
using the chloroform method outlined in section 2.3.1.        
2.3.3. Extraction of DNA from buccal swabs 
Genomic DNA was extracted from buccal swabs using the QIAamp Midi kit (Qiagen). Up 
to 4 buccal swabs were placed in 15 ml tubes and 3 ml of lysis mix added, consisting of 
1 ml phosphate-buffered saline (PBS) (Appendix 1), 1 ml AL buffer (Qiagen) and 80 µl 
protease solution (Qiagen). Tubes were incubated at 56°C for 15 minutes, with occasional 
vortex mixing. To each tube 1.5 ml of 100% ethanol were added and mixed by shaking. 
Sample mixes were applied to QIAamp Midi columns, which were centrifuged at 1,850 x g 
for 3 minutes, discarding the flow-through. To wash the column filters 2 ml of Qiagen AW1 
were applied to the columns which were centrifuged at 4,500 x g for 1 minute, discarding 
the flow-through. A second wash was performed by applying 2 ml of Qiagen AW2 to each 
column and centrifuging at 4,500 x g for 15 minutes, discarding the flow-through. Columns 
were placed on new 15 ml tubes and 150 µl Qiagen AE buffer applied directly to the filter. 
Columns were incubated for 1 minute before centrifuging at 4,500 x g for 1 minute. The 
elution stage was repeated twice to maximise yield, giving a final elution volume of 
approximately 450 µl. 
2.3.4. Extraction of DNA from FFPE tissue 
Genomic DNA was extracted from FFPE tissue using the Nucleospin FFPE DNA kit 
(Macherey Nagel). Sections of embedded tissue were cut using a microtome. Samples 
were deparaffinised by adding 400 µl of paraffin dissolver and heating at 60°C for 3 
minutes, followed by immediate vigorous vortexing. To the cooled mixture 100 µl of buffer 
FL were added, followed by vigorous vortexing and centrifugation at 11,000 x g for 1 
minute. The upper organic layer was removed. To the sample 10 µl of proteinase K 
(2.5 U/mg) were added, mixed by pipetting and incubated at room temperature for 3 
hours. To de-crosslink the DNA 100 µl of D-link buffer were added to the samples, 
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incubated at 90°C for 30 minutes. Samples were allowed to cool to room temperature 
before addition of 200 µl of 100% ethanol, and vortex mixing of tubes. DNA was bound to 
a NucleoSpin FFPE DNA column by applying the mixture to the column, and centrifuging 
at 2,000 x g for 30 seconds. The column was washed twice by applying 400 µl buffer B5 
and centrifuging at 11,000 x g for 2 minutes, discarding the flow-through. The DNA was 
eluted by applying 20 µl of buffer BE directly to the membrane of the column and 
centrifuging at 11,000 x g for 2 minutes. Extraction of FFPE Beagle cerebellum tissue was 
performed by Louise Pettitt. 
2.4. DNA quantification 
Initial quantification of DNA was performed using a Nanodrop spectrophotometer (Thermo 
Fisher). Purity was assessed using 260/230 and 260/280 measurements. Accurate 
assessment of DNA concentration was performed using a Qubit Fluorometer (Invitrogen). 
For high throughput accurate quantification Picogreen methodology was adopted. For 
Picogreen quantification DNA samples were diluted in TE to between 500 and 1,500 pg/µl 
based on Nanodrop spectrophotometry results. In a transparent low profile PCR plate 10 
µl of diluted DNA were combined with 10 µl of 1x Picogreen reagent (concentration not 
specified by manufacturers) (Invitrogen) and mixed by pipetting. Plates were sealed using 
qPCR sealing film (Thermo Scientific). DNA standards of 0, 400, 800, 1,200, 1,600 and 
2,000 pg/µl were made by diluting a λ DNA standard in TE buffer (both Invitrogen). Plates 
were analysed on a Quantica qPCR machine (Techne). Analysis to assess the molecular 
weight of the DNA (100 ng) was performed by 1% agarose gel electrophoresis. 
2.5.   Standard PCR 
Standard PCR was carried out in 12 µl reactions consisting of 0.2 mM dNTPs (NEB), 1x 
PCR buffer (Qiagen), 0.5 µM forward primer, 0.5 µM reverse primer, 0.5 units HotStarTaq 
plus DNA polymerase (Qiagen), template DNA/cDNA and ultrapure water to a volume of 
12 µl. For PCR of GC rich amplicons, Q solution (Qiagen) was also added to a final 1x 
concentration. Cycling parameters for standard PCR were 95°C for 10 minutes, followed 
by 35 cycles of 95°C for 30 seconds, 57°C for 30 seconds and 72°C for 60 seconds, and 
completed with a final elongation stage of 72°C for 10 minutes. Primer sequences are 
shown in Appendix 2. 
2.6. Agarose gel electrophoresis 
For standard 1.5% agarose gel electrophoresis, 1.5 g of agarose were added to 100 ml of 
1x tris-acetate-EDTA (TAE) buffer. Solutions were heated in a microwave on full power 
(800 W) for 2 minutes to dissolve agarose. Liquid gels were cooled to ~60°C before 
addition of 2 µl of 10 mg/ml ethidium bromide solution (Gibco) and cast into a sealed 12 x 
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14 cm tray with an appropriate comb inserted. Set gels were placed into a tank filled with 
1x TAE, combs removed and DNA solutions containing 20% loading buffer loaded into 
wells. Gels were run at 100 V for 1 hour and DNA bands visualised using a UV 
transilluminator.  
2.7. QIAquick PCR product and gel extract purification 
PCRs were diluted in 5 volumes of buffer PB (Qiagen). Agarose gel slices were dissolved 
in 3 volumes of buffer QC (Qiagen) at 50°C for 10 minutes, before adding 1 volume of 
isopropanol. Dissolved gel extracts/PCRs were mixed well before applying to QIAquick 
columns (Qiagen) which were centrifuged at 17,000 x g for 1 minute, discarding the flow-
through. Residual agarose was removed by applying 500 µl buffer QC to gel extract 
columns and centrifuging for 1 minute at 17,000 x g, discarding the flow-through. Columns 
were washed by applying 600 µl buffer PE (Qiagen) and centrifuging for 1 minute at 
17,000 x g. Columns were placed on new collection tubes and re-centrifuged for 3 
minutes at 17,000 x g to remove any residual ethanol. Purified DNA was eluted by placing 
columns on 1.5 ml tubes, applying 50 µl buffer EB (Qiagen) and centrifuging at 17,000 x g 
for 1 minute.  
2.8. Multiscreen PCR product purification 
To purify PCR products for Sanger sequencing, Multiscreen PCR purification plates 
(Millipore) were used. Reaction volumes were adjusted to 200 µl by addition of ultrapure 
water and loaded into wells of the Multiscreen plate. Plates were placed on a manifold and 
a vacuum of -10 psi applied using a pump to draw liquid through the wells until the 
nitrocellulose membranes were completely dry. The pump was turned off and 20 µl of 
ultrapure water applied to the wells, which were incubated at room temperature for 2 
minutes to dissolve the DNA.       
2.9. Sanger sequencing 
Cycle sequencing was performed in 6 µl reactions consisting of ~30 ng purified PCR 
product template, 0.5 µl Big Dye v3.1 (Applied Biosystems), 1 µl of SBDD buffer, 0.27 µM 
forward or reverse oligo, and ultrapure water. Sequencing thermal cycling parameters 
were 96°C for 30 seconds, followed by 44 cycles of 92°C for 4 seconds, 55°C for 4 
seconds and 60°C for 90 seconds. Sequencing products were precipitated by the addition 
of 60 µl of 80% isopropanol to wells, followed by centrifugation at 4,500 x g. Supernatants 
were discarded and pellets washed by applying 100 µl of 60% isopropanol to wells, and 
the plate centrifuged at 4,500 x g for 10 minutes. Supernatants were discarded and the 
plate centrifuged at 150 x g upside-down onto tissue paper for 1 minute to remove any 
large remaining droplets of supernatant. Sequencing plates were placed at 37°C for 30 
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minutes to fully dry and purified reactions resuspended in 10 µl of HiDi Formamide 
(Applied Biosystems). Sequencing fragments were separated and detected using 
ABI3130xl genetic analysers using the parameters stated in Appendix 3 and data 
analysed using Staden Gap software version 4 (Bonfield et al., 1995). 
2.10. RNA extraction 
RNA was extracted from skin, footpad, cerebellum tissue, and buccal cells using the 
Qiagen RNeasy Mini kit. Up to 20 mg of tissue were added to 600 µl of RLT buffer 
(Qiagen) containing 1% beta-mercaptoethanol (Sigma-Aldrich) and disrupted using a 
mortar and pestle. Complete homogenisation of samples was achieved using 
QIAshredder columns (Qiagen). Tissue lysates were centrifuged for 3 minutes at 17,000 x 
g and supernatants transferred to new microcentrifuge tubes. To the lysates 600 µl of 70% 
ethanol were added, which were mixed immediately by pipetting. RNeasy columns were 
loaded with 600 µl of the extracts and centrifuged for 15 seconds at 8,000 x g. Flow-
through was discarded and a further 600 µl of each sample were applied and the columns 
re-centrifuged. Columns were washed by applying 700 µl of buffer RW1 (Qiagen) and 
centrifuging at 8,000 x g for 15 seconds, discarding the flow-through. Two further washes 
using 500 µl of buffer RPE (Qiagen) were performed using the same method. Columns 
were placed on a fresh waste collection tube and centrifuged at 17,000 x g for 3 minutes 
to completely dry the column membranes. The RNA on the columns was eluted using 50 
µl of RNase-free water, applied directly onto the silica membranes, and columns 
centrifuged for 1 minute at 8,000 x g. The RNA-containing flow-through was passed 
through the columns a second time to increase the final yield and concentration. 
2.11. Reverse transcription 
A mixture of 1 µl 500 µg/ml Oligo (dT)15 (Promega), 10-200 ng total RNA, 1 µl of 10 mM 
dNTP mix (Amersham) and ultapure water to a total volume of 12 µl were incubated on a 
thermal cycler at 65°C for 5 minutes and chilled on ice. To the mix 2 µl of 5x first strand 
buffer (Invitrogen), 2 µl of 0.1 mM DTT (Invitrogen) and 1 µl of RNasin (Promega) were 
added, gently mixed by pipetting and heated at 42°C for 2 minutes. To start the reaction 
1 µl of SuperScript II Reverse Transcriptase (200 U/µL) (Invitrogen) was added and mixed 
by pipetting. The contents were incubated at 42°C for 50 minutes, followed by inactivation 
at 72°C for 15 minutes. To remove RNA complementary to the cDNA 1 µl of RNase H 
(Invitrogen) was added to the mixture, which was incubated at 37°C for 20 minutes. 
Targeted regions of the cDNA were amplified using the standard PCR protocol. 
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2.12. Rapid amplification of cDNA ends (RACE) 
Amplification of 5’ ends was performed using the Roche 5’ RACE kit, 2nd generation. First 
strand cDNA synthesis was performed using a gene specific primer (GSP), followed by 
degradation of complementary RNA by RNaseH activity. The cDNA was purified using the 
High Pure PCR purification kit (Roche) according to the manufacturer’s instructions. The 
cDNA was then tailed with dATP and TdT with a recombinant terminal transferase, 
allowing PCR with an oligo(dT) anchor primer and a nested GSP. A second nested PCR 
was performed using an anchor primer and an internal GSP. PCR products were Sanger 
sequenced. 5’ RACE reactions were carried out by Louisa Hayward. Amplification of 3’ 
ends was carried out using the Clontech SMARTer RACE cDNA amplification kit. First 
strand synthesis was carried out using 3’-RACE CDS Primer A (Tailed and anchored oligo 
(dT)30). The 3’ ends were amplified using 2 µl RACE ready cDNA, using a standard PCR 
protocol with a GSP and the SMARTer universal primer mix. 
2.13. Episodic falling candidate gene selection   
Candidate genes were selected by in silico searching of the literature for diseases 
belonging to the muscle hypertonicity category using the PubMed scientific literature 
searching facility (PubMeb National Center for Biotechnology Information, U.S., 2010) and 
Online Mendelian Inheritance in Man. Genes were identified as good candidates based on 
their association with muscle hypertonicity or due to their gene function. A list of candidate 
genes is shown in Table 2.1. 
Table 2.1 Candidate genes for EF 
Gene Human Condition or Gene Function 
ATP2A1 Recessive Brody myopathy 
CACNL1A3 Dominant hypokalemic periodic paralysis 
CLCN1 (CIC1) Myotonia congenita 
GLRA1 Hyperekplexia 
GLRA3 Glycine receptor subunit alpha-3 precursor 
GLRB Hyperekplexia 
GPHN  Hyperekplexia 
KCNE3 Thyrotoxic hypokalemic periodic paralysis 
SCN4A Non-dystrophic myotonia 
SLC32A1 Vesicular inhibitory amino acid transporter (GABA and glycine transporter) 
SLC6A5 Hyperekplexia (sodium- and chloride-dependent glycine transporter 2 (GlyT2)) 
SLC6A9 Sodium- and chloride-dependent glycine transporter 1 (GlyT1) 
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2.14. Microsatellite genotyping 
2.14.1. Microsatellite identification and primer design 
Canine orthologues of the human genes were identified using the Ensembl genome 
browser (www.ensembl.org). Dinucleotide repeat microsatellite markers were searched for 
in the 400 kb of sequence surrounding each gene. Primers for microsatellite amplification 
were designed using the online tool Primer3 (http://frodo.wi.mit.edu/) (Rozen and 
Skaletsky, 2000). At the 5’ end of the forward primers, an 18 bp tail sequence 
(TGACCGGCAGCAAAATTG) was added to allow the amplification of a 5’ fluorescently 
labelled “third primer” of the same 18 bp sequence for visualisation of products on 
ABI3130xl genetic analysers (Oetting et al., 1995).  
2.14.2. PCR amplification of microsatellites using tailed primers 
Microsatellites were amplified by PCR. Reactions consisted of 0.2 mM dNTPs (NEB), 1.5 
mM MgCl2 (Applied Biosystems), 1x PCR Gold buffer (Applied Biosystems), 0.17 µM 
forward primer with 18 bp extension, 0.42 µM reverse primer, 0.5 µM fluorescently 
labelled (6FAM, VIC, NED or PET) third primer, 1.2 units AmpliTaq Gold DNA polymerase 
(Applied Biosystems) and ultrapure water to a volume of 12 µl. Cycling parameters are 
listed in Appendix 4. 
2.14.3. Genotyping by capillary electrophoresis 
Genotyping of microsatellite markers was performed by capillary electrophoresis. On a 
non skirted PCR plate, 1 µl of PCR product was combined with 10 µl HiDi formamide 
(Applied Biosystems) containing 5% Rox 400HD size standard (Applied Biosystems). 
Double stranded products were denatured by heating at 95°C for 1 minute before chilling 
on ice. Plates were run on ABI3130xl genetic analysers using parameters stated in 
Appendix 3 and results visualised and analysed using ABI Genemapper software. 
2.15. Genome scanning 
2.15.1. Homozygosity mapping 
Genome scanning for the IS spinocerebellar ataxia study was performed by homozygosity 
mapping using 6 cases and 6 obligate carriers (parents of affected individuals). The 
genome-wide set of markers used for homozygosity mapping consisted of ~300 genome-
wide microsatellites arranged in multiplex panels of between 3 and 10 markers for PCR. 
Forward primers were fluorescently tagged to allow separation and visualisation of 
products by capillary electrophoresis. PCRs were performed in 17 µl volumes consisting 
of 1x PCR Gold buffer (Applied Biosystems), 2.5 mM MgCl2 (Applied Biosystems), 
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0.15 mM dNTPs (NEB), 1.75% DMSO (Sigma Aldrich), 0.65 units AmpliTaq Gold DNA 
polymerase (Applied Biosystems) and 10-20 ng of genomic DNA. Cycling parameters are 
listed in Appendix 4. Products were separated by capillary electrophoresis on ABI3130xl 
genetic analysers and genotypes analysed and scored using Genemapper v4.0. 
2.15.2. Fine mapping 
Fine mapping was performed using microsatellite markers surrounding the boundaries of 
the disease-associated haplotype. Microsatellites were identified using the Ensembl 
genome browser and genotyped as described in section 2.14. Additional fine mapping 
was performed by SNP analysis at the boundaries of disease-associated regions. The 
disease-associated genomic regions were interrogated for SNPs using the BioMart 
database in Ensembl. Genotyping of SNPs was performed by PCR followed by Sanger 
sequencing. 
2.15.3. Linkage analysis 
Linkage analysis was used to confirm homozygosity mapping results. An extended IS 
pedigree was drawn in Cyrillic and later Progeny software packages. Two-point linkage 
analysis was performed using MLINK (part of the LINKAGE software package) (Lathrop 
and Lalouel, 1984). 
2.15.4. Genome-wide SNP analysis 
A total of 96 DNA samples were prepared for the first batch of genotyping on the Illumina 
CanineHD SNP array. The DNA samples were from 31 EF cases, 19 CKCSID cases and 
39 CKCS controls. Four additional CKCSs with a CKCSID-like phenotype were included 
(2 CKCSs with a dry eye phenotype and 2 CKCSs with rough coat phenotype). One 
previously genotyped Golden Retriever DNA was included as a genotyping control and 
two Italian Spinoni were genotyped for fine mapping and copy number variation analysis. 
The second batch of samples for genotyping on the Illumina CanineHD SNP array 
consisted of 16 cases and 16 controls for the Parson Russell Terrier ataxia project.  
 
The concentration of the DNA samples was initially measured using a Nanodrop 
spectrophotometer. Samples with concentrations lower than 50 ng/µl were concentrated 
using Multiscreen PCR purification plates as described in section 2.8. Samples with a 
260/280 or 260/230 of lower than 1.70 were selected for re-extraction using the Nucleon 
procedure (Section 2.3.1.). Final quantification of DNA was performed using PicoGreen 
(Section 2.4.).  
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DNA samples were sent to the Cambridge Genome Service, Department of Pathology, 
University of Cambridge, for processing on the Illumina CanineHD SNP genotyping array, 
comprising 173,662 genome-wide SNPs. 
2.15.4.1. Raw SNP genotyping data quality control and handling 
Raw SNP genotyping data were visualised in the Genome Studio software package 
(Illumina). SNPs were re-clustered to improve call rates. SNPs were then sorted by cluster 
separation, call frequency, mean normalised intensity of the heterozygous cluster and 
normalised theta value (relative location) of the heterozygous cluster. Cluster boundaries 
were then adjusted to improve the call rate for the SNP or if the clusters were poorly 
defined the SNP was zeroed. Quality checked and edited SNP genotyping data were 
exported from Genome Studio and imported into the pedigree drawing programme 
Progeny. In Progeny cases and control sets were assigned and SNP genotyping data 
exported in a format accepted by the statistical package PLINK (Purcell et al., 2007). 
2.15.4.2. SNP analysis 
Allelic association analysis of SNP genotyping data were performed in the statistical 
package PLINK. Binary files were initially made to define the SNP set. Samples with a 
genotyping call rate of less than 90% (mind 0.1) were excluded. Any SNPs with a 
genotyping call rate of less than 95% (geno 0.05) and a minor allele frequency of less 
than 5% (maf 0.05) were removed. Binary file preparation was performed by implementing 
the following command in Linux: 
 
> plink --noweb --dog --allow-no-sex --file (file name) –-make-founders  
--make-bed --mind 0.1 --maf 0.05 --geno 0.05 -- out (name) 
 
Allelic association analysis was performed using the following command: 
 
> plink --noweb --dog --allow-no-sex --bfile (binary file name) --assoc -
- out (name) 
 
Allelic association analyses were corrected for multiple testing using the Max(T) 
permutations procedure, with the number of permutations set to 100,000 using the 
command --mperm 100000. 
 
Quantile-quantile (QQ) plots, of observed versus expected probability values, were 
constructed to assess datasets for genomic inflation. A value for genomic inflation was 
also obtained by including the --adjust command. Data points were plotted in Excel.  
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> plink --noweb --dog --allow-no-sex --bfile (binary file name) –-assoc -
-adjust --qq-plot --log10 –-out (name) 
 
Multidimensional scaling (MDS) plots were constructed to assess the relatedness of 
individuals used in GWAS. Data points, which were subsequently plotted on a graph using 
Excel, were calculated using the following command.  
 
> plink --noweb --dog --allow-no-sex --bfile (binary file name) --cluster 
--mds-plot 2 --out (name) 
 
Data sets with high genomic inflation values, as indicated by QQ plotting and separated 
case and control clusters in MDS plots were adjusted for population stratification using the 
Fast Mixed Model (FMM) (Astle and Balding, 2009). Files in PLINK format were converted 
to FMM format using a Perl script written by Dr Mike Boursnell, which was implemented in 
Linux. The FMM was then executed in the ‘R’ package for Linux. 
2.16. Massively parallel sequencing 
2.16.1. Target enrichment by long range PCR 
The template for sequencing the entire ITPR1 gene was generated by long range PCR, 
using a high fidelity DNA polymerase. Reactions consisted of 0.2 mM dNTP mix 
(ABgene), 1x HF PCR buffer (or 1x GC buffer when amplifying GC rich sequences), 0.5 
µM forward primer, 0.5 µM reverse primer, 1 unit Phusion hot start polymerase 
(Finnzymes), 20 ng genomic DNA and ultrapure water to a final volume of 50 µl. Cycling 
parameters are listed in Appendix 4.  Genomic regions which failed to amplify with the 
high fidelity polymerase, such as AT or GC rich regions were amplified using standard 
PCR. 
 
A 10% sample of each PCR product was analysed using 1.5% agarose gel 
electrophoresis, to verify product size and assess the reaction specificity. PCR products 
were purified using Multiscreen PCR purification plates (section 2.8) and DNA quantified 
using a Nanodrop spectrophotometer. Purified PCR products were run on a 1% agarose 
gel as a final check of concentration and for artefact band consideration. The 60 PCR 
products forming the contiguous template for sequencing were combined to form an 
equimolar mixture which was Nanodrop quantified and 1,320 ng (40 µl at 33 ng/µl) were 
sent to Fasteris Life Science for library preparation.  
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2.16.2. DNA fragmentation methods for sequencing library preparation 
Sonication, nebulisation, enzymatic and Covaris methods of DNA fragmentation were 
investigated for sequencing library preparation, and results analysed by running DNA on a 
1% TAE agarose gel.     
2.16.2.1. Sonication 
Genomic DNA was sonicated using an adaption of the method described by J. Sambrook 
(Sambrook, 2001). Sonication was performed using 100 µl of DNA (50 ng/µl) at full 
amplitude, for either 10, 15 or 20 cycles of 20 seconds on followed by 20 seconds off, 
using a Misonix XL 2020 Ultrasonic Liquid Processor (cup horn arrangement). The tubes 
containing the DNA were held in an ice bath during sonication. The sonicator was tuned 
according to the manufacturer’s instructions before use.  
2.16.2.2. Nebulisation 
Nebulisers (Invitrogen) were assembled by inserting the provided vinyl tubing over the 
central atomiser, as illustrated in Figure 2.1. The DNA solution was made by adding 5 µg 
of stock DNA in 50 µl TE to 700 µl nebulisation buffer (TE containing 50% glycerol). The 
DNA solution was mixed and placed in the nebuliser and the lid screwed on, before 
placing on ice to chill. Using compressed nitrogen, a pressure of 24 psi was applied to the 
unit for 10 minutes. The DNA solution was recovered from the sides of the nebuliser by 
centrifugation at 450 x g. Recovered DNA was purified using a Qiagen QIAquick PCR 
purification column, with an elution volume of 30 µl.  
 
Figure 2.1 Arrangement of apparatus for nebulisation of DNA 
As pressure is applied the solution is forced up the tubing and out of the central atomiser, shearing the DNA.  
 
2.16.2.3. Enzymatic fragmentation 
This approach used DNA Fragmentase (New England Biolabs) to fragment genomic DNA. 
Genomic DNA (5 µg) was combined with 10 µl Fragmentase reaction buffer, 1 µl 100x 
BSA (10 mg/ml) and ultrapure water to a final volume of 90 µl. The mix was vortexed 
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thoroughly and incubated on ice for 5 minutes. To the reaction mix 10 µl dsDNA 
Fragmentase enzyme solution was added and vortexed thoroughly, before incubating at 
37°C for 30 minutes in a water bath. The reaction was stopped by the addition of 5 µl of 
0.5 M EDTA. Digested DNA was purified using a Qiagen QIAquick PCR purification 
column, with an elution volume of 30 µl. 
2.16.2.4. Covaris shearing 
Covaris shearing of DNA using adaptive focused acoustics was performed by the Eastern 
Sequence and Informatics Hub. Settings for Covaris shearing are shown in Table 2.2. 
Table 2.2 Covaris settings for DNA fragmentation 
Setting Value 
Duty cycle 10% 
Intensity 5 
Cycles or Burst 200 
Time 6 cycles of 60 seconds each 
Temperature 4°C  
 
2.16.3. End repair of fragmented DNA 
End repair was performed using the NEBnext end repair module, by combining 30 µl of 
fragmented DNA with 10 µl end repair buffer, 5 µl NEBnext repair enzyme mix and 
ultrapure water to a final volume of 100 µl. Reactions were incubated on a thermal cycler 
at 20°C for 30 minutes. For repair of DNA fragmented using NEB DNA Fragmentase, 1 µl 
of E.coli DNA ligase was also added to the mix. Repaired DNA was purified using a 
Qiagen QIAquick PCR purification kit, eluting in 37 µl of buffer EB. 
2.16.4. dA tailing of repaired DNA fragments 
Fragment dA tailing was performed using the NEBnext dA tailing module, by combining 37 
µl end repaired blunt DNA, 5 µl NEBnext dA-tailing reaction buffer (10x), 3 µl Klenow 
fragment (5,000 units/ml) (3’ to 5’ exo-), and 5 µl ultrapure water. Reactions were 
incubated on a thermal cycler for 30 minutes at 37°C. DNA was purified using a Qiagen 
QIAquick PCR purification kit, eluting in 25 µl of buffer EB. 
2.16.5. Adapter ligation to dA tailed DNA library 
DNA adapters for the multiplexed pair end module were made by annealing the Illumina 
adapter oligonucleotides, which were synthesised and HPLC purified by Integrated DNA 
Technologies. In a 96 well microplate 15 µl of each adapter oligonucleotide (100 µM) were 
mixed and heated on a thermal cycler at 95°C for 2 minutes, followed by cooling at 0.1° 
per second to 25°C. The double stranded adapter was then snap cooled on ice and 
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diluted to 15 µM by the addition of 70 µl TE buffer. Adapters were stored at -20°C and 
thawed on ice when used.  
 
Adapter ligation was performed using the NEBnext quick ligation module, by combining 
25 µl of dA tailed DNA, 10 µl quick ligation reaction buffer (5x), 10 µl of 15 µM DNA 
adapters and 5 µl quick T4 DNA ligase (400,000 units/ml), and incubating on a thermal 
cycler at 20°C for 15 minutes. DNA was purified using a Qiagen QIAquick PCR 
purification kit, eluting in 15 µl of buffer EB. 
2.16.6. Gel size selection of adapter ligated library 
To the adapted fragments 2 µl of gel loading buffer were added and the entire sample run 
on a 2% Microsieve Low Melt agarose gel (Flowgen) containing 0.3 µg/ml ethidium 
bromide, alongside a 100 bp ladder (NEB). Fragments in the 200 to 300 bp range were 
excised from the gel and purified using the QIAquick Gel extraction kit, eluting in 32 µl of 
buffer EB. 
2.16.7. Amplification of adapted DNA library by PCR 
Size selected fragments were amplified using Finnzymes Phusion DNA polymerase 
(Thermo-Fisher). Reactions contained 3 to 25 ng of template DNA, 1x Phusion mastermix, 
Illumina primer InPE 1.0 and Illumina index primer at a final concentration of 0.5 µM, and 
Illumina primer InPE 2.0 at a final concentration of 0.01 µM. Reactions were made up to a 
final volume of 50 µl with ultrapure water. Cycling parameters are listed in Appendix 4. 
PCR products were purified on a QIAquick PCR purification column and DNA eluted in 
50 µl of EB.  
2.16.8. SureSelect target enrichment 
The SureSelect target enrichment system was used to enrich DNA sequencing libraries 
for genomic regions of interest, in a process of capture by hybridisation using custom RNA 
baits. Two enrichment experiments were carried out. Slightly different methods were 
adopted due to a change in kit reagents and the introduction of a Covaris service at the 
Eastern Sequencing and Informatics Hub, both of which became available for the second 
target enrichment experiment. 
2.16.8.1. RNA bait design for SureSelect target enrichment 
RNA baits were designed for the SureSelect target enrichment system using the online 
tool, e-array (https://earray.chem.agilent.com/earray/). Tiling of baits was set to 2x, and 
repeat sequences were masked during the design process. 
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2.16.8.2. SureSelect target enrichment library preparation 
For the first SureSelect experiment genomic DNA was fragmented using the enzymatic 
procedure outlined in section 2.16.2.3. Library end repair, dA tailing and adapter ligation 
reactions were carried out as detailed in sections 2.16.3. to 2.16.5. Size selection was 
performed as outlined in 2.16.6. The second SureSelect experiment used an enzymatic 
approach for fragmenting DNA from whole blood samples and Covaris shearing for 
fragmenting DNA from buccal swabs. End repair, dA tailing and adapter ligation reactions 
were performed using additional reagents added to the SureSelect kit, comparable to 
those found the NEBnext library preparation kit. 
2.16.8.3. Pre-hybridisation amplification of libraries  
Adapter ligated libraries were subjected to pre-hybridisation amplification reactions for use 
in the SureSelect procedure. Reactions were performed in 50 µl volumes consisting of 
15 µl adapter ligated library, 21 µl nuclease-free water, 1.25 µl InPE primer 1.0 (25 µM), 
1.25 µl SureSelect Indexing Pre-Capture PCR primer (25 µM), 10 µl Herculase 5x reaction 
buffer (Agilent), 0.5 µl dNTP mix (provided with Herculase polymerase) and 1 µl 
Herculase II polymerase (concentration not specified by manufacturer) (Agilent). Thermal 
cycling parameters are listed in Appendix 4. Reactions were purified using AMPure XP 
beads. 
2.16.8.4. Agencourt AMPure XP bead DNA clean-up   
At room temperature AMPure beads (Beckman Coulter) were homogenised by vigorous 
shaking of the stock bottle, before combining 90 µl with a 50 µl reaction mix in a 1.5 ml 
microtube. Tubes were then mixed and incubated at room temperature for 5 minutes, 
before placing on a magnetic stand to separate. The cleared solution was discarded and 
beads washed twice with 70% ethanol, allowing the beads to settle for 2 minutes before 
ethanol removal. Bead containing tubes were then removed from the magnetic stand and 
dried for 5 minutes at 37°C, before addition of 10 µl nuclease free water. Tubes were 
vortex mixed and placed back on the magnetic stand for bead separation and removal of 
the supernatant containing the purified DNA.  
2.16.8.5. Assessment of pre-hybridisation libraries 
Pre-capture libraries were quantified using a Qubit fluorometer, normalised to 147 ng/µl, 
and checked for expected size range by 2% agarose gel electrophoresis. One library was 
also outsourced to Cambridge Genomic Services for analysis on the Agilent Bioanalyser 
DNA 12000 Series II chip, for size checking purposes.  
2.16.8.6. Hybridisation 
SureSelect hybridisation buffer was assembled according to the manufacturer instructions 
and heated to 65°C for 5 minutes to prevent precipitate formation. In a 1.5 ml microtube 
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5 µl of SureSelect bait library and 2 µl of 25% RNase block were combined and placed on 
ice. To a 96 well PCR plate (row B) 3.4 µl of DNA library at a concentration of 147 ng/µl 
were added, combined with 5.6 µl SureSelect block mix, heated at 95°C for 5 minutes and 
then held at 65°C on a thermal cycler with the heated lid set to 105°C. Whilst holding the 
temperature at 60°C, 40 µl of hybridisation buffer were added to row A, the plate resealed 
and temperature held at 65°C for a further 5 minutes. To row C 7 µl of bait library were 
added, the plate resealed and heated for a further two minutes. Maintaining the 
temperature at 65°C, 13 µl of hybridisation mix were swiftly taken from row A and placed 
in row C, mixing by pipette. Without delay, the entire 8 µl of the DNA library mix was 
transferred to row C, mixed by pipetting and the plate sealed with two layers of thermal 
sealing film. The hybridisation mixture was incubated for 24 hours at 65°C. 
2.16.8.7. Streptavidin bead capture 
For each capture a 50 µl volume of Dynal magnetic streptavidin bead solution (Invitrogen) 
was added to a 1.5 ml microtube. Beads were washed by adding 200 µl SureSelect 
binding buffer and vortexing tubes for 5 seconds. Tubes were placed on a magnetic rack 
and beads allowed to settle before removing and discarding the supernatant. Beads were 
washed 3 times, before being resuspended in 200 µl of SureSelect binding buffer. 
 
After the 24 hour incubation period at 65°C, the hybridisation mixture was pipetted directly 
off the plate and into the streptavidin bead solution, inverting 5 times to mix. Tubes were 
placed on a rotary mixer held at a 45 degree angle to mix for 45 minutes at room 
temperature, and pulse centrifuged. Beads were separated by placing tubes on a 
magnetic rack and the supernatant removed. Beads were washed using 500 µl 
SureSelect wash buffer #1, incubating at room temperature for 15 minutes with occasional 
vortexing. After pulse centrifuging, tubes were placed on a magnetic rack to separate the 
beads and the supernatant was removed. The second washing stage consisted of bead 
resuspension in 500 µl SureSelect wash buffer #2 (prewarmed to 65°C) and placing tubes 
on a heat block at 65°C for 15 minutes with occasional vortexing. Beads were separated 
on a magnetic rack and all the supernatant was carefully removed. The second washing 
stage was repeated twice.  A 50 µl volume SureSelect elution buffer was then added to 
the beads, which were vortex mixed and incubated at room temperature for 5 minutes 
before separating the beads with the magnetic rack and placing supernatant (captured 
DNA) in a separate tube. Eluted DNA was combined with 50 µl of SureSelect 
neutralisation buffer and purified using AMPure beads.  
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2.16.8.8. Post-capture amplification 
In a PCR plate 14 µl captured DNA, 22.5 µl nuclease-free water, 5 µl Herculase II reaction 
buffer, 0.5 µl dNTP mix, 1 µl Herculase II Fusion DNA polymerase (Agilent), 1 µl 
SureSelect Indexing Post-Capture PCR primer (25 µM), and 1 µl Index PCR reverse 
primer (25 µM) were combined. Thermal cycling parameters are listed in Appendix 4. 
Reactions were purified using AMPure beads, with a final elution volume of 15 µl. 
2.16.9. mRNA-seq library preparation 
2.16.9.1. RNA extraction 
RNA was extracted from 40 mg of canine cerebellum preserved in RNAlater solution (Life 
Technologies) using the Qiagen RNeasy midi kit. Cerebellum tissue was disrupted in 2 ml 
RLT buffer (stabilised by the addition of 40 µl 2 M dithiothreitol (DTT)) using a mortar and 
pestle. Lysates were transferred to a Qiashredder column, and centrifuged at 17,000 x g 
for 2 minutes to fully homogenise. Lysates were then transferred to a 15 ml tube and 
centrifuged at 4,500 x g for 10 minutes to pellet the cell debris, and the supernatant was 
transferred to a clean 15 ml tube.  One volume of 70% ethanol (~2 ml) was added to the 
supernatant, which was mixed by inversion, applied to an RNeasy midi column and 
centrifuged for 5 minutes at 4,500 x g. After discarding the flow-through, 2 ml RW1 were 
added to the column, which was centrifuged at 4,500 x g for 5 minutes, discarding the 
flow-through. The RNA was DNase treated on-column by applying 160 µl DNase (20 µl 
DNase stock (60 Kunitz units), 140 µl buffer RDD) to the column filter and incubating at 
room temperature for 15 minutes. A further 2 ml RW1 were added to the column, which 
was centrifuged at 4,500 x g for 5 minutes, discarding the flow-through. The column was 
then washed twice using 2.5 ml RPE buffer, centrifuging at 4,500 x g for 2 minutes for the 
first wash and at 4,500 x g for 5 minutes for the second wash, discarding the flow-through 
between washes. The column was then placed on a clean 15 ml collection tube and 150 
µl RNase free water added directly to the column filter and incubated at room temperature 
for 5 minutes. The RNA was eluted by centrifuging the column at 4,500 x g for 3 minutes. 
2.16.9.2. mRNA isolation 
Isolation of mRNA was performed using Sera-mag oligo(dT) magnetic beads (Thermo-
Fisher). Total RNA (4.9 µg) was diluted to a 50 µl volume with nuclease-free water. 15 µl 
of Sera-mag beads were placed in a 1.5 ml tube, washed twice in 100 µl of hybridisation 
buffer (Thermo-Fisher) and resuspended in 50 µl of hybridisation buffer. All washing 
stages were performed by placing bead containing tubes onto a magnetic rack, removing 
supernatant, and adding the buffer before vortexing tubes for 5 seconds. Tubes were then 
placed back on the rack to allow beads to settle, before removing the supernatant and 
proceeding to the next stage. Tubes containing total RNA were placed on a heat block at 
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65°C for 5 minutes to disrupt secondary structures and chilled on ice before transferring 
the total RNA to the resuspended washed beads. The bead solutions were rotary mixed 
for 5 minutes at room temperature to hybridise, before washing beads twice in 200 µl 
wash buffer (Thermo-Fisher) and resuspending in 50 µl elution buffer (Thermo-Fisher). 
The mRNA was eluted from the beads by placing in a heat block at 80°C for 2 minutes, 
before immediately placing the tubes back on the magnetic rack and transferring the 
supernatants to tubes containing 50 µl of hybridisation buffer. A second enrichment stage 
was performed to further increase the mRNA:rRNA ratio. Beads from the first enrichment 
stage were washed twice in 200 µl wash buffer ready for re-use. Eluted mRNA was 
heated for 2 minutes at 65°C, and then quickly chilled on ice and transferred to the 
washed beads. The bead solutions were rotary mixed for 5 minutes at room temperature 
to hybridise, before washing the beads twice in 200 µl wash buffer and resuspending the 
beads in 18 µl elution buffer. The mRNA was eluted from the beads by placing in a heat 
block at 80°C for 2 minutes, before immediately placing the tubes back on the magnetic 
rack and transferring the supernatants to clean tubes.  
2.16.9.3. mRNA fragmentation 
Libraries for mRNA-seq were prepared using the NEBnext Library Prep Master Mix Set for 
Illumina. The messenger RNA was fragmented by adding 18 µl purified mRNA to 2 µl 
RNA fragmentation buffer in a 96 well plate and heated in a thermal cycler for 5 minutes at 
94°C. The plate was then chilled on ice and 2 µl of 10x RNA fragmentation stop solution 
added to reactions. Fragmented mRNA was cleaned-up using an RNeasy mini column. 
Reaction mixes were transferred to a 1.5 ml tube and adjusted to 100 µl by adding 78 µl 
nuclease free water. To the diluted RNA, 350 µl of buffer RLT were added and mixed by 
vortexing, followed by addition of 250 µl of absolute ethanol, before mixing by inversion. 
The RNA mixture was applied to an RNeasy mini column, which was washed and RNA 
eluted according to section 2.10. The elution volume was 20 µl. 
2.16.9.4. First strand cDNA synthesis 
In a 96 well plate 13.5 µl fragmented mRNA and 1 µl random primers were combined. 
Plates were sealed and incubated at 65°C for 5 minutes before chilling on ice. To the 
reaction mix 4 µl first strand synthesis buffer (Invitrogen) and 0.5 µl murine RNase 
inhibitor (NEB) were added, mixed and incubated at 25°C for two minutes. To the reaction 
1 µl SuperScript II Reverse Transcriptase (200 U/µL) (Invitrogen) was added and 
incubated at 25°C for 10 minutes, 42°C for 50 minutes, 70°C for 15 minutes, and then 
held at 4°C. 
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2.16.9.5. Second strand cDNA synthesis 
To the first strand synthesis reaction, 48 µl of nuclease free water, 8 µl second strand 
synthesis buffer (NEB) and 4 µl second strand enzyme mix (NEB) were added and mixed 
by pipetting. Reactions were incubated at 16°C for 2.5 hours before purifying cDNA using 
AMPure beads (Section 2.16.8.4.). 
2.16.9.6. End repair, dA tailing and adapter ligation 
Library end repair, dA tailing and adapter ligation were performed as described in sections 
2.16.3 to 2.16.5 
2.16.9.7. Size selection and library amplification 
Adapter ligated libraries were separated on a 3% 1:1 low melt:standard agarose gel and 
bands excised at the 200-250 bp (main library) and at 300-350 bp (reserve library) 
position using an X-tracta gel extraction tool (Sigma Aldrich). Library DNA fragments were 
purified from excised bands using the QIAquick gel extraction protocol (section 2.16.6). 
Size selected libraries were amplified for multiplexed sequencing as described in section 
2.16.7 and purified using AMPure beads as described in section 2.16.8.4. 
2.16.10. Quantification of sequencing libraries 
The KAPA library quantification kit was used to accurately quantify the libraries for 
Illumina sequencing. Libraries were diluted 1:100,000 with nuclease free water to put the 
concentrations within the range of the DNA standards (0.0002 - 20 pM). Reaction mixes 
containing 4 µl diluted library or standard, 4 µl nuclease free water and 12 µl KAPA SYBR 
Fast qPCR master mix (containing primer premix), were run on an Illumina Eco qPCR 
machine in triplicate with the cycling parameters defined in Appendix 4. Based on the 
threshold cycle (Ct) values of the standards, a standard curve was drawn allowing 
reaction efficiency and r2 values to be calculated. The concentration of the libraries was 
calculated using Ct values and the standard curve equation. Stock concentrations were 
calculated by first adjusting for the size of the library (452 / expected fragment length) and 
then multiplying by the dilution factor.  
2.16.11. Blunt end cloning 
Blunt end cloning was used to check that libraries contained the expected fragment 
sequences using the pT7Blue Perfectly Blunt Cloning Kit (Novagen). Library fragments 
were phosphorylated prior to ligating into the plasmid using the end conversion enzyme 
mix provided. In a 96 well microplate 2 µl of sequencing library, 3 µl nuclease-free water 
and 5 µl end conversion mix were combined, mixed with a tip and incubated on a thermal 
cycler at 22°C for 15 minutes. The reaction was inactivated by heating at 75°C for 5 
minutes, and chilled on ice. For the ligation, 1 µl (50 ng) PT7Blue Blunt Vector and 1 µl T4 
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DNA Ligase (4 Weiss units/µl) were added to the reaction and mixed with the end of a tip. 
The reaction mix was incubated at 22°C for 15 minutes. 
 
The cells used for transformations were NovaBlue Singles™ Competent Cells. Competent 
cells were removed from -80°C storage and placed on ice to thaw. Cells were evenly 
resuspended by gently flicking tubes 3 to 4 times. To the cells 1 µl of ligation reaction was 
added which were then stirred gently to mix and returned to ice for 5 minutes. Heatshock 
was performed by heating the tubes for exactly 30 seconds in a 42°C water bath, and 
returning to ice for 2 minutes. To the tubes 250 µl of room temperature super optimal 
broth with catabolite repression (SOC) medium were then added.  
 
Lysogeny broth (LB) agar plates were made containing 50 µg/ml ampicillin, 12.5 µg/ml 
tetracycline, 50 µg/ml X-gal and 50 µM IPTG (see Appendix 1). Glass Pasteur pipettes 
were sterilised and shaped into spreading tools by heating, and used to evenly spread 
50 µl of the cell mixture over plates. Plates were inverted and incubated overnight at 
37°C. Once colonies reached a 0.5 to 1 mm diameter, plates were placed at 4°C to further 
develop the colour for blue/white colony screening. 
2.16.12. Direct colony PCR 
White colonies were picked using a sterile cocktail stick and deposited into a 
microcentrifuge tube containing 50 µl of TE buffer by twirling. Tubes were vortexed 
thoroughly, and pulse centrifuged to collect the cell solution, which was then transferred to 
a single well of a 96 well plate. The plate was sealed and heated at 95°C for 5 minutes to 
lyse the cells and chilled on ice. The plate was then centrifuged at 4500 x g to pellet the 
debris and 2 µl of supernatant used for standard PCR followed by Sanger sequencing. 
Primers for PCR in the 5’ to 3’ direction were TGCAGGTCGACTCTAGAGGAT and 
GTTTTCCCAGTCACGACGTT, with an expected product size of 105 bp for an uncut 
plasmid. 
2.16.13. Illumina sequencing (outsourced) 
The sequencing template generated by long range PCR was sequenced, after library 
preparation, at Fasteris Life Science. Single-end sequencing was performed to generate 
reads of 33 bp.  
 
SureSelect indexed libraries were pooled to a final concentration of 10 nM, and sent for 
sequencing on an Illumina GAIIx or Illumina HiSeq 2000 at the Wellcome Trust Centre for 
Human Genetics, University of Oxford. Paired-end sequencing with reads of 51 bp was 
performed. 
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2.16.13.1. Illumina MiSeq sequencing 
Sequencing on the Illumina MiSeq platform was performed in-house. Stock libraries were 
diluted to 2 nm with Tris-Cl 10mM, pH 8.5 containing 0.1% Tween 20. Libraries were 
denatured by combining and mixing 10 µl freshly made 0.2 N NaOH solution with 10 ul of 
2 nM library, and incubating for exactly 5 minutes. To the 20 µl of denatured library, 980 µl 
of prechilled HT1 were added to give a library concentration of 20 pM. The library was 
further diluted by combining 500 µl of library with 500 µl HT1 to give a library 
concentration of 10 pM. The MiSeq reagent cartridge was prepared by thawing in a room 
temperature waterbath for one hour before inverting 10 times to mix reagents. The sample 
well was then pierced with a clean pipette tip and a 600 µl volume of 10 pM library loaded 
into the cartridge, before inserting into the sequencer. The flow cell was removed from the 
storage solution before thoroughly flushing with ultra-pure water and drying completely 
with a lint-free tissue, ensuring surfaces were streak free. The flow cell, PR2 bottle and 
emptied waste bottle were installed onto the machine, before linking the sample sheet and 
starting the sequencing run. On run completion a post-run wash was initiated by replacing 
the reagents cartridge with an ultrapure water filled wash cartridge, and the PR2 bottle 
with an ultrapure water filled wash bottle.  
2.16.14. Illumina sequencing data analysis 
The dataset generated from the long range PCR template was analysed using Maq 
assembly software (Li et al., 2008), with the canine genome sequence CanFam2 as a 
reference. De novo assembly was performed at Fasteris Life Science using Edena 
software (Hernandez et al., 2008). Staden gap software (Bonfield et al., 1995) was used 
to align both Edena and Maq assemblies and capillary reads from exon sequencing, for 
comparison with the CanFam2 canine genome build. 
 
For the SureSelect sequencing datasets a Perl script entitled “NGS analysis”, executable 
from the Linux command prompt, was written to handle data in FASTQ format outputted 
from Illumina sequencing experiments. Key commands of the Perl script are listed in 
Appendix 5 and a text file of the full script found on the Supplementary CD. Reads were 
aligned to the canine genome using the program BWA (Burrows-Wheeler Aligner) (Li and 
Durbin, 2009). Aligned reads from BWA were in SAM format (Sequence Alignment/Map). 
The read file manipulation program Samtools (Li et al., 2009) and Picard tools 
(http://picard.sourceforge.net) were used to sort aligned reads, convert read files into 
binary format (BAM), remove PCR duplicate reads and index the aligned reads. The 
Genome Analysis ToolKit (GATK) was used to further improve read alignment, adjust 
quality scores, and make SNP and indel calls (McKenna et al., 2010). Variant calls were 
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annotated using genomic information available on the Ensembl website using the Variant 
Effects Predictor (McLaren et al., 2010). Metrics data files and histograms of GC bias and 
insert size were created by Picard tools. An option to run Pindel, a structural variant 
detection tool was also included in the Perl script (Ye et al., 2009). Sequence alignments 
were visualised in the Integrative Genomics Viewer (IGV) (Robinson et al., 2011). 
2.16.15. De novo assembly of next generation sequencing reads 
Reads from Illumina sequencing experiments were aligned against the dog genome and 
visualised in IGV. Reads aligning across the BCAN transcript were manually extracted in 
FASTA format and de novo assembled using the Staden Gap software package.  
2.17. Quantitative PCR 
Quantitative PCR used to measure gene expression was carried out on an Illumina Eco 
qPCR machine in 10 µl volumes, consisting of 4 µl KAPA Probe Fast, 2 µl ultra-pure 
water, 1x PrimeTime primer mix and 2 µl template cDNA. Cycling parameters are listed in 
Appendix 4. Doubling serial dilutions of cDNA across 7 points were performed to construct 
standard curves and to calculate reaction efficiencies. All reactions were performed in 
triplicate.  
2.18. Western blotting 
2.18.1. Protein extraction 
Canine cerebellum samples (~30 mg) were homogenised in 1 ml ice cold RIPA lysis buffer 
(Sigma-Aldrich), containing one complete protease inhibitor cocktail tablet per 10 ml 
(Roche), using an electric homogeniser. Protein lysates were 4°C centrifuged for 10 
minutes at 14,000 x g, and supernatants removed and stored at -20°C. Protein 
concentrations were measured using a Qubit fluorometer (Invitrogen). 
2.18.2. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Protein extracts (6 µl at 60 ng/µl) were combined with 6 µl 2x Laemmli buffer and 
denatured at 98°C for 5 minutes, before chilling on ice. Protein samples were separated 
by denaturing 6% SDS-PAGE (National Diagnostics) at 200 V for 1 hour.  
2.18.3. Coomassie staining 
Coomassie staining was used to confirm the presence of protein on SDS gels. Gels were 
covered in Coomassie solution and heated in a microwave at 800 W for 10 seconds 3 
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times, shaking between each round of heating. Gels were then destained in 30% 
methanol/10% acetic acid solution on a plate shaker set at 100 rpm for 1 hour. 
2.18.4. Blotting    
Unstained separated proteins on gels were transferred to a nitrocellulose membrane. In a 
blotting tank frame the SDS gel and a piece of nitrocellulose paper were held between 
blotting paper soaked in blotting buffer. Blotting buffer soaked sponges were placed 
outside of the blotting paper and the frame clamped, placed in the blotting tank and 100 V 
applied for 1 hour to complete the transfer. 
2.18.5. Primary probing 
Nitrocellulose membranes were blocked for 16 hours with 5% non-fat dried milk in 
phosphate-buffered saline/0.1% Tween 20 (PBS-T). Blocked nitrocellulose membranes 
were incubated for one hour in 1:200 goat anti-SPTBN2 (Santa Cruz Biotechnology) or 
1:1,000 mouse anti-ACTB (Camlab) primary antibody in blocking buffer.  
2.18.6. Secondary probing 
Primary probed blots were washed in PBS-T, and incubated in 1:10,000 HRP-conjugated 
donkey anti-goat or 1:1,000 HRP-conjugated goat anti-mouse secondary antibody in 
blocking buffer.  
2.18.7. Detection 
Immunoreactive proteins were detected using HRP-conjugate substrate kit for enhanced 
chemiluminescence (GE Healthcare). After rinsing 3 times in PBS-T, nitrocellulose 
membranes were placed protein side up on Saran wrap and surfaces covered with 5 ml of 
combined detection reagent. Excess reagent was poured off and the membrane placed 
protein side down onto a new piece of Saran wrap. Blotting paper was placed on top of 
the membrane to absorb excess reagent, and Saran wrap folded to form a neat flat parcel. 
In a dark room a high performance chemiluminescence film (GE healthcare) was placed 
on top of the wrapped membrane and secured in a dark frame for 2 minutes. Exposed 
films were developed in 1:5 x-ray developer solution (Polycon) and upon image 
appearance placed in non-hardening fixing solution (Photosol), before rinsing in water, 
drying and photographing. 
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2.19. DNA tests 
2.19.1. Italian Spinone spinocerebellar ataxia DNA test 
A multiplex PCR amplifying two microsatellite markers was used as a linkage-based 
diagnostic DNA test. PCRs were performed in 12 µl reactions consisting of 0.2 mM dNTP 
mix (ABgene), 1x GC PCR buffer (Finnzymes), 0.06 µM microsatellite A primers, 0.11 µM 
microsatellite B primers, 1 unit Phusion hot start polymerase (Finnzymes), 2 µl genomic 
DNA (concentration range: 1-100 ng/µl) and ultrapure water to a final volume of 12 µl. 
Primer sequences and cycling parameters are listed in Appendices 2 and 4 respectively. 
Fragment analysis on an ABI 3130xl was performed using 1 µl of PCR product.   
2.19.2. Cavalier King Charles Spaniel DNA test 
A multiplex PCR was developed to assay for both EF and CKCSID associated mutations 
simultaneously. The EF deletion was assayed using one forward primer 5’ of the deletion, 
one forward primer inside the deleted region and a fluorescently labelled reverse primer 3’ 
of the deletion. The CKCSID one base pair deletion was assayed for using a single primer 
pair flanking the deletion, with the forward primer fluorescently labelled. Fragments were 
amplified using standard PCR. Primer sequences are listed in Appendix 2. Fragment 
analysis on an ABI 3130xl was performed using 1 µl of PCR product.     
2.19.3. Beagle neonatal cerebellar cortical degeneration DNA test 
The Beagle NCCD 8 bp deletion was assayed for using a single primer pair flanking the 
deletion, with the forward primer fluorescently labelled. Fragments were amplified using 
standard PCR. Fragment analysis on an ABI 3130xl was performed using 1 µl of PCR 
product. Primer sequences and cycling parameters are listed in Appendices 2 and 4 
respectively 
2.19.4. Parson Russell Terrier late onset ataxia DNA test 
The CAPN1 SNP associated with LOA was assayed for using an allelic discrimination 
(TaqMan) approach. Reactions consisted of 4 µl KAPA Probe Fast mastermix, 2 µl 
genomic DNA (concentration range: 1-100 ng/µl), 0.2 µl of 40x primer/probe mix 
(Appendix 2), and 1.8 µl of ultrapure water. Cycling, detection and analysis were carried 
out on an ABI Step One Plus real-time PCR machine. Primer sequences and cycling 
parameters are listed in Appendices 2 and 4 respectively.  
2.19.5. PCR amplification of GAA triplet repeat expansion 
Amplification across the GAA triplet repeat expansion was performed using the Qiagen 
Long Range PCR Kit. PCRs consisted of 1.25 µl dNTP mix (2 mM), 2.5 µl PCR buffer, 
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0.4 µM forward and reverse primers, 0.2 µl Qiagen LR enzyme mix (1 unit), 2 µl genomic 
DNA (100 ng) and ultrapure water to a final volume of 25 µl. Primer sequences and 
cycling parameters are listed in Appendices 2 and 4 respectively. 
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Chapter 
3. Investigation of two disorders in the Cavalier King Charles Spaniel  
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3.1. Background 
The Cavalier King Charles Spaniel (CKCS) originated from the King Charles Spaniel in 
the early part of the 20th century, with a dedicated breed club forming in 1928. The 
popularity of the CKCS gradually increased and the breed was granted separate Kennel 
Club registration from the King Charles Spaniel in 1945 (Cunliffe, 2004). Today the CKCS 
is one of the UK’s most popular breeds with 5,970 Kennel Club registrations in 2012 (The 
Kennel Club 2013). 
 
In common with many other purebred dog populations, the CKCS suffers from a high 
incidence of inherited disease. Diseases affecting the CKCS are well documented in the 
scientific literature and breed health websites, with a notable focus on neurological 
disorders (Rusbridge, 2005) and mitral valve disease (Beardow and Buchanan, 1993) 
(http://www.cavalierhealth.org/, http://www.aboutcavalierhealth.com/). The health of the 
breed was brought to the attention of the public through two BBC documentaries entitled 
Pedigree Dogs Exposed, which were broadcast in August 2008 and February 2012 
highlighting the painful neurological disorder syringomyelia. 
 
This chapter describes the genetic investigation into two CKCS specific conditions, 
episodic falling (EF) and congenital keratoconjunctivitis sicca and ichthyosiform 
dermatosis (CKCSID).  
3.1.1. Episodic falling 
Episodic falling in the CKCS, also known as sudden collapse, muscle hypertonicity and 
hyperekplexia, is an exercise, excitement or stress induced syndrome caused by an 
increase in muscle tone and a temporary inability to relax the muscles. The condition was 
first reported in 1983, although had been observed in the breed since at least the early 
1960’s (Herrtage and Palmer, 1983).  The onset age is usually between 3 and 7 months 
and inheritance is consistent with an autosomal recessive mode. The clinical signs are 
often variable between cases. Episodes can vary in severity and last from a few seconds 
to several minutes. Episodes often start with an increase in muscle tone, with bunny 
hopping movements (Herrtage and Palmer, 1983, Rusbridge, 2005) and/or presence of a 
deer stalker gait (Wright et al., 1986). The back may become arched and the head held 
close to the ground leading to collapse, either to the side or forwards. Legs may be held 
out in a rigid, extended fashion, although in some cases the dog may return to its feet 
within seconds of a collapse. In severe cases forelegs or hindlegs may become protracted 
until they are positioned over the top of the dog’s head as shown in Figure 3.1 (Herrtage 
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and Palmer, 1983, Shelton, 2004). Dogs appear to remain fully conscious during an 
episode (Herrtage and Palmer, 1983). 
 
 
Figure 3.1 Episodic falling in a ten month old Cavalier King Charles Spaniel 
Severe muscle hypertonicity in a case of EF. The dog displays an arched back and forelimbs are protracted 
over the head. Still image from a video provided by Dr Boaz Levitin DVM, DACVIM (Neurology). 
 
Therapeutic agents are often used to treat EF cases, with dogs often responding well to 
Clonazepam (benzodiazepine) treatment. Reports in the veterinary literature describe 
severe cases with a high episode frequency becoming almost clinically normal after 
administration of the drug (Garosi et al., 2002, Shelton and Engvall, 2002). 
 
Episodic falling shares similarities to human disorders, including hyperekplexia, Brody’s 
myopathy and myotonia. Hyperekplexia is a disease of exaggerated startle response and 
increased muscle stiffness and rigidity, which shows a particularly close resemblance to 
EF in terms of the positive response to the drug Clonazepam. Clonazepam is thought to 
alleviate clinical signs by improving neurotransmission in gamma-aminobutyric acid 
(GABA) pathways (Tijssen et al., 1997). Mutations in several genes have been associated 
with hyperekplexia in humans (Table 2.2). Brody’s myopathy is a disease of exercise 
induced muscle cramping with the inability to relax muscles (Brody, 1969). Mutations in 
the ATP2A1 (ATPase, Ca++ transporting, cardiac muscle, fast twitch 1) gene have been 
associated with Brody’s myopathy (Odermatt et al., 1996). Myotonia is described as a 
disease with delayed skeletal muscle relaxation after sudden and often exaggerated 
contraction, and exists in both autosomal recessive (Becker’s disease) and dominant 
forms (Thomsen’s disease) (Becker, 1977, Thomsen, 1876). Mutations in the CLCN1  
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(chloride channel, voltage-sensitive 1) gene have been associated with both autosomal 
recessive and dominant forms of the disease in humans, in the myotonic “fainting” goat, 
and myotonia in the Miniature Schnauzer and the Australian Cattle Dog (Beck et al., 1996, 
Finnigan et al., 2007, George et al., 1993, Koch et al., 1992, Rhodes et al., 1999). 
Characterisation of many diseases which are closely related to EF at the molecular level 
presents the opportunity to investigate the disease using a candidate gene approach. 
3.1.2. Congenital keratoconjunctivitis sicca and ichthyosiform dermatosis 
Congenital keratoconjunctivitis sicca and ichthyosiform dermatosis (CKCSID), commonly 
known as dry eye and curly coat syndrome, was first reported in the scientific literature in 
2006 (Barnett, 2006). Clinical signs are recognisable at birth, with affected puppies having 
a coat that is rough or “crimped” in appearance (Figure 3.2). Affected puppies are often 
reported to be smaller than unaffected littermates.  
 
 
Figure 3.2 Two week old puppy with CKCSID 
Two week old CKCS puppy displaying clinical signs consistent with CKCSID. Note the rough appearance of 
the coat. (Hartley et al 2011.) 
 
Clinical signs of keratoconjunctivitis sicca (dry eye) are apparent from eyelid opening at 
approximately ten days, with a reduced production of aqueous tears which can result in a 
discharge of tacky mucus and in severe cases ulceration of the cornea. As CKCSID 
affected dogs progress to adulthood, the skin can become hyperkeratinised and 
hyperpigmented across the ventral abdominal region. The coat is harsh and frizzy, with 
scaling and partial alopecia along the dorsum and flanks, which may cause the dog to 
scratch. Footpads also become hyperkeratinised with abnormal growth of nails and 
intermittent sloughing, causing lameness (Figure 3.3).  
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Prognosis for affected individuals is poor and the condition cannot be resolved through 
treatment. Many owners elect to euthanise affected dogs due to difficulties in disease 
management, although life expectancy is not obviously affected by the condition (Hartley 
et al., 2011). 
 
 
Figure 3.3 Nail and footpad abnormalities in a case of CKCSID 
Abnormal growth of a nail and thickening of the footpad. Images provided by Claudia Hartley. 
 
Ichthyosis (thickened, dry and often scaled skin) has been described in other breeds of 
dog including the Norfolk Terrier (Credille et al., 2005), Jack Russell Terrier (Credille et al., 
2009), and Golden Retriever (Grall et al., 2012), with disease-associated mutations 
identified for all three breeds. No syndromes reported in the human literature describe 
clinical signs that are entirely comparable with those seen in cases of CKCSID, although 
individually both keratoconjunctivitis sicca and ichthyosiform dermatosis are widely 
reported. Keratitis-ichthyosis-deafness (KID) syndrome, caused by mutations in the GJB2 
(gap junction protein, beta 2) gene encoding connexin-26, shows some clinical similarities 
to CKCSID (Richard et al., 2002, Skinner et al., 1981). A disease of woolly hair, premature 
tooth loss, nail dystrophy, acral hyperkeratosis and facial abnormalities has also been 
described in a human kindred, but unlike CKCSID no ocular clinical signs were described 
(van Steensel et al., 2001).  
 
The clinical signs and progression of CKCSID in the Cavalier have been described in 
detail by C. Hartley and colleagues, through the diagnosis and follow up of 25 cases 
(Hartley et al., 2011). DNA samples were also collected and used for a subsequent 
candidate gene study, in which microsatellite markers were analysed for association 
between CKCSID and 28 canine orthologues of human disease-associated genes 
(Hartley et al., 2012). No association was found between CKCSID and any of the genes 
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investigated thus ruling out any obvious candidate genes; the study therefore progressed 
to a GWAS, which is described in this chapter. 
3.1.3. Aims 
The aims of this investigation were to identify the mutations responsible for EF and 
CKCSID in the CKCS. As both conditions afflict the same breed, this presented the 
opportunity to map both conditions in parallel using a set of cases for each disease and a 
single set of clinically unaffected controls. Association loci from the independent GWAS 
would be followed up using sequencing techniques in order to identify disease-associated 
mutations, allowing diagnostic assays to be developed. 
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3.2. Results  
3.2.1. EF candidate gene study 
A sample cohort of 12 EF cases and 10 controls was selected for investigation by 
Professor Jacques Penderis (veterinary neurologist). Canine orthologues of genes 
causing a similar condition to EF in humans were selected as candidate genes (see Table 
2.1). For each candidate gene, two flanking microsatellite markers were identified and 
genotyped across the sample cohort. At least one microsatellite was required to be 
informative with a minor allele frequency greater than 0.1 to exclude the gene. The 
genotyping dataset is shown in Table 3.1 (major alleles are highlighted). For microsatellite 
markers segregating with EF, cases were expected to be homozygous for a single allele 
and controls either homozygous or heterozygous for any allele. Upon visual inspection 
marker GLRA1_C4_60.68 showed a pattern suggesting segregation with EF, with 9/12 
cases homozygous for allele 200 and only 3/10 controls with a homozygous genotype for 
allele 200. The gene locus could be excluded however, by the second microsatellite 
marker (GLRA1_C4_60.64). No markers surrounding the other candidate genes showed a 
pattern of linkage disequilibrium with EF based on visual inspection. All three 
microsatellites genotyped around SLC5A9 were monomorphic, so the gene could not be 
formally excluded. The lack of variation across the region may be suggestive of a 
selective sweep in the CKCS breed. 
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3.2.2. Genome-wide association study 
3.2.2.1. Illumina CanineHD SNP array genotyping data 
The 96 DNA samples sent for processing on the Illumina CanineHD SNP array genotyped 
successfully achieving call rates of >99%. Raw genotyping data were imported into 
Genome Studio for viewing and manual processing to increase the overall genotyping call 
rate and remove poor quality SNPs. Overall call rate was initially improved by re-clustering 
the SNP calls (Figure 3.4).  
 
 
Figure 3.4 Improving call rates using the "cluster all SNPs" command 
An example of data improved by the “cluster all SNPs” command in Genome Studio. Each dot on the plots 
represents a single SNP. The areas shaded in red, purple and blue represent the boundaries for calling alleles 
AA, AB and BB respectively. (A) Clustering using the predefined cluster file. (B) Clustering after the “cluster all 
SNPs” command has been executed. The call rate for the SNP has improved from 93% to 100%. 
 
It was noted that SNP calls for four individuals (one Golden Retriever, two IS and one 
CKCS control) often clustered separately for many otherwise monomorphic SNPs. This 
caused reclustering errors because of the absence of a heterozygous calls cluster (Figure 
3.5A). Call rates were subsequently improved by excluding the four individuals and 
repeating the SNP re-clustering command. The individuals were then re-included with the 
new cluster positions in place (Figure 3.5B). Separate clustering was expected for the 
non-CKCS individuals, but the CKCS control individual appeared to be an outlier and was 
therefore excluded from further analysis. 
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Figure 3.5 SNP clustering problems due to the absence of a heterozygous group 
(A) Four individuals often formed a separate homozygous cluster in SNP genotyping data, resulting in calling 
errors. (B) The clustering problem was resolved by removal of the four individuals before repeating the “cluster 
all SNPs” command, to improve the average call rate for the entire dataset from 99.48% to 99.84%. 
 
Re-clustered data were exported from Genome Studio into Progeny, for case-control 
cohort selection. 
 
3.2.2.2. Allelic association analysis 
Genotyping data for case-control cohorts were exported from Progeny for allelic 
association analysis. The sample set for genotyping consisted of 31 EF cases, 19 
CKCSID cases, and a common set of 38 controls. SNPs with a minor allele frequency 
<0.05 and a genotyping call rate <0.95 were excluded from analysis. After filtering 91,427 
SNPs remained for EF and 88,384 for CKCSID. 
 
Allelic association analysis was performed using the statistical package PLINK. Strong 
statistical signals were seen on chromosome 7 for EF (Praw = 1.9 x 10-14) and chromosome 
13 for CKCSID (Praw = 1.2×10−17).  Allelic association plots for EF and CKCSID are shown 
in Figures 3.6 and 3.7 respectively. The top 100 SNPs in both studies were located on 
single chromosomes, producing single distinctive peaks on the association plots. 
 
 
 
 
 
 
3. Disorders in the Cavalier 
 
 
 
75 
 
Figure 3.6 Allelic association analysis plot for EF 
Allelic association analysis plot for 31 EF cases and 38 controls. Each dot represents a single SNP, with -
log10 (p) values on the y-axis plotted against genome position (split into chromosomes) on the x-axis. The 
strongest statistical signal is on chromosome 7 (Praw = 1.9 x 10-14). 
 
  
Figure 3.7 Allelic association analysis plot of CKCSID 
Allelic association analysis plot for 19 CKCSID cases and 38 controls. Each dot represents a single SNP, with 
-log10(p) values on the y-axis plotted against genome position (split into chromosomes) on the x-axis. The 
strongest statistical signal is on chromosome 13 (Praw = 1.2×10−17). 
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3.2.2.3. Correction for multiple testing 
Max(T) permutations analysis (100,000 permutations) was performed using PLINK to 
correct for multiple testing. For EF and CKCSID single statistical signals remained on 
chromosomes 7 and 13 respectively, which surpassed genome-wide significance at the 
5% level (Figures 3.8 and 3.9). The SNPs displaying the strongest statistical signal for EF 
and CKCSID after permutations testing both had a P value of 1.0 x 10−5 (Pgenome). 
 
Figure 3.8 EF association analysis including max(T) permutations 
Plot of P-values for the EF association study after 100,000 max(T) permutations. Pgenome = 1.0 x 10−5. SNPs 
above the red dashed line are genome-wide significant at the 5% level. 
 
Figure 3.9 CKCSID association analysis including max(T) permutations 
Plot of p-values for the CKCSID association study after 100,000 max(T) permutations.  Pgenome = 1.0 x 10−5. 
SNPs above the red dashed line are genome-wide significant at the 5% level. 
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3.2.3.  Population stratification  
Genomic inflation values based on the median chi-squared were 1.57 and 1.62 for the EF 
and CKCSID association analyses respectively, and were suggestive of population 
stratification in both datasets. Quantile-quantile (QQ) plots of observed versus expected 
chi-squared values were plotted as a graphical display of genomic inflation (Figure 3.10). 
The expected pattern for QQ plots in a dataset with no stratification is for the observed 
chi-squared values to match the expected chi-squared values, and closely track the line 
y=x. If there is a true signal in the dataset observed chi-squared values will elevate above 
expected values only for the highest chi-squared values. If genomic inflation is present, 
the observed versus expected datapoints may be consistently elevated along the line y=x. 
 
 
 
Figure 3.10 QQ plot for the EF and CKCSID SNP genotyping datasets. 
QQ plots of observed (y-axis) versus expected (x-axis) chi-squared values for (A) EF and (B) CKCSID. The 
blue dots represent individual SNPs. The green lines have the equation y=x (ie observed chi-squared = 
expected chi-squared). The genomic inflation values for EF and CKCSID were 1.57 and 1.62 respectively.  
 
Observed versus expected chi-squared coordinates for both EF and CKCSID datasets, 
track above the y=x line, and is further evidence of genomic inflation. Multi-dimensional 
scaling (MDS) plots were generated to assess the relatedness of cases and controls in 
the EF and CKCSID studies (Figure 3.11). Related individuals cluster closely together on 
MDS plots. The plots show some separately clustering cases and controls for both EF and 
CKCSID, which may account for the high genomic inflation values. Clustering of controls 
away from cases is probably due to a shared set of controls being selected for both EF 
and CKCSID, rather than tailoring the control set to a particular cohort of cases.  
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Figure 3.11 MDS plots 
MDS plots for (A) EF and (B) CKCSID. Red dots represent cases and blue dots represent controls. 
Coordinates for the plots were calculated using pairwise identity-by-state (IBS) distance. 
 
3.2.4. Adjusting for genomic inflation 
The fast mixed model (FMM) was implemented to adjust for genomic inflation. The two top 
association signals remained statistically associated at 4.1×10−10 and 1.5×10−11 for the EF 
and CKCSID respectively (Figure 3.12).  
 
Figure 3.12 FMM corrected allelic association analysis plots 
FMM adjusted allelic association plots for (A) EF and (B) CKCSID. Strong statistical signals remained on 
chromosomes 7 and 13 for EF and CKCSID respectively.  
 
QQ plots are displayed for the FMM adjusted data in Figure 3.13. The genomic inflation 
value for the EF data after FMM correction was 0.98. Interestingly the genomic inflation 
value for the CKCSID data after FMM correction remained high at 1.83. The QQ plot for 
FMM corrected data of observed versus expected chi-squared values does however show 
the datapoints to more closely follow the line y=x, indicating that the values have been 
adjusted. 
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Figure 3.13 QQ plots of FMM adjusted data 
QQ plots of observed (y axis) versus expected (x axis) chi-squared values for (A) EF and (B) CKCSID after 
adjusting for genomic inflation using the fast mixed model. The green lines track the x=y coordinates. 
 
3.2.5. Investigation of strong statistical signals at the chromosome level 
Strong statistical signals were first investigated at the chromosome level by plotting raw 
SNP p-values across chromosome 7 and 13 for EF and CKCSID respectively. For EF the 
focal point of the strong statistical region was between 40 Mb and 48 Mb on chromosome 
7 (Figure 3.14). For CKCSID the statistical signal was spread over a slightly larger region 
of 32 Mb to 46 Mb on chromosome 13 (Figure 3.15).  
 
 
Figure 3.14 Chromosome 7 allelic association plots for the EF study 
(A) Allelic association plot for EF across chromosome 7. (B) Focal point of the strong statistical signal. The 
signal is interrupted by a region of approximately 1 Mb containing no SNPs due to the minor allele frequency 
filtering parameters defined in the analysis.  
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Figure 3.15 Chromosome 13 allelic association plot for the CKCSID study 
(A) Allelic association plot for CKCSID across chromosome 13. (B) The focal point of the strong statistical 
signal.  
 
Regions of strong association were further investigated by visualising raw SNP 
genotyping data across the disease-associated regions. For EF two individuals defined 
the shared disease-associated haplotype or “critical region” as CFA7:44,093,554-
46,905,272, by a loss of shared homozygosity in cases due to recombination events 
(Figure 3.16). Six individuals suspected to be affected on the basis of phenotype did not 
share the disease-associated haplotype, and are marked with an asterisk in Figure 3.16. 
One of these cases was subsequently reclassified as an epilepsy case in an independent 
neurological work-up. The other cases could not be resolved because the dogs were 
deceased or owners could not be contacted. The critical region contained a 1.2 Mb 
haplotype that was homozygous across 67 of 69 cases and controls, which could be 
suggestive of a selective sweep in the CKCS breed. Two cases were critical in defining 
the EF disease-associated region, and it was therefore imperative that the diagnosis of 
these cases was correct. The case defining the upper boundary (15943) was a typical but 
severe case of EF, with the owner describing clinical signs during an episode of a arched 
back, trembling, collapse, stiff paralysed hind legs, extension of the forelimbs above the 
head and jaw locking. Episodes reportedly lasted from two minutes to up to an hour. A 
video clip was also provided with the dog presenting an episode at 4 months of age, with 
clinical signs consistent with EF. The sample defining the lower boundary of the region 
was 16867 (JP1049). Only a single episode was reported and little further information was 
available for this case. Owner and veterinarian details were unavailable. Sample 16155 
could define the lower boundary at a slightly lower position of 47,048,914 on canine 
chromosome 7. This case had an initial episode at 6 months of age, presenting with 
collapse and hyperextension of limbs. The case was treated with and responded to 
Rivotril. Video footage provided with the case showed clinical signs consistent with EF. 
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This case therefore provided a more assured definition of the 3’ boundary. The EF critical 
region contained 114 genes and was syntenic with human chromosome 1 (Appendix 6). 
 
 
 
Figure 3.16 EF critical region raw genotyping data 
Raw genotyping data across the EF disease-associated critical region. Each column represents an individual 
and SNP markers are listed in rows. Cases are listed on the left, controls on the right. Major alleles are 
coloured in blue, minor alleles in red. Two individuals showed a loss of homozygosity due to recombination 
events, highlighted by a white border, defining the disease-associated haplotype as CFA7:44,093,554-
46,905,272 (boundary marked by black dashed lines). Six cases appear to be apparent outliers that were not 
homozygous for the disease-associated haplotype (columns marked with an asterisk) 
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For CKCSID recombination events in two individuals defined the disease-associated 
haplotype as CFA13:39,648,169-42,481,707, which was shared between all cases (Figure 
3.17). Diagnosis of cases was checked and confirmed in consultation with Claudia Hartley 
(veterinary ophthalmologist). The CKCSID critical region contained 85 genes, and was 
syntenic to regions of human chromosomes 4, 8 and 15 (Appendix 6). 
 
 
Figure 3.17 CKCSID disease-associated critical haplotype 
Raw genotyping data across the CKCSID disease-associated critical region. Each column represents an 
individual and SNP markers are listed in rows. Cases are listed on the left, controls on the right. Major alleles 
are coloured in blue, minor alleles in red. Two individuals showed a loss of homozygosity due to 
recombination events, highlighted by a white border, defining the disease-associated haplotype as 
CFA13:39,648,169-42,481,707 (boundaries marked by black dashed lines).  
 
Using the Ensembl genome browser both regions were interrogated for genes that could 
be potential candidates for the respective disorders. The EF critical region contained no 
genes that were associated with similar conditions in humans. The gene SLURP1 was 
identified in the CKCSID critical region. Mutations in SLURP1 have been associated with 
Mal de Meleda, an autosomal recessive skin disorder in humans, with clinical signs of 
transgressive palmoplantar keratoderma, keratotic skin lesions, perioral erythema, 
brachydactyly and nail abnormalities (Fischer et al., 2001), and was considered a good 
candidate gene for CKCSID that had not previously been investigated.  
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3.2.6. SLURP1 sequencing 
Because of the similarities between Mal de Meleda and CKCSID, the gene was exon re-
sequenced in two CKCSID cases and two control individuals. No polymorphisms were 
identified and the gene was ruled out as being potentially causal. 
3.2.7. SureSelect target enrichment and massively parallel sequencing 
3.2.7.1. Probe design 
Probes (RNA baits) were designed for the SureSelect solution based target enrichment 
system using the online tool e-array (https://earray.chem.agilent.com/earray/). Design 
parameters were set to capture both EF and CKCSID critical regions with 2x bait tiling (ie 
each base was covered by at least two RNA baits where possible) and repeat masking 
was applied (ie no probes were placed across known repeat regions). A total of 57,676 
baits were designed across a combined region of 5,788,900 bp; 29,429 baits for the EF 
region and 28,247 baits for the CKCSID region, achieving a base coverage of 3,749,814 
(64.8%). Bait locations were uploaded to the UCSC genome browser to assess bait 
coverage across exonic regions. Coverage of exons appeared to be nearly complete, 
although isolated examples of exons with no bait coverage were occasionally seen, often 
due to exons being in close proximity to repetitive elements (Figure 3.18).  
 
 
Figure 3.18 Visualisation of baits on the UCSC genome browser 
Positioning of baits across a section of the EF region and displayed by the UCSC genome browser. An exon 
with zero bait coverage is indicated by the red arrow. 
 
3.2.7.2. Investigation of fragmentation methods 
A key stage of library preparation for next generation sequencing is fragmentation of the 
nucleic acid. At the time of investigation the recommended method of fragmentation for 
Illumina sequencing was nebulisation. To help fulfil the aim of completing bench work in-
house, three methods of DNA fragmentation were tested. 
3. Disorders in the Cavalier 
 
 
 
84 
3.2.7.2.1 Sonication 
The results of sonication for 10, 20 and 30 cycles of 20 seconds on / 20 seconds off at full 
power using a cup horn sonicator are shown in Figure 3.19. Fragmentation of DNA with a 
size range of between 100 bp and 1,000 bp was achieved. 
 
Figure 3.19 DNA sonication results 
Results of sonication of high molecular weight genomic DNA (1.5% agarose gel). Lane 1 contains 200 ng non-
treated high molecular weight genomic DNA. Lanes 2, 3 and 4 contain 200 ng genomic DNA sonicated for 10, 
20 and 30 cycles of sonication respectively (20 seconds on / 20 seconds off at full power).   
3.2.7.2.2 Nebulisation 
Nebulisation using a pressure of 24 psi and 50% glycerol buffer produced fragments in the 
150–1000 bp range (Figure 3.20A). On agarose the fragments appeared most abundant 
in the 400–600 bp range. Only 350 µl of the 750 µl starting material could be recovered 
after nebulisation, indicating that half the material is lost during the shearing process, 
through vaporisation. 
3.2.7.2.3 Double stranded DNA Fragmentase 
Genomic DNA was digested for 30 minutes using NEB dsDNA Fragmentase. The process 
yielded fragments of 100-1,000 bp. The highest concentration of fragments was in the 
100-600 bp size range (Figure 3.20B).    
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Figure 3.20 Nebulised and fragmentase treated genomic DNA 
(A) Genomic DNA treated by nebulisation. Lane 1 - 200 ng high molecular weight genomic DNA. Lane 2 - 200 
ng nebulised genomic DNA. (B) Genomic DNA before (lane 3) and after (lane 4) treatment with NEB dsDNA 
Fragmentase. 
 
3.2.7.3. Trial library preparation and clone sequencing 
Trial libraries were prepared to test in-house library preparation using the NEBnext kit. To 
reduce costs, primer and adapter sequences for use in the library preparation were 
synthesised by an oligonucleotide manufacturer, rather than being purchased from 
Illumina. Trial library preparation would also test the effectiveness of these custom made 
oligonucleotides. Three libraries were made in the trial. Libraries 1 and 2 were made using 
nebulised DNA. Library 3 was created from DNA treated with dsDNA Fragmentase. 
Libraries were agarose gel size selected after adapter ligation and amplified with Phusion 
polymerase using the indexing method. Library fragments were checked for correct 
adapter sequences by molecular cloning.  Results are shown in Table 3.2. 
 
Overall 52% of sequenced cloned fragments had perfect adapter sequences at both ends. 
The percentage of correctly adapted fragments was higher for Fragmentase treated DNA 
(77%) compared with nebulised DNA (42%). Fragmentase treatment was chosen for use 
in SureSelect experiments based on cloning results and the high proportion of fragments 
produced in the desired 100-300 bp range. 
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Table 3.2 Summary of the clone sequencing results. 
LIBRARY No CLONE No PCR SEQUENCE ADAPTERS OK? INSERT SIZE 
1 1 3 products NO - - 
1 2 OK YES YES 319 
1 3 OK YES NO 250 
1 4 OK YES NO 113 
1 5 OK YES YES 273 
1 6 OK NO - - 
1 7 OK NO - - 
1 8 OK YES NO 201 
2 1 OK YES NO 212 
2 2 OK YES YES 171 
2 3 OK YES YES 225 
2 4 Faint NO  - 
2 5 OK YES NO 236 
2 6 OK YES NO 251 
2 7 OK YES YES 225 
2 8 OK YES NO 201 
3 1 No product NO - - 
3 2 OK YES YES 286 
3 3 OK YES YES 275 
3 4 OK YES YES 275 
3 5 Two products NO -  
3 6 OK YES NO 248 
3 7 OK YES YES 249 
3 8 OK YES NO 258 
3 9 Unexpected size NO - - 
3 10 OK YES YES 207 
3 11 OK YES YES 274 
3 12 OK YES NO 280 
3 13 OK YES YES 255 
3 14 OK YES YES 293 
3 15 OK YES YES 322 
3 16 OK YES YES 265 
 
3.2.7.4. Sample selection for target enrichment 
Two EF cases, two CKCSID cases and three controls were selected for potential use in 
the first attempt at target enrichment (Table 3.3). Cases were selected that were 
homozygous for the defined disease-associated haplotypes with clinical diagnosis 
confirmed by Jacques Penderis or Claudia Hartley. Controls were selected based on 
haplotype structure across the two disease-associated regions. A control with 
chromosome 7 and 13 haplotypes identical to disease-associated regions, but clinically 
unaffected with respect to EF and CKCSID was selected in an attempt to reduce the 
number of potential causal variants. 
Table 3.3 Individuals selected for target enrichment 
WTH - wild-type haplotype; DAH - disease-associated haplotype. Note control sample 16874, although 
clinically normal, is homozygous for the chromosome 7 and chromosome 13 disease-associated haplotypes. 
Sample ID Clinical status CKCSID region EF region 
6823 Control Heterozygous Homozygous WTH 
6975 CKCSID case Homozygous DAH Homozygous WTH 
9916 CKCSID case Homozygous DAH Heterozygous 
15943 EF case Homozygous WTH Homozygous DAH 
16823 EF case Homozygous WTH Homozygous DAH 
16874 Control Homozygous DAH Homozygous DAH 
16878 Control Homozygous WTH Heterozygous 
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3.2.7.5. Library preparation including pre-capture amplification 
Libraries were fragmented to the 100-600 bp range using dsDNA Fragmentase, and 
prepared using the NEBnext kit. Fragments in the 200-300 bp range were selected after 
adapter ligation. Nine cycles of pre-capture amplification were required to increase the 
concentration of the libraries to 147 ng/µl for the hybridisation stage, which was slightly 
higher than the 4-6 cycles recommended by the SureSelect protocol. The increased 
number of cycles was due to a change in methodologies recommended by SureSelect. In 
the SureSelect Illumina single-end protocol v2.0 (December 2009) the recommended 
fragmentation method was nebulisation and included a size selection stage. In the 
SureSelect Illumina paired-end protocol for multiplexed sequencing v1.0 (May 2010) the 
recommended fragmentation methodology had been changed to Covaris shearing with no 
size selection, allowing a reduction in the number of PCR cycles required. As no Covaris 
service was available at the time of the experiment and to keep the library preparation in-
house a size selection stage was adopted. Results of the pre-capture amplification are 
shown in Figure 3.21. 
 
 
Figure 3.21 Precapture libraries 
(A) Precapture libraries (147 ng) on a 2% agarose gel. Lanes 1 to 7 correspond to samples 6823, 6975, 9916, 
15943, 16823, 16874 and 16878 respectively. (B) Pre-capture library 9916 was subjected to analysis on a 
Bioanalyser DNA 12000 chip. The size range of fragments falls inside of those seen for library preparation 
after Covaris shearing. 
 
3.2.7.6. SureSelect hybridisation and post-capture amplification 
Five libraries were taken forward to the enrichment stage consisting of two EF cases, two 
CKCSID cases and a single control which was homozygous for both the chromosome 7 
and chromosome 13 disease-associated haplotypes. The hybridisation stage was 
followed by 13 cycles of post capture amplification to produce the final sequencing 
libraries, which were quantified using KAPA library quantification qPCR results in 
conjunction with results of accurate library sizing on the Bioanalyser. Libraries were 
pooled in equal amounts to 10 nM. Blunt end cloning of pooled library fragments was 
carried out to check end sequences and to estimate capture efficiency before libraries 
were sent for sequencing. A total of 23 colonies were selected for PCR and sequencing. 
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Results indicated a capture efficiency of 78% and an average insert size of 194 bp (Table 
3.4).   
Table 3.4 Summary of blunt end cloning results to estimate capture efficiency 
Clone sequences not hitting target regions after BLAST searching are highlighted in yellow. 
Clone No. Index No Chromosome Position (Mb) Insert size (bp) Ends ok? 
1 2 13 41.86 221 Y 
2 2 13 41.85 160 Y 
3 2 7 44.85 134 Y 
4 4 7 45.59 231 Y 
5 4 13 42.12 214 Y 
6 4 7 46.08 176 Y 
7 4 1 68.79 256 Y 
8 4 7 45.97 148 Y 
9 4 13 40.27 172 N 
10 5 13 41.49 210 Y 
11 5 7 45.09 166 Y 
12 5 13 42.10 196 Y 
13 5 7 83.59 163 N 
14 5 7 44.96 221 Y 
15 5 7 45.86 190 N 
16 5 1 52.85 244 Y 
17 6 7 46.27 189 Y 
18 6 7 44.85 158 N 
19 6 16 51.72 255 N 
20 6 7 44.53 140 Y 
21 6 13 40.27 172 Y 
22 7 13 42.07 228 Y 
23 7 26 16.22 213 Y 
 
3.2.8. Illumina raw sequencing results 
Illumina sequencing on the GAIIx generated a 3.47 Gb dataset consisting of 68 million 
reads of 51 bp in length. As expected from cloning experiments the mean insert size was 
~200 bp and read share was evenly distributed amongst the chosen indices (Figure 3.22). 
 
Figure 3.22 Summary histograms of CKCS Illumina sequencing 
(A) Proportion of reads allocated to each index. Index 2, 4, 5, 6 and 7 were used in library preparations of 
samples 6975, 9916, 15943, 16823 and 16874 respectively. Label 0 represents reads that could not be 
demultiplexed from the raw data. (B) Insert size histogram. 
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3.2.9. Development of a data analysis pipeline  
Illumina sequencing data for the CKCS was available as raw unaligned FASTQ files only. 
An example of a single read in FASTQ format is shown below. 
 
@SEQUENCE_ID  
TACGATCGATGCTAGCATGCATGCTTGACTGGGGACTGATCGTAGCTAGGATCGTGCAGT 
+  
!''*((((***+))%%%++)(%%%%).1***-+*''))**55CCF>>>>>>CCCCCCC65  
   
The @ symbol which acts as a marker is followed by an identifier tag on the first line. The 
second line details the read sequence. The third line has a + symbol marker and the 
fourth line shows the per base quality score for the sequence in line two. 
 
The two key requirements for analysis of massively parallel sequencing data are the 
ability to align reads to a reference genome and to call variants. A huge number of 
freeware programs are available online for handling and manipulating data generated by 
next generation sequencing platforms. Most are operated from the Linux command 
prompt and long strings of complex commands are often required for their operation. 
Additionally each program has different input requirements, and files often have to be 
manipulated by associated programs before they can be used to perform the desired task. 
This means that a long chain of complex commands have to be executed individually to 
achieve the desired results. To simplify the process a Perl script called “NGS analysis”, 
which could be run from the Linux command line, was written to sequentially process the 
string of required commands, after the user had been prompted to enter simplified details 
for the analysis. The initial user interface is shown in Figure 3.23. 
3.2.9.1. Features of the NGS analysis pipeline     
The NGS pipeline can handle paired-end or single-end Illumina data in FASTQ format and 
single end 454 data in ssq format. Reads are aligned to a reference genome using the 
program BWA. The best practice is to align data to a whole genome, but data can be 
aligned to an individual chromosome to reduce computational requirements. Datasets can 
also be reduced for easier handling. For instance if a target enrichment is performed 
across two genomic regions, alignment files can be created for each region separately to 
reduce file size and subsequent processing time. The pipeline will create SNP and indel 
calls, and there is an option to run the Ensembl Variant Effects Predictor to annotate calls 
with genomic information, such as consequence for variants positioned within exons.  
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Figure 3.23 NGS analysis Perl script user interface 
Screenshot of the user interface displayed at the start of the NGS analysis Perl script. The script was written 
to enable users to enter file names and analysis parameters, before automatic and sequential implementation 
of commands in the script to generate results files.  
 
Other modules in the pipeline include removal of PCR duplicates, an option to run the 
structural variant analysis program Pindel, an option to run an early next generation 
sequencing analysis package called Maq and tools to produce alignment summary, GC 
bias and insert size histograms. Key files are transferred to a new results folder that is 
created at the end of the pipeline. A log is created during the running of the pipeline that 
details the analysis settings selected. If an error appears in the log file the script will 
automatically terminate and send the user an email notification. Email notification is also 
given to users on completion of the analysis, which may take several hours depending on 
the size of the dataset. A summary of results files is listed in Appendix 7. This list is also 
presented in a readme.txt file created at the end of the analysis pipeline. A workflow of 
options available to users of the NGS analysis pipeline is shown in Appendix 8 and a 
video demonstrating use of the NGS pipeline is available on the supplementary CD.    
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3.2.10. Sequence data analysis 
The paired sequencing data files for each sample were passed through the sequence 
analysis pipeline. A summary table of the processed data is shown in Table 3.5. 
 
Table 3.5 Summary statistics for sequencing data 
 Individual 
ID 
No. of 
reads 
(Million) 
Dataset 
size 
(Mb) 
 Target 
enrichment 
efficiency (%) 
Percent bases 
achieving 10x 
Coverage 
PCR 
duplicates 
(%) 
6975 13.1 673 84.8 77.9 14.9 
9916 14.6 746 85.0 79.2 9.5 
15943 12.3 627 85.1 78.7 11.2 
16823 14.2 723 85.7 79.0 13.8 
16874 13.7 701 85.7 80.2 18.5 
 
 
SNP calls across all samples were combined into a single file format using The NGS SNP 
Handler, an Excel macro tool written by Dr Mike Boursnell. Across the five samples a total 
of 13,301 SNPs were identified. The NGS SNP Handler was adapted to accept indel files 
after completion of the CKCS investigation. Re-analysis of the data showed that 1,149 
indels were identified across the five datasets. 
 
Compiled SNP calls from the pipeline were initially filtered by expected segregation 
pattern (ie homozygous in cases and either heterozygous or homozygous wild-type in 
controls). The positions of these candidate SNPs were used to create a Browser 
Extensible Data (BED) file for uploading to the Integrative Genome Viewer (IGV). The five 
indel files that were created by the NGS analysis pipeline were in BED format and could 
be loaded directly into IGV. Ensembl gene predictions were uploaded to IGV to annotate 
the target regions which were then scanned visually for candidate variants occurring in 
exonic regions. This method of analysis revealed no variants for the EF region that could 
be considered as potentially causal. In the CKCSID region one indel was identified in an 
exonic region of FAM83H (family with sequence similarity 83, member H) which fully 
segregated with the disorder. To verify the indel, the sequence alignment files (.BAM files) 
were uploaded to IGV and the sequence reads were viewed across the candidate locus 
(Figure 3.24). The two CKCSID cases were homozygous for the indel at the locus and the 
two EF cases and the control were wild-type homozygous. 
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Figure 3.24 Reads from a CKCSID case aligned across the FAM83H candidate locus 
View in IGV of reads aligned across the FAM83H candidate locus for a single CKCSID case, enabling the 
indel call to be validated. Grey bars represent individual reads. The indel is represented by a solid black 
horizontal line in reads. 
  
As no potential causal SNP or indel calls had been identified for EF, the five read 
alignment files were loaded into IGV and the EF target region manually scanned for other 
potential causal variants. Three large deletions of ~6 kb, ~10 kb and ~16 kb were 
identified, although only the latter was situated across a coding region. The genomic 
positions of the three deletions within the disease-associated interval and a schematic 
overview of normal gene structure are shown in Appendix 6. The 16 kb deletion spanned 
the first three exons of the gene brevican (BCAN) and was potentially a full gene knock-
out (Figure 3.25). 
 
 
Figure 3.25 The 16 kb brevican deletion 
View in IGV across the brevican deletion region. Grey bars represent individual reads. Grey bars with a red 
perimeter indicate reads that have not been mapped in a pair. Blue bars show read pairs with a greater than 
expected insert size based on selected fragment size, indicative of a large deletion. 
 
The two EF cases were homozygous for the deletion, one CKCSID case (ID 9916) was 
heterozygous, and the other CKCSID case was homozygous wild-type (ID 6975). The 
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clinically unaffected control however was homozygous for the deletion, which was not 
consistent with the expected segregation pattern. In the absence of any further strong 
candidate mutations, the deletion was considered to be a strong potential causal variant. 
In order to find other potentially causal variants with a similar segregation pattern to the 
16 kb deletion a second scan across the chromosome 7 target region was performed, 
omitting the control sample from consideration. One additional variant was identified which 
was predicted to cause a coding change. This was a SNP in the gene DENND4B 
(DENN/MADD domain containing 4B) which caused an arginine to a histidine amino acid 
substitution, which followed the same segregation pattern as the BCAN deletion. 
3.2.11. Investigation of candidate variants 
Candidate variants were assessed by genotyping the GWAS sample cohort. As the 
DENND4B mutation was identified in the Golden Retriever included as a genotyping array 
control and the two Italian Spinoni included for the cerebellar ataxia project (described in 
Chapter 4), it was considered to be a common polymorphism. The DENND4B SNP also 
showed a weaker statistical signal across a 30 EF case and 38 control cohort than the 
BCAN deletion and was ruled out as potentially causal (DENND4B Praw = 6.81 x 10-11; 
BCAN Praw = 5.36 x 10-13). The number of cases was reduced from 31 to 30 as a 
DENND4B genotyping result was not obtained for one EF case, and the number of 
successful genotypes needed to be the same for both BCAN and DENND4B to make the 
comparison valid. Over the sample cohort of 31 EF cases and 38 controls the Praw value 
for the BCAN genotyping dataset was identical to the top statistical signal from the EF 
GWAS. Interestingly the BCAN deletion is positioned inside the region that was 
suggestive of a selective sweep because of the high levels of homozygosity seen in the 
SNP genotyping data. The FAM83H mutation fully segregated with CKCSID status in the 
cohort of 19 cases and 38 controls, producing a Praw value of 2.98 x 10-22, which exceeded 
the top statistical signal from the CKCSID GWAS of Praw = 1.2×10−17. 
 
To further validate the associations between the BCAN and FAM83H deletions and EF 
and CKCSID respectively, a panel of 308 CKCS was genotyped for both variants. This 
panel included the 31 EF cases, 19 CKCSID cases and 38 controls used in the GWAS 
analyses, and an additional 17 EF cases, 5 CKCSID cases and 198 controls. Results are 
shown in Table 3.6.  
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Table 3.6 BCAN and FAM83H genotyping results across an extended CKCS cohort 
 BCAN Genotype  
 
(-/-) (-/wt) (wt/wt) 
EF cases 39 3 6 
EF controls 17 62 181 
 
FAM83H  Genotype  
 
(-/-) (-/wt) (wt/wt) 
CKCSID cases 24 0 0 
CKCSID controls 0 38 246 
 
In addition a panel of 341 dogs from 34 other breeds (with at least 2 dogs per breed) were 
assayed for both the FAM83H and BCAN mutations. All 341 dogs were homozygous wild-
type for both polymorphisms. From the panel of 308 CKCS genotyped for 
the BCAN or FAM83H mutations, individuals that were not clinically affected, unrelated at 
the parent level and not related to cases at the parent level were used to estimate the 
mutation frequencies in the UK. From these 122 individuals, the allele frequency of both 
variants was estimated to be 0.08. 
3.2.12. Validating mutation consequence 
To validate the consequence of the two mutations, brain (cerebellum) and buccal epithelia 
cDNA sequencing confirmed the exon boundaries of the BCAN and FAM83H genes 
respectively (Genbank accession numbers JN968466–JN968467). The sequencing reads 
in the BCAN deletion region were exported and de novo assembled to define the exact 
deletion breakpoints (Figure 3.26). Assembly revealed the deletion to be 15,724 bp with a 
small insertion of 5 bp spanning the deletion breakpoints. The FAM83H single base 
deletion is in exon 5, and is predicted to truncate the peptide from 1,151 to 582 amino 
acids, with 257 aberrant amino acids at the C terminal. 
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Figure 3.26 De novo assembly of reads across the BCAN deletion 
Sequence reads mapping to the deletion breakpoints were exported and de novo assembled to define the 
deletion breakpoints. 
3.2.13. Expression analysis 
Quantitative reverse transcription PCR (qRT-PCR) was used to assess FAM83H and 
BCAN expression levels in canine skin and brain (cerebellum) tissues, using ACTB (beta 
actin) as a control gene. BCAN, FAM83H and ACTB reaction efficiencies were estimated 
at 97.5%, 95.7% and 94.3% respectively, with standard curve r2 values all > 0.99. BCAN 
expression was confirmed in the brain, but was not detected in the skin. A similar level of 
FAM83H expression was detected in both skin and brain (Figure 3.27). FAM83H 
expression was also detected in footpad and buccal epithelia by RT-PCR. 
 
 
Figure 3.27 qRT-PCR assessment of FAM83H and BCAN levels 
Limited expression analysis of FAM83H and BCAN using qRT-PCR, with ACTB as a control gene. (S = Skin; 
B = Brain).  
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3.2.14. Diagnostic DNA testing 
A diagnostic DNA test to assay for both the FAM83H and BCAN mutations simultaneously 
was launched in April 2011, offered by the AHT Genetics Services department 
(www.ahtdnatesting.co.uk/).  In the first year of testing, 2,457 samples were tested for 
CKCSID and 2,469 for EF (some owners requested individual disease testing). Dogs with 
two copies of the disease-associated allele were defined as affected, with one copy of the 
disease-associated allele as carriers, and with no copies of the disease-associated allele 
as normal.  Four affected and 196 carrier individuals were identified for CKCSID and 96 
affected and 539 carriers were identified for EF. Samples originated from 26 countries 
worldwide. A summary of testing is shown in Figure 3.28.   
 
 
Figure 3.28 First year results of EF and CKCSID DNA testing 
Ten countries submitting the most samples for EF and CKCSID testing.   
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3.3. Comments and conclusions 
3.3.1. EF candidate gene study 
Although no EF associated genes were identified, the investigation successfully ruled out 
many genes previously associated with hypertonicity disorders. When many strong 
candidate genes are available, a candidate gene study is often a logical first step to take 
before undertaking an expensive GWAS approach. The absence of an association with a 
candidate gene, may suggest that the disorder is caused by a previously unassociated 
gene.  
3.3.2. Parallel mapping of EF and CKCSID by GWAS 
The fact that EF and CKCSID were CKCS specific presented the opportunity to map both 
conditions in parallel using a single set of controls. This approach helped to reduce cost 
and decreased the overall timeframe for the studies as all DNA samples could be sent for 
processing on the CanineHD SNP array in a single batch. The disadvantage of the 
approach was that controls could not be tailored to the individual case sets. For this 
reason a largely unrelated set of controls was chosen, which may have contributed to the 
high genomic inflation values seen for both studies, indicating population stratification. 
Association analysis results for both studies however revealed strong statistical signals on 
single chromosomes, which remained after corrective analysis, indicating that the results 
were not largely affected by the genomic inflation, and confirmed the involvement of 
single, large effect, high penetrance genes, suggesting autosomal recessive inheritance. 
The same level of genomic inflation in the study of complex disease may have had a more 
significant impact on the results, where association signals on several chromosomes can 
be seen, and confidence in the results is crucial.  
 
On analysis of the raw genotyping data there were clear homozygous disease-associated 
haplotypes for EF and for CKCSID, defined by single recombination events in two 
individuals, resulting in a loss of shared homozygosity. Amongst the dogs originally 
defined as EF cases, based on their clinical signs, there were six outliers that were not 
homozygous for the BCAN deletion, highlighting that diagnosis of the condition is not 
simple and that other conditions, such as epilepsy, exist in the breed which may show a 
similar clinical presentation.  
3.3.3. Target enrichment and massively parallel sequencing 
In the absence of any strong candidate genes in the EF critical region and after exclusion 
of SLURP1, a candidate gene in the CKCSID critical region, it was decided that the fastest 
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and most cost effective method of exploring the two gene rich critical regions would be to 
use a newly available solution based target enrichment system (SureSelect) and a 
massively parallel sequencing approach (Illumina/Solexa). The solution based target 
enrichment system could be performed in-house, negating the need to outsource the 
work. 
 
The first stage of library preparation is the DNA fragmentation. Out of the three methods 
that were trialled an enzymatic method was chosen. This method appeared to give the 
most fragments in the desired range after processing, which is critically important 
especially as loss of fragments at the size selection stage may lead to additional PCR 
cycles being required. Any duplicates in sequencing data as a result of PCR are omitted 
during analysis, reducing the dataset size and eventual read depth. Enzymatic 
fragmentation also allowed several DNA samples to be processed in parallel, which was 
more time effective and ensured all samples were subjected to identical treatment. 
 
The entire library preparation was performed in-house. Accurate sizing of libraries on an 
Agilent Bioanalyser was outsourced due to unavailability of resources. Average library 
fragment size could have been assessed by agarose gel electrophoresis, but more 
precise sizing can be calculated using the Bioanalyser, which is important for determining 
final library concentration, especially when pooling libraries for multiplexed sequencing. 
 
Data were analysed in-house using a Perl script to run a pipeline to manipulate sequence 
files, align reads to the genome and make variant calls. The sequencing experiment was 
successful and a high level of target enrichment was achieved, with low levels of PCR 
duplicates. Bait coverage of target regions was limited to 65% because of the high levels 
of repetitive elements, particularly SINEs (short interspersed nuclear elements), present in 
the dog genome. The number of bases achieving at least 10x coverage was 79% 
however, and near complete exonic coverage of the critical region was achieved.  
 
By browsing through read alignments to target regions in IGV, which was annotated with 
filtered SNP and indel positions, deletions in BCAN and FAM83H were identified as strong 
candidate mutations for EF and CKCSID respectively. The dataset was the first large-
scale target enriched sequencing project to be processed by the NGS analysis pipeline, 
and highlighted areas of the analysis tool that could be improved. As both candidate 
mutations were identified by manual browsing, measures were subsequently made to 
make data processing more automated. Firstly the variant effects predictor module was 
added to the NGS analysis pipeline for annotation of SNP and indel calls with gene 
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information. Running indel calls through the predictor would have flagged the 1 bp 
FAM83H deletion as a frameshift mutation, warranting further investigation. Additionally a 
copy number variation (CNV) analysis Perl script was written to compare the number of 
aligned reads between two samples across overlapping genomic windows, and would 
have detected the 16 kb BCAN deletion without manual browsing of the sequence 
alignments.  
3.3.4. Candidate mutations and phenotype concordance 
EF has a variable phenotype in the CKCS and 17 out of 56 dogs that were homozygous 
for the BCAN deletion were reportedly not affected by EF, which suggests that the 
disorder may be influenced by variation in environmental stimuli and potential variants in 
modifier genes. As EF is an exercise-induced condition, differences in levels of activity 
among affected dogs may account for some of the phenotypic variation. One dog in the 
study that was homozygous for the BCAN mutation but did not display clinical signs 
consistent with EF was reported by its owner to be “docile and unexcitable”, suggesting, 
for this dog at least, insufficient environmental stimuli were provided to trigger the 
condition. In addition, nine out of 48 EF cases were not homozygous for the BCAN 
mutation. An extensive neurological assessment would be required to mitigate against 
misclassification of these cases, but this is typically not possible for the majority of canine 
patients due to expense or lack of owner consent. The CKCS breed is also affected by 
idiopathic epilepsy, and the EF episodes may often be difficult to distinguish from epileptic 
seizures, as a definitive diagnostic test is not available for either condition (Rusbridge, 
2005). It is therefore possible that for some cases epilepsy or other neurological 
conditions have wrongly been diagnosed as EF, although it is formally possible that there 
may be a second, genetically distinct form of EF in the CKCS. The EF disease-associated 
region was not completely resequenced due to the repetitive nature of around 35% of the 
sequence, and although unsequenced regions were largely non-coding, potential causal 
mutations could be situated within these regions and therefore would not have been 
identified in the current study. 
 
Results for FAM83H genotyping were fully concordant with CKCSID disease status across 
the extended sample cohort, showing that the CKCSID cases can be precisely diagnosed 
and that the condition has a simple autosomal recessive mode of inheritance, with no 
modifiers.  
 
No mutant BCAN or FAM83H alleles were detected among 341 dogs from 34 other 
breeds. This suggests that the two mutations are limited to the CKCS breed, although only 
a small selection of dogs was tested from just a subset of all dog breed populations. 
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Additional dogs would need to be screened to formally conclude that the mutation is not 
present in any other breeds. 
3.3.5. BCAN  
The EF-associated gene BCAN encodes brevican, which is one of the central nervous 
system specific members of the hyaluronan-binding chondroitin sulphate proteoglycan 
family (Yamada et al., 1994). Brevican is important in the organisation of the nodes of 
Ranvier in myelinated large diameter axons (Bekku et al., 2009) and disruption of this 
region results in a delay in axonal conduction (Bekku et al., 2010). Interestingly the gene 
HAPLN2 (hyaluronan and proteoglycan link protein 2) is tandemly arranged upstream of 
BCAN. HAPLN2 encodes Bral1, a brain specific hyaluronan and protoglycan link protein 
and is co-localised with brevican and versican V2 to form complexes at the nodes of 
Ranvier (Bekku et al., 2010). The BCAN deletion moves the 3′ UTR of HAPLN2 to within 2 
kb of exon 4 of BCAN. Expression analysis would be required to fully establish whether 
the ~16 kb deletion causes a complete knock-out of the BCAN gene and to investigate 
any potential effects on HAPLN2 expression. 
 
Mutations in BCAN have not previously been associated with a disease phenotype and 
brevican-deficient mice are viable, fertile, physiologically normal, display normal behaviour 
and have a normal life expectancy (Brakebusch et al., 2002). However, the absence of 
any apparent abnormalities in brevican-deficient mice may relate to an absence of 
episode triggers within the environment the mice were maintained in. In dogs, episodes 
are induced by exercise or excitement and it is highly likely that mice will not exercise at a 
sufficiently high intensity within their routine laboratory environment.  
 
EF is a condition that becomes self-limiting and can self-rectify in some cases, with some 
dogs becoming clinically normal after a period of months to years of being clinically 
affected. It is interesting to speculate that this might be due to compensatory effects of 
other chondroitin sulphate proteoglycans in the brain, in particular versican V2 (Bekku et 
al., 2009) taking over the role of brevican, although the effect could also be due to 
modified owner and/or dog behaviour in response to the episodes, such as a change in 
exercise levels or the avoidance of trigger events once these have been identified. 
 
An identical mutation in BCAN has recently been associated with EF in the CKCS, by an 
independent research group (Gill et al., 2011). This independent investigation helps to 
further validate the association of BCAN with EF.  
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3.3.6. FAM83H 
Several mutations in the CKCSID-associated gene FAM83H have been associated with 
autosomal-dominant hypocalcification amelogenesis imperfecta (ADHAI) in humans, 
which is a disease of faulty tooth enamel formation (Kim et al., 2008). To date the 
mutations associated with ADHAI have all been found in exon 5 of FAM83H and are either 
nonsense or frameshift mutations leading to a premature stop codon after a sequence of 
aberrant amino acids. Further to this, mutations in the 5′ region of exon 5 appear to result 
in a generalised phenotype, affecting all teeth, compared to mutations occurring in the 3′ 
region, which appear to give a localised phenotype, with just a subset of teeth being 
affected (Urzua et al., 2011). The canine mutation is at a position within the gene that 
would predict a more generalised phenotype. Anecdotal evidence suggests that CKCSID 
cases do show clinical signs of tooth disease, although this is a post-hoc observation and 
would require further investigation to determine the exact nature of the dental problems. 
 
The CKCSID phenotype suggests that FAM83H has an important role in skin 
development and regulation, in addition to enamel formation, at least in the dog. Limited 
expression analysis has revealed that FAM83H is expressed in canine skin, and also in 
the brain (cerebellum), footpad and buccal epithelia, in concordance with previous reports 
that FAM83H may be ubiquitously expressed (Kim et al., 2008). Species-specific 
differences in gene expression and function have not currently been investigated and no 
significant skin or nail phenotypes have been associated with ADHAI in human patients. In 
humans all FAM83H mutations reported to date have been dominant, and no human 
patients with homozygous FAM83H mutations have been reported. In contrast the canine 
mutation is recessive and heterozygous dogs do not have a discernable phenotype, so it 
is interesting to speculate that the gene is playing a different role in enamel formation 
between the two species and that human patients may present additional phenotypes, 
similar to CKCSID, if a deleterious homozygous FAM83H mutation was identified. 
3.3.7. Summary 
Mutations in BCAN and FAM83H have been identified which strongly associate with EF 
and CKCSID respectively, using an efficient parallel mapping and simultaneous 
sequencing approach. Neither of the two genes had been previously associated with 
similar disease phenotypes in other species. The discovery of these mutations may 
suggest potential novel biological functions for FAM83H and BCAN, although formal proof 
of this would require further functional data to confirm the causality of the two mutations 
with respect to their associated disease phenotypes. The study illustrates how two 
disease phenotypes in a single dog breed can be investigated using a very modest 
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sample set to successfully identify disease-associated mutations, using resources 
available in-house where possible to maximise cost effectiveness and efficiency. 
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4.1. Background 
4.1.1. The Italian Spinone 
The Italian Spinone (IS) is a hunting and retrieving dog, first imported into the UK in 1981. 
The IS was granted UK Kennel Club status in 1984, and has since gradually increased in 
popularity, with 441 dog registrations in 2012.           
4.1.2. Spinocerebellar ataxia in the Italian Spinone 
Spinocerebellar ataxia (SCA) is caused by degeneration of nerve cells in the cerebellum, 
brainstem and spinocerebellar tract. SCA in the IS is a progressive neurological disease 
characterised by hypermetria (high stepping gait or overreaching gait), particularly evident 
in the hind limbs (Figure 4.1A), truncal ataxia (loss of coordination), and impaired balance 
(Figure 4.1B). Clinical signs start to appear at three months of age and progress to a 
degree of dysfunction that leads to euthanasia of affected dogs at an average of one year 
of age. The disease shows an autosomal recessive mode of inheritance. The first and 
only scientific paper on SCA in the IS was published in 1996 as a brief communication 
giving a clinical overview of the condition (Wheeler and Rusbridge, 1996). Cases of SCA 
are infrequent, but have been reported in a number of countries including Italy, the UK, 
USA, and Germany.  
 
 
Figure 4.1 Clinical signs of spinocerebellar ataxia in the Italian Spinone 
(A) Hypermetria affects all four limbs but is more obvious in the hind limbs. (B) The forelimbs adopt a wide-
based stance to compensate for the impaired balance. Photos from videos provided by Dr Luisa de Risio. 
4.1.3. Ataxic disorders in other breeds 
Canine hereditary ataxia is widely reported in the veterinary literature and has been 
described in several breeds including the Kerry Blue Terrier (Darke and Kelly, 1976), the 
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Gordon Setter (Steinberg et al., 1981), Border Collie (Clark et al., 1982), the Portuguese 
Podengo (van Tongern et al., 2000), the Bullmastiff (Carmichael et al., 1983), the 
Rottweiler (Boersma et al., 1995), the Scottish Terrier (van der Merwe and Lane, 2001), 
the Papillion (Nibe et al., 2007), the Brittany Spaniel (Higgins et al., 1998), the American 
Staffordshire Terrier (Hanzlicek et al., 2003), the English Bulldog (Gandini et al., 2005), 
the Coton de Tulear (Coates et al., 2002), and the Rhodesian Ridgeback (Chieffo et al., 
1994). Clinical signs are highly variable between breeds, with an age of onset that can 
range from neonatal, which is the case for the Coton de Tulear, through to adult onset 
which is the case for the American Staffordshire Terrier. Clinical signs are frequently 
progressive and dogs in the later stages of the disease are often euthanised on welfare 
grounds, as quality of life diminishes. There are no effective treatments for hereditary 
ataxia, although clinical signs can be stabilised in some breeds without further 
progression. 
 
Ataxic disorders have also been described in the Parson Russell Terrier (Wessmann et 
al., 2004) and the Beagle (Kent et al., 2000), and are described in Chapters 5 and 6 of this 
thesis. 
4.1.4. Spinocerebellar ataxia in humans 
A number of distinct forms of SCA have been reported in humans, classified as SCA1 
through to SCA28 for autosomal dominant forms and SCAR1 through to SCAR12 for 
autosomal recessive forms, based on the chronological order in which they were first 
characterised. Similar to canine ataxias, human ataxias are a highly heterogeneous group 
of disorders, which vary in age of onset, severity of clinical signs and disease progression. 
Early symptoms in ataxic patients may include a difficulty balancing and controlling 
movement. Patients often have trouble walking steadily giving them a drunken 
appearance. Speech and vision may be affected and patients may experience difficulty 
swallowing. As with canine SCA, clinical signs can be progressive, although can stabilise 
for some forms, with variable effects on life expectancy. Hereditary forms of ataxia are 
thought to affect approximately 1 in 25,000 people in the United Kingdom, with 
Friedreich’s ataxia accounting for half of all cases, although this is not a spinocerebellar 
form of the disease (National Health Service 2013). 
4.1.5. Mutations associated with human spinocerebellar ataxia 
Mutations in 27 genes have been associated with SCA in humans, with repeat 
expansions, especially polyglutamate expansions, being a particularly common mutation 
type. Polyglutamate repeat expansions in six different genes account for six forms of 
human SCA (SCA1, 2, 3, 6, 7 and 17) (Higgins et al., 1996, Koide et al., 1999, Lindblad et 
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al., 1996, Orr et al., 1993, Riess et al., 1997, Sanpei et al., 1996). Expanded alleles 
become pathogenic above a particular copy number threshold, with the number of repeats 
often linked to the severity of clinical signs. The mechanism by which polyglutamate 
expansions cause ataxia is not fully understood, but it is thought that expansion may lead 
to protein agglutination and cellular dysfunction. Non-coding mutations have also been 
associated with SCA. A repeat expansion of CTG in the 3’ untranslated region (UTR) of 
the ATXN8OS (ATXN8 opposite strand (non-protein coding)) gene is associated with 
SCA8 (Koob et al., 1999), a CAG repeat in the 5’ UTR of the PPP2R2B (protein 
phosphatase 2, regulatory subunit B, beta) gene is associated with SCA12 (Holmes et al., 
1999), and an intronic pentanucleotide ATTCT repeat expansion in the ATXN10 (ataxin 
10) gene is associated with SCA10 (Matsuura et al., 2000). Heterozygous gene deletions 
and missense mutations have also been associated with human SCA (Tonelli et al., 2006, 
van de Leemput et al., 2007).  
4.1.6. Diagnosis of hereditary spinocerebellar ataxia 
In addition to inherited forms of SCA, other common causes of ataxia in human patients 
include head trauma, brain tumours, cerebrovascular accidents (strokes), viral infections 
and multiple sclerosis. The diagnosis of a hereditary form of ataxia is therefore made by a 
combination of observation of the clinical signs consistent with the disorder and exclusion 
of other possible underlying causes. Magnetic resonance imaging of the brain may detect 
morphological changes associated with degeneration of the cerebellum, and post-mortem 
histopathological examination may confirm cerebellar degeneration. In human patients, 
known causal mutations may be screened in an attempt to confirm the diagnosis and to 
categorise the ataxia type.    
4.1.7. Aims 
The aims of the study were to identify the mutation responsible for SCA in the IS and to 
design a diagnostic test to help reduce the frequency of the disease through a controlled 
breeding programme. 
4. Ataxia in the Italian Spinone 
 
 
 
107 
4.2. Results 
4.2.1. Genome-wide homozygosity mapping 
Six cases and six controls (obligate carriers) were used to perform genome-wide 
homozygosity mapping using 300 microsatellite markers (as the project commenced prior 
to the availability of the first canine high-density SNP genotyping array). Because of the 
small number of cases and controls, results were analysed visually and by comparing 
allele frequency between the case and control groups. 
 
On visual inspection microsatellite markers C20.374 and Ren124F16 showed a pattern 
suggestive of linkage with SCA (Table 4.1). Genotypes for the two markers were all 
homozygous for the same allele in cases and either heterozygous or homozygous in 
controls. The pattern across the two markers was suggestive of a shared homozygous 
haplotype across all cases, with controls (obligate carriers) having one copy of the shared 
haplotype, consistent with the segregation pattern expected for an autosomal recessive 
trait.  
 
Table 4.1 Markers initially suggestive of linkage to SCA in the IS 
Alleles of markers C20.374 and Ren124F16 gave results suggestive of linkage to SCA in the IS. Cases were 
homozygous for a shared haplotype (A) and controls (obligate carriers) were heterozygous for the same 
shared haplotype (B). Homozygous genotypes are highlighted in blue.  
(A) 
Marker Position Cases ID number 
  
(Chromosome:Mb) 5357 5397 5404 6422 6477 6685 
C20.374 20:15.60 191/191 191/191 191/191 191/191 191/191 191/191 
Ren124F16 20:21.93 233/233 233/233 233/233 233/233 233/233 233/233 
(B) 
Markers Position Control ID number 
  
(Chromosome:Mb) 5297 5298 5405 5407 5436 6478 
C20.374 20:15.60 187/191 191/191 182/191 182/191 191/191 191/191 
Ren124F16 20:21.93 233/238 238/240 233/233 233/233 233/238 233/238 
 
4.2.2. Linkage analysis 
Using C20.374 and Ren124F16 and additional microsatellite markers in the surrounding 
region, linkage analysis was performed by genotyping 60 individuals of an extended 
pedigree comprising a total of 13 SCA cases and 47 controls. Two point linkage analysis 
was performed using MLINK, with marker C20.374 giving a maximal LOD score of 4.41 
(theta = 0), which provided significant evidence of linkage to chromosome 20 (Figure 4.2). 
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Figure 4.2 Plot of chromosome 20 LOD scores  
LOD scores for markers on chromosome 20 genotyped across an extended IS pedigree calculated with a 
theta value of zero. The maximal LOD score was 4.41 at 15.60 Mb. 
 
4.2.3. Fine mapping  
Upon confirmation of linkage to chromosome 20, fine mapping was performed using 
additional microsatellite and SNP markers to define the disease-associated haplotype. 
The 13 cases were genotyped for a total of 40 microsatellites and 15 SNPs, to define the 
boundaries of the disease-associated haplotype as chr20:15.60-17.14 based on the 
genomic coordinates of the CanFam2 genome assembly, a region of 1.54 Mb. Genotypes 
of the two boundary defining individuals are shown in Table 4.2. 
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Table 4.2 Boundary defining genotypes for the SCA disease-associated region 
Genotypes of two cases defined the boundaries of the disease-associated haplotype. Heterozygous 
genotypes are shown in blue. All 13 cases were homozygous for the disease-associated interval defined as 
chr20-15.60-17.14. Non-determined alleles are marked as n.d. 
 
Marker Position  (canfam2) 4950 5404 
CFA20_13.17 13.32 247 245 247 247 
C20_13.53 13.68 204 212 204 204 
CFA20_13.70 13.85 240 240 240 240 
CFA20_14.18 14.33 208 208 208 208 
CFA20_14.27 14.42 279 279 279 279 
CFA20_14.34 14.49 203 207 203 203 
CFA20_14.38 14.53 134 134 134 134 
C20_14.44 14.59 230 230 230 230 
CFA20_15.03 15.18 162 157 162 162 
CFA20_15.13 15.28 131 141 131 131 
CFA20_15.27 15.42 261 267 261 261 
CFA20_15.37 15.52 239 233 239 239 
CFA20_15.39 15.54 167 169 167 167 
C20.374 15.60 191 187 191 191 
CFA20_15.59 15.74 285 285 285 285 
CFA20_15.60 15.75 204 204 204 204 
CFA20_15.74 15.89 177 177 177 177 
CFA20_15.82 15.97 n.d. n.d. 183 183 
CFA20_15.90 16.05 n.d. n.d. 328 328 
CFA20_16.06 16.21 246 246 246 246 
CFA20_16.42 16.57 n.d. n.d. 164 164 
C20_16.76 16.91 224 224 224 224 
CFA20_16.77 16.92 155 155 155 155 
CFA20_16.80 16.95 201 201 201 201 
CFA20_16.82 16.97 n.d. n.d. 299 299 
CFA20_16.86 17.01 n.d. n.d. 315 315 
CFA20_16.89 17.04 n.d. n.d. 289 289 
SNP9 17.14 n.d. n.d. C G 
SNP8 17.15 n.d. n.d. G A 
CFA20_17.01 17.16 n.d. n.d. 320 320 
SNP5 17.19 n.d. n.d. T C 
SNP3 17.21 n.d. n.d. T C 
SNP2 17.22 n.d. n.d. A G 
SNP2 17.22 n.d. n.d. C T 
SNP1 17.23 n.d. n.d. T A 
C20_17.09 17.24 n.d. n.d. 245 237 
CFA20_17.16 17.31 n.d. n.d. 132 134 
CFA20_17.24 17.39 297 297 297 303 
CFA20_18.07 18.22 129 129 129 135 
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4.2.4. Gene sequencing 
The disease-associated region contained the five genes BHLHE40 (basic helix-loop-helix 
family, member e40), ITPR1 (inositol 1,4,5-trisphosphate receptor, type 1), SUMF1 
(sulfatase modifying factor 1), SETMAR (SET domain and mariner transposase fusion 
gene) and LRRN1 (leucine rich repeat neuronal 1). The exons and 500 base pairs 
upstream and downstream of each gene were Sanger sequenced in two cases, two 
obligate carriers and a clinically normal Miniature Long Haired Dachshund as an 
additional control. The sequencing data generated were screened for correctly 
segregating polymorphisms (ie homozygous non wild-type in cases, heterozygous in 
obligate carriers and homozygous wild-type in the control). 
4.2.4.1. BHLHE40 
Seven SNPs were identified within BHLHE40, including four in the 5’ UTR, one in intron 3, 
one in exon 4 and one in exon 5. None of the variants fully segregated with disease status 
and were therefore not potentially causal.  
4.2.4.2. ITPR1 
The ITPR1 gene is a strong candidate for the cause of SCA in the IS as mutations in this 
gene have been associated with SCA15 in humans (Hara et al., 2008). Through Sanger 
sequencing a total of 61 polymorphisms were identified in the gene. Twelve exonic SNPs 
were identified, including one non-synonymous base change causing a glutamine to 
glutamic acid substitution. None of the SNPs across the gene segregated appropriately 
with disease status and were therefore not potentially causal.  
 
One polymorphic microsatellite was located in a highly conserved region of the 5’ UTR of 
ITPR1 (Figure 4.3). Alleles of the variant segregated consistently with disease status for 
the five samples initially sequenced. Sequencing of additional obligate carriers revealed 
individuals that were homozygous for the disease-associated allele, indicating its 
presence on a normal haplotype and ruling out the microsatellite as the causal mutation.  
 
HSA  1    GTAACCATGTGGATGTGCTGCTGAAGCGTTTCCTCAAGCTCGCTGGGGTGGGAGGAGAGG  60 
          |||||||||||||||| ||||||||||||||||||||||||||||||||||||||||||| 
CFA  1    GTAACCATGTGGATGTTCTGCTGAAGCGTTTCCTCAAGCTCGCTGGGGTGGGAGGAGAGG  60 
 
HSA  61   AGGAGGAGGAGGTGGTGGTGGAGGAGGAGGCAGGGGGTG------------GAGAGAGAG  108 
          |||||| ||   |||||| |||||||||||||| |||||            ||||||||| 
CFA  61   AGGAGGTGG---TGGTGGAGGAGGAGGAGGCAGAGGGTGGAGAGAGAGAGAGAGAGAGAG  117 
 
HSA  109  AAAGCGCACGCCGAGAGGAGGTGTGGGTGTTCCGCTTCCATCCTAACGGAACGAGCTCCC  168 
          |||||||||||  ||||||||||||||||||||| ||||||||||||||||||||||||| 
CFA  118  AAAGCGCACGCACAGAGGAGGTGTGGGTGTTCCGTTTCCATCCTAACGGAACGAGCTCCC  177 
 
Figure 4.3 A conserved section of the 5’ UTR of ITPR1 containing a microsatellite sequence  
Human (HSA) to dog (CFA) alignment of a conserved section of the 5’ UTR of ITPR1 containing a short 
microsatellite sequence (highlighted in blue). An allele of the microsatellite initially segregated with disease 
status across the five sequenced individuals. The variant was ruled out as causal by additional sequencing. 
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4.2.4.3. SUMF1 
Eleven sequence variations were found including two synonymous exonic, six intronic and 
three 5’ UTR SNPs. An intronic polyT variation was also seen. None of the alleles 
segregated consistently with disease status. 
4.2.4.4. SETMAR 
In SETMAR two SNPs and a mononucleotide repeat variation were seen, all in the 5’ UTR 
and none segregating consistently with disease status.  
4.2.4.5. LRRN1 
One SNP, two microsatellite repeats and a homopolymer repeat sequence variant were 
found in the 5’ UTR, which were ruled out as potentially causal. 
4.2.4.6. Other predicted genes in the disease-associated region 
Two other genes were predicted by Ensembl to be in the disease-associated region 
(SAP18-like and XP_533756.1). Supporting evidence for the SAP18-like gene was weak, 
as the human orthologue is found on chromosome 13 rather than the syntenic region on 
chromosome 3 (Figure 4.4). The gene was however sequenced for completeness. Sixteen 
sequence polymorphisms were found, but no alleles fully segregated with disease status. 
XP_533756.1 was a predicted gene in Ensembl, but was later reclassified as a 
pseudogene (CWC15-like). The pseudogene was sequenced for completeness but no 
polymorphisms were identified. 
 
 
Figure 4.4 Human syntenic regions of canine chromosome 20 
Canine chromosome 20 is syntenic to regions of human chromosomes 3 and 19. The SCA disease-
associated region, indicated by the red marker, is syntenic to a region on human chromosome 3. 
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4.2.5. RNA sequencing 
4.2.5.1.  ITPR1 mRNA sequencing 
The transcript sequence of the top candidate gene, ITPR1, was confirmed by sequencing 
mRNA from canine cerebellum tissue. Comparison of the human ITPR1 gene and the 
canine Ensembl prediction suggested ITPR1 to have an additional untranscribed 
upstream exon. BLAST searching of the additional human exon against the dog genome 
revealed a region on canine chromosome 20 showing 91% sequence similarity in the 
expected position upstream of the first exon of the Ensembl prediction. The exon was also 
confirmed by mRNA sequencing. 
 
Figure 4.5 provides an overview of the key features of the ITPR1 transcript expressed in 
the cerebellum. The translational start point is located in the third exon, as the gene has 
two untranslated exons. An isoform exists with skipping of exon 12. Additionally there are 
splice variants for exon 41, producing two versions of the exon with a 3 base pair 
difference, equating to loss or gain of a glutamine residue. The stop codon is located in 
exon 62. 
  
 
Figure 4.5 Canine ITPR1 transcript structure 
Features of the canine cerebellum ITPR1 transcript. Untranslated regions are shaded in grey. 
 
4.2.5.2. Non-quantitative assessment of critical haplotype gene expression. 
Expression of other genes across the region were assessed in a non-quantitative 
approach using reverse transcription PCR (RT-PCR). Primers were designed to span 
across the entire genes, from first to last exons to confirm expression and transcript 
length. All genes showed some expression in the cerebellum apart from SUMF1. PCR 
products of expressed genes were subsequently sequenced, confirming Ensembl gene 
predictions and intron exon boundaries for BHLHE40, SETMAR, SAP18-like and CWC15-
like. An additional untranslated upstream exon was identified for the LRRN1 transcript. 
PCR products are shown in Figure 4.6. 
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Figure 4.6 Non-quantitative assessment of critical haplotype gene expression by RT-PCR 
PCRs were designed across BHLHE40, SUMF1, SAP18-like, SETMAR, CWC15-like, and LRRN1 to assess 
gene expression, with products shown in lanes 2 to 7 respectively.  
 
4.2.5.3. Using mRNA-seq to assess gene expression 
The availability of mRNA-seq data from experiments detailed in Chapter 6 provided the 
opportunity to scan the SCA disease-associated region and confirm gene expression in 
the cerebellum. The data provided good evidence that all genes listed were expressed to 
some extent across the region, including SUMF1, for which PCR results suggested no 
expression in the cerebellum. A summary of genes expressed in the disease-associated 
region is shown in Table 4.3. 
Table 4.3 Expressed genes across the SCA disease-associated region 
Expression levels of the genes within the disease-associated interval based on data from genome-wide 
mRNA-seq experiments 
Gene Position (canfam2) mRNA-seq approximate 
read depth 
BHLHE40 15,643,983-15,651,394 30 
ITPR1 15,748,745-16,044,359 120 
SUMF1 16,095,419-16,192,508 50 
SAP18-like 16,159,039-16,159,395 30 
SETMAR 16,213,239-16,231,854 10 
CWC15-like 16,345,948-16,346,727 100 
LRRN1 16,618,166-16,653,827 15 
Unknown transcript 16,849,315-16,854,497 5 
 
 
Although there were sequence alignments for the genes SAP18-like and CWC15-like, 
mapping quality of the reads to the reference sequence were indicated as zero. A 
mapping quality value of zero indicates that the alignment is not unique and that the read 
sequence is present elsewhere in the genome. This gives an indication that SAP18-like 
and CWC15-like may be pseudogenes. Displays of mRNA-seq data across genes in the 
region is shown in Appendix 10. 
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4.2.6. Illumina sequencing of the ITPR1 gene 
4.2.6.1. Experiment design 
As the causal mutation had not been identified by exon resequencing of all the genes in 
the region, the causal mutation was assumed to be non-coding or in an uncharacterised 
gene. Given the association of ITPR1 with SCA15 and SCA16 in humans and also ataxia 
in mice (Iwaki et al., 2008, van de Leemput et al., 2007), it was decided to sequence the 
entire gene including introns and 10 kb of upstream and downstream sequence using 
newly available massively parallel sequencing technology. As this was the first massively 
parallel sequencing experiment to be undertaken at the AHT it was decided to use a 
single SCA case for template generation and use the experiment as a pilot study. 
Polymorphisms would be considered as potentially causal if they were in conserved 
regions of the genome. 
4.2.6.2. Template generation 
The work commenced in March 2008 prior to the launch of commercial sequence capture 
methodology, so long range PCR was chosen as a method of template generation. In total 
60 PCRs were required to span the ITPR1 gene and 10 kb of upstream and downstream 
sequence. PCR products were resolved by agarose gel electrophoresis (Appendix 11). 
The total combined PCR product length was 376,356 bp, giving a contig length of 339,597 
bp with no gaps (chr20:15,738,385-16,077,981).  
4.2.6.3. Illumina sequencing and analysis 
Library preparation and sequencing were performed by Fasteris Life Science, Switzerland. 
Sequencing was performed on the Illumina GAII, generating 1,467,675 reads of 33 bp in 
length. Reads were aligned to CanFam2 using the Linux based software package Maq. 
On alignment 88.3% of reads mapped to chromosome 20, giving an average read depth 
of 124, with 98.9% of bases achieving at least 10x coverage. De novo assembly was 
performed using EDENA software at Fasteris Life Science. EDENA software assembled 
70.7% of the reads into 291 contigs when the minimum read overlap was set to 25. The 
total sequence assembled by EDENA was 350,854, with 256,084 mapped by BLAST to 
the target region of chromosome 20, equating to 75.4% base coverage. 
 
Average read depths were calculated across 20 bp windows in Maq, to look for any spikes 
in read depth that could indicate small copy number variation. Datapoints were plotted in 
Excel and an example is shown in Figure 4.7. Although read depth across the target 
region was too variable to consider small copy number variations, a doubling of read 
depth could clearly be seen in positions of overlap between PCR products.  
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Figure 4.7 Read depth over 20 bp windows across the ITPR1 target region 
No obvious copy number variations were noted across the ITPR1 gene, although a doubling of read depth 
was noted in the region of overlap between PCR products.  
 
The consensus sequence of reads aligned to the canine reference and de novo 
assembled contigs, were aligned together using the Staden Gap software package. 
Capillary sequence reads across the gene were also aligned to assess the accuracy of 
the sequencing technology.  
 
A total of 1,018 variants were called by Maq across the target region, including 615 SNPs 
and 469 indels, although the number of indels is likely to be an overestimation due to 
calling inaccuracies in early massively parallel sequencing analysis tools. Six short 
interspersed nuclear elements (SINEs) were identified by visually browsing contig 
alignments to the consensus sequence in Staden Gap. The positions of all variants were 
assessed for sequence conservation by viewing in the UCSC genome browser. Eight 
SNPs in semi-conserved regions and all identified SINEs, detailed in Table 4.4, were 
investigated further by Sanger sequencing five additional samples including one case, two 
obligate carriers and two predicted wild-type individuals based on haplotype analysis. 
None of the polymorphisms segregated with disease status.   
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Table 4.4 Variants in conserved regions of ITPR1 for further investigation 
Variants across the ITPR1 gene were assessed for sequence conservation across species, and sequenced 
across additional cases and controls. None of the variants fully segregated with disease status. 
 
Genomic region Feature 
15747434-15747873 SNP 
15807374-15807822 SNP 
15821684-15822358 SNP 
15883508-15883914 SNP 
15888739-15889265 SINE insertion 
15901797-15902333 Insertion 
15919562-15920003 2 bp deletion 
15930447-15931004 SNP 
15952316-15952708 SNP 
15955174-15955544 SINE insertion 
15990820-15991263 SINE insertion 
16005179-16005716 9 bp deletion 
16010817-16011268 SINE deletion 
16011285-16011680 SINE insertion 
16015255-16015700 SINE deletion 
 
4.2.6.4. Investigation of a possible repeat expansion 
As the sequenced region was manually browsed a large intronic tetranucleotide repeat 
sequence was identified between exon 5 and 6 of ITPR1 (47 perfect repeats, CanFam2 
chr20:15,941,265-15,941,537). Given the association of repeat expansions with human 
SCA, the repeat was assessed by genotyping across two cases, two obligate carriers and 
two wild-type individuals. The cases were both homozygous for a 454 bp amplicon, 
obligate carriers were heterozygous (454,484 and 454,447) and the two wild-type controls 
were homozygous 484 and heterozygous 473,476. As the disease-associated allele was 
not expanded, the variant could be ruled out as causal of SCA.   
4.2.7. Copy number investigation using the CanineHD SNP array 
Two DNA samples were submitted for genome-wide SNP analysis as a means of 
detecting potential copy number variations across the disease-associated region. The 
genotyped individuals were an obligate carrier and the 3’ boundary defining case of the 
disease-associated interval (ID 5404 in Table 4.2). Based on marker BICF2P939857 
being heterozygous in the case, the 3’ boundary could be refined as chr20:17,116,778. 
 
In Genome Studio, individual SNP B allele frequencies and log R ratio values were 
analysed to assess the disease-associated region for possible copy number variations. B 
allele frequencies of 1 and 0 signify homozygous genotypes and frequencies of 0.5 signify 
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heterozygous genotypes. The point of recombination in the genotyped case can be clearly 
defined by B allele frequency, due to loss of homozygosity (Figure 4.8 A). Log R ratios 
show the relative signal intensity of each genotyped SNP. Increased or decreased log R 
ratios may indicate duplications or deletions respectively. Log R ratios for the SNPs 
across the region stayed close to 0 for both the case (5404) and obligate carrier (2275) 
and suggested that there is no copy number variation across the region (Figure 4.8 B). 
 
 
Figure 4.8 Assessing copy number by log R ratio and B allele frequency 
Individual SNP B allele frequencies (A) and log R ratios (B) were used to assess potential copy number 
variation across the disease-associated region. Individual SNPs are marked as blue dots. A shift in log R ratio 
from zero to one would indicate a duplication. For the obligate carrier, heterozygous SNPs located within a 
heterozygous duplication would have a B allele frequency of 0.33 or 0.66.  
4.2.8. Illumina sequencing of the disease-associated interval 
4.2.8.1. Experiment design 
With the availability of target enrichment methodology, a second resequencing experiment 
was performed across the entire disease-associated interval. As the locus for SCA in the 
Parson Russell Terrier (PRT) had also been mapped (Chapter 5), the two regions could 
be captured in parallel using a single combined probe set. A summary of probe design is 
shown in Table 4.5. Probes achieved a base coverage of 2.21 Mb (56.7%) after repeat 
masking. 
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Table 4.5 Summary of target intervals for target enrichment of SCA regions 
Breed Chromosome Position Total baits 
Parson Russell Terrier 18 53,533,360-55,860,486 20535 
Italian Spinone 20 15,601,140-17,116,778 12685 
 
4.2.8.2. Sample selection 
Two IS SCA cases and three controls (obligate carriers) were chosen for sequencing.  
Obligate carriers that had different wild-type haplotypes across the associated region were 
chosen, to aide exclusion of candidate causal variants. Five PRT samples were chosen 
for parallel sequencing (Chapter 5). These samples acted as additional controls for the IS 
SCA study.   
4.2.8.3. Library preparation 
Library preparation was adapted to enable buccal DNA to be used. Buccal swab DNA is 
often highly sheared, so an alternative to enzymatic fragmentation was needed 
(enzymatic fragmentation would have resulted in too many unusable small fragments). As 
the recommended method of fragmentation in the SureSelect protocol was Covaris 
shearing, and a Covaris shearing service had become available since the CKCS targeted 
sequencing experiment, this method was chosen for fragmentation.  
4.2.8.4. Illumina sequencing 
Illumina sequencing was performed at the Wellcome Trust Centre for Human Genetics, 
University of Oxford. Paired-end sequencing with 51 bp read lengths was performed on a 
single lane of a HiSeq 2000 generating a 19.64 Gb dataset. A summary of the dataset is 
shown in Table 4.6. 
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Table 4.6 Summary of the SCA targeted sequencing dataset 
Individual 
ID 
No. of 
reads 
(Millions) 
Dataset 
size 
(Gb) 
 Target 
enrichment 
efficiency (%) 
Bases 
achieving 10x 
Coverage (%) 
PCR 
duplicates 
(%) 
2275 36.5 1.86 77.9 78.4 38.8 
5404 41.2 2.10 78.6 79.6 40.9 
5405 30.9 1.58 77.6 78.8 35.2 
6479 35.3 1.80 78.3 78.9 35.6 
6685 35.9 1.83 78.3 79.0 35.4 
12015 38.4 1.96 77.0 79.2 35.5 
12205 34.9 1.78 77.5 79.6 43.7 
12898 37.9 1.93 76.0 79.1 36.5 
12947 33.8 1.72 76.6 78.7 32.1 
18500 33.6 1.71 76.6 78.7 37.9 
 
4.2.8.5. Data analysis 
4.2.8.5.1 SNP and indel analysis 
Data were processed in Linux using the NGS pipeline (described in Chapter 3). SNP and 
indel calls were aligned across all individuals using the SNP Handler Excel macro 
developed by Dr Mike Boursnell at the AHT. Compiled SNPs were annotated with gene 
consequence predictions and assigned a segregation score based on how well SNPs 
segregated with disease status. In total 4,495 SNPs and indels were identified across the 
SCA disease-associated region. Fifty-two variants segregated appropriately with disease 
status ie homozygous in the two cases and heterozygous in the three obligate carriers. 
Variants for which the disease-associated allele was the same as the reference allele 
were excluded, leaving eight variants. Data from the PRTs were used for further filtering. 
As five of the disease-associated SNPs were present in some or all of the PRT individuals 
this left two SNPs and a 1 bp insertion to consider as potentially causal for SCA in the IS. 
 
The two SNPs were intergenic and in non-conserved regions of the dog genome. The 1 
bp insertion however was within a region of high conservation and worthy of further 
investigation (Figure 4.9). The insertion was located approximately 2 kb downstream of 
the 3’ UTR of BHLHE40. The syntenic region of the human genome has been shown to 
be a major transcription factor binding site through ChIP-seq experiments indicating that 
the sequence could be part of an important regulatory element. The indel was investigated 
by genotyping in 149 Italian Spinoni previously genotyped for the two microsatellite 
markers used for linkage-based diagnostic testing (see section 4.2.9). The results from 
the 1 bp insertion and microsatellite markers were concordant apart from three dogs, in 
which the 1 bp insertion was heterozygous, suggestive of a carrier status, and the 
genotypes of the two microsatellites were suggestive of a normal status. All three 
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individuals shared a rare non-disease-associated microsatellite allele for one of the 
diagnostic markers, suggesting the insertion, in addition to being disease-associated, was 
also present on a rare normal haplotype, indicating that it was therefore not causal of 
SCA. 
 
 
Figure 4.9 Insertion in a conserved region of the SCA associated interval 
A 1 bp insertion which segregated with disease status across the individuals selected for target enrichment 
was identified in a conserved part of the disease-associated region (highlighted in red). An additional 1 bp 
insertion was also identified 300 bp downstream, indicated by the green arrow. This insertion did not fully 
segregate with disease status and was therefore excluded. 
 
4.2.8.5.2 Copy number analysis 
A high resolution scan for copy number variations was performed by comparing read 
count between cases and controls over a sliding window of 10 kb. As SNPs on the 
CanineHD array are approximately every 14 kb an approach using read counting 
increased resolution and ensured the region was evenly investigated. Results are 
displayed in Figure 4.10. The ratio of case read count to control read count remained very 
close to 1 across the captured region, suggesting no copy number variation. Analysis 
across a 5 kb window also suggested no copy number variations, although read depth 
ratio did show more deviation from 1:1. On visual analysis, this was due to very low read 
count over some 5 kb windows, rather than genuine differences in copy number between 
the case and the control. The inability to scan for copy number over smaller sliding 
windows was a consequence of the repeat masked SureSelect bait design, resulting in 
lack of coverage across some regions. Approaches producing more even coverage, such 
as whole genome sequencing would allow for higher resolution analyses for copy number, 
but would also be dependent on read depth as well as overall base coverage.     
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Figure 4.10 Case versus control read count comparison 
Comparison of case and control read counts across overlapping 10 kb windows. Ratios of 1:1 suggest no 
copy number variation between the case and control. 
 
4.2.8.5.3 Other variants in the target enriched sequencing data 
The sequencing data were visually scanned in IGV to search for other variants that could 
be considered causal for SCA in the IS. SINEs detected during the ITPR1 resequencing 
experiment were confirmed manually by visualising data in IGV. Additional variants not 
picked up by automated variant calling programs were also seen and are summarised in 
Table 4.7. 
Table 4.7 Additional variants across the SCA critical region 
Genomic region Feature 
Correct segregation 
pattern 
chr20:15,773,266-15,773,280 14 bp deletion No 
chr20:15,882,747-15,883,097 CTT repeat expansion in SINE Yes 
chr20:15,914,340-15,914,514 SINE deletion No 
chr20:16,104,369-16,104,411 16 bp insertion No 
chr20:16,125,448-16,125,698 SINE deletion No 
chr20:16,133,144-16,139,501 LINE deletion No 
 
4.2.8.5.4 Triplet repeat expansion identification 
The only additional variant to segregate with disease status was a GAA triplet repeat 
expansion. On visual scanning of the sequence read alignments, a 30 bp region showing 
variable coverage between cases and controls was identified (Figure 4.11). In this region 
read depth dropped to zero for cases but remained in all three controls, although the low 
coverage in the controls meant that the profile of the coverage histogram appeared 
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comparable for all individuals. The region that was unsequenced in the cases was located 
in intron 35 of ITPR1 and consisted of a poly(T) tract which was 5’ of a SINE element and 
3’ of a short trinucleotide repeat sequence TTC(8). Just upstream of the region many 
singleton reads (reads lacking an aligned mate) were present. Further investigation 
revealed the sequence of all the unaligned mates to be GAA(17) suggesting expansion of 
the trinucleotide repeat sequence in the cases was potentially responsible for the region’s 
failure to sequence in the DNA from these dogs. 
 
 
Figure 4.11 GAA repeat expansion in ITPR1 intron 
A GAA repeat expansion was identified in the target region, flanking a SINE. In the figure the position of 
capture baits, and repeat elements are highlighted by the blue bars. Grey reads with a red perimeter indicate 
reads with unaligned mates.  
 
The GAA repeat expansion was further investigated by PCR to genotype all individuals of 
known status, ie 13 cases and 16 obligate carriers, to assess whether repeat expansion 
could be causal. All 16 obligate carriers were heterozygous for the repeat expansion. 
Seven of the thirteen cases produced PCR results (results could not be obtained from 
DNA extracted from FFPE tissue). Each of the seven cases had two expanded alleles of 
different lengths, suggesting the repeat sequence is highly mutatable. Example results are 
shown in Figure 4.12. Amplification of the GAA repeat expansion required the use of a 
long range enzyme mix consisting of a blend of Taq polymerase and a proofreading 
enzyme, to enable visualisation of carriers. Results for homozygous repeat expanded 
alleles and wild-type alleles could be produced with a Taq polymerase, but for 
heterozygotes amplification of wild-type alleles outcompeted expanded alleles, making it 
impossible to accurately distinguish wild-type homozygous and heterozygous individuals. 
The reaction using the long range enzyme blend was highly sensitive and lacking 
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robustness making results difficult to repeat and the assay inappropriate for diagnostic 
testing purposes. 
 
 
 
Figure 4.12 PCR analysis of the GAA repeat polymorphism 
The expected wild-type amplicon was 238 bp. PCR products from cases are in lanes 2, 3 ,4, 10, 11, 14, and 
16, from obligate carriers in lanes 5, 6, 7, 12, 13, and 15 and from a homozygous wild-type individual in lane 8. 
Lane 9 contains a no-template control. All cases have two expanded alleles of varying lengths. Results 
suggest expanded alleles ranging from approximately GAA300 – GAA650. 
 
Repeat expansion was confirmed by Sanger sequencing the longer alleles. A single allele 
of a case containing approximately 300 repeat subunits was gel extracted and used as a 
template for Sanger sequencing by capillary electrophoresis. Results confirmed a pure 
TTC.GAA repeat expansion for the allele, although sequencing diminished after 
approximately 60 GAA subunits. The sequencing trace is shown in Figure 4.13.  
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Figure 4.13 Sanger sequencing trace confirming GAA.TTC repeat expansion 
Sanger sequencing of an expanded amplicon produced from a SCA case, confirmed a pure GAA repeat 
expansion, although a complete trace spanning the entire length of the GAA repeat could not be produced. 
 
4.2.9. Allele length distribution and intergenerational repeat stability 
To estimate allele lengths a standard curve was drawn by plotting the migration distances 
of DNA ladder bands on the agarose gel (Figure 4.12) against the known fragment sizes. 
To allow calculation of allele sizes from migration distances an order four polynomial 
regression was performed in Excel (Appendix 12). Using regression equations and based 
on the expected amplicon size of 238 bp for the reference sequence containing eight GAA 
repeats, an estimate of repeat copy number for unknown alleles could be calculated. 
Based on this calculation and the available data, the repeat copy number range for 
expanded alleles could be estimated as 318-651 and for normal alleles as 7-22. Familial 
relationships between individuals allowed intergenerational stability to be assessed. A 
range from an increase of 62 repeat subunits to a decrease of 109 repeat subunits per 
generation was observed. Repeat copy number also fluctuated to a smaller extent 
between siblings (Table 4.8). 
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Table 4.8 Repeat copy number and generational changes 
Repeat copy number estimates based on migration distances on agarose gel. Allele sizes were calculated 
using polynomial regression (order 4) equations (Appendix 12). Allele copy numbers were calculated based on 
the reference amplicon size of 238 bp containing eight GAA repeat units. 
Family Gel Lane ID Relationship 
Allele 1 copy 
number 
Allele 2 copy 
number 
Minimum generational 
expansion/contraction 
1 7 5436 Father 10 495 n/a 
 2 5357 Daughter 414 495 0 
       
2 6 5407 Father 7 480 n/a 
 5 5405 Mother 7 480 n/a 
 3 5397 Daughter 466 542 +62/-14 
 4 5404 Son 453 510 +30/-27 
       
3 13 6479 Father 22 402 n/a 
 12 6478 Mother 10 651 n/a 
 10 6422 Son 357 576 -45/-75 
 11 6477 Daughter 347 559 -55/-92 
 14 6685 Son 318 542 -84/-109 
       
4 15 8636 Father 10 542 n/a 
 16 8637 Son 426 526 -16 
 
4.2.10. DNA testing 
A linkage-based test for SCA using microsatellite markers was launched in 2008. The 
diagnostic potential of seven polymorphic microsatellites within the disease-associated 
haplotype was considered by genotyping 147 individuals, including 13 cases and 16 
obligate carriers. For all the microsatellite markers one or more of the obligate carriers 
was homozygous for the disease-associated allele, indicating that none of the markers 
tested were in complete linkage disequilibrium with SCA. However, using a combination of 
two microsatellites to produce two-marker haplotypes a pattern of complete linkage 
disequilibrium could be achieved with the individuals of known status ie none of the 
obligate carriers were homozygous for both disease-associated allele 204 and 155 of the 
two chosen microsatellites respectively (Table 4.9).  Of the remaining 118 clinically normal 
IS individuals of unknown genetic status, 63 were predicted to be genetically clear (ie 
homozygous wild-type) and 55 were predicted to be carriers (ie heterozygous for the SCA 
mutation). In the run up to the test an additional 147 clinically normal IS were genotyped 
using the two-marker test, with 15 predicted to be carriers and 132 predicted to be clear. 
Out of all 294 individuals tested, only the known affected individuals produced a haplotype 
pattern suggesting a clinically affected status ie no wild-type associated 204/155 
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haplotypes were detected, indicating the high diagnostic value of using a linkage test with 
two markers.  
 
Table 4.9 Microsatellite diagnostic test results for case individuals and obligate carriers 
Disease status of all cases and obligate carriers could be predicted based on a two microsatellite marker 
haplotype (assuming successful PCR amplification).  
 
Sample 
No. 
Status Chr20:15.75 Chr20:16.92 
4489 Affected - - - - 
4490 Affected 204 204 155 155 
4491 Affected 204 204 155 155 
4914 Affected - - - - 
4950 Affected 204 204 155 155 
4951 Affected 204 204 155 155 
5357 Affected 204 204 155 155 
5397 Affected 204 204 155 155 
5404 Affected 204 204 155 155 
6422 Affected 204 204 155 155 
6477 Affected 204 204 155 155 
6685 Affected 204 204 155 155 
8637 Affected 204 204 155 155 
2224 Obligate carrier 200 204 155 155 
2228 Obligate carrier 200 204 155 157 
2236 Obligate carrier 196 204 155 157 
2247 Obligate carrier 200 204 155 155 
2248 Obligate carrier 196 204 151 155 
2255 Obligate carrier - - 151 155 
2275 Obligate carrier 196 204 155 158 
2524 Obligate carrier 196 204 155 157 
5297 Obligate carrier 196 204 151 155 
5298 Obligate carrier 200 204 155 158 
5405 Obligate carrier 196 204 155 166 
5407 Obligate carrier 196 204 155 166 
5436 Obligate carrier 200 204 155 158 
6478 Obligate carrier 200 204 155 158 
6479 Obligate carrier 204 204 155 158 
8636 Obligate carrier 200 204 155 157 
   
 
Since the test was launched in March 2008, the genetic services department at the AHT 
have tested DNA from 497 Italian Spinoni using the microsatellite linkage test. Over this 
period there has been a gradual decrease in the demand for DNA testing (Table 4.10), 
with no samples submitted for testing in 2012. This is probably because once a genetically 
clear line is established no further testing is required. Since the availability of the 
diagnostic test there have been no reported cases of SCA in the IS, suggesting that 
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diagnostic testing in the breed has led to the effective elimination of the mutation from the 
breed. 
 
Table 4.10 Diagnostic test statistics for the SCA test 
 
Year Number 
tested 
Number of 
carriers 
Carrier 
percentage 
2008 223 15 6.7 
2009 128 5 3.9 
2010 98 13 13.3 
2011 48 1 2.1 
2012 0 0 - 
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4.3. Comments and conclusions 
4.3.1. Homozygosity mapping approach 
The investigation of SCA in the IS shows the successful use of a homozygosity mapping 
approach to identify a disease-associated locus. Although homozygosity mapping 
approaches have largely been superseded by the use of GWAS approaches, this study 
demonstrates how a result can be achieved using the homozygosity method in a very 
modest sample cohort of six cases and six controls. Homozygosity mapping using 
microsatellite markers is a cost effective approach, but the technique is relatively labour 
intensive in terms of experimental work and data analysis, and because far fewer markers 
are used than in high-density SNP arrays there is a possibility that a disease-associated 
region may be missed. 
4.3.2. Sequencing of genes in the disease-associated region 
After confirmation of association to canine chromosome 20 by linkage analysis, the exons 
of all five known coding genes in the associated interval were resequenced. Although 
several polymorphisms were identified, all could be ruled out as causal as they did not 
segregate consistently with disease status. This indicated that the causal mutation was 
potentially in a previously unidentified gene or was a non-coding mutation. A range of 
mutation types have been associated with SCA in humans, including genomic deletions, 
point mutations and both intronic and exonic repeat expansions. Glutamine repeat 
expansions are associated with human SCA1, 2, 3, 6, 7 and 17. Intronic repeat 
expansions account for SCA10 and Friedreich ataxia, and 5’ and 3’ UTR repeat 
expansions are associated with SCA8 and SCA12 respectively, highlighting the potential 
for a non-coding mutation to be the cause of SCA in the IS. 
4.3.3. Resequencing of the ITPR1 gene 
The ITPR1 gene has been associated with ataxia in humans (SCA15 and SCA16) and 
mice making it a strong candidate for the cause of SCA in the IS. Given that many 
mutations associated with cerebellar ataxia are non-coding, the ITPR1 gene was 
resequenced entirely including intronic regions and 10 kb of upstream and downstream 
sequence. Although exonic resequencing of ITPR1 had previously ruled out coding 
mutations, functionally important promoters and enhancers of ITPR1 have been described 
in the literature, which if altered could potentially lead to disease progression (Deelman et 
al., 1998, Kirkwood et al., 1997, Zhou et al., 2005). There is also evidence that the 3’ 
region of the ITPR1 transcript is functionally important and may have a role in trafficking of 
the mRNA and defining the location of translation (Bannai et al., 2004). As the ITPR1 
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gene spans a 320 kb region, it would not have been practical to sequence the entire gene 
using standard Sanger sequencing techniques. Instead ITPR1 sequencing presented an 
opportunity to trial newly available “next generation sequencing” technology, using PCR to 
generate a template as solution based enrichment methods were not commercially 
available at the time. Although in the early stages, massively parallel sequencing 
approaches were rapidly advancing, and promised to play an important part in the future 
of genomics. With this in mind the project was an exciting opportunity to learn more about 
the technology and test the in-house data handling capabilities available at the AHT. A 
template from a single case was successfully used to generate sequencing data and in-
house data handling was deemed feasible. Although interesting polymorphisms in non-
coding regions were followed-up, none segregated fully with disease status when 
genotyped in further cases and controls. A long intronic tetranucleotide repeat was 
identified in the sequence which was investigated for expansion by genotyping cases and 
obligate carriers but was also ruled out. 
4.3.4. Copy number investigation  
Copy number investigation was carried out by genotyping one case and one obligate 
carrier on the CanineHD SNP array. The disease-associated region was assessed for 
variations in copy number by assessing B allele frequency and log R ratios. As no 
deviations in log R ratios were seen, copy number variation was ruled out as a potential 
cause of SCA, although as the CanineHD array has a density of one SNP approximately 
every 14 kb, small increases or decreases in copy number could potentially be missed. 
This was the case for the ~16 kb deletion in BCAN which was located between SNPs on 
the CanineHD SNP array, and therefore not identified at the GWAS stage when 
visualising the SNPs across the disease-associated interval. 
4.3.5. Massively parallel sequencing of the entire disease-associated interval 
As mutations in the ITPR1 gene had been ruled out by almost entire sequencing of the 
gene from the 5’ UTR through to the 3’ UTR, albeit using a single case, the next logical 
step was to sequence the entire critical region in a number of cases and controls using 
target enrichment and massively parallel sequencing. Although coding mutations had 
been ruled out by exonic sequencing of all genes in the region, the sequencing 
experiment would serve as a check for coding mutations that could potentially have been 
missed due to inaccurate sequencing through primer site polymorphisms or interpretation 
errors. No additional coding polymorphisms were identified, and although a large number 
of non-coding SNPs and indels were identified through the sequencing analysis pipeline, 
all apart from three could be ruled out either due to an incorrect segregation pattern 
across cases and controls or the case-associated allele matching the reference allele. 
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Being able to exclude all but three potential variants remaining after filtering highlights the 
importance of selecting controls which have different haplotype patterns across the 
associated region, and where possible including control haplotypes with a high degree of 
similarity to the disease-associated haplotype to allow the maximum number of variants to 
be filtered out. All SNPs and indels were eventually ruled out either because the 
polymorphism was present in the set of Parson Russell Terriers which were 
simultaneously sequenced, or by genotyping across a larger sample cohort. Visual 
rescanning of the sequencing data, although very time-consuming and tedious, led to the 
eventual identification of a GAA triplet repeat expansion located in intron 35 of ITPR1, 
which segregated fully with disease status. Cases had extended alleles in the range of 
approximately GAA(318) to GAA(651) in comparison to a wild-type range of GAA(7) to GAA(22). 
Although cases shared a common disease-associated haplotype, all had two expanded 
repeat alleles of varying length, implying that repeat length is highly unstable and prone to 
generational expansion or reduction.  
4.3.6. Comparison between target enriched sequencing attempts 
The failure to identify the repeat expansion during the first targeted resequencing attempt 
highlights a number of key differences between the two sequencing experiments. The 
long PCR capturing the expanded region had an expected amplicon size of 10.6 kb. The 
increase in size of approximately 1 kb for the case amplicon was not sufficient to be 
clearly resolved on a 1% agarose gel. 
 
For the sequencing experiment that used PCR as an enrichment method, reads were 
aligned all the way through the expanded region, and therefore a complete consensus 
sequence was produced highlighting no differences to the reference sequence. Because 
only single-end sequencing was performed, there were no un-aligned read mates to 
indicate potential insertions in the region. Although manual browsing of the sequence read 
alignments was performed, a basic alignment viewing program called Maqview was used, 
which is vastly inferior to IGV which was first launched in November 2008. 
 
Several factors facilitated the identification of the repeat expansion in the second 
massively parallel sequencing experiment using a probe-based target enrichment 
methodology. As mentioned previously the second massively parallel sequencing 
experiment employed a paired-end sequencing strategy, and used IGV to visualise 
sequence read alignments, which has the capability to flag singleton reads. Although this 
is an improved strategy, many singleton reads were also flagged in controls because 
obligate heterozygote carriers were used, so with the cohort of individuals chosen 
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presence of singleton reads alone may not have been enough to identify the causal 
mutation. However, choosing homozygous wild-type individuals as controls may also have 
resulted in some singleton reads as wild-type alleles also varied in length, and sequencing 
reads from some of the longer alleles may not have aligned to the reference genome. This 
was in fact the case for some of the PRT individuals which were sequenced alongside the 
Italian Spinoni, after target enrichment with the same probeset. Bait positioning and the 
absence of capture baits across the repetitive region containing the SINE and GAA triplet 
repeat were the main factors facilitating mutation identification. Because the mutation 
locus and surrounding region contained repetitive elements, a 500 bp region containing 
the repeat expansion was excluded from bait design. In controls sufficient flanking 
sequence was captured by the baits to result in sequence coverage all the way through 
the repetitive region. For cases however, because the repeat expansion increased the 
size of the masked repetitive region no DNA fragments were captured that were of 
sufficient size to span across the GAA repeat. This resulted in a region of zero coverage 
in cases 3’ of the GAA repeat sequence, as no probes 3’ of the GAA repeat were located 
close enough to capture this region. The gap in coverage in cases, but not controls 
provided a discernable difference that led to eventual mutation identification. 
4.3.7. Support for an intronic GAA triplet expansion as the cause of SCA 
4.3.7.1. GAA repeat expansion is the cause of Friedreich ataxia 
Although located in different genes, the GAA triplet repeat expansion discovered in the IS 
is similar to the repeat expansion known to cause autosomal recessive Friedreich ataxia 
in humans (Campuzano et al., 1996). Both the Friedreich ataxia and SCA repeat 
expansions stem from a short GAA repeat on the edge of a SINE. For Friedreich ataxia 
the intronic GAA repeat expansion is located in intron 1 of the frataxin (FXN) gene, and 
results in reduced expression of the FXN transcript, potentially due to the formation of a 
triplex DNA structure and “sticky DNA” (Sakamoto et al., 1999). Triplet repeat copy 
number in Friedreich ataxia patients has been reported to range between 66 and 1,700 
subunits, thus the GAA repeat expansion observed in canine ITPR1 falls within this range 
(Durr et al., 1996, Epplen et al., 1997). Like the repeat expansion event causing SCA 
there is evidence that Friedreich ataxia expanded alleles have a common founder 
(Cossee et al., 1997). Furthermore, large normal alleles also exist, which have arisen from 
a single founding chromosome. These large normal alleles in frataxin represent a pre-
mutation reservoir and catastrophic single generation normal range to pathogenic repeat 
range changes have been observed (Cossee et al., 1997). This evidence suggests that 
even if expanded alleles can be successfully eradicated from the IS gene pool, expansion 
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of a large normal allele is possible, which could cause a resurgence of the disease in a 
breed with an isolated breeding population.  
4.3.7.2. The ITPR1 gene is associated with SCA in humans and mice 
The inositol 1,4,5-trisphosphate receptor, type 1 (ITPR1) gene encodes an intracellular 
inositol triphosphate (IP3) gated calcium release channel. The products of the ITPR1 gene 
form tetrameric proteins which are bound to the membrane of the endoplasmic reticulum. 
A cascade of cellular reactions are involved in the activation of ITPR1. Stimulation of cell 
surface bound G protein coupled receptors or receptor tyrosine kinases, result in a 
cascade of reactions and activation of phospholipase C to produce the secondary 
messenger IP3. On binding of IP3 to the IP3 receptor, the ligand-gated ion channel is 
opened, causing an influx of calcium ions into the cell cytoplasm from intracellular stores 
and activation of many calcium dependent cellular processes (Banerjee and Hasan, 
2005). Cellular processes driven by calcium signalling include fertilisation, 
neuromodulation, cell growth and sensory perception (Berridge, 1993).   
  
The ITPR1 gene is predominantly expressed in the brain and nervous system and shows 
particularly high expression levels in the Purkinje cells of the cerebellum (Furuichi et al., 
1993, Matsumoto et al., 1996). Heterozygous deletion of the ITPR1 gene has been shown 
to cause SCA15 (also designated SCA16) in humans (van de Leemput et al., 2007). 
SCA15 is an autosomal dominant pure cerebellar ataxia with a reported onset age ranging 
from 10 to 66 years (Miyoshi et al., 2001, Storey et al., 2001). Using Epstein-Barr virus 
immortalised lymphocytes ITPR1 protein levels were shown to be considerably lower in 
cell lines derived from affected individuals and haploinsufficiency had been suggested as 
the cause of the disease. Mice that are ITPR1 null display a severe phenotype, although 
most die in utero. Surviving mice show normal behaviour at birth with signs of ataxia 
apparent at day nine. Tonic or tonic/clonic seizures develop at day 20-23 and mice die by 
the weaning period (Matsumoto et al., 1996). A similar but less severe phenotype is 
displayed by the opt mouse, which has an in-frame deletion of exons 43 and 44 of ITPR1 
(Street et al., 1997). For SCA in the IS, the ataxia is less severe than the mouse, perhaps 
due to production of a limited amount of ITPR1 protein. Unlike for human SCA15 cases, 
ataxia has not been observed in heterozygous dogs, perhaps because more ITPR1 
transcript is produced than in haploinsufficient human cases. Alternative explanations 
include insufficient canine longevity to allow disease progression or failure of owners to 
notice phenotypic changes which may be more subtle in quadrupeds. 
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4.3.8. DNA testing 
The linkage-based test for SCA in the IS was launched in April 2008. Since the launch of 
the test there have been no cases of SCA reported to the AHT, suggesting that the 
frequency of expanded alleles in the breed population is now very low. Although a linkage-
based test has been successful for this disorder there are potential risks associated with 
running a linkage-based test. Firstly there is a risk of a recombination event occurring 
between the causal mutation and the marker used, leading to a loss of linkage 
disequilibrium and potentially causing false negative results. Secondly it is possible for 
false positive results to occur because of the disease-associated allele/alleles occurring 
on wild-type haplotypes. Thirdly, because the SCA test used microsatellite markers, there 
is potential for new alleles to form causing the disease-association to be lost. Although the 
causal mutation for SCA has now been identified it is likely that the strategy of using the 
linkage-based test will remain because an assay for the expanded allele, especially for 
identification of heterozygous individuals is not sufficiently robust to run in a diagnostic 
testing laboratory. Refinement of the linkage test may be possible to select markers which 
are very close in location to the causal mutation to reduce the risk of recombination events 
disrupting the linkage disequilibrium, or switching to SNP markers which are much less 
likely to mutate in comparison to microsatellites. 
4.3.9. Summary 
Using a small cohort of six cases and six controls a homozygosity mapping technique was 
used to identify a locus of the canine genome associated with SCA in the IS. Coding 
mutations were ruled out as a possible cause by exon resequencing through capillary 
based methodology. A GAA triplet repeat expansion in intron 35 of ITPR1 was identified 
and strongly associated with SCA through probe-based target enrichment followed by 
massively parallel sequencing. An initial massively parallel sequencing experiment using 
PCR target enrichment failed to lead to identification of the repeat expansion, highlighting 
how choice of methodology can be crucial to mutation identification. The GAA repeat 
expansion is the first repeat expansion associated with canine ataxia, and is only the 
second form of ataxia, after Freidreich ataxia, to be associated with a GAA repeat 
expansion. 
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5.1. Background 
5.1.1. The Parson Russell Terrier 
The Parson Russell Terrier (PRT) was originally developed in the 19th century from foxing 
terriers, with the foundation of the breed type accredited to the Reverend John Russell. In 
the early part of the 20th century the Parson Jack Russell Terrier club was formed with an 
affiliation to the Fox Terrier Club, although it was not until 1990 that full Kennel Club 
recognition was granted, acknowledging the PRT as a separate breed to the shorter 
legged Jack Russell Terrier (JRT). The PRT is a moderately popular breed in the UK with 
approximately 500 registrations per year. The breed is also popular across Europe, 
America and Australia. 
5.1.2. Spinocerebellar ataxia in the PRT 
Spinocerebellar ataxia, often referred to as late onset ataxia (LOA) by breeders to 
distinguish the disorder from a reported juvenile form seen in the JRT, is a disease of 
progressive incoordination of gait, including loss of balance and hypermetria as the 
condition progresses. Clinical signs usually become notable to owners between 6 and 12 
months of age although onset of clinical signs between 4 and 24 months has been 
reported. Upon onset owners may initially notice a slight weaving gait pattern of the hind 
legs, causing the dog to sway slightly when walking. As the disease progresses 
incoordination becomes more notable and a hypermetric (high stepping) gait may be 
observed with occasional hopping. On further progression clinical signs become more 
severe making ambulation difficult, with owners often electing to euthanise affected dogs 
on welfare grounds by five years of age. 
5.1.3. Reports of ataxia in the PRT and related breeds 
Cases of ataxia in breeds closely related to the PRT have been reported in the veterinary 
literature since the 1950s. In 1957 and 1962 two case reports describing a progressive 
ataxia and hypermetria affecting Fox Terriers were published (Bjorck, 1957, Bjorck, 1962). 
The cases described had an age of onset of approximately four months, consistent with 
LOA in the PRT, with test matings suggesting an autosomal recessive mode of 
inheritance. Pathological changes to the spinal cord were noted including bilateral 
demyelination of the cervical, thoracic and lumbar regions. Lesions were also seen in the 
dorsal spinocerebellar tracts. In a more recent study three new cases of ataxia in the 
Smooth-Haired Fox Terrier (SHFT) were investigated and five old cases retrospectively 
reviewed including an affected dog born in 1957 as part of the test mating experiments 
(Rohdin et al., 2010). Onset for the three new cases was four months of age, consistent 
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with previous observations. Full neurological examinations were performed on the three 
new cases and ataxic gait observed with hypermetria in all four legs. Swaying of the trunk 
was observed as the dogs walked and frequent falling was noted. For all three dogs a 
severely decreased menace response was recorded and postural reactions were impaired 
in all four limbs. A fine head tremor, and tremor of the muscles was also seen which 
worsened with excitement. On port-mortem examination no gross pathological changes of 
the nervous system were observed. Histopathological investigation of the spinal cord 
revealed oedema of the myelin sheaths, axonal swelling and macrophage infiltration 
across the circumference of the spinal cord, especially in the fibres of the pyramidal, 
spinocerebellar and ventral reticulospinal tracts. Analysis of the parietal cortex, basal 
ganglia, hippocampus and cerebellum revealed no morphological changes (Rohdin et al., 
2010). 
 
Two cases of ataxia were first described affecting short legged Jack Russell Fox Terriers 
(ie JRT) in 1973 (Hartley and Palmer, 1973). Notably the clinical signs were similar but 
apparent age of onset and progression was different for the two cases. This variability is 
more in line with observations in the PRT, rather than the more consistent onset age 
reported in the SHFT. Of the two cases, the clinical signs described for the later onset 
case are more comparable to those of LOA in the PRT. For this case the clinical signs 
were first apparent at six months of age with swaying of the hind limbs initially observed. 
Incoordination of the hind limbs with occasional collapse was also observed. Significant 
progression of clinical signs was observed on re-examination after fifteen months, with 
increased incoordination, unpredictable hindlimb movements, overprotraction of forelimbs 
and rotational intentional head tremor. For the earlier onset case, an abnormal gait was 
suspected when the puppy became ambulatory. After six months clinical signs had 
become severe, with the dog displaying a “dancing” gait. Additional clinical signs included 
exaggerated abduction, depressed hindlimb hopping reflex, and excessive forelimb 
protraction. Histopathological examination of nervous system tissue showed significant 
lesions of the central auditory pathway, with superior olivary nuclei displaying a marked 
loss of myelinated nerve fibres and moderate diffuse gliosis (increased glial cell numbers, 
predominantly comprising astrocytes, in damaged regions). Similar changes were also 
seen for the cochlear nuclei, but to a lesser extent. Extensive degeneration was also seen 
in nerve fibres connecting the superior olivary and cochlear nuclei and the trapezoid body 
and lateral lemniscus, with many swollen axons. Wallerian-like degeneration (retrograde 
and anterograde axonal degeneration after focal nerve damage) was observed in the 
brain and spinal cord. A second report into hereditary ataxia in the JRT and PRT was 
published in 2004 investigating 35 JRT and PRTs (Wessmann et al., 2004). The aims of 
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the study were to investigate abnormal brain stem auditory-evoked potentials (BAEPs) 
and to calculate mode of inheritance of hereditary ataxia. Affected individuals had an 
average onset age of 4.4 months with a range of 2 to 9 months of age and on average 
were euthanised at the owner’s request at 16 months. In addition to clinical signs of ataxia 
previously described, this report described generalised seizures in some dogs (13/35) as 
evidenced by muscle twitching over the head or limbs, exercise weakness (11/35), 
respiratory distress (7/35) and behaviour changes (7/35). This muscle twitching could 
have represented myokemia rather than generalised seizures, particularly in the absence 
of involvement of the autonomic nervous system and the more recent reports of 
myokemia in the JRT (Vanhaesebrouck et al., 2012). Reduced menace responses were 
observed in one dog. Abnormal BAEP patterns were observed in four of the eight 
individuals investigated. Authors discuss that this may be consistent with the observed 
axonal damage associated with the disease, especially damage to the trapezoid body and 
lateral lemniscus. Histopathological investigation revealed changes across the entire 
nervous system, with bilateral myelopathy and other degenerative changes in the brain, 
brain stem and spinal cord consistent with previously reported cases (Hartley and Palmer, 
1973). Complex segregation analysis across three families containing 115 individuals 
suggested a hereditary cause for the ataxia with a polygenic model most likely, although a 
major gene effect with additional polygenic factors was also not excluded. In the 
discussion Wessmann and colleagues highlighted that although the gait disturbance in the 
JRT and PRT appeared identical to the SHFT, different modes of inheritance have been 
suggested and histopathological investigations indicated brain involvement for the PRT 
and JRT, but not the SHFT, suggesting a different disease process. However, Rohdin and 
colleagues proposed that the different genetic modelling systems used in predicting 
inheritance patterns for the JRT and SHFT may be the primary reason for the different 
conclusions and suggested that clinical signs and histopathological changes were similar, 
implying the same disease process for the two breeds.  
5.1.4. Summary 
Hereditary ataxia in the PRT and related breeds has been described since the 1950s. At 
the AHT a cohort of owner reported cases were collected with a view to performing a 
genetic investigation to improve understanding of the disease, elucidate the mode of 
inheritance and identify the causal mutation(s). Identification of the genetic cause would 
enable the development of a diagnostic test to allow breeders to identify genetic carriers 
or risk factor carriers, depending on the determined mode of inheritance. Identification of 
genetic risk factors would allow investigation into ataxia in related breeds and potentially 
determine whether the same genetic defects underlie ataxia in the PRT, JRT and SHFT. 
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5.2. Results 
5.2.1. Genome-wide association study    
A genome-wide association study was performed with 16 PRT LOA cases and 16 
controls. Where possible first-degree relatives were used as controls (ie parents or 
siblings of cases). Failing this half-siblings were selected as controls or, for isolated cases 
where DNA from relatives could not be obtained, unrelated controls were used. A strategy 
of using close relatives for controls was used with the aim of limiting levels of genomic 
inflation such as the high levels seen in the Cavalier King Charles Spaniel studies 
described in Chapter 3. 
 
DNA samples were genotyped on the Illumina CanineHD array. All 32 samples genotyped 
successfully, achieving a genotyping call rate of >99.8% after reclustering all SNPs in the 
Genome Studio software package. No additional QC or manual editing of SNPs was 
performed before exporting for statistical analysis using PLINK. 
5.2.2. Allelic association analysis 
Allelic association analysis was performed using the statistical package PLINK which was 
implemented at the Linux command prompt. After exclusion of SNPs with a minor allele 
frequency <0.05 and genotyping success rate <0.95, 126,225 SNPs remained. The 
genomic inflation factor based on the median chi-squared value was 0.81 indicating no 
stratification between the case and control populations. Basic allele associated analysis 
on the filtered SNPs revealed a strong statistical signal on chromosome 18 (Praw = 7.04 x 
10-9) (Figure 5.1 A). To correct for multiple testing, allelic association analysis was 
performed using 100,000 MaxT permutations in PLINK, which resulted in a single signal 
on chromosome 18 of genome-wide significance (Pgenome=1.06 x 10-3) (Figure 5.1 B). 
Results are highly indicative of a simple autosomal recessive mode of inheritance for the 
disorder. 
 
5. Ataxia in the Parson Russell Terrier 
 
 
 
139 
 
 
Figure 5.1 Allelic association analysis for LOA in the PRT 
Allelic association analysis on 16 cases and 16 controls. Each dot represents a single SNP, with -log10 (p) 
values on the y-axis plotted against genome position (split into chromosomes) on the x-axis. (A) Raw 
unadjusted –log10(p) values with a strong statistical signal indicated on chromosome 18 (Praw = 7.04 x 10-9). 
(B) Plot of -log10(p) values after 100,000 maxT permutations analysis to correct for multiple testing, showing a 
single peak reaching genome-wide significance on chromosome 18 (Pgenome=1.06 x 10-3). 
 
Identity-by-state (IBS) statistics were calculated using PLINK and values plotted in Excel 
to produce a multidimensional scaling (MDS) plot showing relatedness of individuals used 
in the study. As expected from the genomic inflation value of 0.81 individuals were evenly 
spaced, with no separate clustering of cases and controls (Figure 5.2 A). A quantile-
quantile plot was constructed, which showed the observed probability values to closely 
track the expected values, further confirming the low genomic inflation value (Figure 5.2 
B). 
 
 
Figure 5.2 MDS and QQ plots for LOA in the PRT 
(A) MDS plot showing the relatedness of individuals used for the GWAS based on IBS data calculated from 
SNP genotypes. Cases and controls are evenly mixed on the plot with no clustering, indicating no population 
stratification. (B) Quantile-quantile plot of observed versus expected P values. The genomic inflation value for 
the dataset was 0.81. 
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Raw genotyping data were visualised across the region of genome-wide significance on 
chromosome 18. All but one of the 16 cases were homozygous for a shared haplotype, 
the interval for which was defined by recombination events which had occurred in two 
individuals resulting in loss of the shared homozygosity (Figure 5.3). The disease-
associated interval was a 1.89 Mb region defined as chr18:53,533,360-55,418,743 based 
on the CanFam2 genome build.  
 
Figure 5.3 Raw genotyping data across the disease-associated region for LOA 
Graphical overview of the raw genotyping data across the LOA critical region. Each column represents one 
individual, and SNP markers are listed in the rows with the approximate positions indicated. Major alleles are 
highlighted in blue, minor alleles in red and missing genotypes in white. Interval defining cases are marked by 
a circle at the top of individual columns. The outlying case which is not homozygous for the disease-
associated haplotype is marked with an asterisk.  
 
5.2.3. Investigating genes in the disease-associated region 
The disease-associated region for LOA contained 91 genes and was syntenic to 
chromosome 11 of the human genome (see Appendix 9). Genes within the interval were 
assessed for potential involvement in LOA, with the gene encoding beta-III spectrin 
(SPTBN2) a particularly strong candidate, as mutations in the gene have been shown to 
cause SCA5 in humans (Ikeda et al., 2006). 
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5.2.4. SPTBN2 sequencing 
The SPTBN2 was exon resequenced in an attempt to identify potential causal mutations 
for LOA. No coding or splice site polymorphisms were identified. 
5.2.5. Targeted resequencing of the LOA disease-associated interval 
With no coding mutations identified in the most probable candidate gene and with the 
disease-associated interval containing 91 genes, the most appropriate strategy for 
investigating the disease-associated interval was to use targeted resequencing of the 
entire region. To make the investigation more efficient and cost-effective, probes were 
designed to capture both the disease-associated region for LOA in the PRT and SCA in 
the IS (Table 4.5). 
 
Two LOA cases and three controls were selected for library preparation (five IS DNA 
samples were also chosen). Controls were selected based on haplotype analysis across 
the disease-associated region, and individuals chosen with different haplotype patterns to 
facilitate polymorphism exclusion. Libraries were made using the SureSelect target 
enrichment methodology and sequencing performed on the Illumina HiSeq 2000, 
producing a 19.64 Gb dataset of 51 bp paired-end reads. Further details of the experiment 
design and enrichment statistics can be found in sections 4.2.8.1 – 4. 
5.2.6. Data analysis 
Data were analysed in Linux using the NGS pipeline (described in Chapter 3). SNP and 
indel calls were aligned across all individuals using the SNP Handler Excel macro 
developed by Dr Mike Boursnell at the AHT. Compiled SNPs were annotated with gene 
consequence predictions and assigned a segregation score based on how well SNPs 
segregated according to disease status. In total 7,024 SNPs and 1,507 indels were 
identified across the LOA disease-associated region, with 541 variants segregating in 
accordance with disease status. Sequencing data generated from the five Italian Spinoni 
captured across the same region and ten Siberian Huskies captured across a fully 
overlapping region (chr18:51,770,000-58,240,000) for an unrelated project (data 
generated by Louise Pettitt and Sally Debenham) were used as additional controls to help 
to reduce the number of segregating SNPs to 141. The majority of the SNPs were 
distributed towards the 3’ end of the disease-associated region, although one SNP was 
located in an isolated intergenic position approximately 650 kb 5’ of the next correctly 
segregating SNP, perhaps indicating a more recent mutation event (Figure 5.4). 
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Figure 5.4 Distribution of SNPs across the sequenced region 
Segregating SNPs were mostly distributed towards the 3’ end of the disease-associated region, apart from a 
single intergenic SNP located toward the 5’ end of the region. 
 
5.2.7. In-house targeted resequencing of additional controls 
A second enrichment kit with the same design was used to produce sequencing libraries 
for ten additional PRT controls in an attempt to narrow down the number of potentially 
causal variants. In June 2012 an Illumina MiSeq benchtop massively parallel sequencer 
was acquired by the AHT, presenting an opportunity for the entire workflow of the 
experiment to be completed in-house. In overview, DNA extracted from buccal swabs was 
fragmented by in-house sonication yielding fragments in the 100-800 bp range. Indexed 
libraries were then subsequently prepared using SureSelect target enrichment 
methodology and quantified for sequencing on the Illumina MiSeq platform. Paired-end 
sequencing with 150 bp reads was performed yielding a dataset of 2.07 Gb. The 
individuals used and dataset are summarised in Table 5.1. The data generated were 
processed through the sequence analysis pipeline and variants aligned across all 
samples. In total 6,544 SNPs and 1,559 indels were identified across the ten additional 
controls sequenced. Based on the suggestive haplotypes of the individuals sequenced, 95 
SNPs segregated with the predicted disease status. Using the SNP and indel information 
from the ten additional control samples and the original dataset, 73 SNPs and indels could 
be excluded from the list of segregating variants. 22 SNPs could not be excluded because 
of lack of read depth for the ten additional controls. The remaining 70 segregating SNPs 
and indels were visually checked by browsing the sequence read alignments.   
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Table 5.1 Summary of target-enriched MiSeq sequencing data of ten additional controls 
Libraries from ten additional control individuals were prepared and sequenced completely in-house, to reduce 
the number of disease segregating variants. Capture success and sequencing results are summarised.   
ID Relation to case Suggestive haplotype 
No. of 
reads 
(Million) 
Dataset size 
(Mb) 
Target 
enrichment 
efficiency (%) 
Bases 
achieving 10x 
coverage (%) 
PCR 
duplicates 
(%) 
11291 Dam heterozygous 1.13 170 71.2 58.9 1.9 
11294 Half sibling Wild-type 1.25 188 73.6 59.0 2.6 
11491 Half sibling heterozygous 1.20 180 77.2 59.6 2.4 
12125 Half sibling heterozygous 1.19 179 76.5 60.6 3.0 
12899 Half sibling  heterozygous 1.31 197 77.6 60.7 2.8 
17477 Unrelated Wild-type 1.35 203 54.2 50.3 1.6 
17529 Unrelated Wild-type 1.96 294 15.2 31.2 0.4 
17553 Unrelated Wild-type 1.72 258 76.4 63.4 3.5 
18032 Unrelated Wild-type 1.05 158 77.4 59.4 1.9 
18501 Dam heterozygous 1.20 180 62.1 55.2 1.9 
 
5.2.8. Investigation of segregating variants 
By visualising sequencing data aligned against gene positions, cross species 
conservation data, and variant effect prediction data, three provocative candidate SNPs 
were identified. These were non-synonymous missense mutations in the genes encoding 
the calcium dependent cysteine protease, calpain 1 (CAPN1) and vacuolar protein sorting 
51 homolog (VPS51) and the isolated intergenic SNP which appeared to be in a semi-
conserved DNase1 hypersensitivity region.  
 
The CAPN1 mutation was predicted to cause cysteine to tyrosine amino acid substitution 
(C115Y). Multi-species alignment in the UCSC genome browser across 46 vertebrate 
species shows a very high level of conservation at amino acid 115 of the CAPN1 protein 
(Figure 5.5). Of the 38 species with alignable sequence data, 37 had a cysteine residue at 
position 115. The only species not to have a cysteine residue at position 115 was the 
alpaca, although a 1 bp insertion at residue 124 puts the transcript out of frame and may 
suggest that the gene is non functional in this species. 
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Figure 5.5 Multi-species alignment across residue 115 of the calpain1 peptide 
Alignment across 46 vertebrate species was visualised using the UCSC genome browser to assess the level 
of cross-species conservation for the CAPN1 gene. The reference genome is human (Hg19). 
The mutation in the VPS51 gene was predicted to result in a glutamic acid to lysine amino 
acid change (E24K). Multi-species alignment in the UCSC genome browser across 46 
vertebrate species shows a high level of conservation at the amino acid level (Figure 5.6). 
Of the placental mammal group (human to sloth) 29 of the 30 aligned species have a 
glutamic acid residue (E) at the corresponding locus. The differing species, mouse, has an 
aspartic acid at amino acid 24 of VPS51. Only three of the more distantly related 
vertebrate species (wallaby to lamprey) have alignment data at the questioned position, 
however browsing the adjacent amino acids suggests that the protein is not conserved for 
these species.   
 
 
Figure 5.6 Multi-species alignment across residue 24 of the VPS51 peptide 
Alignment of the VPS51 gene across 46 vertebrate species was visualised using the UCSC genome browser 
to assess the level of cross-species conservation. The reference genome is human (Hg19). 
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The intergenic SNP identified in a semi-conserved region of the canine genome was 
defined as chr18:54,147,546A>G based on the CanFam2 genome build. Browsing the 
corresponding position in the human genome showed that the SNP was positioned in a 
region of DNase1 hypersensitivity, according to data from the ENCODE (Encyclopedia of 
DNA elements) project. As regions of DNase1 hypersensitivity are often indicative of 
regulatory areas of the genome, the SNP identified could potentially be functionally 
important and therefore worthy of further investigation. Investigation of multi-species 
alignments at the base pair level showed the A base to be conserved across many 
placental mammalian species, with 16 out of 20 species possessing an A base at the 
position (Figure 5.7).  
 
 
Figure 5.7 Multi-species alignment across the intergenic associated SNP locus. 
Base-pair level conservation across 33 placental mammalian species, for an isolated intergenic SNP 
polymorphism identified in the canine genome (chr18:54,147,546A>G). The reference genome is human 
(Hg19). 
 
5.2.9. Follow-up investigation of candidate SNPs 
All three candidate SNPs were further assessed by genotyping on an additional cohort 
using allelic discrimination assays (TaqMan). The SNPs were initially genotyped on a 
multibreed panel of 96 healthy individuals, from 32 different breeds. The non-reference 
VPS51 SNP allele was found in four individuals, (one Tibetan Spaniel, one Miniature 
Poodle and two Dobermann Pinschers), indicating that it was likely to be a common 
polymorphism. All 96 individuals of the multibreed panel were homozygous for the 
reference allele for CAPN1 and intergenic SNPs, which were therefore still potentially 
causal for LOA. All three SNPs were subsequently genotyped on an expanded cohort of 
227 PRTs, including the 36 individuals that were used in the initial GWAS study, ten 
additional cases and 185 additional controls. Results are summarised in Table 5.2. 
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Table 5.2 Segregation analysis of the three top LOA associated SNPs 
Results of genotyping an extended PRT cohort for the three top LOA associated SNPs 
  
 Intergenic SNP CAPN1 SNP VPS51 SNP 
Genotype Case Control Case Control Case Control 
w/t homozygous 3 131 3 133 3 128 
Heterozygous 1 69 1 67 1 68 
Mutant homozygous 22 1 22 1 22 5 
 
The intergenic and CAPN1 SNPs most closely segregated with disease status. 
Interestingly some of the genotyping results indicated that a recombination event had 
occurred between the two markers (Table 5.3). The VPS51 SNP was excluded because 
five controls were homozygous for the disease-associated allele.  
 
Table 5.3 Evidence of recombination between CAPN1 and the intergenic SNP 
Six individuals gave discordant genotyping results between the CAPN1 SNP and the intergenic SNP 
candidate. Results provided evidence of a recombination event as the wild-type CAPN1 alleles were found in 
association with non wild-type intergenic SNP alleles and vice-versa.  
 
ID Intergenic SNP genotype CAPN1 genotype 
11166 wild-type Heterozygous 
13365 Heterozygous wild-type 
13539 Heterozygous wild-type 
14280 wild-type Heterozygous 
18046 wild-type Heterozygous 
21275 wild-type Heterozygous 
 
5.2.10. Follow-up of discordant cases and controls 
Based on the CAPN1 variant, the most provocative SNP according to exonic positioning 
and close segregation with disease status, discordant cases and controls were followed 
up by communicating with owners and veterinarians. The single individual reported as 
clinically clear, but homozygous for the disease-associated allele of the CAPN1 mutation, 
was still reported to be clinically healthy by the owner. The owner was asked to provide a 
video of the dog walking, trotting and running, which clearly showed the dog to have an 
ataxic gait, with a weaving pattern of the hind legs, which is typical for cases of LOA in the 
PRT. Video footage was provided when the dog was four years of age, perhaps 
suggesting a slower than normal progression rate for the condition. Three of the four 
owners of the dogs which were clinically affected, but not homozygous for the CAPN1 
disease-associated allele were also successfully contacted. All three dogs had been 
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euthanised on welfare grounds due to disease severity. Video footage was not available 
for the cases, but the clinical signs described were consistent with LOA. The owner of two 
of the dogs was an experienced breeder and veterinarian who had seen a number of LOA 
cases. This owner stated that clinical signs were perhaps more severe and the 
progression rate faster than an average case, but within the expected range. The owner of 
the fourth dog could not be contacted. 
5.2.11. Genotyping of Jack Russell Terriers at the CAPN1 SNP locus 
Five ataxic JRTs were genotyped for the CAPN1 SNP associated with LOA in the PRT. Of 
the five dogs three were homozygous wild-type, one was heterozygous and one was 
homozygous for the disease-associated allele, suggesting that the causal mutation in the 
LOA locus is not a major cause of ataxia in the JRT. 
5.2.12. Predicting functional effects of the CAPN1 variant 
The CAPN1 SNP was the strongest candidate polymorphism based on conservation data 
and segregation analysis across an extended cohort of individuals. Three computational 
tools were used to help assess whether the CAPN1 amino acid change could have an 
important functional effect. These were SIFT (Sorting Intolerant from Tolerant), Polyphen 
(Polymorphism phenotyping) and MutationTaster (Adzhubei et al., 2010, Ng and Henikoff, 
2001, Schwarz et al., 2010). The SIFT algorithm is based on comparing protein sequence 
similarity across species, and assumes that highly conserved amino acids will be highly 
intolerant to changes in identity. The CAPN1 C115Y amino acid change was predicted by 
SIFT to be damaging. The program Polyphen uses both conservation information and 
data from SWISS-PROT, an annotated database of non-redundant protein sequences. 
The output from PolyPhen suggested that the C115Y amino acid change was probably 
damaging with the highest possible level of confidence (Figure 5.8). 
 
 
Figure 5.8 Polyphen output for the CAPN1 C115Y variant 
Polyphen consequence prediction for the CAPN1 non-synonymous SNP. The output suggested the mutation 
to be probably damaging with the maximum score of 1, where a score of 0 is given for an amino acid 
substitution that is predicted to be benign with the maximum level of confidence and a score of 1 indicates that 
an amino acid substitution is likely to be damaging with the maximum level of confidence. 
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The third prediction tool MutationTaster considers both protein sequence and nucleotide 
sequence conservation across a number of model organisms, protein features and 
domains that could potentially cause a reduction in the level of mRNA produced. 
MutationTaster gave the prediction that the CAPN1 non-synonymous SNP was disease 
causing, with a probability score of 1 (maximum score). Residue 115 and the five flanking 
amino acids either side of residue 115 were identical on alignment of human, chimp, cat, 
mouse, Xenopus, zebrafish, Fugu, C.elegans and Drosophila protein sequences (ie 
conserved even in two invertebrate species). On nucleotide sequence alignment base 
identity of the altered base was identical for human, chimp, rhesus, cat, mouse, Xenopus, 
Fugu, although no sequence alignments could be retrieved for zebrafish, C.elegans and 
Drosophila. Protein domain analysis by the MutationTaster package predicted loss of the 
calpain catalytic domain (aa55-354) and loss of a helix domain (aa115-124). A score for 
chemical dissimilarity of 5.29 out of 6 was calculated by MutationTaster, based on the 
Grantham matrix, for cysteine to tyrosine residue change. Using the original Grantham 
matrix of amino acid dissimilarity, cysteine versus tyrosine comparison gave a score of 
194 (range 5-215, mean 100) (Grantham, 1974). 
 
A BLOSUM (BLOcks SUbstitution Matrix) table was used to investigate the evolutionary 
likelihood of a cysteine to tyrosine substitution. Using the BLOSUM64 matrix a C>Y 
substitution has a logarithm of odds value of -3, and indicated that a tyrosine is unlikely to 
be substituted for a cysteine (Henikoff and Henikoff, 1992).    
5.2.13. mRNA-seq data analysis 
A genome-wide mRNA-seq dataset was generated using cerebellum tissue from a LOA 
case and cerebellum tissue from a clinically normal control (See section 6.2.5.). Data 
confirmed expression of CAPN1 in cerebellum tissue. By counting aligned reads across 
genes in the LOA disease-associated region potential differences in the expression 
between the case and the control could be assessed. Significant changes at the 5% level 
before adjustments for sample size and read count are displayed in Table 5.4 (Data 
analysis performed at the Wellcome Trust Centre for Human Genetics, Oxford). 
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Table 5.4 Gene expression changes in a LOA case across the disease-associated region 
List of significant changes in gene expression before P value adjustment for cohort size and read count. Fold 
change values above 1 indicate a reduction in expression in the LOA case cerebellum. 
 
Gene Position 
Read count 
case 
Read count 
control 
Fold 
Change 
P value 
P 
adjusted 
SPTBN2 chr18:53664195-53696100 14322 9912 0.69 0.01 0.37 
RBM14 chr18:53746046-53754057 2219 1565 0.71 0.02 0.49 
BBS1 chr18:53843758-53860191 232 105 0.45 0.02 0.41 
NPAS4 chr18:53933238-53936598 67 17 0.25 0.05 0.68 
FAM89B chr18:54658069-54659575 1198 1678 1.40 0.04 0.62 
SSSCA1 chr18:54660687-54661481 869 1247 1.44 0.04 0.63 
SCYL1 chr18:54693198-54705475 949 1430 1.51 0.02 0.42 
POLA2 chr18:54901204-54917024 605 964 1.59 0.01 0.38 
MRPL49 chr18:55093567-55097563 759 1092 1.44 0.04 0.66 
FAU chr18:55098084-55099271 4892 6692 1.37 0.03 0.53 
VPS51 chr18:55108993-55130845 1846 2535 1.37 0.04 0.60 
PYGM chr18:55423235-55435168 6560 8921 1.36 0.03 0.53 
NRXN2 chr18:55464994-55562401 14452 11026 0.76 0.04 0.65 
 
Although some small changes (less than 2 fold increases/decreases in gene expression) 
were seen across the disease-associated region, none of the changes reached 
significance after adjusting for the small sample size. 
 
Read alignments for the cases and control mRNA-seq datasets were visually inspected as 
a way of checking for mutations in regions not captured by target enrichment. No 
additional polymorphisms were identified in the mRNA-seq datasets. Read depths across 
genes were visually compared for the case and control datasets, confirming no large 
changes in expression across the disease-associated region. 
5.2.14. Copy number investigation 
The sequence dataset was interrogated for copy number variation by assessing the ratio 
of case to control aligned read count across overlapping 5 kb windows. Windows 
containing less than 100 reads for both the case and control dataset were excluded. 
Across the disease-associated region the ratio remained close to 1, excluding copy 
number variants of 5 kb or greater (Figure 5.9). 
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Figure 5.9 Copy number variation investigation 
Potential copy number variants were investigated by comparing the count of read alignments for one case 
versus one control across a sliding 5 kb window. Ratios of greater than one are suggestive of an increase in 
copy number, and ratios of 0.5 and 0 suggestive of heterozygous and homozygous deletions respectively. 
 
5.2.15. DNA test launch 
A diagnostic test was launched in November 2012 based on the CAPN1 SNP for the PRT 
but not the JRT, using the allelic discrimination genotyping assay. Dogs with two copies of 
the disease-associated allele were defined as affected, with one copy of the disease-
associated allele as carriers, and with no copies of the disease-associated allele as 
normal.   
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5.3. Comments and conclusions 
5.3.1. Genome-wide association study 
A GWAS approach using a high-density SNP array to genotype 16 cases and 16 controls 
was successfully used to identify a single locus associated with LOA in the PRT. Reports 
in the scientific literature suggested that a complex pattern of inheritance was most likely 
for LOA in the PRT, so results indicating a single associated locus largely contradicted 
this prediction. Of the 16 cases, 15 were homozygous for a shared haplotype, leading to a 
high level of statistical significance and suggesting that the locus identified was the major 
cause of LOA in the breed. 
 
Because of the high levels of genomic inflation seen in previous association studies, 
particular care was taken when selecting cases and controls for use in the LOA study. 
Where possible first degree relatives were used (ie parents or siblings), and failing that 
half-siblings or unrelated individuals were used as controls. This led to a genomic inflation 
value of 0.81 based on the median chi squared value. This suggested slight genomic 
deflation, meaning that the range of chi squared values were overall lower than expected 
for a randomly selected cohort of cases and controls with no population stratification. The 
low genomic inflation value is likely to be due to first degree relatives being more similar 
genetically in the purebred dog than in human studies, leading to lower than expected 
probability values. Nevertheless a single strong statistical signal remained, and the study 
appeared to be unaffected. Genomic deflation in studies of complex disease could 
however be potentially problematic as significant signals could be masked due to high 
levels of genetic similarity between cases and controls, meaning a high proportion of risk 
factors for disease would be shared in both sets. 
5.3.2. Exclusion of the SPTBN2 gene as the cause of LOA in the PRT 
The gene encoding beta-III spectrin (SPTBN2) provided a strong candidate gene within 
the disease-associated region. Mutations in SPTBN2 have been shown to cause SCA5 in 
humans (Ikeda et al., 2006). Spectrins are important structural components of the plasma 
membrane and play a significant role in restricting and stabilising membrane spanning 
proteins within specific subdomains of the plasma membrane. Beta-III spectrin is primarily 
expressed in the nervous system and the highest levels of expression are found in 
Purkinje cell soma and dendrites (Sakaguchi et al., 1998). Beta-III spectrin has been 
shown to stabilise the glutamate transporter EAAT4 at the plasma membrane of the 
Purkinje cells (Jackson et al., 2001), facilitate protein trafficking by linking the microtubule 
motor to vesicle-bound cargo (Holleran et al., 2001) and maintain a high density of sodium 
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channels within the soma and dendrites of Purkinje cells (Perkins et al., 2010). Beta-III 
spectrin is critical for development of Purkinje cells (Gao et al., 2011).  
 
On exon resequencing of SPTBN2 no non-synonymous, frameshift or splice site variants 
were identified excluding coding changes as a potential cause of LOA in the PRT. 
Targeted resequencing of the LOA disease-associated region enabled coding and non-
coding regions of the SPTBN2 to be investigated, although no potentially causal variants 
were identified. Data from mRNA-seq experiments provided a further check on the 
SPTBN2 transcript helping to exclude mis-splicing and changes in expression levels as 
potential causes of LOA. The SPTBN2 gene was therefore excluded. 
 
Although similar clinical signs of ataxia are shared in both LOA and SCA5, other clinical 
features suggest potentially different mechanisms. Clinical features of SCA5 suggest a 
predominately cerebellar disease (Bauer et al., 2006), whereas histopathological 
examination of LOA cases suggest limited cerebellar pathology, with degeneration of the 
brain stem and spinocerebellar tract involved in disease progression. This evidence 
supports a different genetic cause for LOA and SCA5, although it is possible for different 
mutations in the same gene to result in variable phenotypes. 
5.3.3. Targeted resequencing of the LOA disease-associated region 
Targeted resequencing was successfully used to identify potential causal variants across 
the LOA disease-associated region. In the first round of sequencing on average 79% of 
bases in the target region achieved 10x coverage. This was a high level of coverage for a 
target enrichment experiment, but this still left 21% of the region either unsequenced or 
sequenced at a low level of coverage. Although the non-sequenced regions are largely 
repetitive in nature, which would have been masked during bait design, the missing data 
highlights how mutations in repetitive regions of the genome could be missed. 
 
The second target enriched massively parallel sequencing experiment to sequence ten 
additional controls was completed entirely in-house, satisfying one of the targets set out at 
the start of this thesis. Ten fold less data were produced from one run of the MiSeq 
platform, resulting in 56% coverage of the target region, 23% lower than for the first HiSeq 
run. The data however still served the required function of reducing the number of disease 
segregating variants.  
 
One interesting difference between the MiSeq and HiSeq runs was the average level of 
PCR product duplicates seen, which was 37% for the HiSeq run and 2% for the MiSeq 
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run. The high level of PCR product duplicates for the HiSeq run suggests that the level of 
data produced is approaching the useful limit, as any further increase in data output would 
likely result in further duplicates being produced which are removed by the sequencing 
analysis pipeline. This highlights that although competition in massively parallel 
sequencing technology development has led to an exponential increase in sequence data 
output, usefulness of the data may be limited by the method used to create sequencing 
libraries. 
5.3.4. CAPN1 as a candidate for LOA in the PRT 
5.3.4.1. The calpain family 
The calpain 1 gene (CAPN1) encodes an intracellular calcium dependent cysteine 
protease. Calpains are found throughout the plant, animal and fungal kingdoms, and 
belong to the papain superfamily of cysteine proteases with a catalytic site related to 
caspase and cathepsin family members (Barrett and Rawlings, 2001, Berti and Storer, 
1995). Work to characterise calpain structurally was largely carried out with two 
conventional forms known as µ-calpain (CAPN1) and m-calpain (CAPN2), which 
subsequently was used to define the calpain family in classical and non-classical forms. 
Classical calpains consist of an N-terminal anchor helix region, two protease core 
domains (PC1 and PC2), a C2 like domain (C2L) and a penta EF-hand calcium binding 
domain (PEF) (Figure 5.10). 
 
 
Figure 5.10 The structure of classical calpain 
Classical calpain consists of two protease core domains (PC1 and PC2), a C2 like domain (C2L) and a penta 
EF-hand domain (PEF). The PC1 and PC2 make up the cysteine protease core. The cysteine, histidine and 
asparagine residues make up the catalytic site of the enzyme. 
 
Both CAPN1 and CAPN2 proteins form heterodimeric structures with the small regulatory 
subunit CAPNS1, interacting with the fifth EF-hand motif. On binding of calcium, 
conformational changes result in formation of a catalytic triad of cysteine, histidine and 
asparagine residues and activation of the enzyme (Hosfield et al., 1999). 
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Calpains have limited protease activity and are therefore classified as modulatory 
enzymes that precisely and irreversibly cleave specific protein substrates (Sorimachi et 
al., 1997), although the exact physiological functions of calpains remain unclear.  
5.3.4.2. Calpain gene knockouts 
Advances in the understanding of calpains have been made by analysing targeted gene 
knock-outs. The importance of the ubiquitously expressed µ/m calpains (CAPN1 and 
CAPN2) was shown by targeted knockout of the gene encoding the small regulatory 
subunit CAPNS1 (CAPN4), which resulted in embryonic lethality (Tan et al., 2006). 
Targeted deletion of mouse CAPN2 also resulted in embryonic lethality, although CAPN1 
null mice appear phenotypically normal, apart from an observed reduction in platelet 
aggregation (Azam et al., 2001, Dutt et al., 2006).  
5.3.4.3. Calpain associated disease in human patients 
Mutations in CAPN3 have been associated with limb girdle muscular dystrophy type 2A, a 
progressive atrophy and weakness of the shoulder and pelvic girdle muscles in humans 
(Richard et al., 1995). Calpains have been associated with neuronal necrosis, with 
proteolytic activity increasing as cellular calcium levels rise due to loss of homeostasis 
after trauma (Kampfl et al., 1996). Experimentally induced brain trauma in mice by 
ischaemia (reduction of blood supply to a region of tissue) was shown to result in 
increased proteolysis of frodin (alpha spectrin), a major cytoskeletal protein, an event 
hypothesised to be part of a cascade leading to neuronal cell death (Saido et al., 1993). 
Calpain inhibitors have therefore been suggested as potential therapeutic agents for 
traumatic brain injury (Bralic et al., 2012, Pignol et al., 2006). Calpains have also been 
linked to roles in long term potentiation and Alzheimer’s disease. Despite links to neuronal 
death and disease, there is evidence that calpains may actually contribute to dendrite 
remodelling after neural injury, suggesting a maintenance role in the nervous system 
(Faddis et al., 1997). 
5.3.4.4. The disease-associated CAPN1 mutation 
The disease-associated CAPN1 mutation is a non-synonymous G to A base substitution 
at position 344 of the CAPN1 transcript, resulting in substitution of a cysteine residue for a 
tyrosine (C115Y). This 155 cysteine residue is analogous to the catalytic cysteine residue 
that forms part of a catalytic triad with histidine and asparagine, and is therefore critical to 
the enzymatic properties of the protein (http://www.uniprot.org/uniprot/P07384). This 
suggests that substitution of this residue is likely to have a detrimental effect on enzyme 
activity, and a potential loss of function. Of the three candidate SNPs from resequencing 
of the disease-associated region, the CAPN1 variant showed the strongest pattern of 
segregation on genotyping of an extended cohort of PRT individuals. An extremely high 
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level of conservation was seen across species for CAPN1 orthologues at the amino acid 
level for the 115 cysteine residue. High levels of conservation within species for calpain 
family members (paralogues of CAPN1) further suggest the critical importance of the 
residue. Predictive tools suggest the mutation to be potentially pathogenic and use of 
Grantham and BLOSUM tables suggest tyrosine to have different chemical characteristics 
and cysteine to tyrosine base substitutions to be evolutionarily uncommon. Collectively the 
evidence presents a strong case for the CAPN1 SNP to be deleterious. 
5.3.4.5. The CAPN1 mutation and LOA phenotype 
Although genomic comparisons and predictive tools strongly suggest that the CAPN1 
mutation is likely to be pathogenic, this contradicts the clinically normal phenotype seen in 
the CAPN1 null mouse. Conversely, there have been no suggestions of platelet disorders 
in dogs homozygous for the CAPN1 variant, although this potential defect has not been 
investigated in the dog and does not appear to significantly affect bleeding times in the 
mouse. One possibility is that the null mouse does not have significant longevity for 
clinical signs to be noticed or mice are euthanised before manifestation of clinical signs. 
Another possibility is that the CAPN1 gene has a slightly different role in the mouse with 
the calpain family having a level of redundancy, allowing other family members to 
compensate for loss of calpain 1 activity. A third possibility is that the CAPN1 mutation is 
not the cause of LOA but in fact a marker in linkage disequilibrium with the disorder, 
although the exact residue changed by the CAPN1 variant is highly suggestive. 
 
A possible role for calpain 1 in neuronal maintenance and remodelling best fits the 
potential for a defective calpain 1 protein to be the cause of LOA in the PRT. LOA is 
largely a disease of motor neurone degeneration in the spinocerebellar tract, with 
Wallerian-like degeneration observed on histopathological examination. Defective 
maintenance mechanisms due to lack of calpain 1, leading to neurite degeneration and 
necrosis, would explain these observations. However, processing of substrates by calpain 
1 have been implicated in neurite degeneration, confusing the roles of calpains and 
potentially suggesting involvement in multiple molecular processes and pathways 
(Demarchi and Schneider, 2007, Touma et al., 2007). 
5.3.5. Exclusion of the intergenic SNP 
Although the CAPN1 SNP was considered to be the strongest candidate for the cause of 
LOA based on the exonic location and the predicted effect on protein function, there was 
insufficient evidence to formally exclude the intergenic SNP as causal. In order to exclude 
one of the SNPs an individual that was homozygous for the disease-associated allele, but 
clinically normal would need to be identified. Conversely functional work would be needed, 
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such as the use of a knock-out mouse model, to help confirm a SNP as the causal 
mutation.  
5.3.6. Discordant cases 
Four PRTs and four JRTs which displayed clinical signs consistent with LOA, but were not 
homozygous for the CAPN1 disease-associated allele were identified in the study. 
Diagnosis was not changed on follow-up investigation, although full neurological 
examinations had not been performed to rule out other causes of disease such as 
inflammatory or infectious brain diseases. Six of the discordant cases were homozygous 
for the wild-type CAPN1 allele and two were heterozygous. Genotyping of SNPs across 
the disease-associated region would be required to determine whether recombination 
events had occurred to potentially rule out the CAPN1 SNP. However it is impossible to 
rule out the existence of a genetically distinct, but clinically very similar form of ataxia to 
LOA in the breed. Along with an early onset form that has been reported (personal 
communication, Gary Johnson, University of Missouri), this may indicate that there are 
potentially three genetically distinct forms of ataxia that segregate within the PRT and JRT 
breeds.  
5.3.7. DNA testing 
Given that the CAPN1 variant is at least highly associated with LOA in the PRT, a DNA 
test based on CAPN1 was launched in November 2012. The test would allow breeders to 
identify asymptomatic carriers and by selective breeding reduce the frequency of the 
disease-associated allele in the breed population. The DNA test would also potentially 
benefit the research programme by identifying further clinically affected individuals that 
are not homozygous for the disease-associated mutation. These cases would allow the 
effectiveness of the DNA test to be monitored and if enough cases were collected, allow 
an additional GWAS to be undertaken for a third potential cause of ataxia in the breed. 
Additionally, identification of clinically normal individuals, which are homozygous for the 
disease-associated allele may indicate that the CAPN1 mutation is not causal or could 
imply involvement of a modifier gene affecting age of onset, as demonstrated for 
progressive retinal atrophy in the Miniature Long Haired Dachshund (Miyadera et al., 
2012). Both scenarios would require SNP array genotyping of additional individuals to 
either refine the disease-associated region or to perform an association study to identify a 
second modifying locus.     
5.3.8.  Summary 
Using a GWAS approach and target enriched massively parallel sequencing a disease-
associated SNP in CAPN1 has been identified. The SNP is a missense mutation causing 
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a cysteine to tyrosine substitution at residue 115 of the calpain 1 protein. Cysteine 115 is 
a highly conserved residue and forms a key part of a catalytic triad of amino acids that are 
crucial to the enzymatic activity of cysteine proteases. Given the function and high level of 
conservation, substitution of the cysteine residue is highly likely to have a negative effect 
on the activity of the enzyme, although functional studies would be required to assess the 
extent of activity loss. Loss of CAPN1 activity as a cause of LOA is difficult to prove, 
although a suggested role for CAPN1 in neuronal maintenance fits with the pathogenesis 
of the disease based on histopathological evidence. A DNA test has been launched as a 
breeding tool to help reduce the prevalence of LOA within the breed population.    
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6.1. Background 
At the Centre for Small Animal Studies at the AHT isolated and clinically distinct cases are 
often seen, which represent either rare conditions or previously unseen novel disorders. 
When a four week old Beagle presented with clinical signs of cerebellar ataxia with an 
inability to ambulate, a full clinical investigation was carried out to categorise the condition 
accurately and to rule out other underlying causes, although an inherited basis was 
deemed likely, based on family history. Because of the poor prognosis for the puppy the 
owner elected euthanasia. Prompt post-mortem investigation allowed fresh tissue 
samples to be obtained for histopathological and gene expression studies. No clinically 
similar Beagle cases had been seen previously at the AHT. 
6.1.1. Clinical investigation 
The clinical investigation was carried out at the AHT by Elsa Beltran and Dr Luisa De 
Risio (veterinary neurologists). The four week old puppy had a ten day history of severe 
cerebellar ataxia, and was unable to ambulate from the normal onset age of walking. The 
clinical signs had remained stable since then. The puppy was eating and drinking well, 
with no other gross abnormalities on physical examination.  
 
Neurological examination revealed severe cerebellar ataxia, with a tendency to lean and 
fall towards both sides, resulting in an inability to walk without assistance. Proprioceptive 
positioning was normal while hopping reactions were abnormal with delayed onset of 
protraction and exaggerated response, once initiated. Spinal reflexes were normal in all 
four limbs. Cranial nerve examination revealed an absent menace response bilaterally 
with normal vision. Occasionally when the head was positioned in extension, spontaneous 
rotatory nystagmus was observed. A lesion involving mainly the cerebellum and 
spinocerebellar tracts was suspected. The main differential diagnoses included 
degenerative central nervous system disease, such as neonatal cerebellar cortical 
degeneration (NCCD) and less likely inflammatory/infectious central nervous system 
disease, metabolic disease and neoplasia. Haematology and comprehensive biochemistry 
investigations did not reveal any significant abnormalities. Brainstem auditory evoked 
responses (BAER hearing test) identified clear waves I to V (normal). Based on the 
severity of the clinical signs, normal haematology and biochemistry results, a 
degenerative condition was considered the most likely underlying cause and the breeder 
elected euthanasia. Post-mortem examination was performed an hour after euthanasia, 
and failed to reveal gross pathology. The brain in toto weighed 42 g, whilst the cerebellum 
weighed 5 g (12%, normal 10-12%). Narrowing of folia was not noted.    
6. Beagle cerebellar degeneration 
 
 
 
160 
 
There were no signs of systemic illness in the sire, dam or littermates. Physical and 
neurological examination of the dam, sire and six clinically unaffected littermates, was 
carried out by Elsa Beltran at the AHT, and did not reveal any abnormalities.  
 
The only previous litter from the same sire and dam mating consisted of seven puppies, of 
which two (one female and one male) had clinical signs consistent with NCCD and the 
remainder were clinically normal based on clinical history and video footage provided by 
the breeder when the puppies were eight weeks old. Both clinically affected puppies were 
euthanised at eight weeks of age and paraffin-embedded sections of cerebellum from the 
female were available for histopathological examination. 
6.1.2. Histopathological investigation 
Histopathologial investigations were carried out by Jennifer Stewart at the AHT. 
Histopathologically, the lesions were confined to the cerebellum. Examination of serial 
cerebellar sections of the four week old puppy identified mild loss of Purkinje cells, with 
increased numbers of astrocytes. Moderate numbers of Purkinje cells were shrunken with 
angular cell margins, hypereosinophilic cytoplasm, and condensed nuclei (Figure 6.1). 
Occasional associated swollen dendritic processes were identified. Spheroids were rarely 
seen. Mild spongiosis was present in the granular cell layer.  
 
 
Figure 6.1 Cerebellar folia of a four week old Beagle with NCCD 
Loss of occasional Purkinje cells is indicated by the grey arrow. The black arrow points to a degenerating 
Purkinje cell with hypereosinophilic cytoplasm and a condensed nucleus. 100x magnification. Image provided 
by Jennifer Stewart, Animal Health Trust.  
 
Purkinje cell interface Bielschowsky fiber stain was performed by Dr. Kaspar Matiasek at 
the Institute of Veterinary Pathology, Ludwig-Maximilians University, Munich and 
demonstrated the subacute loss of Purkinje cells, also called “empty baskets” (Figure 6.2).  
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Figure 6.2 Bielschowsky staining of cerebellum tissue from the Beagle NCCD case 
(A) A normal Purkinje cell. (B) Subacute loss of Purkinje cells (PC) is indicated by the presence of “empty 
baskets” (EB). Scale bar: 40 µm. ML: molecular layer; GL: granule cell layer. Image provided by Dr. Kaspar 
Matiasek, Ludwig-Maximilians University.  
 
Examination of slides (Jennifer Stewart, AHT) made from the paraffin embedded tissues 
of the eight week old female from the previous litter identified marked Purkinje cell loss 
with rare remaining, often abnormal, Purkinje cells. Variably swollen or shrunken, 
hypereosinophilic Purkinje cells were identified within the remaining population. 
Correlating astrocytosis replaced previously lost Purkinje cells. Swollen dendritic 
processes and small numbers of spheroids were present. There was moderate to marked 
thinning of the subjacent granular layer. Cerebellar nuclei in both puppies were normal. 
Neuronal storage products were not identified in either puppy. The clinical and 
histopathological investigations confirmed the diagnosis of NCCD in both puppies. 
6.1.3. Previous reports of NCCD in the veterinary literature 
There have been two previous reports of conditions similar to NCCD in Beagle in the 
veterinary literature. Cerebellar cortical degeneration in Beagle dogs was reported by 
Yasuba and colleagues in 1988 (Yasuba et al., 1988). The cases in the study were born 
as a part of a breeding colony so the condition of the puppies could be assessed from 
birth. Three out of a litter of eight puppies were affected and clinical signs were first seen 
from three weeks of age, consistent with the case seen at the AHT. The clinical signs 
showed a slow progression until the affected dogs were euthanised at 14 weeks of age. 
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Histopathological examination revealed thinning of the folia and widened sulci. 
Degeneration to loss of Purkinje cells was observed, and the molecular and granular 
layers were reduced in thickness. 
 
A report of cerebellar cortical abiotrophy by Kent and colleagues was published in 2000 
(Kent et al., 2000). The case was a four and a half month old female, which was one of 
two affected individuals from a litter of five. The owners reported that the affected puppies 
were unable to ambulate normally from the onset of walking, but no progression of clinical 
signs was noted by the breeder. At four and a half months of age the dog was ambulatory 
but had clinical signs of bilateral cerebellar ataxia, with a dysmetric gait and an inability to 
regulate the rate and range of movement, with both hypermetric and hypometric striding. 
Balance was affected, and the dog would fall in all directions (ie sideways, forwards and 
backwards). Purkinje cell loss was observed histopathologically, which was consistent 
with the previously reported case and the AHT case. All areas of the cerebellum were 
more uniformly affected than reported by Yasuba and colleagues, although this may be 
related to age at examination.  
6.1.4. Study approach 
The introduction of massively parallel sequencing techniques has facilitated the use of 
many new DNA sequencing applications. Genome-wide sequencing such as whole 
genome resequencing, whole exome sequencing and genome-wide mRNA sequencing 
(mRNA-seq) can now be achieved in a single, cost effective experiment. Next generation 
sequencing technologies coupled with target enrichment techniques (Asan et al., 2011) 
allow for the simultaneous sequencing of several exomes that can be used to scan coding 
regions of the genome for disease-associated mutations in a case-control approach. An 
example of a successful use of this method is the identification of AFG3L2 mutations in 
spastic ataxia-neuropathy syndrome (Pierson et al., 2011). In the spastic ataxia-
neuropathy syndrome study, DNA from just the father, mother and two affected siblings of 
a consanguineous family was subjected to whole exome sequencing. Although an 
average of 8,585 missense and 87 nonsense changes were identified per individual, use 
of an autosomal recessive model and exclusion of SNPs catalogued in the dbSNP 
database, left just two candidate variants, only one of which was plausibly causal, 
illustrating the potential use of genome-wide sequencing approaches using a minimal set 
of individuals to identify causal variants. 
 
Genome-wide mRNA sequencing is widely used in quantitative gene expression studies 
and can be used to improve genome annotation. This approach has recently been 
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suggested for the canine genome which relies heavily on predictive methods for genome 
annotation (Derrien et al., 2012). Genome-wide mRNA sequencing has the potential to 
confirm exon boundaries, classify previously undiscovered genes, and identify gene 
isoforms resulting from alternative splicing, but its use as a method of identifying coding 
changes associated with inherited disease is not widely reported. 
 
Following identification of a case of NCCD, an mRNA-seq experiment was planned as a 
method of candidate gene sequencing. Ataxia in humans is well characterised and a large 
number of genes and loci have been associated with both autosomal dominant (SCA1-36) 
and autosomal recessive (SCAR1-12) spinocerebellar ataxias. The mRNA sequencing 
data were generated to interrogate canine orthologues of spinocerebellar ataxia 
associated genes identified from human studies with the aim of identifying the causal 
genetic variant responsible for NCCD in the Beagle.  
6.1.5. Summary 
A four week old Beagle with clinical signs of cerebellar ataxia was seen at the AHT. The 
prognosis for the puppy was poor and the owner elected euthanasia.  Neurological and 
histopathologal examinations led to a diagnosis of NCCD. The post-mortem examination 
was performed within an hour of euthanasia, allowing fresh cerebellum tissue to be stored 
in RNAlater. The standard procedure for investigating genetic diseases is to collect a large 
case-control cohort, before undertaking a GWAS approach to identify disease-associated 
loci, which can then be screened for causal mutations. However, the tissue sample 
obtained allowed the trialling of mRNA-seq as a method of candidate gene sequencing in 
an attempt to identify the causal mutation for this disorder and develop a diagnostic DNA 
test. 
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6.2. Results  
6.2.1. Pedigree analysis 
Of a total of 14 dogs from the same sire and dam mating, 3 dogs (2 male and 1 female) 
were affected by NCCD, which was consistent with an autosomal recessive mode of 
inheritance (Figure 6.3). 
 
Figure 6.3 Pedigree of the three Beagle NCCD puppies 
All three affected puppies were from the same sire and dam mating, and included both male and female 
puppies, with ratios of affected to unaffected littermates suggestive of an autosomal recessive mode of 
inheritance. 
 
6.2.2. RNA integrity 
A crucial factor for successful mRNA-seq experiments is integrity of RNA. If the RNA is 
degraded, sequencing libraries are biased towards the 3’ end when using a polyA capture 
method of purifying the mRNA from total RNA. RNA for use in the study was DNase 
treated to ensure no sequenced library fragments originated from genomic DNA. Five total 
RNA samples were extracted from cerebellum tissue of an ataxic Parson Russell Terrier, 
two ataxic Norwegian Buhunds, the NCCD case and from a neurologically normal dog of 
unknown breed. RNA integrity was assessed using the Agilent Bioanalyser RNA assay at 
Cambridge Genomic Services, Cambridge (Figure 6.4).   
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Figure 6.4 RNA integrity numbers (RINs) 
Cerebellum RNA samples were assayed on the Agilent Bioanalyser to assess concentration and RNA 
integrity. The peaks on the electropherogram after 42 and 48 seconds represent the 18s and 28s rRNA 
respectively. An RNA integrity number (RIN) between 0 and 10 is given with 0 indicating completely degraded 
RNA or absence of RNA and 10 indicating fully intact RNA.  
 
Illumina recommend use of RNA with RNA integrity number (RIN) values of greater than 
7.00 for use in library preparation. All total RNAs had a RIN of 9.30 or greater and were 
suitable for library preparation. 
6.2.3. Libraries 
Six libraries were constructed in total. Initially a trial library was made using the NCCD 
Beagle RNA which would be multiplexed with SureSelect libraries for sequencing to 
gauge the effectiveness of library preparation and to calculate the amount of data required 
to successfully use mRNA-seq as a method of sequencing the selected candidate genes. 
After successful sequencing of the trial library, a second batch of libraries was 
constructed, one for each of the samples described in section 6.2.2., with a ~150 bp insert 
size. 
6.2.4. Assessing library content by cloning 
Libraries were assessed for mRNA enrichment success by molecular cloning followed by 
Sanger sequencing. A summary of cloning results is shown in Appendix 13. No cloned 
fragments were ribosomal RNA in origin suggesting successful polyA enrichment. A high 
percentage of reads mapped to 3’ UTR regions of genes (59%), which was suggestive of 
a possible 3’ bias in the libraries. 
6.2.5. Illumina sequencing of mRNA libraries 
Sequencing of mRNA-seq libraries was performed in three stages. Initially the trial Beagle 
library was multiplexed with SureSelect libraries constructed for unrelated projects and 
sequenced on the Illumina HiSeq 2000 platform. The aim was for 5% of the reads 
generated to be attributed to mRNA-seq and the remaining reads for unrelated projects. 
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The sequencing lane produced a 19.68 Gb dataset with 1.39 Gb (7.1%) belonging to the 
mRNA-seq project.  
 
In the second stage the PRT mRNA-seq library (~150 bp inserts) was multiplexed with a 
second batch of SureSelect libraries, aiming for ~10% of the data to be attributed to 
mRNA-seq. The sequencing lane produced a 20.85 Gb dataset with 2.15 Gb (10.33%) 
belonging to mRNA-seq. 
 
To produce a larger dataset for all five libraries and to resolve a demultiplexing issue 
which arose when multiplexing the mRNA-seq libraries with the SureSelect libraries, all 
five libraries were sequenced on a dedicated lane of a HiSeq 2000. A 17.38 Gb dataset 
was produced, which was equally shared between all five libraries. Datasets are 
summarised in Table 6.1. 
 
Table 6.1 Summary of the mRNA-seq datasets 
mRNA-seq datasets were produced through three runs of single lane sequencing on the Illumina HiSeq 2000. 
For runs 1 and 2, partial lanes were allocated to mRNA with the remainder of the lane allocated to sequencing 
of SureSelect libraries. For run 3 the entire lane was dedicated to mRNA-seq. PRT – PRT LOA case; NB – 
Norwegian Buhund ataxia case; U – neurologically normal individual of unknown breed.     
 
mRNA-seq dataset Sequencing lane content Libraries sequenced mRNA-seq dataset 
size (Gb) 
1 Multiplexed SureSelect & 
mRNA-seq 
Beagle cerebellum (Trial 
library) 1.39 
2 Multiplexed SureSelect & 
mRNA-seq PRT cerebellum 2.15 
3 mRNA-seq only Beagle, PRT, NB1, NB2, 
and U 17.38 
 
6.2.6. Assessing the quality of mRNA-seq data   
The mRNA-seq data were available from the Wellcome Trust Centre of Human Genetics, 
Oxford as pre-aligned bam files. The quality of the aligned data were assessed by viewing 
in IGV. No intergenic reads were detected suggesting RNA extraction and DNase 
treatment had successfully removed genomic DNA from the library preparation. Data were 
assessed for 3’ read bias by visualising long transcripts. Figure 6.5 shows the 5’, central 
and 3’ regions of the dystrophin gene (DMD). The DMD gene has a long 14 kb transcript 
spanning a genomic region of 2.2 Mb. The gene is primarily expressed in skeletal muscle, 
but some expression is seen in brain tissue. Although a four fold drop in read depth was 
seen from the 3’ to the 5’ end of the gene, coverage was achieved for all exons, 
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suggesting exonic coverage would be achieved for other genes of a similar length or 
shorter, and expressed at a comparable level.  
 
 
Figure 6.5 Assessment of 3’ bias by visualising a long transcript in IGV 
Long transcripts such as the dystrophin (DMD) transcript were used to assess the level of 3’ bias. Over the 
longest transcripts there appeared to be 3-4 fold decrease in coverage from the most 3’ to 5’ regions. 
 
As several regions of the genome were assessed visually in IGV, it was noticed that there 
appeared to be reads mapping to the exact position of SureSelect baits in the mRNA-seq 
dataset (Figure 6.6). Suggested causes of the problem included contamination of the pre-
amplified mRNA-seq library with a SureSelect library, faulty allocation of reads during 
demultiplexing or cross-contamination of indexing primers. 
 
 
Figure 6.6 Presence of SureSelect reads in mRNA-seq data 
It was noted that in some intergenic regions it appeared that data in the position of SureSelect baits was 
present in mRNA-seq datasets. In exonic regions this issue presented a problem in distinguishing mRNA-seq 
reads from SureSelect reads, especially when expression levels for a particular gene were low. 
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In the first mRNA-seq experiment the trial Beagle cerebellum library was multiplexed with 
SureSelect libraries for the PRT and IS disease-associated regions. Reads in intergenic 
regions were seen at the location of SureSelect baits. In the second mRNA-seq 
experiment the PRT cerebellum library (part of the batch of five mRNA-seq libraries) was 
multiplexed with SureSelect libraries for an unrelated project. Reads in intergenic regions 
were also seen at the location of SureSelect baits, but contamination of the pre-amplified 
mRNA-seq library with material from the SureSelect libraries could be ruled out as the 
mRNA-seq libraries were made prior to synthesis of the SureSelect libraries. The problem 
was resolved by sequencing the mRNA-seq libraries independently on a single lane of an 
Illumina HiSeq 2000. This also presented the opportunity to generate mRNA-seq data for 
a control cerebellum sample from a clinically normal dog and mRNA-seq data for two 
libraries attributed to an unrelated project (Norwegian Buhund libraries). 
6.2.7. Candidate gene selection   
A review of the scientific literature and the Online Mendelian Inheritance in Man (OMIM) 
database indicated 41 human ataxia loci had been identified for which 28 causal genes 
had been characterised. Twenty seven of the genes causing human ataxia had 
orthologous canine genes, and these genes were considered as candidates. Candidate 
genes could only be considered if they were expressed sufficiently to give complete 
exonic coverage from the mRNA-seq dataset.  
6.2.8. Candidate gene analysis 
The dataset used in the initial analysis was created from the Beagle trial library and 
consisted of 13.64 millions reads, with 97.1% of the reads mapping to the dog genome. 
The dataset was sufficient for complete exonic coverage of 24 of the 27 candidate genes. 
No polymorphisms were identified in 11 of the genes. Three genes contained 
polymorphisms in non-coding regions only. Heterozygous SNPs were identified in four 
genes, excluding association with NCCD. Two genes contained synonymous SNPs. Non-
synonymous changes were identified in ITPR1 (chr20:15,780,361G>C;p.E2491Q), 
BEAN1 (brain expressed, associated with NEDD4, 1) (chr5:85,782,181C>T;p.R247Q), 
and ADCK3 (aarF domain containing kinase 3) (chr7:41,059,467A>G;p.S328P). For 
ITPR1 and ADCK3 the non-reference residue is highly conserved amongst vertebrate 
species and therefore could be ruled out as causal. Alignment across vertebrate species 
at the site of the BEAN1 polymorphism indicated that both glutamic acid and glutamine 
residues occur naturally, enabling that variant to also be excluded. An 8 bp deletion was 
detected in exon 29 of SPTBN2 (chr18:53,691,704_53,691,711del) and is shown in Figure 
6.7. The deletion was confirmed by Sanger sequencing. The frameshift is predicted to 
result in a run of 27 aberrant amino acids, followed by premature termination with a 410 
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amino acid truncation (p.G1952insRDRGQGRPLLLMHRHGAGAACQEPLCS*). A 
summary of candidate genes and variants is shown in Appendix 14. 
 
 
Figure 6.7 Identification of an 8 bp deletion in SPTBN2 
Display in IGV of the 8 bp deletion in exon 29 of SPTBN2.   
6.2.9. Genotyping 
Genotyping experiments were performed to establish whether the 8 bp SPTBN2 deletion 
could be potentially causal. Example results are shown in Figure 6.8. The sire and dam of 
the affected dogs were both heterozygous for the 8 bp deletion, and out of the ten 
clinically unaffected siblings tested, seven were heterozygous and three were 
homozygous for the wild-type allele. DNA extracted from FFPE tissue of a previous NCCD 
case from the same sire and dam mating was homozygous for the deletion. Seven other 
clinically unaffected half-siblings, with the same sire as the affected dogs, were either 
heterozygous or wild-type homozygous. An additional 145 Beagles, which were collected 
for an unrelated project and clinically normal with respect to NCCD, were also genotyped. 
Eight dogs were heterozygous for the deletion, and the remaining 137 dogs were 
homozygous wild-type, in full concordance with the mutation being causal. In addition 513 
dogs from 37 other breeds were also genotyped; all were homozygous for the wild-type 
allele. 
 
 
Figure 6.8 NCCD diagnostic test genotype display 
The 8 bp deletion created a PCR product fragment length polymorphism, which individuals could be 
genotyped for as a method of diagnostic testing.   
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6.2.10. qPCR assessment of SPTBN2 levels 
Limited qPCR experiments to assess the expression levels of SPTBN2 in affected and 
normal cerebellum tissues suggested a 63 fold reduction in SPTBN2 transcript levels in 
the affected Beagle (Table 6.2). 
 
Table 6.2 Relative expression analysis data 
Expression levels of SPTBN2 were measured relative to the reference genes beta-actin (ACTB) and tata-box 
binding protein (TBP) using qPCR. Fold change was calculated based on changes in threshold cycle (Ct) 
measurements within (∆Ct) and between (∆∆Ct) the case and control. 
 
Sample Name Assay Name Ct Mean Std Dev. ∆Ct ∆∆Ct Fold ∆ Mean Fold ∆ 
Control ACTB 21.54 0.01 2.14       
Control TBP 24.34 0.01 -0.65       
Control SPTBN2 23.69 0.07         
Beagle NCCD ACTB 17.54 0.03 8.44 6.30 79 x   
Beagle NCCD TBP 21.12 0.05 4.86 5.52 46 x 63 x 
Beagle NCCD SPTBN2 25.98 0.05         
 
6.2.11. Western blot analysis of SPTBN2 protein 
Using western blot analysis with primary antibodies targeting the N-terminal region of 
beta-III spectrin, no full length or truncated beta-III spectrin could be detected in 
cerebellum tissue of the NCCD case, suggesting expression of the protein may have been 
abolished (Figure 6.9). 
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Figure 6.9 Western blot analysis of beta-III spectrin 
Western blot analysis of wild-type individual (wt/wt) and affected Beagle (del/del) cerebellum tissue 
homogenates revealed no detectable beta-III spectrin in the affected Beagle cerebellum. Mouse cerebellum 
(M) was used as a control and beta-actin as a loading control. 
6.2.12. Genome-wide comparison of expression levels 
The availability of a control cerebellum sample allowed for a genome-wide case-control 
comparison of gene expression levels. Based on the comparison between the NCCD 
Beagle cerebellum and the control cerebellum a 10.8x reduction in SPTBN2 expression 
was indicated. This expression change was ranked the 88th largest reduction in 
expression, and 10th most significant change based on P-values genome-wide (Table 
6.3). Data analysis was performed at the Wellcome Trust Centre for Human Genetics, 
University of Oxford. 
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Table 6.3 Top 20 most significant changes in gene expression 
20 most significant differences in gene expression between the control cerebellum and the Beagle NCCD 
cerebellum. Fold change is shown as fold decrease in expression. There are 30,194 annotated genes for the 
CanFam2 genome build. 
 
Rank Gene ID chr position baseMean baseMeanA baseMeanB foldChange P value P Adjusted 
1 PLK5 20 60,478,581 4160 5 8315 1663.67 9.06E-86 1.76E-81 
2 TTR 7 60,920,284 5368 63 10672 169.48 8.58E-78 8.34E-74 
3 DSP 35 10,486,761 1301 48 2555 53.25 3.06E-67 1.98E-63 
4 KIAA1199 3 59,591,949 1353 2598 107 0.04 3.45E-54 1.68E-50 
5 THY1 5 17,512,680 6863 1250 12476 9.98 2.16E-52 7.41E-49 
6 USH1G 9 8,528,280 989 90 1887 20.98 2.29E-52 7.41E-49 
7 SCN1B 1 120,412,273 13827 2802 24852 8.87 1.20E-50 3.33E-47 
8 FAT4 19 18,332,210 1590 3067 114 0.04 7.46E-50 1.81E-46 
9 FBLN2 20 6,920,237 2937 500 5375 10.75 1.14E-48 2.45E-45 
10 NAV1  7 4,136,024 1573 2977 169 0.06 1.81E-48 3.53E-45 
11 SPTBN2  18 53,664,219 5414 917 9912 10.81 5.89E-47 1.04E-43 
12 SEMA6A  11 9,123,714 2141 3961 321 0.08 5.16E-45 8.37E-42 
13 NYNRIN  8 7,374,533 678 1274 82 0.06 6.43E-43 9.62E-40 
14 Novel Un 47,788,156 33270 8388 58152 6.93 1.71E-42 2.38E-39 
15 IFI44  6 71,424,246 1145 2207 83 0.04 1.94E-42 2.51E-39 
16 Novel 31 11,457,222 1863 3409 317 0.09 4.96E-41 6.03E-38 
17 C3orf18  20 41,801,054 1243 185 2301 12.44 5.34E-41 6.11E-38 
18 AOAH  14 50,856,684 602 31 1172 37.83 8.26E-41 8.93E-38 
19 COL6A1  31 41,618,379 1082 2040 124 0.06 2.50E-40 2.55E-37 
20 OAS1  26 13,402,378 1197 2271 122 0.05 2.87E-40 2.79E-37 
 
 
Independent analyses of genome-wide gene expression were carried out for the PRT 
transcriptome against the control transcriptome and the NB transcriptomes against the 
control transcriptome. Fold change values obtained were compared to the top 20 genes 
showing the largest fold changes for the Beagle transcriptome (Table 6.4). Although there 
are some Beagle specific expression changes, many of the same genes show large 
changes in expression for the PRT and NB, suggesting that the changes may due to the 
small sample size, rather than being of true significance.  
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Table 6.4 Fold change comparisons between PRT, NB and BE libraries 
Comparison of expression fold changes associated with the PRT, NB and BE transcriptomes against the 
control transcriptome. Fold change is shown as fold decrease in expression. 
Rank Gene ID Chr Position PRT vs control fold 
change 
NB vs control fold 
change 
BE vs control fold 
change 
1 PLK5 20 60,478,581 1.65 2.65 1663.67 
2 TTR 7 60,920,284 51.35 34.45 169.48 
3 DSP 35 10,486,761 1.57 22.44 53.25 
4 KIAA1199 3 59,591,949 2.39 0.09 0.04 
5 THY1 5 17,512,680 
- - 20.98 
6 USH1G 9 8,528,280 1.39 2.35 9.98 
7 SCN1B 1 120,412,273 1.82 2.27 8.87 
8 FAT4 19 18,332,210 
- 0.12 0.04 
9 FBLN2 20 6,920,237 2.14 1.64 10.75 
10 NAV1  7 4,136,024 0.53 0.17 0.06 
11 SPTBN2  18 53,664,219 0.69 0.50 10.81 
12 SEMA6A  11 9,123,714 0.45 0.25 0.08 
13 NYNRIN  8 7,374,533 0.05 0.04 0.06 
14 Novel Un 47,788,156 4.16 5.05 6.93 
15 IFI44  6 71,424,246 
- - 0.04 
16 Novel 31 11,457,222 0.29 0.23 0.09 
17 C3orf18  20 41,801,054 1.47 2.26 12.44 
18 AOAH  14 50,856,684 1.59 7.86 37.83 
19 COL6A1  31 41,618,379 0.57 0.16 0.06 
20 OAS1  26 13,402,378 0.46 0.39 0.05 
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6.3. Comments and conclusions 
6.3.1. Study approach 
Genome-wide mRNA sequencing of a single Beagle NCCD case was used as a method 
of candidate gene sequencing. A number of factors made the choice of genome-wide 
mRNA sequencing an appropriate study approach. DNA was available from only two 
cases, therefore to perform a GWAS additional cases would have been needed, which 
would have delayed the outcome of the study. Very few cases of NCCD have been 
reported in the UK, so even collecting a modest cohort of 12 cases and 12 controls would 
have taken a considerable length of time, whereas an approach using a single case 
allowed the project to commence immediately. The phenotype for NCCD was both severe 
and early onset. With a severe disease it is reasonable to suspect a causal mutation with 
a severe consequence, such as one that causes a significant change in gene expression 
or that causes a deleterious effect on the function of a protein. The number of affected 
individuals across the two litters was highly suggestive of a simple autosomal recessive 
mode of inheritance. This meant that a single homozygous gene mutation was probably 
responsible for the condition, and because of LD, genes which contained heterozygous 
polymorphisms could be ruled out immediately. A fresh tissue resource was available for 
the case. Post-mortem examination was carried out immediately after euthanasia, and 
cerebellum tissue stored immediately in RNAlater solution. This enabled highly intact RNA 
to be extracted with a RIN value of 10. And finally a large number of genes had previously 
been associated with ataxia in human studies, providing a number of candidate genes to 
be investigated. 
6.3.2. Advantages of mRNA-seq 
As well as being an appropriate approach for studying NCCD in the Beagle, mRNA-seq 
has additional advantages for use in mutation identification. As previously stated, the 
sample collection stage required when performing a GWAS can be avoided when using 
the mRNA-seq approach, which shortens study time-frames especially when cases are 
rare. The approach has advantages over exome enrichment and sequencing 
methodology, in that the method can be performed in all species with reference genome 
sequence builds, without the need for a proprietary kit. The mRNA-seq approach is also 
not dependent on reference genome annotation, which may be inaccurate or incomplete 
in some species. In addition a much smaller dataset is required for an mRNA-seq 
approach in comparison to using whole genome sequencing. mRNA-seq also gives some 
information about gene expression levels, although this can be a disadvantage if disease 
causing genes show limited expression or are drastically reduced in diseased tissues. 
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Because only an mRNA-enrichment stage is required followed by a standard library 
preparation the approach is highly cost-effective. Only a small amount of data is required 
(for example, data generated from a partial lane of an Illumina HiSeq 2000 is adequate) 
and therefore small scale mRNA-seq approaches can “piggy-back” by multiplexing with 
other projects requiring larger amounts of data, such as SureSelect target enrichment 
sequencing experiments. 
6.3.3. The SPTBN2 gene 
Using mRNA-seq an 8 bp deletion in the SPTBN2 gene encoding beta-III spectrin was 
identified, that segregated consistently with NCCD in the Beagle. Spectrins are a family of 
cytoskeletal proteins, with tetrameric structures comprising two alpha and two beta 
subunits, with diversity and specialisation of function. Spectrins are important structural 
components of the plasma membrane and play a significant role in restricting and 
stabilising membrane spanning proteins within specific subdomains of the plasma 
membrane. The spectrin cytoskeleton was first discovered in erythrocytes and has since 
been identified in a variety of cells (Bennett and Baines, 2001). Beta-III spectrin is 
primarily expressed in the nervous system and the highest levels of expression are found 
in Purkinje cell soma and dendrites (Sakaguchi et al., 1998). Beta-III spectrin has been 
shown to stabilise the glutamate transporter EAAT4 at the plasma membrane of the 
Purkinje cells (Jackson et al., 2001), facilitate protein trafficking by linking the microtubule 
motor to vesicle-bound cargo (Holleran et al., 2001) and maintain a high density of sodium 
channels within the soma and dendrites of Purkinje cells (Perkins et al., 2010). Beta-III 
spectrin is critical for development of Purkinje cells (Gao et al., 2011). The identification of 
an 8 bp deletion in SPTBN2, a gene associated with spinocerebellar type 5 (SCA5) in 
humans (Ikeda et al., 2006), that fully segregates with the disease provides a strong 
candidate variant for NCCD in the Beagle. 
6.3.4. Human mutations in SPTBN2 
In humans, three mutations in SPTBN2 have been shown to cause autosomal dominant 
spinocerebellar ataxia type 5 (SCA5) (Ikeda et al., 2006). The causal mutations identified 
include two in-frame deletions of 39 and 15 bp which alter the structure of the 3rd of 17 
spectrin repeats, and a single base pair substitution causing an amino acid change 
(L253P) in a highly conserved region of the calponin homology domain. The consequence 
of the two in-frame deletions in beta-III spectrin is predicted to be disruption of the highly 
ordered triple alpha helical structure of the spectrin repeat, causing conformational 
changes in the tetrameric alpha-beta spectrin complex (Ikeda et al., 2006). Studies 
suggest the resulting mutant protein may affect the localisation of EAAT4 and GluRδ2, 
one possible outcome of which is glutamate signalling abnormalities and Purkinje cell 
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death (Ikeda et al., 2006). The L253P missense mutation has been shown to result in loss 
of interaction with the Arp1 subunit of the dynactin-dynein complex, affecting the role of 
beta-III spectrin in vesicle trafficking, preventing transport of both beta-III spectrin and 
EAAT4 to the cell membrane from the Golgi apparatus in Purkinje cells causing cell 
dysfunction and death (Clarkson et al., 2010). 
 
More recently a homozygous nonsense mutation in SPTBN2 has been associated with 
developmental ataxia and cognitive impairment in humans (Lise et al., 2012). Three 
individuals from a consanguineous family were observed to have the disorder. Onset of 
walking was typically delayed to seven years of age and an obvious dysmetric gait was 
observed, consistent with the affected Beagle puppy’s inability to ambulate. All affected 
individuals had intelligence quotient (IQ) scores falling within the learning disabled range. 
Genome sequencing was performed to rule out any other potential genetic causes of the 
cognitive impairment, and use of a mouse model confirmed a role for SPTBN2 in both 
cognitive development and function. No obvious cognitive defects were observed for the 
affected Beagle puppy, although cognitive function was not fully investigated.         
6.3.5. Beta-III spectrin knock-out mice 
Experimentally induced beta-III spectrin deficiency in mice from two independent studies 
resulted in phenotypes that resemble NCCD in Beagle dogs (Perkins et al., 2010, 
Stankewich et al., 2010). One beta-III spectrin deficient strain was produced by targeting 
replacement of exon 3 to 6 of SPTBN2 with the neomycin-resistance gene, resulting in a 
frameshift and a premature stop codon in exon 7. As a result no full length beta-III spectrin 
is produced in beta-III spectrin deficient mice, although a low level of near full length 
protein is produced due to novel exon 1 (rather than exon 2) to exon 7 splicing (Perkins et 
al., 2010). Homozygous beta-III spectrin deficient mice develop characteristics of 
progressive cerebellar ataxia from a few weeks of age with cerebellar atrophy and 
Purkinje cell loss. In the parallel study the beta-III spectrin deficient mouse strain is the 
result of beta-geo insertion between exons 25 and 26 resulting in premature termination in 
spectrin repeat 14, which is closer to the position of the Beagle mutation, although results 
in the loss of the ankyrin binding domain (Stankewich et al., 2010). The beta-III spectrin 
deficient mice from this study display a mild non-progressive ataxia by 6 months and a 
myoclonic seizure disorder by one year (Stankewich et al., 2010).  It is apparent that onset 
of ataxia is later for the beta-III spectrin deficient mouse in comparison to Beagle NCCD 
cases, with mice not showing significant signs of ataxia until six months of age (past 
sexual maturity). This is more comparable to the human disease, though the differences in 
the modes of inheritance suggest different mutational effects. Deficient mice also show 
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only a mild ataxia and remain ambulatory, while the dogs described are more severely 
affected both in terms of degree of ataxia and Purkinje cell loss. In the study by 
Stankewich and colleagues, no Purkinje cell loss was documented in mice by 18 months 
of age, only atrophy of the dendritic arbor. Disparity in phenotype between species may 
suggest differences in cerebellar development, function, and potentially the involvement of 
beta-III spectrin. Further understanding of canine cerebellar function would be required to 
shed light on the described differences and common principles. 
 
It has been shown that heterozygous mice, generated by exon 2-6 replacement, do not 
display any characteristics of cerebellar ataxia (Clarkson et al., 2010), in common with 
heterozygous dogs in the Beagle population, suggesting that SCA5 in heterozygous 
humans is caused by dominant negative effects of mutant beta-III spectrin, rather than 
haploinsufficiency. Histopathological examination in heterozygous mice revealed normal 
size and morphology of the cerebellum and immunostaining studies showed no changes 
in Purkinje cell morphology. These histopathological findings cannot be correlated with 
heterozygous Beagle dogs as none underwent post-mortem examination and all of them 
are currently alive and clinically unaffected. Interestingly, slight motor impairments were 
reported for heterozygous mice generated by beta-geo insertion between exons 25 and 
26, perhaps indicating that the truncated protein is having a slight dominant negative 
effect, and illustrates how disease progression is dependent on the positioning of SPTBN2 
mutations.  
6.3.6. Deletion mechanism 
The 8 bp deletion in the dog is located at a tandem repeat sequence, suggesting 
homologous recombination as the deletion mechanism. The position of a SNP 
(c.5580T>C) 18 bp downstream of the deleted sequence removes a possible termination 
site for the mutant protein and extends the sequence of potential aberrant amino acids 
from 6 to 27.  
6.3.7. Expression analysis 
6.3.7.1. Quantitative PCR approach 
Expression analysis was limited, due to the availability of only one case and one control. 
Results are suggestive of a 68x reduction in the relative expression levels of SPTBN2 in 
the NCCD case cerebellum, which may be due to nonsense mediated decay. Even 
though SPTBN2 expression is greatly reduced in NCCD affected cerebellum tissue, 
sufficient read depth from the mRNA-seq experiment was still achieved, because of the 
high levels of SPTBN2 expression normally seen in the cerebellum.  
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6.3.7.2. Genome-wide expression analysis 
Because of the availability of cerebellum mRNA-seq data from a clinically unaffected 
individual from the third mRNA-seq dataset, genome-wide expression analysis was 
carried out. Insufficient cases and controls were available to perform a complete 
investigation, but results did show that even on a genome-wide scale with a one case and 
one control approach the change in expression level of SPTBN2 was highly significant 
and one of the greatest fold changes genome-wide. Further investigation of highly 
significant fold changes by comparing other case-control analyses to the Beagle case-
control analysis showed that many of the significant changes were shared. Although these 
changes could account for compensatory gene regulation changes in ataxic brains, it is 
also very possible that these changes were specific to the control. This is a consequence 
of some genes that can show large fluctuations in gene expression and further controls 
would be needed to mitigate against this problem. It is important to reiterate that the 
experimental design was far from perfect. The control dog in the investigation was of 
unknown breed. Differences in cerebellum gene expression across breeds has not been 
investigated, but it is feasible that dogs that are bred for increased balance and poise, 
such as herding dogs, may have changes in cerebellum gene expression as a result of 
this selection process. Results of the qPCR expression analysis suggested a higher fold 
change in SPTBN2 gene expression than the mRNA-seq data. qPCR is often considered 
the gold standard when investigating gene expression. It is possible that there was a slight 
increase in 3’ bias for the control library, this could result in fewer reads across the entire 
transcript and would result in less of a difference between the NCCD Beagle and the 
control read count across the gene.  
6.3.8. Protein analysis 
Further to a reduction in mRNA levels, no full length or truncated beta-III spectrin was 
detectable in NCCD affected cerebellum tissue by western blot analysis. This may 
indicate that the 8 bp deletion results in a full knock-out of SPTBN2. A full gene knock-out 
eliminates the possibility of a dominant negative effect that could be caused by a 
truncated form of the beta-III spectrin protein, which is consistent with the observation that 
heterozygous dogs do not show clinical signs. 
6.3.9. NCCD in other breeds 
Although NCCD is likely to be heterogeneous in different canine breeds, screening for the 
SPTBN2 deletion in non-Beagle cases has not been investigated to confirm this. It is 
possible that the mutation could exist at very low frequencies in other breed populations, 
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especially those closely related to the Beagle, but extensive screening of large numbers of 
individuals would be required to fully investigate this possibility.   
6.3.10. Summary 
Genome-wide mRNA-seq was used to successfully identify the causal mutation for NCCD 
in the Beagle. This novel study approach was applicable due to the availability of a fresh 
tissue resource and many suitable candidate genes, and allowed genetic investigations to 
commence in a time and cost effective manner without the need to collect a large case-
control sample cohort. 
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7.1. Overview 
This study aimed to use the dog as a model to demonstrate the advances in genetic 
mapping and DNA sequencing techniques. This thesis has demonstrated how the 
available techniques can be adapted to suit the particular disease under investigation, and 
how choice of technique can be dependent on sample availability and resources. In this 
section the choice of techniques and study limitations is discussed. Potential for further 
work is also discussed, highlighting how advances in technology may influence strategic 
choices in the future. 
7.2. Genetic mapping strategies 
Two genome-wide mapping strategies were used during the course of the investigations. 
These were homozygosity mapping using microsatellite markers and genome-wide 
association analysis using a high-density SNP array. Both techniques were successfully 
used to map disease loci to distinct regions of the canine genome. The homozygosity 
mapping approach demonstrated how a very small sample cohort of six cases and six 
controls can be sufficient to successfully map an autosomal recessive condition in the 
dog. As the technique uses PCR followed by fragment length analysis using capillary 
electrophoresis, both the experimental work and data analysis could be carried out in-
house. The high levels of LD in the dog were essential for the homozygosity mapping 
study to succeed. Only 300 genome-wide microsatellites were used for the analysis, 
meaning that on average markers were spaced 8 Mb apart. Fortunately one of the 
markers analysed was located within the interval of shared homozygosity, allowing the 
pattern of linkage disequilibrium between cases and controls to be observed. 
 
Genome-wide association study approaches using a high-density SNP array were used to 
investigate three of the conditions presented in this thesis. A huge advantage of using 
whole genome SNP genotyping arrays is the level of throughput that can be achieved. 
The Illumina CanineHD SNP assays 173,000 genome-wide SNPs equating to 
approximately one every 14 kb. Although it is impossible to avoid outsourcing of the 
genotyping work when in-house facilities are not available, results can be produced for 
small cohort studies within a few weeks of sample submission to a service provider. Linux 
based data analysis is rapid, enabling basic allelic association analysis results to be 
obtained within a few hours. The density of the CanineHD SNP array means that the fine 
mapping required after microsatellite-based approaches can be omitted completely. Raw 
genotyping data can be visualised to clearly identify the position of recombination events 
marking the disease-associated interval and also gives an indication of potential outliers. 
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Although use of high-density SNP arrays holds many advantages for carrying out disease 
mapping studies, there are some potential obstacles to consider. Because of the high 
number of markers tested it is more likely that false positive associations could be 
detected by chance. This can be relatively easily corrected for by performing permutations 
analysis or carrying out Bonferroni correction on allelic association analysis results. A 
greater problem is the risk of producing false positive results due to high levels of genomic 
inflation, which essentially means that ranked observed probability values are greater than 
expected values. Genomic inflation is caused by population stratification, where in the 
most extreme situation, cases and controls cluster in separate groups of closely related 
individuals. Population stratification is particularly problematic when performing disease 
mapping studies in the purebred dog. Because breed groups are genetically isolated, with 
only a small proportion of individuals within a breed used as breeding stock, it is not 
unusual for the majority of cases to originate from particular breeding lines. Case DNA 
samples received for studies often come from the pet dog population however, so 
obtaining healthy related individuals as controls is not always possible, especially as 
individual details have to be kept confidential. Although a high level of genomic inflation 
was seen when parallel mapping two disorders in the Cavalier King Charles Spaniel, the 
results did not appear to be greatly affected. This was mainly due to the strength of 
statistical signal obtained when mapping these autosomal recessive disorders and also 
because of the ability to apply analysis tools to correct for the effects of stratification in 
datasets. The opposite problem was seen when mapping the locus for late onset ataxia in 
the Parson Russell Terrier, where genomic deflation was seen. Again the overall 
conclusions were not adversely affected because of the strength of the signal. Population 
stratification is a much more significant problem to consider when mapping complex 
inherited diseases. High levels of genomic inflation could result in a large number of false 
positive results being produced. Although corrective tools are available they are modelled 
for use in human association analysis studies where the high levels of genomic inflation 
seen in dog studies are not evident. Very careful selection of cases and controls is 
arguably the best method of controlling the problem, such as selecting first degree 
relatives as controls. However for complex disorders many asymptomatic relatives may 
share risk factors for disease, and therefore use of first degree relatives may reduce the 
strength of true positive signals. Although extremely rapid, the use of whole genome SNP 
arrays is an expensive approach usually costing around £120 per sample. In addition a 
large lump sum is usually required to fund a project as some service providers only offer 
to process a minimum of 48 samples in one batch. There are some situations where the 
use of microsatellite markers may be more appropriate. Genotyping using individual 
microsatellite markers is inexpensive and data can be analysed relatively rapidly. 
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Although individuals SNP markers can be genotyped rapidly using an allelic discrimination 
approach (TaqMan), probes are relatively expensive. Therefore microsatellite markers are 
more appropriate for use in a candidate gene study approach when only a few individuals 
need to be genotyped for a small number of genetic markers. Microsatellite markers also 
tend to be more informative, due to a greater number of potential alleles. 
7.3. Candidate gene study approaches 
In this thesis two very different candidate gene studies are described, one of which 
successfully led to the identification of a disease-associated mutation and the other which 
was unsuccessful. The unsuccessful attempt used microsatellite markers to assess 
candidate genes for linkage to EF in the CKCS. Although there were many strong 
candidate genes and well defined cases were available, none were found to be linked to 
EF. Subsequently a novel disease-associated locus was identified using a GWAS 
approach and a mutation identified in a gene not previously associated with a muscle 
hypertonicity condition. This unsuccessful attempt highlights the risks of using a candidate 
gene approach in situations where the causal gene has not previously been associated 
with a similar condition in other species, or is not a functional candidate. Candidate gene 
studies are still however a cost-effective method of excluding many strong candidates, 
before more expensive GWAS approaches are undertaken, especially for conditions with 
strong/early onset phenotypes. 
 
In the second candidate gene study a novel approach of genome-wide mRNA-seq was 
used. Although the approach is unconventional, it is a highly cost effective method of 
enrichment. Unlike for exome enrichment of genomic DNA, a proprietary kit is not required 
as mRNA can be isolated using a simple method of polyA enrichment. For partially 
degraded total RNA samples, ribosomal RNA removal kits are also available for enriching 
mRNA levels. Unlike exome sequencing using probe-based genome enrichment which 
relies heavily on the extent and accuracy of genome annotation, with mRNA all coding 
regions expressed in a particular tissue are enriched including all exons and splicing 
isoforms. There is also selective enrichment towards genes that are more highly 
expressed, so only genes which are important in the function of the tissue under 
investigation are analysed. Using mRNA-seq allowed the candidate gene study to 
commence with just a single case. This is especially significant for rare or emerging 
disorders where the collection of additional cases may be time consuming or even 
impossible. If the study had not led to the direct identification of the causal mutation the 
dataset may still have become useful at a later date if a disease-associated locus had 
been identified using a GWAS approach. The sequencing data across the associated 
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interval could then have been analysed for disease-associated mutations without the need 
for an additional target enrichment sequencing approach. Alternatively all the other genes 
sequenced by the mRNA-seq approach could have been analysed for non-synonymous 
mutations, rather than just the initial candidates, and any provocative mutations identified 
investigated in further cases and controls.  
7.4. Use of massively parallel sequencing techniques 
The use of massively parallel sequencing techniques forms a large part of the research 
work contributing to this thesis and clearly demonstrates the development of next 
generation sequencing technology over the last five years. Sequencing projects 
completed as part of this thesis are summarised in Table 7.1. 
 
Table 7.1 Summary of massively parallel sequencing projects 
The massively parallel sequencing projects completed as a part of this PhD thesis. 1 x represents single-end 
sequencing and 2 x represents paired-end sequencing. 
Project Date Platform Read length (bp) Dataset size  (Gb) 
ITPR1 sequencing Mar 2008 Illumina GAII 1 x 33 0.05 
CKCS projects Sep 2010 Illumina GAIIx 2 x 51 3.47 
LOA/SCA projects Sep 2011 Illumina HiSeq 2 x 51 19.64 
mRNA-seq Mar 2012 Illumina HiSeq 2 x 51 17.38 
LOA additional controls Jun 2012 Illumina MiSeq 2 x 150 2.07 
 
7.4.1. Target enriched massively parallel sequencing 
When ITPR1 was sequenced, in March 2008, massively parallel sequencing technology 
was still in its infancy. Reads were short and although paired-end sequencing had been 
developed, it was not routinely available through the limited number of service providers. 
As a new and unfamiliar user of the technology the PCR product template was sent to the 
service provider (Fasteris) for library preparation and sequencing. Analysis of the data 
was performed in-house with support from Fasteris, although the amount of freely 
available software was limited at that time. The software package, Maq, was chosen 
based on recommendation, which could be implemented relatively easily through an 
“easyrun” Perl script. SNP calling was accurate, but calling of indels was not reliable and 
contained many false positives. Although a data visualisation tool called Maqview was 
available (Figure 7.1), the text like display made visualisation of sequence variants 
difficult. The viewer could therefore only be used as a means of variant verification after 
automated SNP and indel calls had been made.  
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Figure 7.1 The Maqview sequence alignment visualisation tool 
The Maqview sequence alignment viewer: a Linux based visualisation tool with a text based display output. 
 
Limitations in massively parallel sequencing and data analysis were the reason why the 
GAA repeat expansion in the ITPR1 gene was not identified in the first sequencing 
experiment. The consensus sequence output from Maq was identical to the reference 
sequence over the expanded region. Although a drop in read depth was observed across 
the expanded region, some of the short reads had been aligned into the repeated region 
and because the dataset consisted of single-end reads, no singleton reads were present 
which would have warranted further investigations. 
 
In-house library preparation needed to be fully investigated for the second attempt at 
massively parallel sequencing for the CKCS projects. The SureSelect solution based 
target enrichment system had been launched by Agilent technologies, which enabled in-
house capture in the standard laboratory for the first time. In the early edition kit, however, 
no reagents or guidelines were provided for library preparation pre-capture. Illumina kits 
were extremely expensive at the time and the required primer and adapter sequences had 
to be purchased separately making library preparation potentially costly. It was therefore 
decided to use the NEBnext library preparation kit with library amplification and adapter 
oligos being produced by an oligo manufacturer, enabling the project to go ahead without 
the need to raise additional funds. A number of fragmentation methods were investigated, 
and an enzymatic method was ultimately chosen because, unlike nebulisation (the 
method initially recommended by Illumina), samples could be processed in parallel. 
Sonication was also considered but excluded as an option because of concerns it may 
cause too many damaging nicks to the DNA backbone making library preparation 
inefficient. As recommended by Agilent at the time an agarose base size selection stage 
was also included. 
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Developments to the Agilent kit resulted in changes to the methodology for the second 
target enriched library preparation experiment. In the new ‘XT’ version of the kit all 
reagents for library preparation were included, meaning that no supplementary kits or 
custom made adapters were required. The newly developed Covaris DNA shearing 
apparatus was also recommended for DNA fragmentation omitting the need for a size 
selection stage. This was a convenient development because the only available DNA 
samples from the PRTs selected for sequencing were from buccal swab samples. 
Although DNA from buccal swabs is suitable for most molecular applications, it is highly 
fragmented and contains fragment sizes evenly distributed from 20 kb+ to 100 bp. 
Enzymatic methods would have been unsuitable as too much material would have been 
lost during fragmentation, and libraries would require additional rounds of PCR 
amplification leading to more PCR duplicates in the final sequencing dataset. High 
molecular weight DNA extracted from whole blood was however available from the ISs 
selected for target enrichment. Enzymatic fragmentation was therefore attempted for that 
investigation and a fragment size range was achieved that was highly comparable to 
Covaris shearing. Buccal swab DNA was therefore outsourced for Covaris shearing. Very 
similar size ranges could be achieved with both methods demonstrating how methodology 
can be selected to best suit the available DNA resources, with the same end result. 
 
Unlike for previous target enriched sequencing attempts which required some outsourcing 
for library preparation and massively parallel sequencing, the workflow for the third target 
enriched massively parallel sequencing experiment, which was part of the LOA in the PRT 
project, was completed entirely in-house. Although the DNA to be used in the experiment 
originated from buccal swabs, outsourcing of fragmentation was avoided by 
reinvestigating the use of sonication. It was found that libraries could be successfully 
created using sonicated DNA and although the fragment size range was slightly greater 
than that achieved by Covaris shearing, the size range was suitable for target enrichment. 
Sequencing was achieved using a newly acquired Illumina MiSeq. 
7.4.2. Development of a sequence analysis pipeline  
The amount of data produced in the later massively parallel sequencing projects made the 
development of a custom sequencing analysis pipeline essential, not only for the projects 
described in this thesis but also for future projects to be undertaken at the AHT. Although 
Maq, the program initially used in data analysis, was still functional, many other alignment, 
sorting and handling programs had been developed which were faster and more accurate. 
Also as targets increased from kilobase through to megabase regions there was a need 
for a greater level of automation for analysing data and annotating variant calls. Most 
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freely available software tools for massively parallel sequence data analysis are Linux 
based and require implementation at the command prompt by entering the program 
address and listing a number of parameters. Furthermore, the programs tend to work in a 
modular fashion making implementation of each program by entering commands 
laborious and time consuming as the run time for each module is not easy to predict. 
Therefore to make analysis of the sequencing data easier to implement and more 
accessible to other users a sequence data analysis pipeline was developed. The pipeline 
was written as a Perl script which could be implemented with a simple one word alias at 
the command prompt (NGS ENTER), meaning that no expert knowledge of Linux was 
required to use it. Users were then prompted to enter the parameters for analysis such as 
file names and analysis details. The pipeline was flexible, allowing users to choose which 
modules were included in the analysis, from a simple alignment to full variant analysis and 
annotation. Error checking was incorporated into the Perl script, so if an error message 
was reported by the program the script would terminate and notify the user by email. 
Users were also notified by email when the analysis had successfully completed. 
Notification of errors and pipeline completion, meant users could allow the scripts to run in 
the background without the need for constant checking. On the completion of a run results 
files were placed in a new folder with readme.txt files explaining the results.  
7.4.2.1. Pipeline problems and redevelopment 
A number of problems were encountered during the development of the Perl script. One of 
the largest problems was the server resource available at the AHT. Files produced by 
massively parallel sequencing are large files of several gigabytes in size. Files produced 
by Illumina GAII machines in the first two sequencing experiments could be handled 
without problems. Data from the initial experiment were analysed using the Maq easyrun 
script which completed within a few hours, although the reference sequence used was just 
the 340 kb reference sequence rather than the entire genome reference. Use of a partial 
genome reference sequence is not recommended however, because it may result in the 
best alignments to the genome not being found, and potentially weaker alignments being 
accepted. The second sequencing experiment was a significantly larger dataset consisting 
of five paired files of probe-based target-enriched sequencing data. At this stage Maq 
analysis had been superseded by an early version of the NGS sequence analysis 
pipeline. Separately initiated pipelines had to be set up for each file pair, which could be 
performed in parallel using the split screen feature of the Linux command prompt. 
Although this approach makes the analysis more convenient, one disadvantage is that 
memory resources are split, which was particularly problematic with the resources 
available at the AHT. It was found that the five file pairs could be analysed in parallel if 
aligning to a partial genome reference, such as a chromosome or a targeted region, but 
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there was insufficient capacity to align all five paired datasets against the entire genome 
using the parallel approach. Individual analysis of a single file pair against a whole 
genome reference sequence took approximately 24 hours. 
 
A more significant challenge for in-house data analysis came from sequencing data 
derived from the Illumina HiSeq 2000, which generated approximately five fold more data. 
The data analysis pipeline had been enhanced by including a variant effect predictor 
module and a structural variant analysis module, improving the output but increasing the 
run time of the script significantly. Analysis of a single file pair took approximately three 
days when aligning the data to the canine genome sequence. The server was not solely 
used for sequence data analysis, and if other users needed to perform tasks (such as 
GWAS analyses) the system would be extremely slow or would crash completely. For the 
first two sequencing experiments data were provided as raw unaligned FASTQ files only. 
However, in later sequencing runs data were provided in both unaligned FASTQ and 
aligned bam file format. To reduce running time the pipeline was changed to allow 
handling of the aligned .bam files as the input files. In addition the per-base depth of 
coverage module was disabled as it provided little useful information and contributed 
considerably to the run time, allowing a single pair of files to be analysed in approximately 
one day. This was a significant improvement, but meant that all ten file pairs still took ten 
days to analyse.  
 
Attempts were made to develop a separate data analysis pipeline for analysis of mRNA-
seq datasets, but unfortunately the widely used programs Tophat and Cufflinks required 
more memory than was available on the AHT Linux server (Trapnell et al., 2012). To use 
the mRNA-seq data to investigate candidate genes for canine ataxia the raw alignments 
to the canine genome therefore had to be used. This is suboptimal because exon 
boundaries are not considered for standard alignments to the genome and therefore many 
misalignments were apparent across the exon-intron boundaries. Because of the number 
of misalignments, data had to be analysed manually as computational methods of calling 
variants would have suggested a large number of splice site mutations. Analysis of gene 
expression by counting the reads aligned against the genes in the canine genome also 
had to be outsourced to the Wellcome Trust Centre for Human Genetics, Oxford.  
 
The original NGS analysis pipeline was developed in the summer of 2010. Since then new 
analysis programs have been written by external institutes and old modules have been 
updated leaving the pipeline outdated. The ever increasing amounts of data produced by 
massively parallel sequencing techniques meant that a faster and more streamlined 
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pipeline was required, especially if large-scale experiments such as whole genome 
sequencing were to be considered. The purchase of a new 64-bit server by the AHT 
provided the opportunity to redevelop the pipeline including the most up-to-date modules. 
This redevelopment is currently being carried out by Dr Mike Boursnell based on the 
original Perl script. Most modules function in the same way as the original script with 
some notable improvements. The updated script allows a list of data files to be specified 
at the start of the script, so file pairs can be analysed consecutively without the need to 
initiate separate analysis runs in split-screens. Because of the vastly increased speed of 
the new server, consecutive rather than parallel analysis does not significantly increase 
the run time. Variant calls are made by considering a set of alignment .bam files rather 
than being called independently. This method increases the dataset and improves the 
accuracy of variant calls. Additionally a single more manageable variant calls file is 
produced containing a table of variant calls across all the specified samples. Thirdly 
variant annotation occurs after a separate variant handling stage in Excel, vastly 
increasing processing speed. The changes highlight the constant need to keep the 
pipeline up to date as sequencing technology evolves. As sequencing technology further 
develops, even larger datasets with long read lengths are likely. New sequencing 
applications may become available and it is therefore crucial to modernise procedures 
accordingly to enable appropriate handling of data.   
7.4.3. Comparison of target enrichment approaches 
Two target enrichment methods were employed during the investigations. These were 
long range PCR and probe-based target enrichment. There are advantages and 
disadvantages to each technique, which makes each of them more suitable for particular 
applications. Long range PCR is a very standard technique that can be performed in most 
basic laboratories, without the need to purchase a proprietary kit. The major advantage of 
a PCR based enrichment is that, barring regions of extreme GC richness (>80%), a 
complete template of contiguous PCR can be created for the target region of interest. This 
results in the ability to achieve near 100% sequence coverage of target regions (see 
Table 7.2).  
 
Table 7.2 Summary of the four target enriched sequencing experiments 
Enrichment 
attempt Method Platform 
 Dataset 
size (Gb) 
Average target 
enrichment 
efficiency (%) 
Bases 
achieving 10x 
coverage (%) 
PCR duplicates 
(%) 
1 LR PCR GAII 0.05 88.3 98.9 Unknown 
2 Probe capture GAIIx 3.47 85.3 79.0 13.6 
3 Probe capture HiSeq2000 19.64 77.4 79.0 37.2 
4 Probe capture MiSeq 2.07 66.1 56.8 2.2 
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Long range PCR is a rapid technique. Primers can be designed, ordered and received 
within a couple of days, and PCRs can be set up and analysed in a day. Potentially, with 
an in-house sequencing facility, experiments could be designed, carried out and analysed 
within a week. Long range PCR is not a completely robust technique however. A pure, 
high quality source of genomic DNA is required, and amplification success is roughly 
inversely proportional to amplicon length. As a consequence there is a compromise 
between amplification success rate and the number of primer pairs/amplicons that need to 
be designed. Using short amplicons (eg 2-3 kb) may result in a high frequency of 
successful PCRs, but is an expensive strategy requiring a large number of primer pairs to 
be ordered. A strategy using long amplicons (10 to 20 kb) is initially inexpensive, but is 
likely to result in a higher failure rate, requiring primer redesign. Having to perform several 
rounds of primer redesign is both time consuming and expensive. The strategy of using 
longer amplicons was adopted for sequencing of the 340 kb ITPR1 target region. This 
strategy was largely successful, with eventual contiguous coverage of the 340 kb target 
region requiring 60 PCRs with an average amplicon length of 6.3 kb. However, two 
particularly difficult regions were identified which required several rounds of primer design 
and PCR before successful amplification could be achieved. If a PCR failed a single pair 
of new primers was designed to cover the same region. If amplification failed again then 
the target region would be split into two, primers designed and possible combinations of 
the available primers used for PCR. For the particular regions in question, a fully 
contiguous sequence of overlapping amplicon was eventually achieved, with the smallest 
amplicon being 121 bp. Several rounds of primer design were required to get to this stage, 
which added several weeks to the study period. To reduce study timeframe these difficult 
regions could have been excluded from investigation after one or two rounds of primer 
design, if both case and control group PCRs failed to produce product bands. However, 
this would lead to an increased risk of the causal mutation not being identified. 
Amplification of regions larger than 340 kb would be time consuming and challenging, 
although once primers have been purchased and successful amplification has been 
achieved, large numbers of individuals could be processed at a relatively low cost. For this 
reason long range PCR is more suitable for processing multiple samples for small target 
regions. 
 
The advent of probe-based enrichment systems enabled target regions of several 
megabases to be investigated for the first time and the launch of a solution based system 
made this technology accessible for use in the standard laboratory environment. Although 
a proprietary kit is required, the protocol is streamlined for processing of up to 12 samples 
in parallel. Cost per sample is high, and unlike for long range PCR, if processing of more 
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than 10 samples is required additional kits (or a larger kit size) must be purchased. The 
experiments in this thesis have shown that although probe-based target enrichment is 
highly effective, experimental design is hindered by a high frequency of repeat sequences 
in the canine genome. Because probes designed to non-unique sequences in the genome 
would lead to a very high level of non-specific capture, and as a result lower coverage of 
target regions, repeat masking is applied during probe design. For this reason base 
coverage by probes was only 56.7 and 64.8% for the two target enrichment experiments 
described. Ultra-deep sequencing using the GAIIx and HiSeq 2000 resulted in >10x 
coverage for 79% of target regions however, due to capture of regions flanking probes 
sequences (read depth around a probe is approximately normally distributed). The smaller 
dataset produced by the MiSeq however resulted in a smaller percentage of bases 
achieving 10x coverage (56.6%). The level of PCR duplicates observed for probe-based 
capture is proportional to the number of reads, and inversely proportional to the target 
capture size. It is also influenced by library preparation method. Including a gel size 
selection stage reduces the number of unique sequences and is therefore likely to 
increase the number of PCR duplicates. The number of PCR duplicates in a dataset is 
important because they are removed during analysis to avoid variant calling bias. 
Sequencing of probe-based capture libraries on the HiSeq produced the highest level of 
PCR duplicates at 37%. This suggests that the amount of useful data is approaching a 
limit for probe-based capture experiments and that production of additional reads may not 
significantly improve the quality of the dataset. As massively parallel sequencing 
technology continues to advance it will therefore be essential to carefully consider 
platform choice and potentially adopt a greater level of multiplexing to maximise 
sequencing experiment efficiency. 
 
Identification of an intronic causal mutation within a repetitive region of the dog genome 
highlights the potential limitations of using probe-based enrichment techniques which 
result in incomplete capture of target regions. Although the intronic GAA repeat expansion 
was identified using target enrichment of the disease-associated interval, exact bait 
positioning facilitated mutation identification. Because the mutation locus and surrounding 
region contained repetitive elements, a 500 bp region containing the repeat expansion 
was excluded from capture-probe (bait) design. In controls sufficient flanking sequence 
was captured by the baits to result in sequence coverage all the way through the repetitive 
region. For cases however, because the repeat expansion increased the size of the 
masked repetitive region, no DNA fragments were captured that were of sufficient size to 
span across the GAA repeat. This resulted in a region of zero coverage in cases 3’ of the 
GAA repeat sequence, as no probes 3’ of the GAA repeat were located close enough to 
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capture this region. The gap in coverage in cases, but not controls provided a discernable 
difference that could be followed up, allowing mutation identification. The variation may 
also have been difficult to identify using a whole-genome sequencing approach as 
complete coverage would be achieved for both cases and controls. Singleton reads would 
be highlighted in the region, but potentially also present in control individuals with long 
normal GAA repeat alleles. 
7.4.4. Genome-wide mRNA-seq  
In this thesis the versatility of the mRNA-seq method was explored by using the approach 
to fulfil a variety of functions. Although mRNA-seq is most commonly used as a method of 
high-throughput gene expression level analysis or to facilitate genome annotation, it was 
used here as an alternative method of targeted exome enrichment. Although there is now 
a kit available for targeted canine exome enrichment, use of the mRNA-seq does hold 
some advantages. Firstly mRNA-seq enrichment has an extremely simple workflow. 
mRNA enrichment from total RNA can be achieved by using a polyA capture using bound 
oligo(dt) sequences. Oligo(dt) probes are not a new technology and products are widely 
available either in column or bead format, making them inexpensive in comparison to 
probe-based exome enrichment. Efficiency of mRNA enrichment from total RNA using 
oligo (dt) probes is near 100%, in comparison to exome enrichment methodology where 
closer to 70% target enrichment is expected, meaning more on-target sequence reads 
and therefore higher read depth when using mRNA-seq. Furthermore mRNA-seq is a 
precise method of exome capture. Unlike exome enrichment, no flanking intronic 
sequences are captured, which may equate to a large proportion of the sequencing 
dataset, although it is dependent on target fragment size. For disease studies mRNA-seq 
selectively enriches the most highly expressed genes for a particular tissue. High levels of 
expression for particular genes may indicate their importance in the function of a particular 
tissue, and therefore mutations in these genes may be more likely to disrupt function. The 
combination of high enrichment efficiency, precise exon capture and greater enrichment of 
highly expressed genes, enabled a disease-causing mutation to be identified using a 1.39 
Gb dataset. Even if the causal mutation had not been identified with the candidate gene 
approach used, the mRNA-seq dataset could have been revisited subsequent to a GWAS 
study once a disease-associated genomic region had been identified. As with other 
methods there are risks associated with the use of mRNA-seq as a method of candidate 
gene sequencing, the obvious risk being that if the mutation is not in a candidate gene 
then the causal mutation will not be identified. Although ataxia is well studied in humans 
with many causal genes identified, there are some remaining disease loci for which 
neither the causal gene or mutation have been identified. Mutations within these loci 
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would be far more difficult to pinpoint, and also to prove as causal, although potentially 
more scientifically significant than identification of causal mutations in previously 
associated genes. Although mutations are most likely to be in the highly expressed genes 
for a particular tissue under investigation, there were three ataxia associated genes for 
which insufficient gene coverage was achieved to allow the entire sequence to be 
determined. Although this was a small proportion of the candidate genes investigated it 
still shows that genes expressed at a lower level can play a pivotal role in the function of a 
tissue if disrupted. RNA is a notoriously difficult material to work with, and both storage 
and extraction method are critical to experiment success. Although brain tissue contains a 
relatively high lipid content, it is a good tissue to work with for the extraction of RNA. The 
RNA content of the tissue is high, the RNase levels are low and the tissue is soft making 
disruption and homogenisation prior to RNA extraction straightforward. Tissues such as 
bone, which is extremely hard and contains little RNA, or pancreas, which contains an 
extremely high level of RNases, would be more challenging tissues to work with. Kits are 
available to perform mRNA-seq experiments from low quantities of fragmented RNA, and 
even using RNA from FFPE tissue using rRNA removal techniques rather than polyA 
enrichment. The advantage and risks of using mRNA-seq as a method of candidate gene 
sequencing imply that these things must be considered before undertaking an 
investigation, as the approach is not suitable for all situations.  
 
Disease characterisation is a very important factor which is likely to influence the success 
of the experiment. The NCCD Beagle case was well characterised before the start of the 
investigation. The phenotype was constant, severe and early onset which enabled the 
diagnosis to be easily made. Histopathological examinations were undertaken which 
clearly indicated that degeneration of the cerebellum was leading to manifestation of 
clinical signs and therefore it was highly likely that genes expressed in the cerebellum 
tissue played an important role in pathogenesis. Pedigree information was available for 
the known cases, suggesting an autosomal recessive mode of inheritance for the disease. 
Affected individuals were present in two separate litters produced from the same mating, 
indicating that the condition was likely to be inherited. All the evidence suggested a single 
major effect gene mutation was the cause, which was highly likely to be expressed in the 
cerebellum. A tissue resource was also available as the affected dog investigated was 
euthanised, and many suitable candidate genes were available. In summary mRNA-seq is 
a suitable method of candidate gene sequencing, but the chances of success of the 
technique are very dependent on type and characterisation of the condition under 
investigation, how well similar conditions have been characterised in human studies and 
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the availability of a suitable tissue resource which has been shown to be involved in 
disease pathogenesis. 
 
For the study of LOA in the PRT the mRNA-seq data were used for multiple purposes. 
Although a target enrichment approach had been used to amplify the LOA disease-
associated region, the mRNA-seq dataset from the LOA cases cerebellum provided an 
excellent method of checking gene annotation. The data could also be used to double 
check sequence data across coding regions of the LOA disease-associated interval, 
which had not been sequenced to a high level of coverage or had been missed due to 
positioning near to a repetitive element or high-GC content of the sequence. The effects of 
variants potentially affecting splicing could also be investigated. Cerebellar RNA from a 
control sample was also sequenced, allowing expression levels to be investigated. 
Sequence read alignments could be assessed visually by browsing in IGV, but regrettably 
computational analysis of comparative gene expression had to be outsourced to the 
Wellcome Trust Centre for Human Genetics, Oxford, because the AHT Linux server did 
not have sufficient memory to allow the analysis programs to run. Although a gene 
expression analysis project would not normally be carried out using just one case and one 
control, the dataset proved highly informative. No significant differences in gene 
expression were observed across the disease-associated region for the PRT study and 
there appeared to be quite few major differences in gene expression across the genome. 
This may indicate that a relatively small collection of tissues samples would be required to 
perform a full genome-wide study of gene expression, depending on the condition under 
investigation and the tissue type.  
 
Unlike targeted resequencing approaches which generate data that are likely only to be 
used for a specific project, genome-wide mRNA-seq data could potentially be used for 
projects in the future. The dataset has already been used on several occasions to check 
levels of gene expression and accuracy of genome annotation, even for projects where 
the site of pathogenesis is not the cerebellum. Individuals used in mRNA-seq could be 
used as additional controls in the future, and if a larger dataset is required it would still be 
possible to return to the original libraries to perform additional sequencing runs and 
acquire more data. To allow in-house data analysis and to avoid outsourcing, 
development of an mRNA-seq data analysis pipeline would be a future priority. 
7.4.5. Limitations of massively parallel sequencing technology 
Massively parallel sequencing techniques have revolutionised the way in which regions of 
the genome can be investigated in disease studies; and genome sequencing projects that 
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once would have taken years can now be completed in a few days. The technology is not 
without its limitations however. The limitations associated with target enrichment 
techniques and mRNA-seq have already been discussed. One particular difficulty that was 
encountered for all the projects was the ability to identify SINEs within sequencing 
datasets. Repetitive elements, in particular SINEs are especially abundant in the dog 
genome (Wang and Kirkness, 2005). Evidence for this is provided by only being able to 
achieve 56% to 65% bait coverage for target enrichment projects due to repeat masking, 
leading to reduced region coverage. During the development of the sequence alignment 
pipeline a program for identification of SINEs could not be identified. This meant that the 
only method of SINE identification was to view the sequence read alignments manually. 
As SINEs are flanked by repeat sequences, some elements could be identified because of 
a doubling of read depth which could be seen in the coverage histogram in IGV, but this 
was not consistent between SINEs. Therefore to ensure all SINEs were identified 
sequence read alignments had to be scanned. This is a highly laborious process as 
alignments around SINEs often look spurious making them difficult to distinguish from 
poor sequence read alignments. This was achievable for small target regions of a few 
megabases, but it would be difficult to manually scan larger amounts of data such as 
whole exome capture or whole genome sequencing. 
 
Another limitation is cost. Some small scale sequencing projects that would require more 
sequencing data than could be quickly and cost effectively achieved by Sanger 
sequencing, would potentially be sequenced to a extremely high read depth using a 
massively parallel approach. Using a high level of multiplexing is potentially a solution to 
this, although may increase study timeframes as additional projects and libraries may 
need to be completed before the sequencing run can commence. 
 
Data analysis is a particular limitation for smaller institutions such as the AHT. Benchtop 
sequencing platforms such as the MiSeq have made massively parallel sequencing 
extremely accessible. Firstly the increasing amount of data generated by massively 
parallel sequencing means that significant disk space is required just for storage 
purposes, although the advent of cloud storage technologies may be more widely used in 
the future. A huge number of free software packages are available for data analysis, but 
software choice is largely made on recommendation rather than suitability. Some of the 
best supported packages are under constant redevelopment making it challenging to keep 
analysis pipelines up to date. 
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As massively parallel sequencing technology and handling software continues to develop 
many of the difficulties that are currently experienced may become less problematic in the 
future, although the ever increasing dataset sizes may still present a challenge. New 
technology holds the promise of even greater read lengths and data quality in the future.   
7.5. Developing massively parallel sequencing technologies 
Although current platforms such as the Illumina MiSeq and Life Technologies Ion Proton 
are under constant development, much of the focus regarding new technologies is on 
single molecule sequencing methodologies. One strand-sequencing platform that is 
currently available is the Pacific Bioscience RS system. The Pacific Bioscience system 
works through anchored single DNA polymerase molecules at the bottom of holes of just 
tens of nanometres in diameter. Upon binding of a single stranded DNA molecule, 
fluorescent nucleotides are detected as they are held by the polymerase before 
incorporation into the elongating strand (Eid et al., 2009). The fluorophores are attached 
to the pyrophosphate group which is naturally cleaved as part of the elongation process 
allowing detection to occur in real-time by capturing a video rather than still images. As 
the nanopore is smaller than the wavelength of visible light, the light generated by the 
laser cannot pass all the way through the pore, resulting in low background fluorescence 
of unincorporated nucleotides and a high signal to noise ratio. The major advantage of 
strand sequencing is that much longer read lengths can be achieved with single molecule 
sequencing technology. The Pacific Bioscience RS system is capable of producing read 
lengths in excess of 10,000 bp with an average read length of 3,000 bp. Long read 
lengths can facilitate de novo assembly and alignment of reads to a genome. Assembly 
across repetitive regions of the genome are less challenging because reads flank into 
unique regions, helping genome assembly which may be especially difficult for some 
small microbial genomes containing many mobile repetitive elements. Large insertions 
and structural variants may also be much easier to identify and interpret with long read 
technology. Also no PCR amplification is required in the sequencing process minimising 
bias. Although useful for some applications, the Pacific Bioscience RS system is not 
currently a popular platform, partly due the large footprint of the machine, but mainly due 
to the low read accuracy in comparison to other next generation sequencing technologies. 
Much of the hope for improved single DNA molecule sequencing is now being pinned on 
products currently being developed by Oxford Nanopore. The technology being developed 
by Oxford Nanopore uses protein nanopores as biological sensors. Two systems are 
currently under development: an exonuclease based sequencing system which is being 
developed in strategic alliance with Illumina (Clarke et al., 2009) and a strand sequencing 
based system (Lieberman et al., 2010). Both systems work by flowing a continuous 
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current through a nanopore and measuring the characteristic change in current that 
occurs as molecules pass through the pore. In the case of a single stranded DNA 
molecule the patterns of current disruption created can be used to determine all four 
nucleotide bases as they pass through the nanopore. In exonuclease sequencing an 
exonuclease is bound near the entrance of the nanopore. Single stranded DNA molecules 
are fed into the exonuclease and nucleotides cleaved one by one. Nucleotides then flow 
through the nanopore causing a disruption of current that can be measured. In the strand 
sequencing method a DNA polymerase is bound to the nanopore which unzips double 
stranded DNA and feeds a single strand into the nanopore. The disruption in current as 
the strand passes through the nanopore can be used to determine the nucleotide 
sequence. Both strands of the DNA can be sequenced, by ligating a hairpin loop on the 
end of the double stranded DNA. Once the first unzipped strand has been sequenced the 
hairpin is fed through the nanopore and sequencing continues for the reverse strand. Two 
products are currently under development, the GridION system and the MinION, which 
are based on strand sequencing technology. The GridION system is an expandable 
sequencing system consisting of “nodes” which can be used singularly or in racked multi-
node systems depending on data requirements. DNA samples prepared for sequencing 
are loaded onto cassettes that contain all the required reagents, which are inserted into 
the nodes of the system for sequencing. The MinION prototype is a miniaturised 
sequencing system which is approximately the size of a smart phone. The MinION is a 
stand alone single use sequencing platform which only requires USB connection to a 
laptop computer for operation. MinION units are projected to cost less than $1000, so 
have huge potential for use in a clinical setting. Nanopore technology is potentially highly 
versatile and nanopores could be adapted for analysis for several substrates including 
DNA, RNA, miRNA and proteins. The versatility and affordability of developing nanopore 
systems, along with high accuracy levels and minimal sample preparation would make the 
technology a very exciting proposition; although currently there are no sample datasets 
available and no products have been launched so it is not known how long it will take for 
this promise to be realised. Oxford Nanopore is not the only company aiming to make 
sequencing using nanopore technology a reality. Genia have developed a nanopore 
technology which utilises principles of both Oxford Nanopore and Pacific Bioscience to 
form a novel sequencing method. The Genia system uses a DNA polymerase attached to 
a membrane bound nanopore, which has a constant current flowing through it. The 
substrate for the DNA polymerase is nucleotides which are molecularly tagged on the 
pyrophosphate group. When the polymerase binds a DNA molecule and nucleotides are 
sequentially incorporated the tagged pyrophosphate groups are cleaved and pass through 
the nanopore. The unique current disruption signatures created by each tag as it passes 
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through the nanopore can be used to determine the nucleotide sequence of the template 
(Kumar et al., 2012). If this technology comes to fruition, Genia claim that they are aiming 
toward a $100 genome. 
7.5.1. Applications of new sequencing techniques in the mapping of dog diseases 
With the growth of massively parallel sequencing technologies showing no signs of 
slowing down, and price per base sequencing cost becoming increasingly less expensive, 
there are a number of new applications that may become applicable for use in the study of 
genetic disease in the dog. The use of genome-wide mRNA-seq has been used as a 
method to identify causal mutations in genetic diseases, and assuming that a more 
automated pipeline of variant analysis can be developed it is highly likely that more 
genome-wide sequencing studies will be undertaken in the future, potentially leading to 
the investigation of more individual cases in a “personal genomics” approach. Applying a 
genome sequencing approach to answer clinical questions could be possible with a high 
level of automation and if costs become sufficiently low. Cancer panels are available for 
targeted enrichment of genes known to cause cancer in humans so it is feasible that as 
our knowledge of genomics and disease genetics increases we may in future be able to 
answer clinical questions and perhaps one day tailor therapeutics based on genetic 
information. A vast number of disease-associated mutations have been identified in the 
dog so it may be possible that a sequencing assay will be designed in the future to test for 
all known mutations if there is a suitable demand for such a service. 
 
Although the tools for GWAS such as genome-wide SNP arrays have not advanced at the 
same rate as for massively parallel sequencing, there is potential for advances in this field 
through the use of massively parallel sequencing approaches. A genotyping-by-
sequencing (GBS) approach using restriction enzyme digestion of genomic DNA has been 
developed for use in maize and barley GWAS studies (Elshire et al., 2011). This 
methodology may become more applicable as sequencing costs are further reduced. 
Another potential methodology for use in GWAS is genotyping-by-exome sequencing. 
Although use of this method would rely on a reduction in cost of probe-based capture and 
would be a bioinformatics challenge, the potential advantage would be that if a significant 
association was found then sequencing data would be immediately available for 
investigation of genes in the disease-associated interval. Use of genotyping-by-genome 
sequencing may also become a possibility if the $100 genome becomes a reality, 
although would require a finely tuned data analysis pipeline to reduce complexity, make 
genotyping calls and perform association analysis. 
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Using a GBS approach there may soon be the opportunity to move away from the use of 
microsatellite markers in DNA profiling (fingerprinting) systems and move to a higher 
throughput and automatable approach using SNPs. Microsatellites are still routinely used 
in both human and canine genetics, largely because of large historical databases of 
profiles that have built up over the years making it difficult to move to a new system, 
especially for forensic science purposes. It has been suggested recently however that it 
may be possible to assay for both microsatellite sequences and SNPs in a parallel 
approach using next generation sequencing technology (Bornman et al., 2012). Linking 
this back to the dog it may one day be possible to test for multiple genetic diseases and 
produce a DNA profile in a single experiment at very little cost.    
7.6. Study limitations and future work 
Although five novel mutations have been associated with five genetic diseases in the dog, 
no functional work has been performed to prove that mutations are truly causal, and to 
potentially investigate the reasons why the mutations have a pathogenic effect. This is 
especially significant for mutations in BCAN, FAM83H and CAPN1 which have not 
previously been associated with similar human conditions. Although knock-out mice have 
been created for BCAN and CAPN1, they were reported to be clinically normal, so 
perhaps it would be worth revisiting these models to reassess the potential clinical signs. 
No knock-out mouse exists for the FAM83H gene so future development of a murine 
resource may help improve understanding of the clinical signs seen in the dog and also 
amelogenesis inperfecta in human patients. Although the CAPN1 mutation is predicted to 
result in replacement of the highly conserved catalytic cysteine residue, loss of enzymatic 
activity would only be confirmed by using a specific assay. This may involve synthesis of a 
mutant protein and development of a custom assay. In the study of SCA in the IS the 
effects of the GAA repeat expansion on ITPR1 expression levels could not be investigated 
due to lack of a suitable tissue resource.  
7.7. Concluding remarks 
In this thesis the dog model has been successfully used to demonstrate the advances in 
disease mapping and sequencing techniques over the last five years. The unique 
population structure of the purebred dog has enabled large case-control cohorts for 
disease studies to be collected over short timeframes due to the high frequencies of 
particular diseases within certain breed populations. The efficiency of the dog model has 
been shown using GWAS approaches with a minimal sample cohort or in parallel with 
other diseases, demonstrating the advancement from microsatellite approaches through 
to genome-wide SNP array methodology. The long disease-associated intervals seen in 
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GWAS results demonstrate the high levels of LD seen in the dog, facilitating identification 
of disease loci. Investigation of genes in disease-associated intervals has shown the 
transition from Sanger sequencing through to massively parallel approaches, and the 
potential advantages and limitation have been described. A novel approach of candidate 
gene sequencing using genome-wide mRNA-seq has been established, which shows how 
individual clinical cases could be investigated using massively parallel sequencing in the 
future, and raises the prospect of an era of personal genomics as sequencing technology 
continues to advance. In this thesis five new disease-associated mutations have been 
identified, included three mutations in genes that have not been associated with similar 
diseases in humans or studies of other model organisms, showing how the dog model can 
be used to improve our understanding of genetics and provide new candidate genes for 
disease studies in humans. 
 
Advances in massively parallel sequencing show no signs of slowing down with the 
development of new technologies.  Extremely long read length with increased accuracy, 
higher levels of throughput and the potential to reduce cost are now on the horizon. It may 
soon be feasible to perform a GWAS by sequencing and with a streamlined bioinformatics 
pipeline go from sample cohort to identification of disease-associated mutation in a single 
process. A personal genomics era may also be around the corner, but as data output 
increases, data handling and storage may become increasingly difficult and potentially 
limiting. The prospects for the future of genetics remain extremely exciting, but as 
complexity increases, making the technology accessible presents a huge challenge. 
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Appendices 
 
Appendix 1  Reagents and recipes 
 
Nucleon Reagent A (pH 8)   
 6.304 g  Trizma hydrochloride  
 438.12 g Sucrose 
 4.066 g  Magnesium chloride 
 40 ml  Triton 
 3.6 l  H2O 
 
Adjusted to pH 8 with 2 M NaOH.  
Autoclaved. 
 
Nucleon Reagent B (pH 8) 
 63g  Trizma hydrochloride   
 22.3g  EDTA     
 8.8g  NaCl     
 800 ml  H2O 
 
Adjusted to pH 8 with 2 M NaOH. 
Autoclaved. 
10 g Sodium dodecyl sulphate (SDS) added and volume adjusted to 1 l with ultrapure water. 
 
Lysogeny broth agar (pH 7.5) 
 10 g   Bacto-tryptone  
 5 g   Yeast extract 
 10 g   NaCl 
 800 µl  H2O 
 
Adjusted to pH 7.5 with 2M NaOH.  
15 g of agar added and volume adjusted to 1 l with ultrapure water. 
Autoclaved and cooled to ~50°C. 
  
 1 ml  Ampicillin (50 mg/ml) 
 1 ml  Tetracycline (12.5 mg/ml) 
 1 ml  Blue-White Select (40 mg/ml X-Gal, 40 mg/ml IPTG) (Sigma-Aldrich) 
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TE - 50x stock solution 
 20 ml  Tris-HCl (1 M, pH 7.5) 
 400 µl  EDTA (0.5 M, pH 8.0) 
 19.6 ml  H2O 
 
TAE - 50x stock solution 
 700 ml  H2O 
 242 g  Trisma-base 
 57.1 ml  Glacial acetic acid 
 37.2 g  Na2EDTA 
 
Adjusted to pH 8 with 2 M NaOH.  
 
SBDD buffer 
 160 ml  1 M Trisma-base pH 9.0 
 3 ml  1 M MgCl2   
 50 ml   Tetramethylenesulphone 
 290 ml   ddH2O 
 
Laemmli 2x sample buffer 
4%   SDS 
20%   Glycerol 
125 mM  Tris, pH 6 .8 
0.02%   Bromophenol blue 
200 mM  DTT 
  
SDS-PAGE running buffer 
25 mM   Tris base 
190 mM  Glycine 
0.1%   SDS 
 
Blotting buffer (western blotting) 
50 mM   Tris base 
380 mM  Glycine 
0.1%   SDS 
20%   Methanol 
 
  
 
 
 
Appendices 
 
 
 
203 
Appendix 2  Primer sequences 
 
Illumina Genome Analyser library preparation primers 
 
Primer Name Sequence (5' to 3') 
Multiplexing Adapters 1 5’Phosphate-GATCGGAAGAGCACACGTCT 
Multiplexing Adapters 2 ACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Multiplexing PCR Primer 1.0 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT 
Multiplexing PCR Primer 2.0 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
PCR Index primer 1  CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGAGTTC 
PCR Index primer 2 CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTC 
PCR Index primer 3 CAAGCAGAAGACGGCATACGAGATGCCTAAGTGACTGGAGTTC 
PCR Index primer 4 CAAGCAGAAGACGGCATACGAGATTGGTCAGTGACTGGAGTTC 
PCR Index primer 5 CAAGCAGAAGACGGCATACGAGATCACTGTGTGACTGGAGTTC 
PCR Index primer 6 CAAGCAGAAGACGGCATACGAGATATTGGCGTGACTGGAGTTC 
PCR Index primer 7 CAAGCAGAAGACGGCATACGAGATGATCTGGTGACTGGAGTTC 
PCR Index primer 8 CAAGCAGAAGACGGCATACGAGATTCAAGTGTGACTGGAGTTC  
PCR Index primer 9 CAAGCAGAAGACGGCATACGAGATCTGATCGTGACTGGAGTTC 
PCR Index primer 10 CAAGCAGAAGACGGCATACGAGATAAGCTAGTGACTGGAGTTC 
PCR Index primer 11 CAAGCAGAAGACGGCATACGAGATGTAGCCGTGACTGGAGTTC 
PCR Index primer 12 CAAGCAGAAGACGGCATACGAGATTACAAGGTGACTGGAGTTC 
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Genotyping primers for the episodic falling candidate gene study 
Gene CFA Position Forward primer sequence Reverse primer sequence 
Amplicon 
size (bp) 
CACNL1A3 7 5.29 TTTTAGTCAAAGAGCTTGAAACG CCTTATCTCACAAGGACATTCAGA 281 
CACNL1A3 7 5.34 TCACAAACAACATAGTGCCAAT TCTTTGAGGAAGTTTGTTTGCT 273 
ATP2A1 6 21.26 GGTAAGTTTGGAGGGAGATGC TGATCAGAGGCTGAAGGAGAA 215 
ATP2A1 6 21.56 CAATGGGAAAGTGTCCTGCT GTGGTATGGCTCCCTGCTC 256 
CLCN1 16 9.26 GGTATTGTTTGCTCCTGTCCA TCACATGCATGAGGTTCATTT 190 
CLCN2 16 9.47 GAACAGTGCCAGCTAACAAGG AGCAGCCTTCTCATGTGTTGT 87 
GLRA1  4 60.64 AGCCTTGAAGCCAGTCACAC TGGCTAGGAAGCAACTGGAT 147 
GLRA1  4 60.68 CCCAGCCATGTGGAGTCTAT TGTAACCGAGGACGGTTCTT 187 
GLRA3  25 28.14 AACTGAGGATCTGGGCATTG GCCCAGTTGGTAAGCATTTG 191 
GLRA3  25 28.25 AGTTCTGTTCAGGGCAGGAAT AACAGGTTTTGTCTGGTGGTG 132 
GLRB 15 57.00 CCAAAGTTCGTTCCTGTAAAGT TTATCCCAGTGACCAAGTGTG 140 
GLRB 15 57.36 TGAGGCTGTTAAACGTCCCTA GAGCAAATGGATTAGGTCTGC 108 
GLRB 15 57.49 AACTTCCTTGTGATTGTCATGG CCAAATTGGTACCGTTTGAAAG 193 
GLRB 15 57.57 AAACAGTGTCTTCCCCATCAA TAGGATATGAGAGGCCCAGGT 274 
GPHN  8 43.92 GAAAAGGAATGATGTTGCAGGT ATGGTCTTCAGGTTTTGCTCA 91 
GPHN  8 43.98 CGGGAACCACATTTCTCATTA ATTTCCTTCAGACCCTTTCCA 292 
KCNE3 21 26.87 CCTCACACCTCACAGCACATA CCAGCTCCAATGTCACCTCTA 233 
KCNE3 21 27.01 ACAAATGGCAAACTTTCATCCT GAACTGCCATGTGATCTACTAATTC 259 
SCN4A 9 14.81 CCGCCCTAGAGGAAGATTTA ATCTGGTCACTGGTGTGCAA 165 
SCN4A 9 15.01 CTCTGCAGCCCACTTGTGTA AACCCCAGTGGTATTGCTTG 188 
SCN4A 9 15.36 TACCAGCCGGAGTAGTTCTCA CTCCTAGGCAGGAGCCATTAC 280 
SLC32A1  24 30.09 CTTGGTCCCTTCCTGTACCTC TTTCATTCTCCACTCCTGTGC 233 
SLC32A1  24 30.15 CCTGTGACCAGGATTCACTGT CTGACTTCACGCCATACACCT 291 
SLC6A5  21 45.757 GACAGGCCTCCTCTGTGAATA TCTCCTCTTCACCTTCCATCA 164 
SLC6A5  21 45.760 GCTTTCGACTCATCCTTACCC CAGGGAGTATTTTCCCCTGTC 229 
SLC6A5  21 45.77 ACTGTCCGCCAGTGTGTATG GCAAGATGCATTGAAAGGTG 163 
SLC6A5  21 45.92 CCAAGTCTGTGACGGAGAATC TTCCTGATGATCTTGCCTTTG 172 
SLC6A9 15 18.87 CTTTGTGCCACCAGTTTCTGT TCTGAACCTGTGACGACTTGA 227 
SLC6A9 15 19.01 CATTGGCTTCCTCAGTTTCAG TGGGCAGTTCAAGAATGTACC 189 
SLC6A9 15 19.012 CTGAAGCCTGTGGTTGGAAT TCTGCTTCAGTCCCCTCTGT 220 
SLC6A9 15 19.02 AACCTTGCCTAGGGACACCT AATATGCAGGGAGCACATCC 215 
SLC6A9 15 19.31 GACTGCCAACTCCAACCCTAT GTGTCCAGGATTGACTCTCCA 284 
SLC6A9 15 19.43 TCCTGCAACTAAGCCTTGAGA CTGCATTCATAGACTGCCTTG 150 
 
SLURP1 PCR and sequencing primers 
 
Forward Name Sequence Reverse Name Sequence 
Amplicon 
size (bp) 
SLURP1_5U_F GATGTGGGCAGTGAACAAAGT SLURP1_5U_R GGAAGTGGCTGTGAGTCAGC 556 
SLURP1_X1_F ACTGCCTGAGGGTCTGTGAGT SLURP1_X1_R TTCCTCTCTGAGCCTTGGTCT 468 
SLURP1_X2_F CTCAGAGAGGAACGCAGTGTC SLURP1_X2_R CTCCAGTGATACCCTGTGACC 566 
SLURP1_X3_F GGTCACAGGGTATCACTGGAG SLURP1_X3_R CCTTCCATGAAATGAGTCCAA 541 
SLURP1_3U_F CTGGCAGAGAATAAAGCAAGC SLURP1_3U_R CCAAGCTGGCATGTCCTTAG 511 
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BCAN and FAM83H cDNA PCR and sequencing primers 
 
Forward Name Forward  Sequence Reverse Name Reverse Sequence Amplicon Size (bp 
BCAN_cDNA_1 AGTGGAGAAAGGGGTTTTGTG BCAN_cDNA_2 CACTCAGCACCAGGGACAC 582 
BCAN_cDNA_3 GGTCAAGTGGACCTTCCTGTC BCAN_cDNA_4 CTGGGTCCACCACTCCATAGT 500 
BCAN_cDNA_5 TTCTCTACCGGGAAGGCTCT BCAN_cDNA_6 GGAAGCAGTACACGTTGAAGC 585 
BCAN_cDNA_7 AGTGTGCGCTATCCCATTGT BCAN_cDNA_8 GATGGCCTAGGCTGTAGGACT 626 
BCAN_cDNA_9 GTCCTCCGAAGAGGAAGACAA BCAN_cDNA_10 CTGAACCCGCACTGAGGT 547 
BCAN_cDNA_11 ACAGGGAGCTCTGAGGATAGC BCAN_cDNA_12 GCCATCTGACCACAAGAAGTC 531 
BCAN_cDNA_13 GGAGGAACAGGACTTCATCAAC BCAN_cDNA_14 CGTGGTCACTTCCTATGATGG 628 
BCAN_cDNA_15 GTAGACACGGTGCTTCGCTAC BCAN_cDNA_16 GGCTGGTTTTACTGGTTCTCC 577 
FAM83H_F3 GGTACCTGCCACCTCACTACA FAM83H_R3 GTCAGCCATGTCCAGGAAGT 530 
FAM83H_F4 CTACTGGCCCATGAACTCAGA FAM83H_R4 CTCCTCATCGAAGCTGGAGAC 538 
FAM83H_F5 TCTGCCCAGCAGGTGGTG FAM83H_R5 GGTCGAGGAAAGAGGGGAATC 586 
FAM83H_F6 GTGGATTTCCTGCGCGTG FAM83H_R6 AAGGCGTCCATCTCCAGGT 599 
FAM83H_F7 GGAGCTACAGCTTCATGTGGT FAM83H_R7 TCTGAAAGCGCAGGTCGT 594 
FAM83H_F8 AAGCGGCACAGCTTCGCA FAM83H_R8 CATGGCAGCCGCTCAGGTAG 556 
FAM83H_F9 TGGACTACGTGCCGTCCAG FAM83H_R9 CGCTGAAGATCAGGGAGGAG 543 
FAM83H_F10 CGAGGCATACGAGGACGAC FAM83H_R10 AAAGGAGTCGCGCAGGTC 571 
FAM83H_F11 CCGAGCTCCTGGAGAAGTACA FAM83H_R11 GACTCCTCGGCGAAGGTAAG 553 
FAM83H_F12 AGGCACCTCACCCTGAGC FAM83H_R12 GATCTGCTCCAGAATGGCTTT 500 
FAM83H_F13 CAGCTGCTGAGCCCCAAG FAM83H_R13 ATGAACTTGCCCACCTTGCT 599 
FAM83H_F13 CAGCTGCTGAGCCCCAAG FAM83H_R14 GTTCTGCTGCCTGGTGTGAAG 723 
FAM5END_1F AGCCACCTGACTTGCTCAGTA FAM5END_1R ACTGCCAGGCGGTAATACTCT 566 
FAM5END_2F CGCCCTTTCTACACTGTGTCT FAM5END_2R GTCTGAGTTCATGGGCCAGTA 420 
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PCR primers for fine mapping of the IS spinocerebellar ataxia disease-associated region 
Marker 
type 
Canfam2 
position 
chr20 (Mb) 
Primer pair 
name 
Forward sequence Reverse sequence 
Amplicon 
size (bp) 
Micro chr20:13.32 CFA20_13.17 GGGGTTCAATCTCAAACCATT GTATACATCGGGCCAAAGACA 233 
Micro chr20:13.68 CFA20_13.53 GGTCACAAAACTGCTTTGCTC GAGCTTACCATGTGCCATATTC 196 
Micro chr20:13.85 CFA20_13.70 GCCCATTGTTCACACATAACC TTTCAAGGGATGCTGAGATGT 230 
Micro chr20:14.33 CFA20_14.18 TCCTCCCAGATAGCCTCTGAT TTTTGGAGTAGGCATCACGAC 189 
Micro chr20:14.42 CFA20_14.27 CCTGCTGGCCTACTCTGAAA GGAGTTCTCCAGAGAAACAGGA 264 
Micro chr20:14.49 CFA20_14.34 TTTGGCTATGCCTGAACCTT CTCAATGGCCACACTATGGA 184 
Micro chr20:14.53 CFA20_14.38 CCACCCACTAGAATGTAAACTCC GAGCCAGAACTATTCCAGATGC 116 
Micro chr20:14.59 CFA20_14.44 CGATGTCTCCTGACCTCATTG CCTGAGTTGTACCAGGGCATA 216 
Micro chr20:15.18 CFA20_15.03 GGCTCCATATTCAGTGGGAAT TCCTGGTACTGATGAGGCACT 146 
Micro chr20:15.28 CFA20_15.13 TGAAACAGAGAAACAGGAATGG TAACAGGGTGAGTTGCACTGG 121 
Micro chr20:15.42 CFA20_15.27 GGGCACAACTTATTGCAGACT TCAGACCCATTGGCCATAGTA 244 
Micro chr20:15.52 CFA20_15.37 AGCTCAATTACCCAACAATGC TTAAACCAAAGCGTCTTCAGC 225 
Micro chr20:15.54 CFA20_15.39 CATCAGGCTTCCTGTATGGAG TCTCATGACAACCCTGAGAGG 151 
Micro chr20:15.74 CFA20_15.59 GGAGCTCCTCACTGGGTCTTA TCTTATGGTCCAAACAGGTTGA 268 
Micro chr20:15.75 CFA20_15.60 CTGGCCCATTAGTGCATAGTC GGTTCACTCTAGTCATTGTTTGC 188 
Micro chr20:15.89 CFA20_15.74 AGGCTTCATCATGTGAAATGG CTGATTTGGTTGGAATTGGTG 168 
Micro chr20:15.97 CFA20_15.82 AGCAGAGATTGTTTGCTGCTT GCCCTTTACTTACTGGCCATC 166 
Micro chr20:16.05 CFA20_15.90 TGTAGGCCACACAACCATGTA CCCAGATGTTAATAGCCGTGA 259 
Micro chr20:16.21 CFA20_16.06 TGGAGGGTAAGAAGTCCCAAC TCCCTCATCTTGACAACTGGT 228 
Micro chr20:16.57 CFA20_16.42 AGGCCTCAGTGTTTCACCATA GTCCAAAATGCATTGTTACTCC 150 
Micro chr20:16.91 CFA20_16.76 AAACAGAGGGTCAGGCTCATT CCCATAGTGTGATCCTGGAGT 208 
Micro chr20:16.92 CFA20_16.77 ATAAATGGCAACACTTCCTTCC GCCAAAACAGAGAAGGAACCTA 137 
Micro chr20:16.95 CFA20_16.80 GTTGTGTGAAGGCCAGAAGAG GTGGCCAAAAATCCCTAAGAG 238 
Micro chr20:16.97 CFA20_16.82 GGGGGTTTCTTTATTTTGGTG ACCCAAACATACTAACTTGAAAAAGG 279 
Micro chr20:17.01 CFA20_16.86 TTTTCATGGGCCTTAGTGAAG TTCCTTATGATGCTGGTGGTC 299 
Micro chr20:17.04 CFA20_16.89 GGATCGAGTTCCGTTTCG TGGTTCTTGTGAGTGTCATGG 272 
SNP chr20:17.14 DOG_SNP_9 TAGCAAGGGAAAAGCCATCTT GTCAGACAGCTCAATGCATCA 402 
SNP chr20:17.15 DOG_SNP_8 ATACCCCAAAGAGTGCTGGAC TCAGGAGGGATCAATCTAGGA 425 
Micro chr20:17.16 CFA20_17.01 AATGAGCTCAGTTGGGGAAG TTAGCACGGTTGTTTTCCTTG 305 
SNP chr20:17.19 DOG_SNP_5 CGCTATGGTGTCAGACCACTT AACACAGGCCTGCTTACACCT 467 
SNP chr20:17.21 DOG_SNP_3 TTCACCAGGCCACAGTATAGG GAAACCAGGAATTGGATGCTT 500 
SNP chr20:17.22 DOG_SNP_2 TGGGGACTCTTCTTCACCAC GGCATTTCAAGGTCACAGGT 544 
SNP chr20:17.23 DOG_SNP_1 TGAAAGGACACATGCAAAGC GATGCATAAGCCATGGTGTG 358 
Micro chr20:17.24 CFA20_17.09 TGGTTAATGTCTGCCTTCAGC ACCTCCAACTTGGTTCCTGAC 220 
Micro chr20:17.31 CFA20_17.16 CCTAACCAGAGAGAGGCCAAT AAGATAATCCCTGCGGTAAGA 115 
Micro chr20:17.39 CFA20_17.24 CAAGGCCTGTGTTACCCTGA TGTAGGTGCCCCACTTCTTT 289 
Micro chr20:18.22 CFA20_18.07 CAACTCAGCAGTTGGGTTAGC GGTGGACAAGATTTGTTTTGC 126 
 
Primers for non-quantitative end-point PCR checking for gene expression of genes in the IS 
spinocerebellar ataxia disease-associated region 
Forward name Sequence Reverse name Sequence 
Amplicon 
size (bp) 
BHLHE40_cd1f GACGTTCCGCTACTGCAGAC BHLHE40_cd1r TCTGAGACCACACGGTGAAG 594 
SUMF1_cd1f CACCAAGATGGTCCTCATCC SUMF1_cd1r GCACAGCGATACCTGTAGCA 700 
SAP18_cd1f ACGAGTTTTGCAACGGAAAC SAP18_cd1r AAGGAGGTGGTGCCTGATTT 253 
SETMAR_cd1f CTTGGAGAACGTGCCTGTG SETMAR_cd1r CATGCCCAGTTCCTTCTGAT 871 
XP_cd1f AACCTGCAAGAGGTTGGAGA XP_cd1r CTGGGATGGACCAGTGAGAT 509 
LRRN1_cd1f GCCCTCTGCACCCTACTTCT LRRN1_cd1r TTCCAATCACAGGGTTTTCC 893 
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Primers for PCR and exon resequencing of SCA disease-associated interval genes 
Forward name Forward sequence Reverse name Reverse sequence 
AmpliconSize 
(bp) 
BHLHE40_U1_F CCAGGAGACGGGAACTTACTT BHLHE40_U1_R AGCCAAGTGAATGAGAAGTGG 505 
BHLHE40_U2_F AACTGAAGCAGCACCTCAAAG BHLHE40_U2_R GCGGTGTGTCTTACCTTGCTA 514 
BHLHE40_1_F GGGTAGAACACGTAGCTCCAA BHLHE40_1_R CAACTTACCCAGGTAGGTCTCC 520 
BHLHE40_2_F GAGACCTACCTGGGTAAGTTGG BHLHE40_2_R GCACTCGTTAATCCGGTCAC 575 
BHLHE40_3_F CTTCTGTGAAACGGCTTGAAC BHLHE40_3_R CGGTTCTCACTTCATTTGCAT 461 
BHLHE40_4_F GTCAGAGCTTTCTCCTGATGC BHLHE40_4_R CAGCATTCCAAACGAAAAGTC 576 
BHLHE40_5.1_F CCCGATCGTATTACTTTTGGA BHLHE40_5.1_R ATTCTCCTCCGTAGCCACTGT 501 
BHLHE40_5.2_F CTTCAAGGAGAAACCCAGCTC BHLHE40_5.2_R AGTCTCTGAGGCATGAGCAAG 543 
BHLHE40_5.3_F TGCTGGAGAAGTGCTGGTATC BHLHE40_5.3_R AAGCCCAGAGATCTGCTACAA 521 
BHLHE40_5.4_F ACCAAAGACTAGGGGACCTTG BHLHE40_5.4_R GCTATGCCAGTGTCTGCTACC 585 
BHLHE40_5.5_F CCCCCTCAGATACATCCAAAT BHLHE40_5.5_R TCTAGCTCTGCTCGTTGAAGG 594 
BHLHE40_5.6_F TGGTGCCTATTCCTAGGTCTC BHLHE40_5.6_R AAGGCAATGACTTTATACCAAAA 455 
BHLHE40_5.7_F CTTGTTTTCCGACTCATCCAG BHLHE40_5.7_R GTATCACACAACTGGGGCATT 448 
ITPR1.U4_F CTCGCGTTAGTCCACCTCCT ITPR1.U4_R GGACTACGAGTCCCAGAATCC 550 
ITPR1.U3_F TCTGCCTGAGCTACCTGGAT ITPR1.U3_R GAGCTCGTTCCGTTAGGATG 507 
ITPR1.U2_F GTTCTGCTGAAGCGTTTCCT ITPR1.U2_R AATGCCATTCCAGTCCAGAA 478 
ITPR1.U_F GAAGGCTACCCATTCTGGACT ITPR1.U_R AAACTGCCACCTTCTTTAGCC 524 
ITPR1.ex1_F TTTGCGTGCCTAGTCTCACTT ITPR1.ex1_R ACTGCCCTCTGGATCTCAAAT 490 
ITPR1.ex2_F TCATTTAAGTGCCTGCCTGTC ITPR1.ex2_R TGACAAGCAAGTCAGCATTTG 642 
ITPR1.ex3_F CCATCATGGATGTGGTTAAGG ITPR1.ex3_R TCGTGATGAGACCCAAAAATC 648 
ITPR1.ex4_F AAGGGCCTTGTCTTGTCATTT ITPR1.ex4_R TCCGAGAAAGACACTGGCTAA 438 
ITPR1.ex5_F TATGAACTGGCGACATTGGTT ITPR1.ex5_R AATTGCTCTTATTGGCCCTGT 581 
ITPR1.ex6_F AACATCCATCTTGTCCACAGC ITPR1.ex6_R TGTTTCCCAAACACTGGTTTC 558 
ITPR1.ex7_F CTTCAGGCAATGTTCTGCTTC ITPR1.ex7_R GTAAAAGAGGCCCTTCACTGG 662 
ITPR1.ex8_F CTGCTTCTTGGGCAGTATGAG ITPR1.ex8_R CACATCCAGCATCCTTCAGAT 563 
ITPR1.ex10_F AGGGATCCCGAGTTGTAGAAT ITPR1.ex10_R AAAGCAGAAGGAAAAGCAAGG 535 
ITPR1.ex11_F CAGAGGGAAGGGACAAGTTTT ITPR1.ex11_R GGGCATTCCAAGAGATACCAT 450 
ITPR1.ex12_F ATGGTTCTTTTCCTGCCAACT ITPR1.ex12_R GCTTCAAGAAAGGCAGTGATG 384 
ITPR1.ex13_F TCAGTATGCAGACGTTTTCTCC ITPR1.ex13_R CCAACAAAACACAGCTCCCTA 364 
ITPR1.ex14_F AGCTCCAGCTTTTTGGATAGC ITPR1.ex14_R TCAGAGTAACACTGGCCCCTA 538 
ITPR1.ex15_F GGAAGAATGGATCTGCTTGTG ITPR1.ex15_R AGTTGATCAAGCCTTCCAGGT 363 
ITPR1.ex16_F CCACCACCTGTGAGGTTGTAT ITPR1.ex16_R GAAGGGAACTTCTCTGGCATC 454 
ITPR1.ex17_F TTCTCATCAGGGACTGTTGCT ITPR1.ex17_R AGCTAGGATTCCACCACAGGT 436 
ITPR1.ex18_F TCCATCCACTGCTTCCTTATG ITPR1.ex18_R AGTGCAGACATCCACTGAACC 496 
ITPR1.ex19_F TGCAAGGCAGATAGAATCACC ITPR1.ex19_R GACTCCCTGGAACAATCAACA 507 
ITPR1.ex20_F TCGATGTTCAGGTGTTCAATG ITPR1.ex20_R CATGCCATCTTTCACATTCTTC 574 
ITPR1.ex21_F GGCGCCTCAAATGATTACATA ITPR1.ex21_R GATAGGATTCACCCTGGGTACTT 556 
ITPR1.ex22_F TCAGAAATGGCAAGCAAGGTA ITPR1.ex22_R AGTGGAGAGTTGGCGTCTTCT 562 
ITPR1.ex23_F TGAGTCCCCAGAGTTTTGATG ITPR1.ex23_R AAATGGCACTGAACAATGAGC 502 
ITPR1.ex24_F TTGTCAGGGTGCTAAAGTTTG ITPR1.ex24_R CCAAGATGGAAGGAAACAAGA 600 
ITPR1.ex25_F ACCTGGCTTCACAGCTTTACA ITPR1.ex25_R GCACTTGGGGAAACCTACTTC 427 
ITPR1.ex26_F AGGAGCTGGGAATCTGGATAA ITPR1.ex26_R TGGTAACAAGCAGCTGAACCT 554 
ITPR1.ex27_F CTTTCGGCACTTCAGTCAGAG ITPR1.ex27_R GTCCAAGGTGACACGGAAGTA 527 
ITPR1.ex28_F CAAGTGACTCAGGCTGAAACC ITPR1.ex28_R GCAAGCTTCTTTCTCCCTGTT 346 
ITPR1.ex29_F GAGGTGGGCGAGAACTCTTAC ITPR1.ex29_R CTTCATGTCTTCGCCAATGAT 386 
ITPR1.ex30_F GTCTGCTGGCCTAGCAATATG ITPR1.ex30_R ACCAGCAACTCTTTGGTGCTA 512 
ITPR1.ex31_F TGGCAGAAAGTGAGAAAGGAG ITPR1.ex31_R CTTAGGGTTGGGGAAGTCAAC 500 
ITPR1.ex32_F TGATACATGAGTGCTGGTCTGA ITPR1.ex32_R AGGTCTCTGCACCATGAGGT 584 
ITPR1.ex33_F ATTGCCCTACATGGTTGTTCA ITPR1.ex33_R GGCAAGCTGAAATTATGTGGA 469 
ITPR1.ex34_F ACACGTGGCTAGGAACTTGAA ITPR1.ex34_R TATGAATGCCTTGCAGAATGG 517 
ITPR1.ex34B_F CTTTCTTGGGTCATGGTGAGA ITPR1.ex34B_R CACACGAAATTGCCTTATGCT 392 
ITPR1.ex35_F CAGGGACCTGAGGTAATTTGC ITPR1.ex35_R ACTTTCTGAGAGCAGGGCTTT 566 
ITPR1.ex36_F CATGCAAGTGACATGTTTTGG ITPR1.ex36_R CTATGGCCAAACTTGGGTTTT 409 
ITPR1.ex37_F TTGCCTAGCTTGTGGTCATTT ITPR1.ex37_R GGCACAGAAGATGATCGGTTA 483 
ITPR1.ex38_F CCCTTTTGCTGTTACTGACCA ITPR1.ex38_R GGCAAGCAGCCTATAAGACAA 551 
ITPR1.ex38b_F CAGATGTCACCGTGAGCTGTA ITPR1.ex38b_R GGACAAATGGCAAACAAACTC 401 
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Primers for PCR and exon resequencing of SCA disease-associated interval genes (continued) 
ITPR1.ex39_F AGCCATGTCACCTCATCTTTG ITPR1.ex39_R TCAGAGAGGCACATCTCACCT 404 
ITPR1.ex40_F AATTGTGAGGATTTGCCCTCT ITPR1.ex40_R TCAACACCAACAAAAGCTGTC 466 
ITPR1.ex41_F AACTGAGTACCCCCGTGTTTT ITPR1.ex41_R AATTACCCAGAGGGTTGCTGT 460 
ITPR1.ex42_F ACCTTCCTTGTGGGGTTTTTA ITPR1.ex42_R TCCATCATAGAAGAGCCTTGG 431 
ITPR1.ex43_F CAGGCTCTGATCTCTGTGAGG ITPR1.ex43_R ACCAATGCATGGTAGTTCAGC 415 
ITPR1.ex44_F TTGGAGTGTTTGGCTAACCTT ITPR1.ex44_R TTGTCCCTGTGGAGATGGTAG 551 
ITPR1.ex45_F CATCATGGAGGCTGTCTCTTC ITPR1.ex45_R CTAGGCCAACAGGCAATGTTA 491 
ITPR1.ex46_F TACTGGGAGTGGCAAGAATTG ITPR1.ex46_R ATTTGCAGGGGAAGACTGAAT 414 
ITPR1.ex47_F TCTGCCATAGGATGAAACGTC ITPR1.ex47_R TCTCAAGAGGGGTAAGGAGGA 408 
ITPR1.ex49_F CTTGGTCCAGCTACAGCAAAT ITPR1.ex49_R AAAGGAAAAGCAAGTCGAAGC 446 
ITPR1.ex50_F CATGTCCCTCATAGCCACTGT ITPR1.ex50_R CTGTGCTTGGACATCATTCCT 506 
ITPR1.ex51_F TGAATGCTGAGCCTATGACCT ITPR1.ex51_R CGCTTACCAGCTACAAAGGTG 462 
ITPR1.ex52_F TGAGCCTATGAGTCAACCTCAA ITPR1.ex52_R AGGCTCATGGAGACCATTTCT 561 
ITPR1.ex53_F GTGTGACGGACTACGTCTGGT ITPR1.ex53_R GCAATTTTCTGCACTGAAAGC 435 
ITPR1.ex54_F CTTAGATCTGGGCACTTGGTG ITPR1.ex54_R CTCTAGATCCCGGAAATGAGG 457 
ITPR1.ex55_F CCCATCTCGGTTTTCACTATG ITPR1.ex55_R CGTACCATACTGCCCTTTGAA 550 
ITPR1.ex56_F TGTGCAGACTTGGTGTAAACG ITPR1.ex56_R TACTGGCCTTCCTTCTGAACA 526 
ITPR1.ex57_F AGGTGACTCCTGCTTTTTGG ITPR1.ex57_R AGTCACACCCTCCGTCTAACA 595 
ITPR1.ex58_F ATGTTAGGCCCATCGAGTCTT ITPR1.ex58_R ACGCCAAGACACATTCATTTC 532 
ITPR1.ex59_F AGACCCAAGTCCCTCTCACTC ITPR1.ex59_R GAGCCTCATTGTTTCCTCCTT 554 
ITPR1.ex60_F GCCTGATGAAAGAGGTCACAA ITPR1.ex60_R AAAGTGCAGTGAAGGGGAACT 454 
ITPR1.ex61_F TGCCTAGGAAGATGTCCCTTT ITPR1.ex61_R GGTTCAAGTGCAAATCAGGTG 538 
ITPR1.ex61.2_F AGTTCTGATTCACCCACAAAGA ITPR1.ex61.2_R GAGTTTAAATGATCAGGTCAGAAGC 621 
LRRN1_1_F TGTGCATTTGATGATTTTACCC LRRN1_1_R AGCTCAACTCCTGACACTCCA 481 
LRRN1_2_F AGGCACATCTCCAGACTTTGA LRRN1_2_R GCCAGCCCTACCTCCTTAATA 645 
LRRN1_3_F GATTGCAATGATCTCCGCTTA LRRN1_3_R CAAGTTGAGGGACTTTGACCA 604 
LRRN1_4_F AGTTATCGATAGCCGCTGGTT LRRN1_4_R TTTTGGTAAACGGCATTCAAG 525 
LRRN1_5_F GGAACTTGTTTCTGTGGATCG LRRN1_5_R TGGGCAACACAAGTGTATCTTC 612 
LRRN1_6_F TACTGGGTCACTCCTCTTGGA LRRN1_6_R CTAATGACGGCAAACATGGAT 560 
LRRN1_7_F CAGGGTCCCAGTAGATGTTCA LRRN1_7_R GAAATATCCACCCGTCCTCTC 574 
LRRN1_8_F TTAACCTCTGGGAAGGTGACA LRRN1_8_R CAAAAGGTTCAATGCTGCTTC 547 
SAP18_1_F GCAGGTACAAATCCTCCATCA SAP18_1_R CCAAACTTGTCAGTCCTGCTC 398 
SAP18_2_F AGAGGCCAGAAGAAGGATCAG SAP18_2_R CTCGATAGCCAGGCCTTTTAG 562 
SAP18_3_F TACACTTGGATGGATGCAACA SAP18_3_R GCAAAACTGCTTTGTCATGGT 430 
SETMAR_U1_F CGGCGTCTGTAAGACAGAAAG SETMAR_U1_R GAGCAGGGTTCTGAAGTGCT 556 
SETMAR_U2_F TTCTGGGAAACCGAGAACAC SETMAR_U2_R CCTCAGGCTCCTCCTCAGAC 572 
SETMAR_1_F TCGGGAAAGGTGAGAGAAAA SETMAR_1_R AGAGGCGCCCACAGAACTAC 448 
SETMAR_2_F GGTCAGGTTCCCTGTTCAGT SETMAR_2_R CCAGCCTTTCTTATCCGTCTT 483 
SETMAR_2.2_F GTCCTATGCCAGTGCAGTGAT SETMAR_2.2_R TGATTTGGCACCACAATAACA 522 
SETMAR_3_F GCCAAAGATATTTTGCCAGAAG SETMAR_3_R AAACGTAGTCATTTAGCCACATCT 531 
SUMF1_U_F GGTTCTCTCATGTTCCCAGGT SUMF1_U_R GAGTTGATTTGGGAGGTAGCC 569 
SUMF1_1_F GGGTTCACAGTTGGCTAGAAGT SUMF1_1_R ATCCCGACCCTGTCCAAG 545 
SUMF1_1.2_F CTGGGTCTCGTCTTCCTGCT SUMF1_1.2_R TGGGGTGTGGTTAGAATCTCC 364 
SUMF1_2_F GCTGGGTGTTTACTGTGTGCT SUMF1_2_R AGGCTTGAATCCTAGCTCCAC 497 
SUMF1_3_F AGCTGAGGATACCTGGTGGTT SUMF1_3_R AGGAGGGTGGCATTTGTAGTT 466 
SUMF1_4_F CATGCTGGTGCTTATGATATGG SUMF1_4_R GGCACAGTGCTTGGGTATTTA 480 
SUMF1_5_F CTGTGGTGGAAGGTGACAGAT SUMF1_5_R CAAAAGGCTCTGAGGAGGACT 551 
SUMF1_6_F TGAGCTAGTTGTGCGGAAGTT SUMF1_6_R TGAATGCAGGAAGAGACTGGT 401 
SUMF1_7_F CATTTTGACTGTCGGGATGAA SUMF1_7_R TGCTCACAGACATTTCTGCAC 445 
SUMF1_8_F ATGCTGCCAAGCAGCTTATTA SUMF1_8_R AGTGGATGGGACATTTTAGGG 460 
SUMF1_9_F TGGTGAACTGTGAATGTCCAA SUMF1_9_R TAAAGCACAGCGATCATCTCC 514 
XP53_U_F TGAAAGGGAACTTGGAGATCA XP53_U_R GACCAAGGTCTAGTGCGACAG 513 
XP53_1.1_F TCCCTTGAGCAAAAGCTGTAA XP53_1.1_R GTCTTCTTTGACACCGACGAG 466 
XP53_1.2_F GAAGAGGTTCGCAACTGTGAC XP53_1.2_R TGTGAAATTCAGATCGCAGTG 514 
XP53_1.3_F TTGAGTGGAAACCCTCTCCTT XP53_1.3_R CAATTCCCAAGTCCTCATCAA 368 
XP53_2_F TTAGAGGAGGATGGGATTGCT XP53_2_R GCATATCTGCCACATCAGTCA 461 
XP53_3_F GTCTTGATTTCCTGCCTTTCC XP53_3_R GAGCTGCATAATGAGCCAGAC 359  
Appendices 
 
 
 
209 
 
Primer for ITPR1 cDNA sequencing 
Forward name Forward sequence Reverse name Reverse sequence 
Amplicon  
size (bp) 
ITPR1_cd1_f AGTTCTGGCTTTGATCCTGGT ITPR1_cd1_r AATGCTGACTTGGAGCACTGT 1538 
ITPR1_cd2_f GACCGTGAACACCAGTGACTT ITPR1_cd2_r CCACCCTACACACGTCAGAGT 1877 
ITPR1_cd3_f CTCATGGTCGAAATGTCCAGT ITPR1_cd3_r TCCAGCTCATCCTTGGTCTTA 1966 
ITPR1_cd4_f CCGACATCCTAATTGAGACCA ITPR1_cd4_r GACGTCCTCTCCCGAATTAAC 2081 
ITPR1_cd5_f ATGCTGCAGACTTGGAAAAGA ITPR1_cd5_r TTGGAAGCTCCGCTACTATCA 2197 
ITPR1_cd6_f TCTGGGACTCGTAGTCCTTCC ITPR1_cd6_r GCAGAGCTGGAAGCCTCTTAT 861 
 
Internal primers for sequencing 
ITPR1_cd1_in1f GCGGAGTAGGAGATGTGCTC 
ITPR1_cd1_in2r TCCAAACCTTTAGAGTAGCAATCA 
ITPR1_cd2_in1r CGAAGAATTGTGGAGGCAAT 
ITPR1_cd2_in2r GGGCACAGGAAACACAATCT 
ITPR1_cd2_in3r GATATTGTGCCCCACATTCC 
ITPR1_cd3_in1r GTAGTGGTCATCGGGGTCAG 
ITPR1_cd3_in2r CTTGTCAAGGTGGCACTGAA 
ITPR1_cd3_in3r GGTCATCATTTCTCGGAGAGTC 
ITPR1_cd3_in4r ACTTGGCTGTCAAGGTCCAC 
ITPR1_cd4_in1f CTGCCGTCTCATGCTTCATA 
ITPR1_cd4_in2f AGCAAAATGGCAAAAGGAGA 
ITPR1_cd4_in3f TCCCAGACTTCGGAAACATC 
ITPR1_cd4_in4f TTCAGTCAGAGGCAGGAGGT 
ITPR1_cd4_in5f GTGCCTCTGTGAGGAAGAGC 
ITPR1_cd5_in1r AGAGCCACACCTCCTCTTCA 
ITPR1_cd5_in2r GCCGGCAGATATGTCTGAAT 
ITPR1_cd5_in3r TTTCTCCAGCTTCCCAGCTA 
ITPR1_cd5_in4r ACTCCAGGCATTCTTCCTCA 
ITPR1_cd3_altf CGAAAGTGGTGGCTTCATTT 
ITPR1_cd3_altr GTGCTGTATGGTGGTGTTGC 
ITPR1_cd3_alt2f GCGGCTTCTAGAGACTACCG 
ITPR1_cd3_alt2r TGAAACACTCGGTCACTGGA 
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Long range PCR primers across ITPR1 
See Appendix 10 for PCR products on agarose gel 
Gel 
Lane 
Forward 
primer 
genomic 
position 
(kb) 
Forward primer sequence 
Reverse 
primer 
genomic 
position 
(kb) 
Reverse primer sequence 
An
n
ea
lin
g 
Am
pl
ic
o
n
 
si
ze
 
(bp
) 
Co
n
di
tio
n
s 
2 16077.9 CAACTGAGCCTGAGAAAGCTGAAG 16068.6 CTTTGGAGAAATCCATCACCACTG 64 9300   
58 16069.0 TGGGGACGTTAGTTAAAGTCTCTGC 16067.2 TCAGCAGAACATCCACATGGTTAC 64 1833 GC 
59 16067.3 GATTCTGGGACTCGTAGTCCTTCC 16065.2 CTGGTCCTCCACCATGTTATTCTG 64 2067 GC 
3 16065.5 GCCTGAATGTCAAGGAATCTGATG 16060.7 CGGGGTAGGTGATGAGTAAAGACC 64 4778   
4 16061.0 GTCATTCAGCTTTCATCACCCATC 16050.9 ACTCTGGCCATGATGAACTGTCTC 64 10131   
5 16052.5 TTAGTTCCTGACGCCAGTGCTTAG 16043.6 CTCTTCTCGAAACAGGAGGAGGAG 64 8980   
6 16044.6 ACTGCAAAGTTGTTGGCTGACTTC 16033.8 AGTGCCATCCTGAGACTGTGATTC 64 10857   
7 16035.3 ATGAGCAAGGCAGCATTCTGATAG 16024.1 CTGCTGATTCCATTCCTGTAGGTG 64 11184   
8 16025.6 CTTGCCCTTAAGGAATTTGCAATC 16014.2 CAGTGGGTTAGATGGGTACTGTGC 64 11454   
9 16014.8 TGACCTGGATTGCTGAGAAGTAGC 16005.1 GCAAATCAGGAATCCCTACAGGAC 64 9701   
10 16006.4 CCTGTATTGATTTCGCTGGAGATG 15995.3 CTGCAGTACCAATCTACCCTGGTG 64 11154   
11 15996.9 GCCGTCTGAGCAGGTAACCTAAC 15986.1 ATGGCTAATAAACTGTGGGGATGG 64 10769   
12 15987.9 TTCTGGACTAGCAGGTTGTGGATG 15978 CACCTCAAAGGACTGCATGAAGAG 64 9889   
13 15978.5 CCTGGTGGTACCTAGACATGGTTG 15976.1 TTTTAGGGACAAGGCATACAATGG 64 2394   
14 15976.3 ATCTCACAGAGACTTCCCCTGACC 15974.6 CTGTGACCCAACCGTAAATGAAAG 64 1699   
62 15975.2 TCAGTCTCTGCATCCAGTGTTGAC 15969.6 GGTTTAACAACCCAACCCTCTGAC 64 5604 GC 
15 15970.1 AGTGCAGTGGACGATTAAGACAGC 15959.9 AATTCTACATCCCTGGCACCTCTC 64 10216   
16 15960.3 CCTCTCCACACATTGGATTAGGTG 15950.5 TCAGCAATGAGTGAGTGACGTAGC 64 9864   
17 15951.0 TTCCTAAAAGGGCCTTGTCTTGTC 15940.2 CTTCATTGTTACCCTGGTGAGTGG 64 10804   
18 15941.4 GAAAATAGTGCGTGAGTCCAATGC 15930 ATAAGCAGGGAAATGAGGCAAGAG 64 11494   
19 15930.4 TGGGAGGCTATTTCTTCTTTGGAG 15920.7 GCTCTCCCAATGTTCATGTAATGC 64 9713   
22 15921.5 AAGCTTTTAGGTCAGATGGCCAAG 15911.4 GGGTGGGAGGAGTCATTTTGTAAC 64 10121   
23 15912.9 GAACATCATGTCTGATCCCCAAAG 15901 TCTGAGCTCTTGGTCATTGTTTCC 64 11959   
24 15902.4 CTGAGGGTGATTGTTGGTAACAGG 15893.7 TTCACCAAGAACTTCCTTGAGCAC 64 8769   
25 15894.3 TCCAGGCAGTTTAAGCACTACAGG 15889.3 AGTGGACAAAGTGCTGGACAACTC 64 5045   
26 15889.4 AACAATTTCCAGCTCTGCAGTGAG 15888.4 GACCAGCACTCATGTATCAAGTGG 64 976   
27 15888.6 CCCTATACAGTCCTGGGGACAATG 15885.5 TCAAACTACCAGGGCAGAGTTGAG 64 3221   
28 15886.2 CTCAGACACCTTCCTGAGCTTGAG 15875.6 TCCCATCAAACGGTGGTCTATATG 64 10603   
29 15876.0 AGAGATTGGCTGGCCTCAGTAAAG 15872.2 CGGTGCATTCACTTGTAGGGATAG 64 3825   
30 15872.4 AATGGACCTCTGTCCTTCATCTCC 15870.7 CTGCTATTAACCTTTGCCCATTCC 64 1659   
31 15870.9 TGTAGCTTGGTGGCAACTTTATGG 15869.5 AAGACGGAAATGACCTCACACTTG 64 1403   
32 15869.8 GGGGTGTTGCATTAAACCATTTC 15868.6 TTGTGGGTGGACTTCAAAACATTC 64 1193   
66 15868.7 TGCCTAAGGTCGTCACACAG 15868.3 TTCTTCTAGCAGCCCTGAGC 58 472 HST+ 
70 15868.3 GCTCAGGGCTGCTAGAAGAA 15868.2 TCATTGTTGGTCCTCTGCAT 58 124 HST+ 
33 15868.2 ATGCAGAGGACCAACAATGA 15866.4 AACACGTGGACCAAGAGAACAGTG 58 1822   
34 15866.6 GAGTTTGTTTGCCATTTGTCCTTG 15863.1 GGCAATTACTGCTGAAGGTCACAC 64 3509   
35 15863.4 AGGTGCTTCTGCAAGCAAAGTATG 15858.8 AGAAATTTCACCACGACAGCTCAG 64 4619   
36 15859.4 AATCGTGGAGCTGTCTTTCACAAG 15854.9 ATGGTCAGTTTGCAATCAAGCAAG 64 4547   
37 15855.9 TAAGTGGCTGGAACCTAGGAAAGC 15846.8 TCCTGGAACCACAGGTCTCTACTG 64 9174   
38 15847.3 AGGGATGTTGGAGATGAGAAGGTC 15836.77 AGTAGCCCCTCAGTGAAAATGGAG 64 10569   
68 15836.9 GTTGGCAAAGCTGATATTTGAACC 15835.3 CTCCAGGCATAATCAGCACTCCTT 58 1631   
71 15835.3 AAGGAGTGCTGATTATGCCTGGAG 15835.1 TTCTCAGAACACTTCTGGATGATGC 58 191 HST+ 
69 15835.2 TTTAGAATACCGAAGAACCCATTT 15834.7 TTCTTTGCTGACGCACTTGAGAAC 58 505   
44 15835.0 CCTGAGCAAGACCTAACCCTGAAG 15832.9 TTCTCACCTCTCACAGGCTTATCG 64 2192   
45 15833.1 GCAACATAAGCCCACAAACTGTTC 15828.5 TTGTCGACCTCTAAACACCTCCTG 64 4559   
46 15829.5 TATTGAATGTTTAGGGGCCATCTG 15819.5 GTTCCCATCAAGTACCACAGCATC 64 9935   
47 15820.1 TGAGGAGGTTAATGAGCCACTCTG 15809.2 TGGGGATTCTTTAGAGCAGTAGCC 64 10926   
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Long Range PCR primers across ITPR1 (continued) 
48 15810.0 CACAAGCACCCATGTTTAAGTTCC 15804.7 GTAACTGGGTATTCCCTGGCTTTG 64 5404   
49 15805.2 TTGTTCAGGATGGAGACTGGAGAC 15800.1 CTAATGAACTACACCAGGGCATCG 64 5055   
63 15800.3 TGGTTATCACACCCGTCCAAATAG 15798.7 ATGTCCACGAAGACTTTGATGCTC 64 1622 GC 
50 15798.9 TCCATAGAGCTGCTTGAGTTCCAC 15796.3 ATGCAAGTCATAACCTTCCTGCTG 64 2541   
51 15796.8 CATGCAGGGTTTTAGATGTTCCAG 15790.7 AGCAATTTTCTGCACTGAAAGCAC 64 6162   
52 15791.4 TGAGTGCTTCTCTCAGGGAATTTG 15780.6 AATCCTCAGCCCAGACCAGTTTAG 64 10740   
64 15781.1 TGGTGGGAAATTGCAGGATAATAAC 15777.6 ACAATGTGCATGTTCTGGGTTAGG 64 3500 GC 
65 15777.9 CTGCAGATGGTACCAGGCATTAAG 15773.5 TACTTAACCCTGAGCCTGCCTTTC 64 4400 GC 
53 15774.0 AGAGTTTCGATTGTGATCCAGCAG 15766.8 TGAGAAGAAGTGGGTTGGTGAAAG 64 7200 GC 
54 15767.2 ACACACCTTGGTAATCGACTCTGG 15758.2 TTGAGATTCTTTCCCTCACCTTCC 64 8911   
55 15758.6 AAGATGAAGAAAGTTCCCGAGGTG 15748.3 AACATTTCTGACTGCCTGTCTTGC 64 10437   
56 15750.5 GTGTATGGGTGGCAAAGAACAGAC 15742.6 GTTTGAATTTGCACCTTTGTGGAG 64 7893   
57 15743.3 TCCCTTGTCCTTAGCTTCCAACTC 15738.3 TGATATCCAGAAATGGGATTGGTG 64 5057   
 
ITPR1 polymorphism sequencing primers 
Genomic region Feature Forward primer Reverse primer Size (bp) 
15888739-15889265 SINE insertion TAGGATTCCGGTGGAAGGTAG CCCAGGACTGTATAGGGCTTC 533 
15990820-15991263 SINE insertion CTACCTCTCTTTTGGCATGGAT CTTTGCAATGCTTGCTAATCAC 445 
15883508-15883914 SNP CAACCTCAGAAGGAGAAGCAG TTCTGCAGGCTGTACGAATG 407 
15930447-15931004 SNP CACCAATTACCAGTGCCAGTT TCAGAGCTCCAACATATGGAA 555 
15901797-15902333 possible insertion ACTGAGGACAGGGATTGGTCT CCAGCAAAGTGCTTTACGTATG 549 
15821684-15822358 SNP GGGAGCACAAGTAGGAAGGAC TGAAGGACAGGTCAGAAATGG 675 
15919562-15920003 2 bp deletion TGTCATGGAGAGCAAAGAAGC TGATCTGTCCTCACTCCTGGT 442 
16015255-16015700 SINE deletion CAAAAGGCCAATGTGTGTTCT GCCCTGCTGAGTCTTTAAGGT 425 
16011285-16011680 SINE insertion TTCTCAGTATTCATTGGGCAGA CACTGCATTCTCCAACACTCA 407 
16010817-16011268 SINE deletion GCACCAGAGTCCCATAATCAA GAAAAGATACACACCCACATGC 538 
15807374-15807822 SNP CAGTACTTGGCACATGGAACA AGGAAGCTCAGCATTCTTTCC 451 
16005179-16005716 9 BP deletion GAAGGTCACATTGAGGATTCAG TCAGGAATCCCTACAGGACAA 538 
15955174-15955544 SINE insertion AACGTTGTGGTGTACTGAATGC TGGTACAACTCTAATGCGAGGA 376 
15747434-15747873 SNP AGCAAGGATTTGTGCTTCCTT GATAACACCAGGCGACTTTGA 444 
15952316-15952708 SNP GTCCAAATAGCAAAGGGCAAT CCAAGTCAAACACCCCACTTA 393 
 
Primers for amplification across the ITPR1 GAA triplet repeat expansion 
Name Forward primer Reverse primer Size (bp) 
ISP_GAA_3 GGTGAGGAGCATGTTCTGGT TGTCTCAGCGGTTGAATGTC 238 
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Primers for PCR amplification and exon sequencing of the SPTBN2 gene 
Exon Forward primer Sequence Reverse primer Sequence 
Amplicon 
size (bp) 
1 SPTBN2_1_F GACGGAATTCTCCTGGTTGA SPTBN2_1_R GTGGGTGCCCCCTATAATG 452 
(2)+3 SPTBN2_(2)+3_F ACTTTTAGCTCCCAGCTTTGC SPTBN2_(2)+3_R TACTCTTGGCACTGGAATTGG 644 
4 SPTBN2_4_F GACCTCACTTCTGGGGTCTTC SPTBN2_4_R GGCTTGGGCAGATTAAGATTC 538 
5 SPTBN2_5_F GCTTTGGCTCTGTGAACTTTG SPTBN2_5_R TGGATATCACAGCAACCACAA 484 
6+7 SPTBN2_6+7_F TGACTTCTGACCCATTCTGCT SPTBN2_6+7_R CCAGCTCTTGTCTGGATGTTC 666 
8 SPTBN2_8_F GGGCACCACACTACATAAAGG SPTBN2_8_R AAAGGAAACCCCTTACCCATT 425 
9+10 SPTBN2_9+10_F ATTCGGGGTGAGTGATTCAAG SPTBN2_9+10_R GATTGCTTCTGGCACTTTGAG 693 
11 SPTBN2_11_F ATTTTCTGGCTTTTGCACTGA SPTBN2_11_R GGGGCGTGTTGTACAAGATAA 446 
12 SPTBN2_12_F TCCAGTCCTCACCTAGAAGCA SPTBN2_12_R AACCCTTTCTCCTGTTCAAGC 552 
13 SPTBN2_13_F GAGGCTTGAACAGGAGAAAGG SPTBN2_13_R GCCCTGTTTGCTCTGTGTATC 616 
14 SPTBN2_14_F GACAGAACTGGGGTGTCACTG SPTBN2_14_R CCCTAATGCTGTCACCTACCA 526 
15.1 SPTBN2_15.1_F TGGTAGGTGACAGCATTAGGG SPTBN2_15.1_R TCTGCCTGGAACTGGTAGAGA 581 
15.2 SPTBN2_15.2_F CTTGAAGCTTACGCTGGAACA SPTBN2_15.2_R TTGTAGCAAGAGCAGGCAGTT 685 
16 SPTBN2_16_F CTCCCCACTTGACCCATAGAT SPTBN2_16_R GCTCATTCTCCCTTGACTCCT 518 
17.1 SPTBN2_17.1_F AGGAGTCAAGGGAGAATGAGC SPTBN2_17.1_R ATCTAAGCTGCGCAGGAAGTC 576 
17.2 SPTBN2_17.2_F GGCTTGGAGAGGTACAAGCTG SPTBN2_17.2_R TATGTTCTCCCAGTCCACCAG 600 
18 SPTBN2_18_F GTTTGGGCTGTTAAGGTCCTC SPTBN2_18_R GCACTATCCAGCTGCTTCATC 499 
19 SPTBN2_19_F GTGGTCAGAATGGGACTAAGC SPTBN2_19_R GCATATGCAGTGAAGCATAAGG 460 
20 SPTBN2_20_F GCTCTTGGTTCCTCCATGTC SPTBN2_20_R GGAGGTTTGGCACTAAAGACC 513 
21 SPTBN2_21_F GGTCTCTGTGGCTTCTTTGTG SPTBN2_21_R GACGTGGCCTTGAGAAATACC 658 
22 SPTBN2_22_F ACTGAGGTAGGCCATGAGGAT SPTBN2_22_R ACTTTCAGTGCCAAAGGGAAG 503 
23 SPTBN2_23_F TTCCCTTTGGCACTGAAAGTA SPTBN2_23_R CCTAAGGTTGTTAGGCCTTCG 499 
24 SPTBN2_24_F GTGGGTTTCCATTGTAGCAGA SPTBN2_24_R TGCTTCTTTACCTCTGCTTGG 574 
25 SPTBN2_25_F TCCAAGAGATGTGGAAACACC SPTBN2_25_R TGTACCAAAGGCTCCACAGTC 471 
26 SPTBN2_26_F AGCCAAGACATGATTGACCAC SPTBN2_26_R TGACCTCCTTTCTGCACAGTT 627 
27 SPTBN2_27_F TGCTCTGCAGAAGAAACCTGT SPTBN2_27_R GCATCCTCCTAGCATTTCTGA 617 
28 SPTBN2_28_F CTCCTGCTTCTCTGATGGATG SPTBN2_28_R GGCCTCTATCTCTGCCTTGAT 529 
29 SPTBN2_29_F TACTGGACACCACGGACAAGT SPTBN2_29_R GGCAGAGACGTGAGTTAGCAC 578 
30 SPTBN2_30_F TCCAACTCTTCTCCAGAACCA SPTBN2_30_R CAGAGAAATGGCAGGTCAGAG 461 
31 SPTBN2_31_F GGCAGTAGCTTCCTCCATGTC SPTBN2_31_R TCCTGAAGCTGCAGTGACAAT 450 
32+33 SPTBN2_32+33_F TACCCATTGTCACTGCAGCTT SPTBN2_32+33_R GCTGCTCTGCTCAAGTCTCTG 657 
34 SPTBN2_34_F AGGAGGAAGAACGGAGGAAAC SPTBN2_34_R GGGAAAGTGAGGAATGGTGTC 624 
35 SPTBN2_35_F CCCAGAGGTGTGGGTGTTAAT SPTBN2_35_R CCAGAGGACCCTCCTCCTTAC 543 
36 SPTBN2_36_F CGAGCTCAGAAACAGGAACAG SPTBN2_36_R TGGATGTTGTCAGTGGTCAGG 501 
37 SPTBN2_37_F ACAGGAAGGGTTTGGGAATCT SPTBN2_37_R GAAGCTGGAAAGCCTACGAGA 477 
38 SPTBN2_38_F CCAGTGAGGTGAAGTAGTCCAG SPTBN2_38_R AAAGAAGTTGGGAGATGGGAGT 607 
 
qPCR primers and probes 
Primers used for qPCR assays of gene expression 
All probes were 5’ 6-FAM and 3’ Iowa Black labelled, with internal ZEN labelling. 
Assay name Forward primer sequence Probe sequence Reverse primer sequence Amplicon  
size (bp) 
SPTBN2 TGGATGGTGAAGAGCAGAAC TTCTCAGTGAACTTGGGTGGCTTCTC TCCTTCAATTCCTATCGCACG 83 
ACTB CCAACCGTGAGAAGATGACC CGAGACTTTCAACACCCCAGCCA CGTACAGGGACAGCACAG 90 
TBP TCTGGCATATTTCCTCGCTG ACTGTTCTTCACTCTTGGCTCCCG TTCAGTTCTGGGAAGATGGTG 78 
BCAN CACCGTGTCTACTTCATAGCG CACAGGACACCAGCCCCATCTT GAGTGATGTACCCTGCAACTAC 133 
FAM83H CCACGTGAAGGAGAAGTTTCTG TGTAGCTCCCGCTCATCACCAC TTCTCGAAGGACCACATGAAG 81 
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Diagnostic testing primers 
Primers for assaying the mutations causing episodic falling and congenital keratoconjunctivitis sicca and 
ichthyosiform dermatosis in the Cavalier King Charles Spaniel 
Forward primers Reverse primers Expected product  
size (bp) 
Name Sequence Name Sequence Wild-type Mutant 
CKCSID_F 6Fam-CTTACACCCTGGCCCCGTA CKCSID_R GGTCGAGGAAAGAGGGGAAT 135 134 
EF_F 6Fam-TGTGCTCAGGAGTCTGTCCA EF_bridge_R GCAACCTACTCAGACCTGGAA 15,831 115 
EF_F 6Fam-TGTGCTCAGGAGTCTGTCCA EF_normal_R GGAGCAAATGCTCTGGAAGG 105 N/A 
 
 
Primers for assaying two microsatellites markers linked to spinocerebellar ataxia in the IS  
Forward 
name 
Forward sequence Reverse 
name 
Reverse sequence Amplicon 
size (bp) 
Micro 1 F CTGGCCCATTAGTGCATAGTC Micro 1 R GGTTCACTCTAGTCATTGTTTGC 188 
Micro 2 F TCTCCATCTTCATTTCAGCATT Micro 2 R TGCAGTATTTGTCTTTCCCTGT 230 
 
TaqMan assay for the CAPN1 non-synonymous SNP associated with spinocerebellar ataxia (late onset ataxia) in 
the Parson Russell Terrier. Reporter 1 was a major groove binding probe with 5’ VIC and 3’NFQ labelling. Reporter 
2 was a major groove binding probe with 5’ FAM and 3’NFQ labelling. (VPS51 and Intergenic SNP assays designs 
also shown) 
Assay Forward primer Reverse primer  Reporter 1 Reporter 2 
CAPN1 GGGTGAGGGAGGCAATGG GCAGAGCAGGCCTGATATGG AGAAGCCAACAGTCCC AGAAGCCAATAGTCCC 
VPS51 CCTTCCGCCGACGCT GCAGCCGCTGGACCT AGGCGGAGGCCC AGGCGAAGGCCC 
PRT_54.15 
GTCAGCATTTCCTTGCATC
TTGTTA 
GAGGCTGCCATAGAAAGATTT
ACCT 
TAGAGTTGGACTTTTTC AGTTGGGCTTTTTC 
 
Primers for assaying the mutation causing neonatal cerebellar cortical degeneration in the Beagle 
Forward name Forward sequence Reverse name Reverse sequence Amplicon 
size (bp) 
SPTBN2_29F TACTGGACACCACGGACAAGT SPTBN2_28R GGCCTCTATCTCTGCCTTGAT 268 
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Appendix 3  ABI3130xl genetics analyser running parameters 
Standard sequencing parameters on ABI3130xl genetics analysers 
 
Parameter Setting 
Oven temperature (°C) 60  
Polymer fill volume (nl) 4840  
Current stability 5.0 
Pre-run voltage (V) 15.0 
Pre-run time (s) 180  
Injection voltage (V) 1.2  
Injection time (s) 5 
Voltage number of steps 20 
Voltage step interval (s) 15 
Data delay time (s) 80 
Run voltage (s) 13.2 
Run time (s) 1200 
 
Standard fragment analysis settings for genotyping on ABI3130xl genetics analysers 
 
Parameter Setting 
Oven temperature (°C) 60 
Polymer fill volume (nl) 6500 
Current stability 5.0 
Pre-run voltage (V) 15.0 
Pre-run time (s) 180 
Injection voltage (V) 3.0 
Injection time (s) 10 
Voltage number of steps 20 
Voltage step interval (s) 15 
Data delay time (s) 60 
Run voltage (s) 15.0 
Run time (s) 1000 
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Appendix 4  Non-standard PCR cycling parameters 
 
Microsatellite amplification using tailed primers (Section 2.14.) 
Initial denaturation 
94°C for 4 minutes 
30 cycles of: 
94°C for 1 minute 
57°C for 1 minute 
72°C for 1 minute 
8 cycles of: 
94°C for 1 minute 
57°C for 1 minute 
72°C for 1 minute 
Final elongation 
72°C for 30 minutes 
Hold at 4°C  
 
Amplification of fluorescently labelled primers (Section 2.15.1.)  
Initial denaturation 
95°C for 10 minutes 
30 cycles of: 
95°C for 30 seconds 
57°C for 30 seconds 
72°C for 30 seconds 
Final elongation 
72°C for 10 minutes 
Hold at 4°C  
 
Long range PCR (Section 2.16.1) 
Initial denaturation 
98°C for 10 minutes 
35 cycles of: 
98°C for 8 seconds 
57°C for 15 seconds 
72°C for 6 minutes 
Hold at 4°C  
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Amplification of adapter ligated library fragments (Section 2.16.7) 
 
Initial denaturation 
98°C for 30 seconds 
18 cycles of: 
98°C for 30 seconds 
65°C for 30 seconds 
72°C for 30 seconds 
Final elongation 
72°C for 5 minutes 
Hold at 4°C  
 
SureSelect pre-hybridisation amplification (Section 2.16.8.3) 
 
Initial denaturation 
98°C for 10 seconds 
9 cycles of: 
98°C for 10 seconds 
65°C for 15 seconds 
72°C for 15 seconds 
Final elongation 
72°C for 5 minutes 
Hold at 4°C  
 
SureSelect post-capture amplification (Section 2.16.8.8) 
 
Initial denaturation 
98°C for 10 seconds 
13 cycles of: 
98°C for 10 seconds 
57°C for 30 seconds 
72°C for 30 seconds 
Final elongation 
72°C for 5 minutes 
Hold at 4°C  
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Quantification of sequencing libraries (section 2.16.10.) 
Initial denaturation 
95°C for 3 minutes 
35 cycles of: 
95°C for 30 seconds 
60°C for 45 seconds 
 
Quantitative PCR (section 2.17.) 
Initial denaturation 
95°C for 3 minutes 
40 cycles of: 
95°C for 10 seconds 
60°C for 30 seconds 
 
IS diagnostic DNA test (Section 2.19.1) 
Initial denaturation 
98°C for 30 seconds 
36 cycles of: 
98°C for 8 seconds 
55°C for 15 seconds 
72°C for 30 seconds 
Final elongation 
72°C for 1 minute 
Hold at 4°C  
 
PRT diagnostic DNA test (Section 2.19.4) 
Pre-PCR read 
25°C for 30 seconds 
Initial denaturation 
95°C for 30 seconds 
40 cycles of: 
95°C for 3 seconds 
60°C for 10 seconds 
Post-PCR read 
25°C for 30 seconds 
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Amplification across the GAA triplet repeat region (Section 2.19.5) 
Initial denaturation 
93°C for 3 minutes 
35 cycles of: 
93°C for 15 seconds 
60°C for 30 seconds 
68°C for 3 minutes 
Hold at 4°C  
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Appendix 5  Key commands of the NGS analysis Perl script 
 
1 Index the reference sequence (FASTA format) 
 
> bwa index -a is ref.fasta 
2 Finds suffix array (SA) coordinates of good hits for each read 
 
> bwa aln ref.fasta reads1.fastq > aln_sa1.sai 
> bwa aln ref.fasta reads2.fastq > aln_sa2.sai 
 
3 Convert SA coordinates into chromosomal coordinates (PE data) 
 
 bwa sampe ref.fasta aln_sa1.sai aln_sa2.sai reads1.fastq reads2.fastq > aligned.sam 
 
4  Create the fasta sequence dictionary file 
 
>  java16 -jar /opt/picard/CreateSequenceDictionary.jar R=ref.fasta O=ref.dict 
 
5 Create the fasta index file 
  
>  samtools faidx ref.fasta  
 
6  Sort the SAM file generated by BWA 
 
>  java16 –Xmx2g -jar /opt/picard/SortSam.jar I=aligned.sam O=aligned_sorted.sam 
 SO=coordinate 
 
7  Convert the SAM file from BWA to a BAM file 
 
>  java16 –Xmx2g -jar /opt/picard/SamFormatConverter.jar I=aligned_sorted.sam 
 O=aligned_sorted.bam 
 
 
8 Duplicate removal 
 
> samtools rmdup aligned_sorted.bam aligned_sorted2.bam 
 
 
9 Create an index for the BAM file 
 
>  java16 –Xmx2g -jar /opt/picard/BuildBamIndex.jar I=aligned_sorted2.bam 
 
10 Count covariates 
 
> java16 -Xmx2g -jar /opt/gatk/GenomeAnalysisTK.jar -R ref.fasta -I 
 aligned_sorted2.bam  -T CountCovariates -cov ReadGroupCovariate -cov 
 QualityScoreCovariate -cov  CycleCovariate -cov DinucCovariate -recalFile 
 reads.csv --default_platform illumina 
 
11 Table recalibration  
 
> java16 -Xmx2g -jar /opt/gatk/GenomeAnalysisTK.jar -R ref.fasta -I 
 aligned_sorted2.bam  -T  TableRecalibration -outputBam recal.bam -recalFile 
 reads.csv -- default_platform  Illumina 
 
12  Index the new BAM file 
 
> samtools index recal.bam  
 
13  Creating intervals  
 
> java16 -Xmx2g -jar /opt/gatk/GenomeAnalysisTK.jar -T RealignerTargetCreator -I 
 recal.bam -R $ref -o forRealigner.intervals 
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14  Realigning  
 
> java16 -Xmx2g -jar /opt/gatk/GenomeAnalysisTK.jar -I recal.bam -R ref.fasta - T 
 IndelRealigner -targetIntervals forRealigner.intervals --output cleaned.bam 
 
15 Sort the cleaned BAM file 
 
> java16 -Xmx2g -jar /opt/picard/SortSam.jar I=cleaned.bam O=cleaned_sorted.bam 
 SO=coordinate VALIDATION_STRINGENCY=LENIENT 
 
16 Create an index for the cleaned and sorted BAM file 
 
> java16 -Xmx2g -jar /opt/picard/BuildBamIndex.jar I=cleaned_sorted.bam 
 VALIDATION_STRINGENCY=LENIENT 
 
17 IndelGenotyper  
 
> java16 -Xmx2g -jar /opt/gatk/GenomeAnalysisTK.jar -T IndelGenotyperV2 -R  ref.fasta 
 -I cleaned_sorted.bam -O indels.raw.bed -o detailed.output.bed --verbose 
 
 
18  Make SNP calls  
 
> java16 $mem -jar /opt/gatk/GenomeAnalysisTK.jar -R $ref -T UnifiedGenotyper -I 
 cleaned_sorted.bam -stand_emit_conf 10.0 -varout snps.raw.vcf -stand_call_conf 50.0  
 --platform SOLEXA 
 
19 Pindel (Structural Variant analysis) 
  
> java16 -Xmx2g -jar /opt/picard/SortSam.jar I=cleaned_sorted.bam 
 O=queryname_sorted.bam SO=queryname VALIDATION_STRINGENCY=LENIENT 
 
> perl /opt/pindel/bam2pindel.pl -i queryname_sorted.bam -o sv -s $name -pi (insert 
 size) 
 
> cat sv_chr1.txt sv_chr2.txt sv_chr3.txt sv_chr4.txt sv_chr5.txt sv_chr6.txt 
 sv_chr7.txt sv_chr8.txt sv_chr9.txt sv_chr10.txt sv_chr11.txt sv_chr12.txt 
 sv_chr13.txt sv_chr14.txt sv_chr15.txt sv_chr16.txt sv_chr17.txt sv_chr18.txt 
 sv_chr19.txt sv_chr20.txt sv_chr21.txt sv_chr22.txt sv_chr23.txt sv_chr24.txt 
 sv_chr25.txt sv_chr26.txt sv_chr27.txt sv_chr28.txt sv_chr29.txt sv_chr30.txt 
 sv_chr31.txt sv_chr32.txt sv_chr33.txt sv_chr34.txt sv_chr35.txt sv_chr36.txt 
 sv_chr37.txt sv_chr38.txt sv_chrX.txt sv_chrM.txt sv_chrUn.txt>all.txt 
 
> pindel022 -f $ref -p all.txt -c ALL -o pindel 
 
> pindel2vcf -p pindel_BP  -r $ref -R canfam2 -d 2006 
> pindel2vcf -p pindel_D  -r $ref -R canfam2 -d 2006 
> pindel2vcf -p pindel_INV  -r $ref -R canfam2 -d 2006 
> pindel2vcf -p pindel_LI  -r $ref -R canfam2 -d 2006 
> pindel2vcf -p pindel_SI  -r $ref -R canfam2 -d 2006 
> pindel2vcf -p pindel_TD  -r $ref -R canfam2 -d 2006 
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20 Create GC bias metric histogram 
 
> java16 -Xmx2g -jar /opt/picard/CollectGcBiasMetrics.jar REFERENCE_SEQUENCE=ref.fasta 
 INPUT=cleaned_sorted.bam O=out1.junk CHART_OUTPUT=GC_bias.pdf 
 VALIDATION_STRINGENCY=LENIENT 
 
21 Create alignment summary metrics 
 
> java16 -Xmx2g -jar /opt/picard/CollectAlignmentSummaryMetrics.jar 
 I=aligned_sorted.bam O=Alignment_Summary.xls R=ref.fasta 
 VALIDATION_STRINGENCY=LENIENT 
 
22 Create insert size histogram  
 
> java16 -Xmx2g -jar /opt/picard/CollectInsertSizeMetrics.jar INPUT=aligned_sorted.bam 
 O=out2.junk MINIMUM_PCT=0.05 HISTOGRAM_FILE=INSERT_SIZE.pdf 
 VALIDATION_STRINGENCY=LENIENT 
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 Appendix 6  CKCS critical regions, features and human synteny 
 
EF disease-associated interval 
Deletion positions are indicated by the blue arrows, with genes in close proximity highlighted with a blue box. 
 
 
 
Schematic overview of the genes in close proximity to the three identified deletions.  
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CKCSID disease-associated interval 
FAM83H is highlighted with a blue box.   
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Appendix 7  Results files from the NGS analysis pipeline 
 
The following information is displayed in a readme.txt file included in the results folder 
created on completion of the NGS script. 
 
======================== 
Summary of results files 
======================== 
 
PDF FILES 
 
GC_ Bias.pfd Histogram of GC content of aligned reads 
INSERT_SIZE.pdf Insert size histogram 
 
ALIGNMENT FILES 
 
raw_align.bam Raw alignments to the reference 
best_align.bam Best alignments to the reference after processing by GATK 
 
SNP AND INDEL CALLS 
 
INDELS.bed  List of Indels 
SNPS.vcf  List of SNPs 
annotated_indels.xls List of Indels annotated using the Ensembl database 
annotated_snp.xls List of SNPs annotated using the Ensembl database 
 
STRUCTURAL VARIANT FILES 
 
SV_Break_points.txt 
SV_Deletions.txt 
SV_Inversions.txt 
SV_Long_insertions.txt 
SV_Non_template_seq_in_deleletion.txt 
SV_Tandom_Dup.txt 
 
INFORMATION FILES 
 
Depth_summary  Summary of reads depth across the target region 
Log.rtf   Run log for the NGS pipeline 
Duplicate_info.rtf fraction of PCR duplicate reads in the dataset 
Alignment_Summary.xls Alignment summary information 
 
NOTES 
 
.bam files must have an associated .bai index file for loading into IGV 
Alignment_Summary.xls can be used to calculate success of target enrichment 
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Appendix 8  NGS analysis user input workflow  
 
 
Paired-end or Single-end dataset? 
 Please select your platform type? 
Illumina 454  
Please enter a name for this analysis 
Please enter your email address 
Enter .ssf file name 
SE / PE 
 Are you starting with raw reads (.fastq) or aligned reads (.bam)? 
Input .bam file name 
aligned raw 
reference >2 
Gb? 
Input reference name 
Input fastq file 1 
Enter memory settings 
Input fastq file 1 
Input fastq file 2 
Focus on alignments to one genomic region? 
yes 
Enter genomic coordinates 
Annotate SNP and INDEL calls? 
no 
(For PE data) (For SE data) 
(For aligned data) 
Include Maq analysis? 
Perform structural variant analysis? 
(For PE data only) 
SUMMARY – PRESS ENTER TO PROCEED 
no Input expected insert size 
yes 
For alignments focused to a single 
chromosome 
Enter chromosome number 
Input reference name 
SUMMARY – PRESS ENTER TO PROCEED 
DATA ANALYSIS 
BEGINS 
(SE data) 
DATA ANALYSIS 
BEGINS 
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Appendix 9  Genes in the LOA interval and human syntenic region 
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Appendix 10  Expressed genes across the SCA critical region  
 
Reads are shown in grey. Read pairs spanning exons are shown in red. A histogram of 
read depth is shown in grey for all genes. For the unknown transcript a conservation 
histogram is shown in blue. 
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Appendix 11  Long range PCR products spanning ITPR1 
Primer details, expected product sizes and lane contents are listed in Appendix 2. 
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Appendix 12  GAA repeat number calculations 
 
Migration distance measurements relative to the 100 bp ladder band. 
 
Band size (bp) Relative migration (mm) 
100 0 
200 7 
300 12.5 
400 17.5 
500 22 
600 25.5 
700 29 
800 32 
900 34.5 
1000 36.5 
1200 40.5 
1500 45.5 
2000 51 
3000 58 
 
 
Estimates of GAA repeat copy number based on PCR product migration. 
 
 
Gel lane ID Allele Migration (mm) Calculated size (bp) 
GAA copy 
number 
estimate 
2 5357 1 45 1456 414 
  2 48 1699 495 
3 5397 1 47 1613 466 
  2 49.5 1840 542 
4 5404 1 46.5 1572 453 
  2 48.5 1745 510 
5 5405 1 9 234 7 
  2 47.5 1655 480 
6 5407 1 9 234 7 
  2 47.5 1655 480 
7 5436 1 9.5 243 10 
  2 48 1699 495 
8 PRT 1 9.5 243 10 
  2 10.5 261 16 
9 NTC n/a n/a n/a n/a 
  n/a n/a n/a n/a 
10 6422 1 42.5 1286 357 
  2 50.5 1942 576 
11 6477 1 42 1256 347 
  2 50 1890 559 
12 6478 1 9.5 243 10 
  2 52.5 2166 651 
13 6479 1 11.5 280 22 
  2 44.5 1420 402 
14 6685 1 40.5 1169 318 
  2 49.5 1840 542 
15 8636 1 9.5 243 10 
  2 49.5 1840 542 
16 8637 1 45.5 1493 426 
  2 49 1792 526 
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Graphs for production of a regression line equation for estimating unknown band sizes on 
agarose gel. 
 
 
 
 
 
Please note the independent variable has been plotted on the y axis for optimal regression line calculation and 
equation purposes. 
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Appendix 13  mRNA-seq library fragment cloning results 
 
150 bp insert library 
Clone 
number 
Target 
insert size 
(bp) 
Index Insert 
size (bp) Gene Region 
1 150 2 140 TTC7B Intronic 
2 150 7   SYT1 3’ UTR 
5 150 4 184 VDAC2 3’ UTR 
11 150 5 79 CACNA1D Exonic 
13 150 5 136 KPNA4 3’ UTR 
15 150 2 121  - Intergenic 
16 150 7 120 STAU1 3’ UTR 
19 150 6 139 IL16 Exonic 
21 150 7 215 MEGF8 3’ UTR 
24 150 7 155 RABGAP1L 3’ UTR 
26 150 5 162 SFRS18 3’ UTR 
30 150 4 149 MYO18A Exonic 
32 150 4 198 THEM55A Exonic 
35 150 5 141 MTMR9 3’ UTR 
36 150 ? 140 PSD3 3’ UTR 
39 150 4 154 SEPHS1 Exonic 
40 150 5 166 ARL6IP1 3’ UTR 
41 150 2 162 RNF152 3’ UTR 
43 150 4 129 SLC7A1 3’ UTR 
45 150 ? 166 RPL41 Exonic 
     
150 
    
250 bp insert library 
Clone 
number 
Target 
insert size 
(bp) 
Index Insert 
size (bp) Gene Region 
49 250 5 229 TET3  3’ UTR 
51 250 ? 239 FAM13b 3’ UTR 
52 250 5 86 FIBCD1 Exonic 3’ end 
55 250 ? 237 ssx21p Exonic 
57 250 4 260 TPD52L2 3’ UTR 
58 250 6 274 SET Exon/ 3’ UTR 
62 250 4 258 UBC Exonic 
63 250 5 239 FAM13B  3’ UTR 
64 250 ? 290 SNAP25 3’ UTR 
65 250 4 303 IL16  intronic 
66 250 4 255 REEP5 3’ UTR 
67 250 4 252 CMPK1 3’ UTR 
68 250 5 269 RMND1 Exon/ 3’ UTR 
71 250 5 238 MTCH1 3’ UTR 
82 250 5 231 ECD  3’ UTR 
83 250 5 286 (COX3) unknown 
74 250 4 265 ACVR1B 3’ UTR 
75 250 4 297 YEPL4 3’ UTR 
78 250 5 268 CHD9 3’ UTR 
79 250 5 230 (COX3) unknown 
82 250 5 220 PTTG1IP 3’ UTR 
84 250 4 304 unknown unknown 
      
251 
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Appendix 14  Ataxia candidate genes  
Summary of candidate genes investigated for sequence polymorphisms after mRNA-seq of a 
single Beagle NCCD case. 
 
Ataxia 
type 
Associated 
gene 
Human 
Loci 
GRCh37/hg19 
region 
 CanFam2 syntenic 
region Notes 
SCA1 ATXN1 6p22.3  chr6:16,299,344
-16,761,721 
chr35:18,460,465-
18,865,962 Heterozygous SNPs identified - gene excluded 
SCA2 ATXN2  12q24.12  chr12:111,890,019-112,037,480 
chr26:12,091,459-
12,206,061 No polymorphisms identified 
SCA3 ATXN3 14q32.12 chr14:92,524,897-92,572,965 
chr8:4,316,475-
4,352,391 No polymorphisms identified 
SCA4 - 16q22.1 chr16:66,700,000-70,800,000  
chr5:79,600,000-
85,600,000 n/a 
SCA5 SPTBN2  11q13.2  chr11:66,452,720-66,488,870 
chr18:53,664,195-
53,696,100 
8 bp deletion exon 29. Frameshift. Prediction: 
27 Aberrant amino acids, 410 amino acid 
truncation (p.I1953Rfs*28).   
SCA6 CACNA1A  19p13.2  chr19:13,317,256-13,617,274 
chr20:51,822,254-
52,037,590 Heterozygous SNPs identified - gene excluded 
SCA7 ATXN7  3p14.1  chr3:63,850,233
-63,982,293 
chr20:30,222,502-
30,361,703 No polymorphisms identified 
SCA8 ATXN8OS 13q21.33  chr13:70,681,345-70,713,885 
chr22:27,500,593-
27,536,451 Insufficient read depth to analyse 
SCA9 - - - - n/a 
SCA10 ATXN10  22q13.31  chr22:46,067,678-46,241,187 
chr10:23,331,497-
23,495,457 No polymorphisms identified 
SCA11 TTBK2  15q15.2  chr15:43,036,542-43,213,007 
chr30:12,667,929-
12,836,871 Heterozygous SNPs identified - gene excluded 
SCA12 PPP2R2B  5q32  chr5:145,969,068-146,461,033 
chr2:43,854,239-
44,295,609 No polymorphisms identified 
SCA13 KCNC3  19q13.33  chr19:50,818,765-50,832,634 - No canine orthologue 
SCA14 PRKCG  19q13.42  chr19:54,385,467-54,410,901 
chr1:106,377,729-
106,388,206 No polymorphisms identified 
SCA15 ITPR1  3p26.1  chr3:4,535,032-4,889,524 
chr20:15,748,595-
16,067,260 
4 Exonic SNPs. 1 Non-synonymous SNP 
(p.E2491Q). Q residue conserved across 
mammalian species 
SCA16 
(see 
SCA15) 
- -  - - n/a 
SCA17 TBP  6q27  chr6:170,863,471-170,881,946 
chr12:75,485,739-
75,496,000 No polymorphisms identified 
SCA18 IFRD1*  7q22-q32   chr7:112,063,199-112,117,258 
chr14:59,850,326-
59,898,828 No coding polymorphism identified 
SCA19 - 1p21-q21  chr1:94,700,000 
- 155,000,000  
multiple 
chromosomes n/a 
SCA20 12 gene duplication 11q12  
chr11:61,453,94
0-61,746,519 
chr18:57,759,467-
57,508,030 n/a 
SCA21 - 7p21.3-p15.1  
ch7:10,075,254-
28,198,059 
multiple 
chromosomes n/a 
SCA22 - 1p21-q21  chr1:94,700,000 
- 155,000,000  
multiple 
chromosomes n/a 
SCA23 PDYN  20p13  chr20:1,959,402
-1,974,931 
chr24:22,050,982-
22,054,521 Insufficient read depth to analyse 
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Ataxia candidate genes continued 
SCA24 
(see 
SCAR4) 
- - - - n/a 
SCA25 - 2p21-p13  chr2:41,800,000
-75,000,000 chr10,chr17 n/a 
SCA26 - 19p13.3  chr19:998,644-4,392,667  
chr20:58,226,442-
60,850,479 n/a 
SCA27 FGF14  13q33.1  chr13:102,373,205-103,054,124 
chr22:54,328,225-
54,929,598 No coding polymorphisms identified. 
SCA28 AFG3L2 18p11.21 chr18:12,328,943-12,377,275 
chr7:80,792,562-
80,830,840 No polymorphisms identified 
SCA29 - heterogen
eous 
- - n/a 
SCA30 - 4q34.3-q35.1  
chr4:179,213,35
6-184,216,082 
chr16:47,000,000-
53,000,000 n/a 
SCA31 BEAN1  16q21  chr16:66,460,816-66,527,432 
chr5:85,780,302-
85,806,244 
1 non synonymous exonic SNP (p.R247Q). 
Conservation data suggests R or Q acceptable. 
SCA32 - 7q32-q33   chr7:131125523
-132115310 
chr14 77,000,000-
86,000,000 n/a 
SCA33 
not 
characteris
ed 
- - - n/a 
SCA34 - 6p12.3-q16.2  
chr6:46,200,000 
- 100,600,000 chr12 n/a 
SCA35 TGM6   20p13  chr20:2,361,554
-2,413,399 
chr24:21,697,299-
21,709,977 Insufficient read depth to analyse 
SCA36 NOP56  20p13  chr20:2,633,178
-2,639,039 
chr24:21,559,606-
21,563,511 No polymorphisms identified 
SCAR1 SETX 9q34.13 chr9:135,136,827-135,230,372 
chr9:55,244,347-
55,323,850 Heterozygous SNPs identified - gene excluded 
SCAR2 - 9q34-qter  chr9:137,919,616-138,285,463 
chr9:53,000,000-
55,000,000 n/a 
SCAR3 - 6p23-p21 chr6:13,400,000 
- 46,200,000 chr35,chr12 n/a 
SCAR4 - 1p36 chr1:3,584,862-15,028,985 chr5,chr2 n/a 
SCAR5 ZNF592  15q25.3 chr15:85,291,818-85,349,663 
chr3:56,896,457-
56,914,856 No coding polymorphism identified 
SCAR6 - 20q11-q13 chr20:19,831,375-43,649,175 chr23,chr24 n/a 
SCAR7 - 11p15 chr11:2754932-7292350 chr18,chr21 n/a 
SCAR8 SYNE1  6q25.1-q25.2  
chr6:152,442,81
9-152,958,534 
chr1:45,428,916-
45,877,003   
SCAR9 ADCK3 1q42.13  chr1:227,127,938-227,175,246 
chr7:41,056,946-
41,076,326 
1 non-synonymous SNP (p.S328P.) P is 
conserved among species 
SCAR10 ANO10  3p22.1  chr3:43,407,818
-43,663,560 
chr23:5,692,957-
5,911,487 No polymorphisms identified 
SCAR11 SYT14  1q32.2  chr1:210,111,538-210,337,633 
chr7:11,556,473-
11,746,853 One synonymous SNP identified 
SCAR12 - 16q21-q23  chr16:65,067,301-82,980,450 
chr5:71,732,917-
87,083,276 n/a 
Friedreic
h ataxia FXN  9q21.11  
chr9:71,650,479
-71,715,094 
chr1:91,355,667-
91,378,319 One synonymous SNP identified 
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